<SEC-DOCUMENT>0000721371-24-000121.txt : 20241101
<SEC-HEADER>0000721371-24-000121.hdr.sgml : 20241101
<ACCEPTANCE-DATETIME>20241101085841
ACCESSION NUMBER:		0000721371-24-000121
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241101
DATE AS OF CHANGE:		20241101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11373
		FILM NUMBER:		241417215

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cah-20240930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:537b797f-b836-409a-bf04-ad11625945c4,g:bd28f3d8-0395-4523-ae63-79ccc2df931a,d:088c97dfd3044fc38835caa8c41eddc8-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:cah="http://www.cardinal.com/20240930" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cah-20240930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0000721371</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-26">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-29">false</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" id="f-281">http://fasb.org/us-gaap/2024#GainLossOnSalesOfAssetsAndAssetImpairmentCharges</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cah-20240930.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="states"><xbrli:measure>cah:states</xbrli:measure></xbrli:unit><xbrli:unit id="numberofusterritories"><xbrli:measure>cah:numberOfUSTerritories</xbrli:measure></xbrli:unit><xbrli:unit id="lawsuit"><xbrli:measure>cah:lawsuit</xbrli:measure></xbrli:unit><xbrli:unit id="plaintiff"><xbrli:measure>cah:plaintiff</xbrli:measure></xbrli:unit><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>cah:segment</xbrli:measure></xbrli:unit><xbrli:unit id="segments"><xbrli:measure>cah:Segments</xbrli:measure></xbrli:unit><xbrli:unit id="reportable_segments"><xbrli:measure>cah:Reportable_Segments</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:OptumRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cah:IntegratedOncologyNetworkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cah:SpecialtyNetworksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cah:TransactionDataSystemInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OutcomesDivestitureAxis">cah:OutcomesDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cah:TransactionDataSystemInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-08</xbrli:startDate><xbrli:endDate>2025-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:CityOfBaltimoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2038-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">naics:ZZ921150</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:IVCApril2023AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-30</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:IVCApril2023AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:IVCApril2023AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:FY24Q1GoodwillImpairmentGMPDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:FY24Q1GoodwillImpairmentGMPDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:September2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:June2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:September2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:DateInitiatedAxis">cah:January2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:DateInitiatedAxis">cah:January2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cah:A375MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cah:A375MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A375MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A375MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cah:A375MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-31</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearAndPrecisionHealthSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearAndPrecisionHealthSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:AtHomeSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:AtHomeSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:OptiFreightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:OptiFreightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i088c97dfd3044fc38835caa8c41eddc8_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-2">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September&#160;30, 2024</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">1-11373</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Cardinal Health, Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:566.25pt"><tr><td style="width:1.0pt"/><td style="width:145.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:31.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:277.75pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">31-0958666</ix:nonNumeric></span></td></tr><tr style="height:23pt"><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">7000 Cardinal Place</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Dublin</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">43017</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">614</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">757-5000</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"><tr><td style="width:1.0pt"/><td style="width:198.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:138.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:198.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common shares (without par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">CAH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-22">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="f-23">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of the registrant&#8217;s common shares, without par value, outstanding as of October&#160;25, 2024, was the following: <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">242,010,503</ix:nonFraction>.</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_7"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:22pt;font-weight:700;line-height:100%">Cardinal Health</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:100%"> </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:18pt;font-weight:700;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Q1 Fiscal 2025 Form 10-Q                                                                                                                                   </span></div></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:91.080%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_13">2</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_31">Explanation and Reconciliation of Non-GAAP Financial Measures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_31">15</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_40">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_40">18</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_43">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_43">18</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_46">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_46">19</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_49">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_49">19</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_52">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_52">19</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_64">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_64">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_127">38</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_130">Form 10-Q Cross Reference Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_130">39</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_133">40</a></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">About Cardinal Health</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, Inc., an Ohio corporation formed in 1979, is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists, and manufacturers for integrated care coordination.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics. As used in this report, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2025 and fiscal 2024 and to FY25 and FY24 are to the fiscal years ending or ended June&#160;30, 2025 and June 30, 2024, respectively.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2024 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates, and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook, and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected, or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (&#8220;2024 Form 10-K&#8221;). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the "Overview of Consolidated Results" section of MD&amp;A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the &#8220;Explanation and Reconciliation of Non-GAAP Financial Measures&#8221; section following MD&amp;A in this Form 10-Q. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at September&#160;30, 2024 and June&#160;30, 2024, and in our condensed consolidated statements of earnings/(loss) and our condensed consolidated statements of cash flows for the three months ended September&#160;30, 2024 and 2023. All comparisons presented are with respect to the prior-year period, unless stated otherwise. Our previously reported segment results have been recast to conform to our new reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. All of the revisions are reflected throughout this Form 10-Q. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_82">Note 1</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. This discussion and analysis should be read in conjunction with the MD&amp;A included in the 2024 Form 10-K. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Overview of Consolidated Results</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended September&#160;30, 2024 decreased 4 percent to $52.3 billion due to the expiration of the OptumRx contracts, partially offset by branded and specialty pharmaceutical sales growth from existing customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Operating Earnings/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP operating earnings/(loss)</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">568</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP operating earnings</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">625</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had GAAP operating earnings of $568 million during the three months ended September&#160;30, 2024 and a GAAP operating loss of $32&#160;million during the three months ended September 30, 2023, which included the impact of pre-tax goodwill impairment charges related to the GMPD segment of $585 million. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP operating earnings increased 12 percent to $625 million from the prior-year quarter primarily due to increased contribution from branded pharmaceutical and specialty pharmaceutical products, which includes the favorable impact from the earlier seasonal launch of the COVID-19 vaccine distribution, and the performance of our generics program.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Diluted EPS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.193%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">($ per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2),(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.70</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.07</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.22</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.11)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.72&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Diluted earnings per share attributable to Cardinal Health, Inc. ("diluted EPS").</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures." </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) For the three months ended September 30, 2023, GAAP diluted EPS and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 249 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period. For the three months ended September 30, 2023, non-GAAP diluted EPS is calculated using a weighted average of 250 million common shares, which includes potentially dilutive shares. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) For the three months ended September 30, 2023, impairments and (gain)/loss on disposals of assets, net includes a pre-tax goodwill impairment charge of $585 million, related to the GMPD segment. For fiscal 2024, the net tax benefit related to this charge was $45 million and was included in the annual effective tax rate. As a result, the tax benefit for the three months ended September 30, 2023 increased approximately by an incremental $102 million, and increased the provision for income taxes during the remainder of fiscal 2024.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2024, GAAP diluted EPS increased from the prior-year quarter primarily due to the factors impacting GAAP operating earnings/(loss) discussed above. The goodwill impairment charge related to the GMPD segment had a $(1.76) per share after-tax impact on GAAP diluted EPS during the three months ended September 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP diluted EPS increased 9 percent to $1.88 from the prior-year quarter primarily due to the factors impacting non-GAAP operating earnings discussed above.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $2.9 billion at September&#160;30, 2024 compared to $5.1 billion at June&#160;30, 2024. During the three months ended September&#160;30, 2024, net cash used in operating activities was $1.6 billion, which was primarily impacted by the unwinding of the negative net working capital associated with the OptumRx contracts and the normal timing of payments to vendors. Cash used in operating activities for the quarter also includes the impact of our annual payment of $366&#160;million related to the agreement to settle the vast majority of the opioid lawsuits filed by states and local governmental entities (the "National Opioid Settlement Agreement"). In addition, we deployed cash of $375 million for share repurchases and $90 million for capital expenditures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Significant Developments in Fiscal 2025 and Trends</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Pharmaceutical and Specialty Solutions Segment</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OptumRx Contracts</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx would expire at the end of June 2024. Sales to OptumRx generated 17 percent of our consolidated revenue in fiscal 2024; however, due to the class of trade, sales to OptumRx generated a meaningfully lower operating margin than the overall Pharma segment. The expiration of the OptumRx contracts and unwinding of the negative net working capital associated with the contracts adversely impacted our results of operations, including segment profit, financial condition, and cash flows during the three months ended September 30, 2024. While we anticipate offsetting the impact through a combination of onboarding new customers, growth from existing customers, and cost savings, we expect some adverse impacts to continue throughout the remainder of fiscal 2025.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2024, we announced that we entered into a definitive agreement to acquire Integrated Oncology Network (&#8220;ION&#8221;), a physician-led independent community oncology network, for a purchase price of $1.1 billion in cash, subject to certain adjustments. ION includes more than 50 practice sites in 10 states representing more than 100 providers. ION supports a complete continuum of care across its member sites including medical oncology, radiation oncology, urology diagnostic testing, and other ancillary services. The acquisition will build on our Navista oncology practice alliance and is expected to expand our holistic suite of clinical and practice management solutions designed to support independent community oncology practices. This transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals. We plan to fund the acquisition with available cash and existing borrowing arrangements. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash. The acquisition further expands our offerings in key therapeutic areas and accelerates our upstream data and research opportunities with biopharma manufacturers.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Branded Pharmaceuticals</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal 2024, we saw increased demand for GLP-1 pharmaceuticals, and our sales increased significantly, despite periodic supply shortages. These increased sales positively impacted our Pharma segment and consolidated revenue for the fiscal 2024; however, GLP-1 sales did not meaningfully contribute to segment profit. Future demand for these medications is unpredictable and our ability to meet demand may be impacted by additional supply constraints.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal 2024, we began distributing commercially available COVID-19 vaccines following the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval. Distribution of these vaccines had a greater than anticipated benefit to our Pharma segment profit in fiscal year 2024, especially in the second quarter. We expect COVID-19 vaccine distribution to continue to favorably impact our Pharma segment profit in fiscal 2025, but to a lesser extent than in fiscal 2024. In August 2024, the FDA approved the 2024-2025 commercial COVID-19 vaccines, and our Pharma segment profit was positively impacted by distribution of these vaccines in the first quarter of fiscal 2025. Due to the earlier seasonal launch of the COVID-19 vaccine distribution, we expect a lower contribution from the vaccine distribution in the second quarter of fiscal 2025 compared to the prior-year quarter. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generics Program</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of our Pharma segment generics program positively impacted the year-over-year comparison of Pharma segment profit during the three months ended September&#160;30, 2024. The Pharma segment generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes, the Red Oak Sourcing, LLC venture ("Red Oak Sourcing") with CVS Health Corporation ("CVS Health"), and generic pharmaceutical contract manufacturing and sourcing costs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The frequency, timing, magnitude, and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, generic pharmaceutical manufacturer pricing changes, and generic pharmaceutical contract manufacturing and sourcing costs all impact Pharma segment profit and are subject to risks and uncertainties. These risks and uncertainties may impact Pharma segment profit and consolidated operating earnings during the remainder of fiscal 2025 and beyond.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Global Medical Products and Distribution Segment</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Volumes</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We experienced Cardinal Health brand medical products sales growth during fiscal 2024 and expect further growth in fiscal 2025 and beyond. The timing, magnitude, and profit impact of this anticipated sales growth is subject to risks and uncertainties, which may impact GMPD segment profit.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20240930_g1.jpg" alt="36" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:220px"/><img src="cah-20240930_g2.jpg" alt="37" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:220px"/><img src="cah-20240930_g3.jpg" alt="4947802332370" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:220px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.705%"><tr><td style="width:1.0%"/><td style="width:75.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47,990</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,588&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,123</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,186</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52,299</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,671&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52,277</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,650&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.230%"><div style="margin-bottom:3pt"><span><br/></span></div></div><div style="display:inline-block;max-width:3.539%;min-width:2.539%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.231%"></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical and Specialty Solutions </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma segment revenue decreased 5 percent to $48.0 billion from the prior-year quarter primarily due to the expiration of the OptumRx contracts, partially offset by branded and specialty pharmaceutical sales growth from existing customers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Medical Products and Distribution</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GMPD segment revenue increased 3 percent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.1 billion from the prior-year quarter primarily due to higher volumes from existing customers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue increased 13 percent to $1.2 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the prior-year quarter due to growth across the at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics operating segments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold decreased 5 percent to $50.4 billion from the prior-year quarter due to the factors affecting the changes in revenue and gross margin.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.230%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div></div><div style="display:inline-block;max-width:3.539%;min-width:2.539%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.231%"><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div></div></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.230%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Gross Margin</span></div></div><div style="display:inline-block;max-width:3.539%;min-width:2.539%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.231%"></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><img src="cah-20240930_g4.jpg" alt="892" style="height:225px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="cah-20240930_g5.jpg" alt="893" style="height:225px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.858%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,902</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin increased 9 percent to $1.9 billion from the prior-year quarter primarily due to the increased contribution from branded pharmaceutical and specialty pharmaceutical products and the positive performance of our generics program in the Pharma segment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin rate grew 45 basis points to 3.64 percent from the prior-year quarter primarily due to the increased contribution from branded pharmaceutical and specialty pharmaceutical products and favorable changes in the overall product mix for the Pharma segment, largely driven by the expiration of the OptumRx contracts.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Distribution, Selling, General, and Administrative ("SG&amp;A") Expenses</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.705%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A expenses</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,277</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses increased 8 percent to $1.3 billion from the prior-year quarter primarily due to higher health and welfare costs and costs to support sales growth for existing customers.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_121">Note </a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_121">13</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.705%"><tr><td style="width:1.0%"/><td style="width:75.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">530</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">642</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(74)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(596)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total consolidated operating earnings/(loss)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">568</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical and Specialty Solutions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma segment profit increased 16 percent to $530 million from the prior-year quarter primarily due to increased contribution from branded pharmaceutical and specialty pharmaceutical products, which includes the favorable impact from the earlier seasonal launch of the COVID-19 vaccine distribution, and the performance of our generics program. This was partially offset by the expiration of the OptumRx contracts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Medical Products and Distribution</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GMPD segment profit decreased to $8 million from the prior-year quarter due to higher manufacturing and health and welfare costs, largely offset by an improvement in net inflationary impacts, which includes the effects of mitigation actions, and growth from existing customers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other profit increased 8 percent to $104 million from the prior-year quarter due to the performance of OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Logistics.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Corporate during the three months ended September&#160;30, 2024 are due to the factors discussed in the "Other Components of Consolidated Operating Earnings/(Loss)" section that follows.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Components of Consolidated Operating Earnings/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to revenue, gross margin, and SG&amp;A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"/><td style="width:74.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(40)</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Employee Severance</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2024, restructuring and employee severance costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and certain initiatives to rationalize our manufacturing operations. During the three months ended September&#160;30, 2023, restructuring and employee severance costs were primarily related to certain projects resulting from reviews of our strategy, portfolio, capital-allocation framework, and operations and the implementation of certain enterprise-wide cost-savings measures.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization and Other Acquisition-Related Costs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquisition-related intangible assets was $68 million and $64 million for the three months ended September&#160;30, 2024 and 2023, respectively. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairments and (Gain)/Loss on Disposal of Assets, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2023, we recognized a $585&#160;million pre-tax non-cash goodwill impairment charge related to the GMPD segment and recognized a pre-tax gain of $53 million related to the divestiture of the Outcomes&#8482; business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation (Recoveries)/Charges, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2024 and 2023, we recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $43 million and $41 million, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Earnings Before Income Taxes</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the items discussed above, earnings before income taxes was impacted by the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.858%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, increased to $32 million from the prior-year quarter primarily due to decreased interest income from cash and equivalents and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Provision for/(Benefit from) Income Taxes</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2024 and 2023, the effective tax rate was 23.0 percent and 75.1 percent, respectively. The decrease in the effective tax rate for the three months ended September 30, 2024 compared to the prior-year quarter was primarily due to the tax effect of the prior-year goodwill impairment charge. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_106">Note 8</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; for additional information.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2023, we recognized a $585&#160;million pre-tax charge for goodwill impairment related to the GMPD segment. The net tax benefit related to this charge is $45 million for fiscal 2024. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charge during the three months ended September&#160;30, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to pre-tax loss for the three months ended September&#160;30, 2023 resulted in recognizing an incremental interim tax benefit of approximately $102&#160;million, which impacted the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended September&#160;30, 2023 and prepaid expenses and other assets in the condensed consolidated balance sheets at September&#160;30, 2023. This interim tax benefit reversed in the remaining quarters of fiscal 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Pillar Two Initiatives</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Organization for Economic Cooperation and Development ("OECD") published guidance on the establishment of the Pillar Two initiative for a global minimum tax rate of 15 percent. These rules are generally effective for fiscal 2025. We are closely monitoring developments, but we do not currently expect these rules to have a material impact on our effective tax rate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"/><td style="width:24.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently believe that, based on available capital resources and projected operating cash flow, we have adequate capital resources to fund our operations and expected future cash needs as described below. If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $2.9 billion at September&#160;30, 2024 compared to $5.1 billion at June&#160;30, 2024. During the three months ended September&#160;30, 2024, net cash used in operating activities was $1.6 billion, which was primarily impacted by the unwinding of the negative net working capital associated with the OptumRx contracts and the normal timing of payments to vendors. Cash used in operating activities for the quarter also includes the impact of our annual payment of $366&#160;million related to the National Opioid Settlement Agreement. In addition, we deployed cash of $375 million for share repurchases and $90 million for capital expenditures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2024, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases, payments to vendors, and tax payments in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and equivalents balance at September&#160;30, 2024 included $471 million of cash held by subsidiaries outside of the United States. </span></div></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Financing Arrangements and Financial Instruments</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit Facilities and Commercial Paper</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity at September&#160;30, 2024 include a $2.0 billion commercial paper program, backed by a&#160;$2.0 billion&#160;revolving credit facility, which expires in February 2028. We also have a&#160;$1.0&#160;billion&#160;committed receivables sales facility through September 2025. At&#160;September&#160;30, 2024, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, we entered into a new 364-Day Revolving Credit Facility, under which we have access to $1.0 billion of committed liquidity through October 2025. We also increased our commercial paper program from $2.0 billion to $3.0&#160;billion. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of September 30, 2024, we were in compliance with this financial covenant. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of&#160;$5.2 billion and $5.1 billion at September&#160;30, 2024 and June&#160;30, 2024, respectively. We plan to repay our outstanding 3.5% Notes due 2024 at maturity in November 2024 with $400 million of proceeds from the debt issuance in fiscal 2024, $200 million of which were invested in short-term time deposits and classified as prepaid expenses and other in our condensed consolidated balance sheets.</span></div></div></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"/><td style="width:24.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Capital Deployment</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Opioid Litigation Settlements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $5.0 billion accrued at September&#160;30, 2024 related to certain opioid litigation, as further described within </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_103">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the remaining payment amounts to occur through 2038. During the three months ended September&#160;30, 2024, we made our fourth annual payment of $366&#160;million under the National Opioid Settlement Agreement. The amounts of future annual payments may differ from the payments that we have already made. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures during the three months ended September&#160;30, 2024 and 2023 were $90 million and $92 million, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On each of May 7, 2024 and August 15, 2024, our Board of Directors approved a quarterly dividend of $0.5056 per share, or $2.02 per share on an annualized basis, which were paid on July 15, 2024 and October 15, 2024 to shareholders of record on July 1, 2024 and October 1, 2024, respectively.</span></div><div style="text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2024, we deployed $375 million for repurchases of our common shares under an accelerated share repurchase ("ASR") program. We funded the repurchases with available cash. This program concluded in the second quarter of fiscal 2025, which reduced the amount remaining under our existing share repurchase authorization to approximately $3.1 billion. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_115">Note 11</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Integrated Oncology Network Acquisition</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2024, we announced that we have entered into a definitive agreement to acquire Integrated Oncology Network, a physician-led independent community oncology network, for a purchase price of $1.1 billion in cash, subject to certain adjustments. The acquisition is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:24.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Other Items</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A in the 2024 Form 10-K addresses our contractual obligations and cash requirements, as of and for the fiscal year ended June 30, 2024. Other than the considerations noted above in connection with our proposed acquisition of Integrated Oncology Network, there have been no subsequent material changes outside the ordinary course of business to those items.</span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_28"></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below are supplemental disclosures to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2024</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in the 2024 Form 10-K.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management&#8217;s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ, including due to the risks discussed in "Risk Factors" and other risks discussed in the 2024 Form 10-K and our other filings with the SEC since </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2024</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">At-Home Solutions Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our fiscal 2024 annual impairment test, the fair value of our at-Home Solutions reporting unit exceeded its carrying amount by less than 1 percent. A decrease in future cash flows, an increase in the discount rate or a decrease in the terminal growth rate, among other things, could result in a goodwill impairment for at-Home Solutions. During the three months ended September 30, 2024, there were no indicators of goodwill impairment for the at-Home Solutions reporting unit. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Medical Products and Distribution Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal 2024, we recorded $675 million of goodwill impairment charges related to our GMPD reporting unit. GMPD goodwill was fully impaired during the third quarter of fiscal 2024. </span></div></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The "Overview of Consolidated Results" section within MD&amp;A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Exclusions from Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors&#8217; assessment of the business for the reasons identified below: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">LIFO charges and credits</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results. We did not recognize any LIFO charges or credits during the periods presented.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">State opioid assessments related to prior fiscal years</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Shareholder cooperation agreement costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs such as legal, consulting, and other expenses incurred in relation to the agreement (the "Cooperation Agreement") entered into among Elliott Associates, L.P., Elliott International, L.P. (together, "Elliott") and Cardinal Health. These include costs incurred to negotiate and finalize the Cooperation Agreement and costs incurred by the Business Review Committee of the Board of Directors formed under this Cooperation Agreement, tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework, and operations. We have excluded these costs from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business operations and may obscure analysis of trends and financial performance. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Restructuring and employee severance costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because they are not part of the ongoing operations of our underlying business and include, but are not limited to, costs related to divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance, and realigning operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Amortization and other acquisition-related costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity&#8217;s initial </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Impairments and gain or loss on disposal of assets, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current, and forecasted financial results. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.85pt;text-decoration:underline">Litigation recoveries or charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations. </span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Definitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth rate calculation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP operating earnings:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP earnings before income taxes: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earnings/(loss) before income taxes excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net, (7) litigation (recoveries)/charges, net and (8) loss on early extinguishment of debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP net earnings attributable to Cardinal Health, Inc.:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ne</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t earnings/(loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net, (7) litigation (recoveries)/charges, net and (8) loss on early extinguishment of debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP effective tax rate: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for/(benefit from) income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net, (7) litigation (recoveries)/charges, net and (8) loss on early extinguishment of debt divided by (earnings before income taxes adjusted for the eight items above). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliations</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.786%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings/ (Loss)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings Growth Rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/ (Loss) Before Income Taxes</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision for/(Benefit from) Income Taxes</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings/(Loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Growth Rate</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1,2</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Growth Rate</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions, except per common share amounts)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">568</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">541</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">124</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">416</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.70</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.07</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.22</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.11)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">625</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">598</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">138</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">460</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="24" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> 3</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.72&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attributable to Cardinal Health, Inc.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the three months ended September 30, 2023, GAAP diluted EPS and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 249 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period. For the three months ended September 30, 2023, non-GAAP diluted EPS is calculated using a weighted average of 250 million common shares, which includes potentially dilutive shares. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023, impairments and (gain)/loss on disposals of assets, net includes a pre-tax goodwill impairment charge of $585 million, related to the GMPD segment. For fiscal 2024, the net tax benefit related to this charge was $45 million and was included in the annual effective tax rate. As a result, the tax benefit for the three months ended September 30, 2023 increased approximately by an incremental $102 million, and increased the provision for income taxes during the remainder of fiscal 2024. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.158%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span><br/></span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_40"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the quantitative and qualitative market risk disclosures included in the&#160;2024&#160;Form 10-K since the end of fiscal&#160;2024&#160;through&#160;September&#160;30, 2024.</span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_43"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of September&#160;30, 2024. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of September&#160;30, 2024, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended&#160;September&#160;30, 2024&#160;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legal proceedings described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_103">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.</span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_49"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the information in this Form 10-Q and the risk factors discussed in "Risk Factors" and other risks discussed in the 2024 Form 10-K and our filings with the SEC since June&#160;30, 2024. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Our pending acquisition of Integrated Oncology Network subjects us to various risks and uncertainties.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in the MD&amp;A section, on September 20, 2024, we announced that we entered into a definitive agreement to acquire Integrated Oncology Network (&#8220;ION&#8221;), a physician-led independent community oncology network for a purchase price of $1.1 billion in cash, subject to certain adjustments. The acquisition will build on our Navista oncology practice alliance, and is expected to expand our holistic suite of clinical and practice management solutions designed to support independent community oncology practices. Consummation of the pending acquisition is subject to various risks and uncertainties, such as the ability to successfully complete the acquisition on a timely basis, which includes receipt of required regulatory approvals and satisfaction of other closing conditions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are successful in completing the acquisition, we will be subject to other risks, including the following: we may fail to realize the synergies and other benefits we expect from the acquisition; the use of a significant portion of our cash may have an adverse effect on our liquidity, limit our flexibility in responding to other business opportunities, and increase our vulnerability to adverse economic and industry conditions; we may fail to retain key personnel of the acquired businesses; future developments may impair the value of our purchased goodwill or intangible assets; we may face difficulties establishing, appropriately integrating or combining operations and systems; we may encounter unforeseen internal control, regulatory or compliance issues, including with respect to physician office management; and we may face other additional risks relating to regulatory matters, legal proceedings, and tax laws or positions.</span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_52"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:15.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid&#160;per Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares<br/>Purchased<br/>as Part of Publicly Announced Programs&#160;(2,3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Dollar Value of<br/>Shares That May<br/>Yet be Purchased<br/>Under the Program&#160;(3)<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2024</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.46&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,493&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aug 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,736,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,735,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sept 2024</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.72&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,193&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,737,035</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">109.65</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,735,978</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,193</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Reflects 143, 191 and 723 common shares purchased in July, August, and September 2024, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On August 21, 2024, we entered into an ASR program to purchase common shares for an aggregate purchase price of $375 million and received an initial delivery of 2.7 million common shares using a reference price of $109.65. The ASR program concluded on October 30, 2024 at a volume weighted average price per common share of $110.10 resulting in a final delivery of 0.7 million common shares. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_115">Note 11</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On June 7, 2023, our Board of Directors approved a new $3.5 billion share repurchase program, which will expire on December 31, 2027. As of September 30, 2024, we had $3.2 billion authorized for share repurchases remaining under this program.</span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_55"></div><div style="margin-bottom:3pt;margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.158%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 10b5-1 Plan Adoptions and Modifications</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2024, no director or officer <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-30"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-31">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-32"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-33">terminated</ix:nonNumeric></ix:nonNumeric> a "Rule 10b5-1 trading arrangement" or "non-Rule10b5-1 trading arrangement" as each term is defined in Section 408(a) of Regulation S-K under the Exchange Act.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_61"></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Earnings/(Loss)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:75.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-34">52,277</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-35">54,650</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-36">50,375</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-37">52,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-38">1,902</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-39">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution, selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-40">1,277</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-41">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-42">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-43">25</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="f-44">74</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="f-45">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="f-46">1</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="f-47">541</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="f-48">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="f-49">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating earnings/(loss)</span></div></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-50">568</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-51">32</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-52">5</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-53">1</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-54">32</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-55">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings/(loss) before income taxes</span></div></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-56">541</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-57">44</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for/(benefit from) income taxes</span></div></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-58">124</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-59">33</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-60">417</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-61">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net earnings attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-62">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-63">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net earnings/(loss) attributable to Cardinal Health, Inc. </span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="f-64">416</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-65">12</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(loss) per common share attributable to Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-66">1.71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-67">0.05</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-68">1.70</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-69">0.05</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-70">243</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-71">249</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-72">245</ix:nonFraction></span></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"/><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-73">249</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared per common share</span></td><td style="background-color:#c4c4c4;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#c4c4c4;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-74">0.5056</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c4c4c4;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#c4c4c4;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c4c4c4;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-75">0.5006</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income/(Loss)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-76">417</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-77">11</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-78">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-79">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain/(loss) on derivative instruments, net of tax</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-80">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-81">3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss), net of tax</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-82">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-83">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income/(loss)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-84">429</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-85">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-86">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-87">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total comprehensive income/(loss) attributable to Cardinal Health, Inc. </span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-88">428</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-89">26</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-90">2,867</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-91">5,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-92">11,781</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-93">12,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-94">15,619</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-95">14,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-96">2,591</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-97">2,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="f-98">47</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="f-99">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-100">32,905</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-101">34,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-102">2,535</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-103">2,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-104">6,388</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-105">6,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-106">1,231</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-107">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-108">43,059</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-109">45,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-110">30,365</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-111">31,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations and other short-term borrowings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="f-112">940</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="f-113">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-114">3,373</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-115">3,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-116">34,678</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-117">35,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-118">4,224</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-119">4,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-120">7,433</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-121">8,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; deficit:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="f-122"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="f-123">500</ix:nonFraction></ix:nonFraction> thousand</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares, Issued&#8212;<ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-124"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-125">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-126">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-128"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-129">755</ix:nonFraction></ix:nonFraction> million </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">shares, Issued&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-130"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-131">327</ix:nonFraction></ix:nonFraction> million </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">and June 30,2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="f-132">2,827</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="f-133">2,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings/(accumulated deficit)</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-134">14</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-135">286</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares in treasury, at cost:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-136">85</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-137">83</ix:nonFraction> million shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> and June 30, 2024, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-138">5,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-139">5,677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-140">155</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-141">167</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cardinal Health, Inc. shareholders' deficit</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-142">3,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-143">3,213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-144">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-145">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-146">3,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-147">3,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; deficit</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-148">43,059</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-149">45,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders' Deficit</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:29.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.053%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></div></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained Earnings/(Accumulated Deficit)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-150">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-151">2,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-152">286</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-153">83</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-154">5,677</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-155">167</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-156">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-157">3,212</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="f-158">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-159">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-160">417</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></div></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-161">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-162">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="f-163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-164">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-165">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-166">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-167">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-168">75</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-169">3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-170">303</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-171">378</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:Dividends" scale="6" id="f-172">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Dividends" scale="6" id="f-173">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="f-174">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-175">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="f-176">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-177">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-178">2,827</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-179">14</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-180">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-181">5,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-182">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-183">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-184">3,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:29.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-185">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-186">2,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-187">642</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-188">76</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-189">4,911</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-190">151</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-191">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-192">2,957</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-193">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-194">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-195">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-196">14</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-197">14</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="f-198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-199">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-200">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-201">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-202">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-29" xsi:nil="true" name="us-gaap:PaymentsForRepurchaseOfCommonStock" id="f-203"/></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-204">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-205">505</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-206">505</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:Dividends" scale="6" id="f-207">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:Dividends" scale="6" id="f-208">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-209">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-210">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-211">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-212">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-213">2,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-214">780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-215">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-216">5,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-217">165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-218">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-219">3,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-220">417</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-221">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-222">182</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-223">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on sale of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="f-224">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="f-226">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="f-227">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-228">30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-229">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="f-230">16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="f-231">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decrease in trade receivables</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="f-232">288</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="f-233">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in inventories</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-234">678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="f-235">1,073</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase/(decrease) in accounts payable</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="f-236">1,394</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="f-237">1,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities and operating items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-238">508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-239">959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by/(used in) operating activities</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-240">1,647</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-241">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from divestitures, net of cash sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="f-242">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="6" id="f-243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-244">90</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-245">92</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-246">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-247">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from net investment hedge terminations</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" format="ixt:fixed-zero" scale="6" id="f-248">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" scale="6" id="f-249">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-250">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-251">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of long-term obligations</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-252">9</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-253">7</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net tax withholding from share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="f-254">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="f-255">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends on common shares</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-256">128</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-257">131</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-258">375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-259">500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-260">540</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-261">666</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rates changes on cash and equivalents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-262">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-263">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net decrease in cash and equivalents</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-264">2,266</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-265">206</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-266">5,133</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-267">4,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and equivalents at end of period</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-268">2,867</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-269">3,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.989%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements </span></div><div style="margin-bottom:1pt;text-align:center"><span><br/></span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_82"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-270" continuedAt="f-270-1" escape="true"><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-271" continuedAt="f-271-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2025 and 2024 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2025 and June 30, 2024, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments, and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2025 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2025. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the "2024 Form 10-K"). </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revision of Prior Period Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed in the 2024 Form 10-K, we revised our prior period financial statements to correct for an accounting error related to the at-Home Solutions operating segment that was not </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="f-271-1"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material, individually or in the aggregate, to our previously issued Consolidated Financial Statements, as well as other unrelated immaterial errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. See Note 1 and Note 16 to the "Consolidated Financial Statements" in the 2024 Form 10-K for additional information.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Updated Segment Reporting Structure</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. The remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics, are not significant enough to require separate reportable disclosures and are included in Other. The Pharma reportable segment consists of all businesses formerly within our Pharmaceutical segment, excluding Nuclear and Precision Health Solutions. The GMPD reportable segment consists of all businesses formerly within our Medical segment, excluding at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_121">Note 13</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for segment results under the new reporting structure.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:MajorCustomersPolicyPolicyTextBlock" id="f-272" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expired at the end of June 2024, would not be renewed. Sales to OptumRx generated <ix:nonFraction unitRef="rate" contextRef="c-38" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="f-273">17</ix:nonFraction> percent of our consolidated revenue in fiscal 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-274" continuedAt="f-274-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards And Disclosure Rules Not Yet Adopted </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the FASB on our consolidated financial statements as well as material updates to previous assessments, if any, from the 2024 Form 10-K.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in the 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div></ix:nonNumeric></div></div></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:24.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.989%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="f-274-1"><ix:continuation id="f-270-1"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Disclosure</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in the 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Climate-Related Disclosures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the SEC issued final rules on climate-related disclosures that will require annual disclosure of material climate-related risks and material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the rules require disclosure in the notes to the financial statements of the effects of severe weather events and other natural conditions, subject to certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates. These rules also require disclosure of climate risk oversight practices of the Board of Directors and management, and the disclosure of governance, risk management, and strategy related to material climate-related risks. In April 2024, the SEC voluntarily stayed the new rules pending the completion of judicial review. We are currently evaluating the impact of adoption of these final rules on our disclosures.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the three months ended September 30, 2024.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_1241"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-275" continuedAt="f-275-1" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Acquisitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2024, we announced that we have entered into a definitive agreement to acquire Integrated Oncology Network ("ION"), a physician-led independent community oncology network, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" name="us-gaap:BusinessCombinationPriceOfAcquisitionExpected" format="ixt:num-dot-decimal" scale="9" id="f-276">1.1</ix:nonFraction>&#160;billion in cash, subject to certain adjustments. ION includes more than 50 practice sites in 10 states representing more than 100 providers. ION supports a complete continuum of care across its member sites including medical oncology, radiation oncology, urology diagnostic testing and other ancillary services. This transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="f-277">1.2</ix:nonFraction> billion in cash. Specialty Networks creates clinical and economic value for providers and partners across multiple specialty group purchasing organizations ("GPOs"): UroGPO, Gastrologix and GastroGPO, and United Rheumatology. </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="f-275-1"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the purchase price for the acquisition of Specialty Networks is not yet finalized and is subject to adjustment as we complete the valuation analysis of the acquisition. The pro forma results of operations and the results of operations for Specialty Networks have not been separately disclosed because the effects were not significant compared to the consolidated financial statements.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_85"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-278" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 5, 2023, we signed a definitive agreement to contribute the Outcomes&#8482; business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a <ix:nonFraction unitRef="number" contextRef="c-41" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" format="ixt:num-dot-decimal" scale="-2" id="f-279">16</ix:nonFraction> percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="f-280">53</ix:nonFraction>&#160;million during the three months ended September 30, 2023, which was included in <span style="-sec-ix-hidden:f-281">impairments and (gain)/loss on disposal of assets, net</span> in our condensed consolidated statements of earnings/(loss). This gain includes our initial recognition of an equity method investment in the combined entity for $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-6" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-282">147</ix:nonFraction>&#160;million, which was recorded in other assets in our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the divestiture of the Outcomes&#8482; business did not meet the criteria to be classified as discontinued operations. The Outcomes&#8482; business operated within our former Pharmaceutical segment and its results before the divestiture are reflected within the Pharma segment.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_88"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-283" continuedAt="f-283-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Restructuring and Employee Severance </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-284" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="f-285">16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="f-286">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="f-287">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="f-288">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-289">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-290">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs, and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional project management, and costs associated with vacant facilities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2024, restructuring and employee severance costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and certain initiatives to rationalize our manufacturing operations. During the three months ended September&#160;30, 2023, restructuring and employee severance costs were primarily related to certain </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.989%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="f-283-1"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">projects resulting from reviews of our strategy, portfolio, capital-allocation framework, and operations and the implementation of certain enterprise-wide cost-savings measures.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-291" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2024</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-292">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-293">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-294">97</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="f-295">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:RestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="f-297">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-298">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-299">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-300">10</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-301">94</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-302">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-303">94</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_91"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-304" continuedAt="f-304-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Goodwill and Other Intangible Assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-305" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2024</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-306">3,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-308">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-309">4,725</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-313">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-314">3,555</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-315">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-316">1,170</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-317">4,725</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight&#174; Logistics.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, we performed interim quantitative goodwill impairment testing for GMPD. This quantitative testing resulted in the carrying amount of GMPD exceeding the fair value, resulting in a pre-tax impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-318">585</ix:nonFraction>&#160;million. GMPD goodwill was fully impaired during the third quarter of fiscal 2024. </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><ix:continuation id="f-304-1"><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" id="f-319" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-320">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-321">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-322">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-323">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-324">3,651</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-325">2,495</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-326">1,156</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-61" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-327">11</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-328">562</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-329">415</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-330">147</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-62" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-331">7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-332">1,047</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-333">699</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-334">348</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-63" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-335">7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-336">5,260</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-337">3,609</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-338">1,651</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-339">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-340">5,272</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-341">3,609</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-342">1,663</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-343">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-344">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-345">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-346">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-347">3,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-348">2,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-349">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-350">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-351">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-352">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-353">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-354">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-355">363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-356">5,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-357">3,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-358">1,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-359">5,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-360">3,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-361">1,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-362">68</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-363">64</ix:nonFraction> million for the three months ended September&#160;30, 2024 and 2023, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2025 through 2029 is as follows: $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="f-364">200</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-365">246</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-366">219</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-367">191</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="f-368">186</ix:nonFraction>&#160;million.</span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.989%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-369" continuedAt="f-369-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Long-Term Obligations and Other Short-Term Borrowings </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="9" id="f-370">5.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="9" id="f-371">5.1</ix:nonFraction> billion at September 30, 2024 and June 30, 2024, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="9" id="f-372">30.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="9" id="f-373">31.8</ix:nonFraction> billion at September 30, 2024 and June 30, 2024, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity at September 30, 2024 include a&#160;$<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-374">2.0</ix:nonFraction>&#160;billion&#160;commercial paper program, backed by a $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-375">2.0</ix:nonFraction>&#160;billion&#160;revolving credit facility, which expires in February 2028. We also have a&#160;$<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="f-376">1.0</ix:nonFraction> billion committed receivables sales facility through September 2025. At September 30, 2024, we had <ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:OtherShortTermBorrowings" format="ixt:fixed-zero" scale="6" id="f-377">no</ix:nonFraction> amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, we entered into a new 364-Day Revolving Credit Facility, under which we have access to $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet" format="ixt:num-dot-decimal" scale="9" id="f-378">1.0</ix:nonFraction>&#160;billion of committed liquidity through October 2025. We also increased our Commercial Paper program from $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-379">2.0</ix:nonFraction>&#160;billion to $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-380">3.0</ix:nonFraction>&#160;billion. </span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-369-1">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of September 30, 2024, we were in compliance with this financial covenant.</ix:continuation> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_103"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-381" continuedAt="f-381-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Commitments, Contingent Liabilities and Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of <ix:nonNumeric contextRef="c-74" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:duryear" id="f-382">10</ix:nonNumeric> years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="cah:AggregateAnnualAssessment" scale="6" id="f-383">100</ix:nonFraction> million annual assessment on all manufacturers and distributors that was assessed based on each </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><ix:continuation id="f-381-1" continuedAt="f-381-2"><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturer or distributor's share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new opioid excise tax and limited the OSA to two years (2017 and 2018).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Since fiscal 2021, we have made certain payments to New York State for our portion of the assessment in 2017 and 2018. However, we, and other distributors, challenged the OSA as unconstitutional. In May 2024, the New York Appellate Division held that the 2017 assessment was unconstitutionally retroactive, directing a refund of assessments paid for calendar year 2017, but upheld the 2018 assessment. Both parties have appealed the decision of the New York Appellate Division to the New York Court of Appeals, the state's highest court. We have not recorded a receivable for any possible recoveries related to these assessments.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation, and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we distribute, source, manufacture, or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims, and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier, or other industry participants. Internal investigations, subpoenas, or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-381-2" continuedAt="f-381-3"><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation, and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net, in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, other pharmaceutical wholesalers, and other participants in the pharmaceutical supply chain have been named as defendants in lawsuits related to the distribution of opioid pain medications. These lawsuits seek equitable relief and monetary damages based on a variety of legal theories, including various common law claims, such as public nuisance, negligence, unjust enrichment, personal injury, as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act, and various other statutes. Plaintiffs in these lawsuits include governmental entities, as well as private parties, such as unions and other health and welfare funds, hospital systems and other healthcare providers, businesses, and individuals.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information, subpoenas, and other requests from other DOJ offices. These investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, as of September 30, 2024, we have $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-7" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="9" id="f-384">5.0</ix:nonFraction>&#160;billion accrued for these matters, of which $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="f-385">789</ix:nonFraction>&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During fiscal 2024, we recognized expense of $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" name="us-gaap:LitigationSettlementLoss" format="ixt:num-dot-decimal" scale="6" id="f-386">340</ix:nonFraction>&#160;million </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in connection with opioid-related matters, including agreements in principle with counsel representing classes of third-party payors and acute care hospitals, and settlements with the City of Baltimore and the State of Alabama. This expense was partially offset by a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="cah:IncomeAsAResultOfPrepayments" format="ixt:num-dot-decimal" scale="6" id="f-387">105</ix:nonFraction>&#160;million related to prepayments at a prenegotiated discount of certain future payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" sign="-" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-388">344</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of the agreements described below is an admission of liability or wrongdoing. Please see below for additional description of these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we along with two other national distributors (collectively, the "Distributors") entered into the National Opioid Settlement Agreement to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. In addition to the Distributors, parties to the National Opioid Settlement Agreement include <ix:nonFraction unitRef="states" contextRef="c-78" decimals="0" name="cah:SettlingStates" scale="0" id="f-389">48</ix:nonFraction> states, the District of Columbia and <ix:nonFraction unitRef="numberofusterritories" contextRef="c-78" decimals="0" name="cah:SettlingUSTerritories" scale="0" id="f-390">5</ix:nonFraction> U.S. territories. Over <ix:nonFraction unitRef="rate" contextRef="c-79" decimals="3" name="cah:PercentageSettlingSubdivisions" format="ixt:num-dot-decimal" scale="-2" id="f-391">99</ix:nonFraction> percent of political subdivisions in settling states (by population as calculated under the National Opioid Settlement Agreement) that had brought opioid-related suits against us have chosen to join the National Opioid Settlement Agreement or have had their claims addressed by state legislation (together with settling states and territories that joined the National Opioid Settlement Agreement, the "Settling Governmental Entities").</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal 2024, we recognized a $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:LitigationSettlementLoss" format="ixt:num-dot-decimal" scale="6" id="f-392">22</ix:nonFraction>&#160;million charge in litigation (recoveries)/charge, net in the condensed consolidated statements of earnings/(loss) related to an agreement with the Alabama Attorney General under which we agreed to pay approximately $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-393">123</ix:nonFraction>&#160;million to the State of Alabama over a period of ten years to resolve opioid-related claims brought by the State and its political subdivisions (the "Alabama Settlement"). Including the National Opioid Settlement Agreement, the Alabama Settlement and a prior settlement with the State of West Virginia, we have now resolved the opioid-related claims of all 50 states and the District of Columbia. Additionally, in August 2024, we entered into a settlement agreement with the City of Baltimore to resolve its opioid-related claims. Under this agreement, we agreed to pay $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-394">153</ix:nonFraction>&#160;million. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the National Opioid Settlement Agreement, through October 2024, we have paid the Settling Governmental Entities approximately $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="9" id="f-395">1.9</ix:nonFraction>&#160;billion. We expect to pay Settling Governmental Entities additional amounts up to $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="9" id="f-396">4.4</ix:nonFraction>&#160;billion </span></div></div></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-381-3" continuedAt="f-381-4"><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through 2038. The National Opioid Settlement Agreement also includes injunctive relief terms related to Distributors&#8217; controlled substance anti-diversion programs. A monitor is overseeing compliance with these provisions until 2027. In addition, the Distributors have engaged a third-party vendor to act as a clearinghouse for data aggregation and reporting, which Distributors will fund for 10 years. As a result of the National Opioid Settlement Agreement, the vast majority of lawsuits brought against us by political subdivisions have been dismissed. We continue to engage in resolution discussions with certain nonparticipating political subdivisions. We intend to defend ourselves vigorously against all remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Settlements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the National Opioid Settlement Agreement. In July 2022, a judgment in favor of the Distributors was entered in a bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington. Plaintiffs have appealed this decision to the Fourth Circuit Court of Appeals. In July 2022, we entered into separate agreements to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions and Native American Tribes for approximately $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-397">124</ix:nonFraction>&#160;million over 11-years and $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-398">136</ix:nonFraction>&#160;million over five years, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The National Opioid Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses, and individuals alleging personal injury. There were approximately <ix:nonFraction unitRef="lawsuit" contextRef="c-87" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="f-399">367</ix:nonFraction> lawsuits brought by private plaintiffs pending as of October 28, 2024. Of these, <ix:nonFraction unitRef="lawsuit" contextRef="c-88" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="f-400">98</ix:nonFraction> are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in all of these matters. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following resolution discussions with certain private plaintiffs, during the three months ended September 30, 2024, Distributors finalized agreements with classes of third-party payors and acute care hospitals to settle their claims for $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-401">213</ix:nonFraction>&#160;million. These agreements remain subject to certain contingencies, including court approval. Active litigation brought by hospital and third-party payor plaintiffs, including certain scheduled trials, has been stayed as to Distributors pending court approval of these settlements. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving <ix:nonFraction unitRef="plaintiff" contextRef="c-90" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="f-402">21</ix:nonFraction> plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. Following cross-appeals, in September 2024, The Georgia Supreme Court affirmed the defense verdict in full. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in ongoing legal proceedings with insurers related to their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. During fiscal 2024, we received $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-6" name="us-gaap:InsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="f-403">34</ix:nonFraction>&#160;million in insurance recoveries related to these matters and $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:InsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="f-404">9</ix:nonFraction>&#160;million in the three months ended </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024. We have not recorded a receivable for any additional recoveries related to these insurance litigation matters as of September 30, 2024. Certain recoveries from our insurers are recorded in the Pharmaceutical and Specialty Solutions segment. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Department of Justice Civil Investigative Demand</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we received a Civil Investigative Demand ("CID") from the Department of Justice focused on potential violations of the Anti-Kickback Statute and False Claims Act in connection with a 2022 transaction in which we purchased a minority ownership interest in a rheumatology managed services organization and a group purchasing organization. We are cooperating with this investigation.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by plaintiffs that allege personal injuries associated with the use of inferior vena cava ("IVC") filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve approximately <ix:nonFraction unitRef="lawsuit" contextRef="c-92" decimals="0" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt:num-dot-decimal" scale="0" id="f-405">4,375</ix:nonFraction> claims for $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-406">275</ix:nonFraction>&#160;million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we made settlement payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="6" id="f-407">275</ix:nonFraction>&#160;million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, while we have also entered into agreements to settle the vast majority of IVC filter product liability claims, these settlements will not resolve all of them, and we intend to continue to vigorously defend ourselves in the remaining lawsuits. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" sign="-" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-408">103</ix:nonFraction>&#160;million during fiscal year 2023, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At September 30, 2024, we had a total of $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-409">289</ix:nonFraction>&#160;million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets, which includes the $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="6" id="f-410">275</ix:nonFraction>&#160;million in the qualified settlement fund.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters condensed consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided </span></div></div></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="f-381-4"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anti-competitive pricing information to manufacturers, and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the amended complaint. We are vigorously defending ourselves in this matter, which remains pending as of September 30, 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation Proceeds</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="cah:IncomefromSettlementsofClassActionLawsuits" scale="6" id="f-411">43</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="cah:IncomefromSettlementsofClassActionLawsuits" scale="6" id="f-412">41</ix:nonFraction> million, which were recognized in litigation (recoveries)/charges, net, during the three months ended September 30, 2024 and 2023, respectively.</span></div></ix:continuation><div id="i088c97dfd3044fc38835caa8c41eddc8_106"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-413" continuedAt="f-413-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Income Taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of our pre-tax earnings/(loss) (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2024 and 2023, the effective tax rate was <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="f-414">23.0</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="f-415">75.1</ix:nonFraction> percent, respectively. The tax rate during the three months ended September 30, 2023 reflects the impact of the tax effects of the goodwill impairment charge recognized in the same quarter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, we recognized a $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-416">585</ix:nonFraction>&#160;million pre-tax charge for goodwill impairment related to the GMPD segment. The net tax benefit related to this charge is $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-417">45</ix:nonFraction>&#160;million for fiscal 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charge during the three months ended September 30, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to pre-tax loss for three months ended September 30, 2023 resulted in recognizing an incremental interim tax benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-418">102</ix:nonFraction>&#160;million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended September 30, 2023 and prepaid expenses and other assets in the condensed </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="f-413-1"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated balance sheets at September 30, 2023. This interim tax benefit reversed in the remainder of fiscal 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-419">952</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-420">981</ix:nonFraction> million of unrecognized tax benefits at September 30, 2024 and June&#160;30, 2024, respectively. The September 30, 2024 and June&#160;30, 2024 balances include $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-421">871</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="f-422">882</ix:nonFraction> million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2024 and June&#160;30, 2024, we had $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="f-423">69</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="f-424">65</ix:nonFraction> million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) from income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits, or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between <ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:fixed-zero" scale="6" id="f-425">zero</ix:nonFraction> and a net decrease of $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="f-426">20</ix:nonFraction> million, exclusive of penalties and interest.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years <ix:nonNumeric contextRef="c-101" name="us-gaap:OpenTaxYear" id="f-427">2015</ix:nonNumeric> through the current fiscal year.</span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_109"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="f-428" continuedAt="f-428-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Fair Value Measurements </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assets and Liabilities Measured on a Recurring Basis</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-429" continuedAt="f-429-1" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-430">678</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-431">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-432">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-433">678</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-434">105</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-435">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-436">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-437">105</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="f-438">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" sign="-" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="f-439">37</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="f-440">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" sign="-" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="f-441">37</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.989%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="f-429-1" continuedAt="f-429-2"><ix:continuation id="f-428-1" continuedAt="f-428-2"><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-442">1,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-445">1,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-446">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-449">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" sign="-" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="f-451">87</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="f-452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" sign="-" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="f-453">87</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="f-429-2"><ix:continuation id="f-428-2">(2)&#160;&#160;&#160;&#160; The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</ix:continuation></ix:continuation> </span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_112"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-454" continuedAt="f-454-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><ix:continuation id="f-454-1" continuedAt="f-454-2"><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency revenue and expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three months ended September&#160;30, 2024 and 2023, there were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="f-455">no</ix:nonFraction> gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2023 we entered into pay-floating interest rate swaps with total notional amounts of $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="f-456">100</ix:nonFraction> million. These swaps were designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency, and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive income/(loss) were $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="f-457">3</ix:nonFraction> million and immaterial for the three months ended September&#160;30, 2024 and 2023, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were a $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" scale="6" id="f-458">1</ix:nonFraction> million loss and a $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" scale="6" id="f-459">1</ix:nonFraction> million gain for the three months ended September&#160;30, 2024 and 2023, respectively. Losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="width:100.000%"><ix:continuation id="f-454-2" continuedAt="f-454-3"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reclassified into net earnings within the next 12 months are $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="6" id="f-460">3</ix:nonFraction>&#160;million. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we entered into &#165;<ix:nonFraction unitRef="jpy" contextRef="c-117" decimals="-6" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-461">18</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-462">120</ix:nonFraction>&#160;million) cross-currency swaps maturing in September 2025 and &#165;<ix:nonFraction unitRef="jpy" contextRef="c-118" decimals="-6" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-463">18</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-464">120</ix:nonFraction>&#160;million) cross-currency swaps maturing in June 2027. In June 2024, we terminated the &#165;<ix:nonFraction unitRef="jpy" contextRef="c-119" decimals="-6" name="cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-465">18</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-6" name="cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-466">120</ix:nonFraction>&#160;million) cross-currency swaps with a maturity date of June 2027.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we terminated the &#165;<ix:nonFraction unitRef="jpy" contextRef="c-120" decimals="-6" name="cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-467">38</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-468">300</ix:nonFraction>&#160;million) cross-currency swaps entered into in January 2023 and received a net settlement in cash of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-469">28</ix:nonFraction>&#160;million, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains and losses from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were a $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-470">22</ix:nonFraction>&#160;million loss and a $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-471">11</ix:nonFraction>&#160;million gain for the three months ended September&#160;30, 2024 and 2023, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="f-472">2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="f-473">3</ix:nonFraction>&#160;million during the three months ended September&#160;30, 2024 and 2023, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions, and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="f-474">1</ix:nonFraction>&#160;million loss and an immaterial gain during the three months ended September 30, 2024 and 2023, respectively. The principal currencies managed through foreign currency contracts are the </span></div></div></ix:continuation><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="f-454-3"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">euro, Chinese renminbi, Canadian dollar, Indian rupee, and Brazilian real.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2024 and June 30, 2024 approximate fair value due to their short-term maturities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="f-475" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="f-476">5,072</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="f-477">4,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-478">5,164</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-479">5,092</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div></ix:continuation><div id="i088c97dfd3044fc38835caa8c41eddc8_115"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-480" continuedAt="f-480-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Shareholders' Deficit </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2024, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-481">375</ix:nonFraction> million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="c-128" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-482">2.7</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-483">109.65</ix:nonFraction>. The program concluded on October 30, 2024 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-130" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-484">110.10</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="c-131" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-485">0.7</ix:nonFraction> million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-486">500</ix:nonFraction> million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="c-133" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-487">4.4</ix:nonFraction>&#160;million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-488">90.57</ix:nonFraction>. The program concluded on October 31, 2023 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-489">88.22</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="c-136" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-490">1.3</ix:nonFraction>&#160;million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-491" escape="true"><ix:continuation id="f-480-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2024</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-492">138</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-493">29</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-494">167</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-495">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-496">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-497">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-499">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-500">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to Cardinal Health, Inc., net of tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="f-501">5</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-502">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-503">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-504">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-505">133</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-506">22</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-507">155</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-508">137</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-509">14</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-510">151</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-511">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-512">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-513">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-515">2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-516">2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="f-517">3</ix:nonFraction> million</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-518">11</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-519">3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-520">14</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-521">148</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-522">17</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-523">165</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_118"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-524" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="f-525" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("EPS"):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-526">243</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-527">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-528">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="f-529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-530">245</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-531">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units, and performance share units that were excluded from the computation of diluted EPS were immaterial for the three months ended September 30, 2024 and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-532">2</ix:nonFraction> million for the three months ended September 30, 2023, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-6" name="cah:AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod" format="ixt:num-dot-decimal" scale="6" id="f-533">1</ix:nonFraction>&#160;million of which were anti-dilutive as a result of the net loss during the period.</span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i088c97dfd3044fc38835caa8c41eddc8_121"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-534" continuedAt="f-534-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Segment Information </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-535">two</ix:nonFraction> reportable segments: Pharma segment and GMPD segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, which are sold in the United States, Canada, Europe, Asia, and other markets. In addition to distributing Cardinal Health brand products, this segment also distributes a broad range of medical, surgical, and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers in the United States and Canada.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining <ix:nonFraction unitRef="segments" contextRef="c-55" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="f-536">three</ix:nonFraction> non-reportable operating segments included in Other are Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics. These operating segments respectively operate nuclear pharmacies and radiopharmaceutical manufacturing facilities, distribute medical products to patients' homes in the United States, and provide supply chain services and solutions to our customers.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="f-534-1"><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-537" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for the two reportable segments and disaggregated revenue within the remaining operating segments, included in Other, and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-538">47,990</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-539">50,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-540">3,123</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-541">3,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-542">373</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-543">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">at-Home Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-544">739</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-545">667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Logistics</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-546">74</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-547">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-548">1,186</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-549">1,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-550">52,299</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-551">54,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="f-552">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="f-553">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-554">52,277</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-555">54,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-556" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-557">51,891</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-558">54,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-559">408</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-560">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-561">52,299</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-562">54,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="f-563">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="f-564">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-565">52,277</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-566">54,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate technology and shared functions expenses, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided, and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shareholder cooperation agreement costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets, net; we recognized a pre-tax goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-567">585</ix:nonFraction>&#160;million during the three months ended September 30, 2023; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for/(benefit from) income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending and certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="f-568">12</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="f-569">6</ix:nonFraction>&#160;million for the three months ended September 30, 2024 and 2023, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-570" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-571">530</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-572">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-573">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-574">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-575">104</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-576">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-577">642</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-578">564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-579">74</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-580">596</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-581">568</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-582">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160; Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Logistics.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Segment Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="f-583" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for two reportable segments and the remaining operating segments, included in Other, and Corporate: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-584">29,215</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-585">29,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-586">7,148</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-587">7,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-588">2,611</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-589">2,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-590">4,085</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-591">6,319</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-592">43,059</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-593">45,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><span><br/></span></div></div></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:24.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.989%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-594" escape="true"><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">14. Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors, and employees. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-595" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-596">19</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-597">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-598">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-599">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-600">30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-601">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-602"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-603">4</ix:nonFraction></ix:nonFraction>&#160;million for both the three months ended September&#160;30, 2024 and 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="c-183" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-604">three years</ix:nonNumeric>. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-605" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-187" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-606">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-187" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-607">70.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-183" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="f-608">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-183" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-609">107.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-183" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="f-610">0.8</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-183" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-611">72.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-183" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="6" id="f-612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-183" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-188" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-614">1.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-188" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-615">90.60</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2024, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-616">110</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-183" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-617">two years</ix:nonNumeric>.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a <ix:nonFraction unitRef="reportable_segments" contextRef="c-185" decimals="0" name="cah:VestingPeriodinyearsforShares" format="ixt-sec:numwordsen" scale="0" id="f-618">three</ix:nonFraction>-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved and our total shareholder return relative to the S&amp;P 500 Health Care Index, vested shares may range from <ix:nonFraction unitRef="number" contextRef="c-189" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="f-619"><ix:nonFraction unitRef="number" contextRef="c-190" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="f-620">zero</ix:nonFraction></ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-191" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="f-621"><ix:nonFraction unitRef="number" contextRef="c-192" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="f-622">240</ix:nonFraction></ix:nonFraction> percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="f-623" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-193" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-624">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-625">97.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-185" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="f-626">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-627">113.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-185" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="f-628">0.3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-629">108.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-185" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="6" id="f-630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-194" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-632">1.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-194" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-633">98.81</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2024, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-634">63</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-185" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-635">two years</ix:nonNumeric> if the performance goals are achieved.</span></div></div></div></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.857%"><tr><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/721371/000119312508230011/dex31.htm">Amended and Restated Articles of Incorporation of Cardinal Health, Inc., as amended (incorporated by reference to Exhibit 3.1 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137123000027/exhibit32-restatedcodeofre.htm">Cardinal Health, Inc. Restated Code of Regulations (incorporated by reference to Exhibit 3.1 to Cardinal Health's Current  Report on Form 8-K filed on May 11, 2023, File No. 1-11373</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000721371/000072137124000112/cardinalhealth-creditagree.htm">364-Day Credit Agreement, dated October 8, 2024 (incorporated by reference to Exhibit 10.1 to Cardinal Health&#8217;s Current Report on Form 8-K filed on October </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000721371/000072137124000112/cardinalhealth-creditagree.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000721371/000072137124000112/cardinalhealth-creditagree.htm">, 2024, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000721371/000072137124000112/fourthamendmenttoipaa.htm">Fourth Amendment to Issuing and Paying Agency Agreement, dated October 8, 2024 (incorporated by reference to Exhibit 10.2 to Cardinal Health&#8217;s Current Report on Form 8-K filed on October </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000721371/000072137124000112/fourthamendmenttoipaa.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000721371/000072137124000112/fourthamendmenttoipaa.htm">, 2024, File No. 1-11373)</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> *</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a25q1_10qx093024xexhibit311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a25q1_10qx093024xexhibit312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a25q1_10qx093024xexhibit321.htm">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a25q1_10qx093024xexhibit991.htm">Statement Regarding Forward-Looking Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)</span></td></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%">*Certain provisions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Cardinal Health Website</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health&#160;uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases,&#160;SEC filings, and certain other information on its website.</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"/><td style="width:27.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.306%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-Q Cross Reference Index</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form 10-Q Cross Reference Index</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"/><td style="width:6.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I. Financial Information</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_64">Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_64">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_40">Quantitative and Qualitative Disclosures about Market Risk </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_40">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_43">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_43">18</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II. Other Information</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_46">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_46">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_49">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_49">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_52">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_52">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_55">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_55">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_127">38</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i088c97dfd3044fc38835caa8c41eddc8_133">40</a></span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:3.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i088c97dfd3044fc38835caa8c41eddc8_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.075%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Information</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.005%"><tr><td style="width:1.0%"/><td style="width:4.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JASON M. HOLLAR</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jason M. Hollar</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ AARON E. ALT</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aaron E. Alt</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a25q1_10qx093024xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i972577f4718e4324b623db67f693860a_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.1</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jason M. Hollar, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;1, 2024 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:470.25pt"><tr><td style="width:1.0pt"></td><td style="width:147.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:319.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a25q1_10qx093024xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ifcf98e6145cc4eb0b9c07b2d812ff590_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.2</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Aaron E. Alt, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;1, 2024 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:136.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:372.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; AARON E. ALT</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aaron E. Alt</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a25q1_10qx093024xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i31f58e87579b4c5b8a5e84a08fe0e408_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></td></tr></table></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jason M. Hollar, Chief Executive Officer of Cardinal Health, Inc. (the &#8220;Company&#8221;) and Aaron E. Alt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the Periodic Report on Form 10-Q for the quarter ended September 30, 2024 containing the financial statements of the Company (the &#8220;Periodic Report&#8221;), which this statement accompanies, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; November&#160;1, 2024 </font></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; AARON E. ALT</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aaron E. Alt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>a25q1_10qx093024xexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i37523642815c40c78fe33e7bb3ef082f_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Statement Regarding Forward-Looking Information </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this exhibit, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2024 (the &#8220;2024 Form 10-K&#8221;), and our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">competitive pressures in the markets in which we operate, including pricing pressures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the pricing of and demand for generic pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significantly increased costs for commodities and other materials used in the Global Medical Products and Distribution segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities and the possibility that we may not successfully offset or mitigate these increases&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other components of our pharmaceutical generics program&#59;  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in the timing or frequency of the introduction of branded pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the nonrenewal of a large Pharmaceutical and Specialty Solutions segment customer at the end of fiscal year 2024, including the adverse impact of unwinding the negative net working capital associated with this customer and the risk that we may not be successful in mitigating the negative impact to segment profit&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">costs or claims resulting from quality issues, or other potential or alleged errors or defects in our manufacturing or sourcing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including the investigations by the U.S. Department of Justice which concerns our anti-diversion program, our anti-diversion policies and procedures and our distribution of certain controlled substances&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the national opioid settlement agreement, including the risk that the maintenance of the required changes to distributors' controlled substance anti-diversion programs may result in unforeseen costs or operational challenges and the risk that if we fail to or are alleged to have failed to comply with the terms of the settlement agreement, we could incur monetary or other penalties or result in additional lawsuits being filed against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties related to Cardinal Health Brand products, including our ability to manage cost and infrastructure, retain margin, increase volume and improve performance&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from acquisitions, including possible liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the tax benefit from our self-insurance loss claims, including, certain state courts' interpretation of laws and insurance policies in ways that may impact our self-insurance loss, which could negatively impact our financial position&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services, including the risk that failure to comply with the requirements set forth therein could result in monetary or other penalties&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our high sales concentration with certain key customers, including CVS Health Corporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to certain business process initiatives, including IT infrastructure activities and outsourcing relationships, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce ethylene oxide (&#34;EtO&#34;) emissions, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with industry reliance on EtO to sterilize certain medical products that we manufacture or distribute, including the possibility that regulatory actions to reduce EtO emissions could become more widespread, which may result in increased costs or supply shortages&#59; and risks that the lawsuits against us alleging personal injury resulting from EtO exposure could become more widespread&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of healthcare fraud and abuse laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from pharmaceutical manufacturers' restriction of sales under the 340B drug pricing program to contract pharmacies, which may adversely impact our customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties arising as a result of the Supreme Court decision on Dobbs vs. Jackson, including uncertainties associated with states' proposed and adopted laws which may impact our ability to distribute or store certain pharmaceutical products and the risk that we could incur unforeseen costs to comply with these new laws in various jurisdictions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in hospital buying groups or hospital buying practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks to our business and information and controls systems in the event that business process improvements, infrastructure modernization or initiatives to use third-party service providers for key systems and processes are not effectively implemented&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the risk that we may not effectively implement and maintain data governance structures across businesses to allow us to access and interpret our data, which could put us at a competitive disadvantage relative to our peers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, government investigations, shareholder lawsuits or other legal proceedings&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility that our business performance or internal control over financial reporting may be adversely impacted if we are not successful at attracting, retaining and developing talent&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the importation of products or source materials used in products that we manufacture or distribute, including risks associated with our country-of-origin determinations and the possibility that we could experience additional supply disruptions as a result of the Uyghur Forced Labor Prevention Act or other similar regulations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain adequate intellectual property protections&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to introduce and market new products and our ability to keep pace with advances in technology&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significant charges to earnings if goodwill or intangible assets become impaired&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to general political, business, industry, regulatory and market conditions&#59; and </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other factors described in the &#8220;Risk Factors&#8221; section of the 2024 Form 10-K.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; and similar expressions generally identify &#8220;forward-looking statements,&#8221; which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cah-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:537b797f-b836-409a-bf04-ad11625945c4,g:bd28f3d8-0395-4523-ae63-79ccc2df931a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cah="http://www.cardinal.com/20240930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardinal.com/20240930">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardinal.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarnings" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings">
        <link:definition>9952151 - Statement - Condensed Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952153 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofShareholdersEquity" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity">
        <link:definition>9952154 - Statement - Condensed Consolidated Statement of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>9952156 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.cardinal.com/role/Acquisitions">
        <link:definition>9952157 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestitures" roleURI="http://www.cardinal.com/role/Divestitures">
        <link:definition>9952158 - Disclosure - Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeverance" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance">
        <link:definition>9952159 - Disclosure - Restructuring and Employee Severance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>9952160 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowings" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings">
        <link:definition>9952161 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigation" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation">
        <link:definition>9952162 - Disclosure - Commitments, Contingent Liabilities and Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cardinal.com/role/IncomeTaxes">
        <link:definition>9952163 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardinal.com/role/FairValueMeasurements">
        <link:definition>9952164 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.cardinal.com/role/FinancialInstruments">
        <link:definition>9952165 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cardinal.com/role/ShareholdersEquity">
        <link:definition>9952166 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthInc" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc">
        <link:definition>9952167 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.cardinal.com/role/SegmentInformation">
        <link:definition>9952168 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.cardinal.com/role/ShareBasedCompensation">
        <link:definition>9952169 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.cardinal.com/role/AcquisitionsTables">
        <link:definition>9954472 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresTables" roleURI="http://www.cardinal.com/role/DivestituresTables">
        <link:definition>9954473 - Disclosure - Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceTables" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables">
        <link:definition>9954474 - Disclosure - Restructuring and Employee Severance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>9954475 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables">
        <link:definition>9954476 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables">
        <link:definition>9954477 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.cardinal.com/role/ShareholdersEquityTables">
        <link:definition>9954478 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncTables" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables">
        <link:definition>9954479 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.cardinal.com/role/SegmentInformationTables">
        <link:definition>9954480 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables">
        <link:definition>9954481 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954482 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDetails" roleURI="http://www.cardinal.com/role/AcquisitionsDetails">
        <link:definition>9954483 - Disclosure - Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDetails" roleURI="http://www.cardinal.com/role/DivestituresDetails">
        <link:definition>9954484 - Disclosure - Divestitures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails">
        <link:definition>9954485 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
        <link:definition>9954486 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceNarrativeDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails">
        <link:definition>9954487 - Disclosure - Restructuring and Employee Severance Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
        <link:definition>9954488 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>9954489 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails">
        <link:definition>9954490 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails">
        <link:definition>9954491 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails">
        <link:definition>9954492 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954493 - Disclosure - Income Taxes Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9954494 - Disclosure - Fair Value Measurements Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>9954495 - Disclosure - Financial Instruments Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
        <link:definition>9954496 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>9954497 - Disclosure - Shareholders' Equity Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>9954498 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails">
        <link:definition>9954499 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails">
        <link:definition>9954500 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails">
        <link:definition>9954501 - Disclosure - Segment Information Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails">
        <link:definition>9954502 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyGeographicalSegmentsDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails">
        <link:definition>9954503 - Disclosure - Segment Information Revenue by Geographical Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentProfitbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails">
        <link:definition>9954504 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAssetsbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails">
        <link:definition>9954505 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>9954506 - Disclosure - Share-Based Compensation Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
        <link:definition>9954507 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
        <link:definition>9954508 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
        <link:definition>9954509 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cah_Amortizationandotheracquisitionrelatedcosts" abstract="false" name="Amortizationandotheracquisitionrelatedcosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_Netproceedstaxwithholdingsfromsharebasedcompensation" abstract="false" name="Netproceedstaxwithholdingsfromsharebasedcompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" abstract="true" name="BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_OptumRxMember" abstract="true" name="OptumRxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PharmaceuticalAndSpecialtySolutionsMember" abstract="true" name="PharmaceuticalAndSpecialtySolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_IntegratedOncologyNetworkMember" abstract="true" name="IntegratedOncologyNetworkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SpecialtyNetworksMember" abstract="true" name="SpecialtyNetworksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OutcomesDivestitureAxis" abstract="true" name="OutcomesDivestitureAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_OutcomesDivestitureDomain" abstract="true" name="OutcomesDivestitureDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OutcomesDivestitureMember" abstract="true" name="OutcomesDivestitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TransactionDataSystemInvestmentMember" abstract="true" name="TransactionDataSystemInvestmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_FacilityExitAndOtherCosts" abstract="false" name="FacilityExitAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_GMPDMember" abstract="true" name="GMPDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_IPRDTrademarksandOtherMember" abstract="true" name="IPRDTrademarksandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_TrademarksAndPatentsMember" abstract="true" name="TrademarksAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_ShortTermCreditFacilitiesMember" abstract="true" name="ShortTermCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_CommittedReceivablesSalesFacilityProgramMember" abstract="true" name="CommittedReceivablesSalesFacilityProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_CVSHealthMember" abstract="true" name="CVSHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_OpioidLawsuitsMember" abstract="true" name="OpioidLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_ClassActionLawsuitsMember" abstract="true" name="ClassActionLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_ProductLiabilityLawsuitsMember" abstract="true" name="ProductLiabilityLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_NewYorkOpioidStewardshipActMember" abstract="true" name="NewYorkOpioidStewardshipActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_OpioidLitigationAxis" abstract="true" name="OpioidLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_OpioidLitigationDomain" abstract="true" name="OpioidLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_TotalOpioidLitigationMember" abstract="true" name="TotalOpioidLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_LawsuitTypeAxis" abstract="true" name="LawsuitTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_LitigationTypeDomain" abstract="true" name="LitigationTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_PlaintiffTypeAxis" abstract="true" name="PlaintiffTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_PlaintiffTypeDomain" abstract="true" name="PlaintiffTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_PrivatePartiesMember" abstract="true" name="PrivatePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_CityOfBaltimoreMember" abstract="true" name="CityOfBaltimoreMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_AgreementsAxis" abstract="true" name="AgreementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_AgreementsDomain" abstract="true" name="AgreementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_IVCApril2023AgreementMember" abstract="true" name="IVCApril2023AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_AggregateAnnualAssessment" abstract="false" name="AggregateAnnualAssessment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_IncomeAsAResultOfPrepayments" abstract="false" name="IncomeAsAResultOfPrepayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_SettlingStates" abstract="false" name="SettlingStates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_SettlingUSTerritories" abstract="false" name="SettlingUSTerritories" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_PercentageSettlingSubdivisions" abstract="false" name="PercentageSettlingSubdivisions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cah_LossContingencyLawsuitsNumber" abstract="false" name="LossContingencyLawsuitsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_IncomefromSettlementsofClassActionLawsuits" abstract="false" name="IncomefromSettlementsofClassActionLawsuits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TaxMatterAxis" abstract="true" name="TaxMatterAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_TaxMatterDomain" abstract="true" name="TaxMatterDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_GoodwillImpairmentAxis" abstract="true" name="GoodwillImpairmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_GoodwillImpairmentDomain" abstract="true" name="GoodwillImpairmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_FY24Q1GoodwillImpairmentGMPDMember" abstract="true" name="FY24Q1GoodwillImpairmentGMPDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_MaturityDateAxis" abstract="true" name="MaturityDateAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_MaturityDateDomain" abstract="true" name="MaturityDateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_September2025Member" abstract="true" name="September2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_June2027Member" abstract="true" name="June2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_DateInitiatedAxis" abstract="true" name="DateInitiatedAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_DateInitiatedDomain" abstract="true" name="DateInitiatedDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_January2023Member" abstract="true" name="January2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" abstract="false" name="DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CarryingAmountofLongTermandotherShortTermBorrowings" abstract="false" name="CarryingAmountofLongTermandotherShortTermBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" abstract="true" name="ShareRepurchaseProgramAggregatePurchasePriceAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" abstract="true" name="ShareRepurchaseProgramAggregatePurchasePriceDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_A500MillionShareRepurchaseProgramMember" abstract="true" name="A500MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cah_A375MillionShareRepurchaseProgramMember" abstract="true" name="A375MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod" abstract="false" name="AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_ProjectCostsOnInvestmentAndOtherSpending" abstract="false" name="ProjectCostsOnInvestmentAndOtherSpending" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_NuclearAndPrecisionHealthSolutionsMember" abstract="true" name="NuclearAndPrecisionHealthSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_AtHomeSolutionsMember" abstract="true" name="AtHomeSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OptiFreightMember" abstract="true" name="OptiFreightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SegmentRevenuebyGeographicTable" abstract="true" name="SegmentRevenuebyGeographicTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_SegmentRevenuebyGeographicLineItems" abstract="true" name="SegmentRevenuebyGeographicLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_VestingPeriodinyearsforShares" abstract="false" name="VestingPeriodinyearsforShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cah-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:537b797f-b836-409a-bf04-ad11625945c4,g:bd28f3d8-0395-4523-ae63-79ccc2df931a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20240930.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_c47be5c1-8d22-468c-bb48-80e53849fff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0e5af95d-ee55-4c73-8345-0fc535a84ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c47be5c1-8d22-468c-bb48-80e53849fff1" xlink:to="loc_us-gaap_Revenues_0e5af95d-ee55-4c73-8345-0fc535a84ee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e05b59cb-d908-4a39-852b-a21fefdb8414" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c47be5c1-8d22-468c-bb48-80e53849fff1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e05b59cb-d908-4a39-852b-a21fefdb8414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_61cbdbf9-5d20-4bf9-bc0e-b711bdb90077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12509ef6-7a6d-4e75-81c0-7c20a7b17322" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_61cbdbf9-5d20-4bf9-bc0e-b711bdb90077" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12509ef6-7a6d-4e75-81c0-7c20a7b17322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0d72aeb4-858c-4eaa-90c9-e7cba93388c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_61cbdbf9-5d20-4bf9-bc0e-b711bdb90077" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0d72aeb4-858c-4eaa-90c9-e7cba93388c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b04df7b3-f1ab-4041-89fb-b8b738fe609c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a99dc451-5ad4-45be-a284-5b1d7d570249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b04df7b3-f1ab-4041-89fb-b8b738fe609c" xlink:to="loc_us-gaap_ProfitLoss_a99dc451-5ad4-45be-a284-5b1d7d570249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d1effec9-8560-4f73-9b48-4e483d3883af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b04df7b3-f1ab-4041-89fb-b8b738fe609c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d1effec9-8560-4f73-9b48-4e483d3883af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_803fe8dc-0058-4f09-ba49-ca16b67bdb96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ca6ce27a-b941-4af1-aa89-b7cd95621eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_803fe8dc-0058-4f09-ba49-ca16b67bdb96" xlink:to="loc_us-gaap_GrossProfit_ca6ce27a-b941-4af1-aa89-b7cd95621eb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b577c1d7-73a9-40d3-8871-8abc3b221d45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_803fe8dc-0058-4f09-ba49-ca16b67bdb96" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b577c1d7-73a9-40d3-8871-8abc3b221d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_6eb86eab-a8b2-486e-9c9b-f9c7deed52e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_803fe8dc-0058-4f09-ba49-ca16b67bdb96" xlink:to="loc_us-gaap_RestructuringCharges_6eb86eab-a8b2-486e-9c9b-f9c7deed52e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_75a6d08c-24a9-4629-aee3-d0a6fdca5c02" xlink:href="cah-20240930.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_803fe8dc-0058-4f09-ba49-ca16b67bdb96" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_75a6d08c-24a9-4629-aee3-d0a6fdca5c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_471d0623-1e30-4261-b115-7485ad1227bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_803fe8dc-0058-4f09-ba49-ca16b67bdb96" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_471d0623-1e30-4261-b115-7485ad1227bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_49f04684-45c7-4996-8398-9f2cded614c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_803fe8dc-0058-4f09-ba49-ca16b67bdb96" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_49f04684-45c7-4996-8398-9f2cded614c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8a82460-8187-40be-889f-d3072e9702e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4490c85c-2fc2-4b27-8961-e4478c91a06d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8a82460-8187-40be-889f-d3072e9702e5" xlink:to="loc_us-gaap_OperatingIncomeLoss_4490c85c-2fc2-4b27-8961-e4478c91a06d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c81c74a8-ee8e-4dfb-9f85-fc9ddb15f199" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8a82460-8187-40be-889f-d3072e9702e5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c81c74a8-ee8e-4dfb-9f85-fc9ddb15f199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3d445d6a-57da-4b47-bc0e-62eabb702f65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8a82460-8187-40be-889f-d3072e9702e5" xlink:to="loc_us-gaap_InterestExpense_3d445d6a-57da-4b47-bc0e-62eabb702f65" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20240930.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5797a018-8f5d-40c4-a5c0-729eee48304c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ee28de61-82ca-4e85-907b-efef9c89813f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5797a018-8f5d-40c4-a5c0-729eee48304c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ee28de61-82ca-4e85-907b-efef9c89813f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cc0fbf1c-11dc-4add-a6b2-778b07cfa2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5797a018-8f5d-40c4-a5c0-729eee48304c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cc0fbf1c-11dc-4add-a6b2-778b07cfa2fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_55f9b2ef-0d1b-4dca-9309-ae3f3c3f2763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0dd878d5-8dc2-4787-8759-6f6848133488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_55f9b2ef-0d1b-4dca-9309-ae3f3c3f2763" xlink:to="loc_us-gaap_ProfitLoss_0dd878d5-8dc2-4787-8759-6f6848133488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2c0df5aa-3542-4e3a-805f-7bce1e359a54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_55f9b2ef-0d1b-4dca-9309-ae3f3c3f2763" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2c0df5aa-3542-4e3a-805f-7bce1e359a54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6fdd43bc-f8df-4c09-ac19-cdfddd260f60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a76c5713-6270-453e-aef7-a87ba14295d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6fdd43bc-f8df-4c09-ac19-cdfddd260f60" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a76c5713-6270-453e-aef7-a87ba14295d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_33dfdbb2-78a2-44ea-9d07-d6ea1f027cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6fdd43bc-f8df-4c09-ac19-cdfddd260f60" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_33dfdbb2-78a2-44ea-9d07-d6ea1f027cdf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20240930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_49d4fb73-d210-467f-b9de-bc98f1f994d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a97dfcee-72b3-4f56-9d84-8140eea1fb50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_49d4fb73-d210-467f-b9de-bc98f1f994d6" xlink:to="loc_us-gaap_AccountsPayableCurrent_a97dfcee-72b3-4f56-9d84-8140eea1fb50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6b1e0f11-a55f-4d88-9781-94513ca6db43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_49d4fb73-d210-467f-b9de-bc98f1f994d6" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6b1e0f11-a55f-4d88-9781-94513ca6db43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d27ce419-a5fd-4a8c-9045-0675000bee63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_49d4fb73-d210-467f-b9de-bc98f1f994d6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d27ce419-a5fd-4a8c-9045-0675000bee63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5bb1a0f0-4ffd-4bce-b10f-e517a11f1514" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_274d3215-a704-4395-87a8-0f7154b59094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bb1a0f0-4ffd-4bce-b10f-e517a11f1514" xlink:to="loc_us-gaap_AssetsCurrent_274d3215-a704-4395-87a8-0f7154b59094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_af565b05-c885-40bf-9d02-093d0960d075" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bb1a0f0-4ffd-4bce-b10f-e517a11f1514" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_af565b05-c885-40bf-9d02-093d0960d075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_fbae69f5-68c7-4e5c-9503-f44a9b1bf500" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bb1a0f0-4ffd-4bce-b10f-e517a11f1514" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_fbae69f5-68c7-4e5c-9503-f44a9b1bf500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_447c0ee9-8740-4ff2-81d7-9a7150f2aa71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bb1a0f0-4ffd-4bce-b10f-e517a11f1514" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_447c0ee9-8740-4ff2-81d7-9a7150f2aa71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c11b22c8-59d6-4cd6-95d0-90f2e3cd3709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_308b51e6-600a-46d3-9056-a77ec2f2136a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c11b22c8-59d6-4cd6-95d0-90f2e3cd3709" xlink:to="loc_us-gaap_PreferredStockValue_308b51e6-600a-46d3-9056-a77ec2f2136a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_66b38576-a3e4-45a5-a080-08c2a5bd9395" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c11b22c8-59d6-4cd6-95d0-90f2e3cd3709" xlink:to="loc_us-gaap_CommonStockValue_66b38576-a3e4-45a5-a080-08c2a5bd9395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a572c66-2089-4cda-8422-4396fbe16307" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c11b22c8-59d6-4cd6-95d0-90f2e3cd3709" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a572c66-2089-4cda-8422-4396fbe16307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_fd1b3954-8246-4cdf-8c35-091698f80f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c11b22c8-59d6-4cd6-95d0-90f2e3cd3709" xlink:to="loc_us-gaap_TreasuryStockValue_fd1b3954-8246-4cdf-8c35-091698f80f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6a36cf63-2213-4bf5-aa55-f2d3007282e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c11b22c8-59d6-4cd6-95d0-90f2e3cd3709" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6a36cf63-2213-4bf5-aa55-f2d3007282e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_756e693f-620d-4c9f-a579-44ccd6b9569b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5d55a4cf-1b59-4cc7-a928-9821b4a80477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_756e693f-620d-4c9f-a579-44ccd6b9569b" xlink:to="loc_us-gaap_LiabilitiesCurrent_5d55a4cf-1b59-4cc7-a928-9821b4a80477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f5afd82c-4ecd-454c-9839-a0a7e6a77c88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_756e693f-620d-4c9f-a579-44ccd6b9569b" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f5afd82c-4ecd-454c-9839-a0a7e6a77c88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_e95c591b-2bf5-4eb7-aa90-93307eef0151" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_756e693f-620d-4c9f-a579-44ccd6b9569b" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_e95c591b-2bf5-4eb7-aa90-93307eef0151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58b1981a-8624-4491-8ed5-8d0db1af77c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_756e693f-620d-4c9f-a579-44ccd6b9569b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58b1981a-8624-4491-8ed5-8d0db1af77c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_086ebb6b-f871-4590-a32b-a091b1a252ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_cd60adcc-23f1-452f-8612-559d0b2ff0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_086ebb6b-f871-4590-a32b-a091b1a252ee" xlink:to="loc_us-gaap_ReceivablesNetCurrent_cd60adcc-23f1-452f-8612-559d0b2ff0e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c03cd2e8-d74a-499d-a88f-f646d6521aad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_086ebb6b-f871-4590-a32b-a091b1a252ee" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c03cd2e8-d74a-499d-a88f-f646d6521aad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_604942f5-9413-4ec8-8bc6-3be0c6472611" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_086ebb6b-f871-4590-a32b-a091b1a252ee" xlink:to="loc_us-gaap_OtherAssetsCurrent_604942f5-9413-4ec8-8bc6-3be0c6472611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_de6c6e88-c277-45fa-8331-56053687ad57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_086ebb6b-f871-4590-a32b-a091b1a252ee" xlink:to="loc_us-gaap_InventoryNet_de6c6e88-c277-45fa-8331-56053687ad57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c1847820-8e0c-4d76-a982-b578bea1850d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_086ebb6b-f871-4590-a32b-a091b1a252ee" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c1847820-8e0c-4d76-a982-b578bea1850d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0bf15b83-957a-4012-a936-1795fdcc8613" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b4b4ac6a-4b67-4cdc-b084-e72883f7f58d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0bf15b83-957a-4012-a936-1795fdcc8613" xlink:to="loc_us-gaap_StockholdersEquity_b4b4ac6a-4b67-4cdc-b084-e72883f7f58d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e468ae66-1e57-48d5-bba7-7b3f3f2ab9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0bf15b83-957a-4012-a936-1795fdcc8613" xlink:to="loc_us-gaap_MinorityInterest_e468ae66-1e57-48d5-bba7-7b3f3f2ab9f7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20240930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c296e96-7013-4c33-82d7-6163be0a8c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c99eadac-0dac-4909-98a8-a8080884f46f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c296e96-7013-4c33-82d7-6163be0a8c2f" xlink:to="loc_us-gaap_ProfitLoss_c99eadac-0dac-4909-98a8-a8080884f46f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_024133eb-b1ef-4281-8a96-e10de2ea1978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c296e96-7013-4c33-82d7-6163be0a8c2f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_024133eb-b1ef-4281-8a96-e10de2ea1978" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_9abb96b6-f7bf-4a52-933a-5be483078b36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c296e96-7013-4c33-82d7-6163be0a8c2f" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_9abb96b6-f7bf-4a52-933a-5be483078b36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_70ccdad6-7e61-47f0-8da7-9110d06bdbca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c296e96-7013-4c33-82d7-6163be0a8c2f" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_70ccdad6-7e61-47f0-8da7-9110d06bdbca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_99945619-e367-4052-abb0-e030010c35b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c296e96-7013-4c33-82d7-6163be0a8c2f" xlink:to="loc_us-gaap_ShareBasedCompensation_99945619-e367-4052-abb0-e030010c35b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_6ea28840-5314-4d54-8db0-c4cbda037bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c296e96-7013-4c33-82d7-6163be0a8c2f" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_6ea28840-5314-4d54-8db0-c4cbda037bf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_8a8e6153-af7b-4a55-beeb-84e6bfac8200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c296e96-7013-4c33-82d7-6163be0a8c2f" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_8a8e6153-af7b-4a55-beeb-84e6bfac8200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2388b96b-a7d5-4d66-8bd8-e54041f9ce17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c296e96-7013-4c33-82d7-6163be0a8c2f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2388b96b-a7d5-4d66-8bd8-e54041f9ce17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4c849c74-5e69-4b2b-a2fa-47a3c7dc1d45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c296e96-7013-4c33-82d7-6163be0a8c2f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4c849c74-5e69-4b2b-a2fa-47a3c7dc1d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5fec9db5-f0d9-4252-939d-bff34a42d00e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c296e96-7013-4c33-82d7-6163be0a8c2f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5fec9db5-f0d9-4252-939d-bff34a42d00e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c3dff9f-46bc-46e2-bdb3-d04c65b62a40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_09f32c9e-bb32-4a30-96ad-0d51205ccecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c3dff9f-46bc-46e2-bdb3-d04c65b62a40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_09f32c9e-bb32-4a30-96ad-0d51205ccecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e2ab56b-a716-4d44-8be5-0eef0bd545a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c3dff9f-46bc-46e2-bdb3-d04c65b62a40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e2ab56b-a716-4d44-8be5-0eef0bd545a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ae67191-d398-4416-880e-0e6e05213a49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c3dff9f-46bc-46e2-bdb3-d04c65b62a40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ae67191-d398-4416-880e-0e6e05213a49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e634d52-fcb0-4bd8-81d9-62beaca54956" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c3dff9f-46bc-46e2-bdb3-d04c65b62a40" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e634d52-fcb0-4bd8-81d9-62beaca54956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdb571a7-5959-4918-8b46-d172cf3f9e25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c64a3aa5-bc0a-4bba-945d-38e9f553f8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdb571a7-5959-4918-8b46-d172cf3f9e25" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c64a3aa5-bc0a-4bba-945d-38e9f553f8b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_167e88a3-227b-4578-89a9-743e066b962e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdb571a7-5959-4918-8b46-d172cf3f9e25" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_167e88a3-227b-4578-89a9-743e066b962e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_dc5a5a81-3a8d-4436-a0e3-fa5ed603fa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdb571a7-5959-4918-8b46-d172cf3f9e25" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_dc5a5a81-3a8d-4436-a0e3-fa5ed603fa0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_f05aceeb-4e1a-4cea-8154-ce0b654071c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdb571a7-5959-4918-8b46-d172cf3f9e25" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_f05aceeb-4e1a-4cea-8154-ce0b654071c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0871246-c050-4b83-b51c-2c5ef414ff47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3eb56cbf-fe61-496f-8099-4a4699e5252e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0871246-c050-4b83-b51c-2c5ef414ff47" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3eb56cbf-fe61-496f-8099-4a4699e5252e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_adb34821-f305-408a-ae53-d3238a1c28e7" xlink:href="cah-20240930.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0871246-c050-4b83-b51c-2c5ef414ff47" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_adb34821-f305-408a-ae53-d3238a1c28e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_b1e3bec7-3077-4859-8303-87287b4907c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0871246-c050-4b83-b51c-2c5ef414ff47" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_b1e3bec7-3077-4859-8303-87287b4907c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7c308863-52aa-4a95-adf8-e54ed99cf2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0871246-c050-4b83-b51c-2c5ef414ff47" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7c308863-52aa-4a95-adf8-e54ed99cf2f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b25877c9-32e2-46ea-b8ec-52e24fe333c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_af4eb1e6-1b37-492b-850e-077c71522091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_b25877c9-32e2-46ea-b8ec-52e24fe333c1" xlink:to="loc_us-gaap_SeveranceCosts1_af4eb1e6-1b37-492b-850e-077c71522091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_f06e3846-6c96-4531-94f8-472972cb34fa" xlink:href="cah-20240930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_b25877c9-32e2-46ea-b8ec-52e24fe333c1" xlink:to="loc_cah_FacilityExitAndOtherCosts_f06e3846-6c96-4531-94f8-472972cb34fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76549522-3e09-4755-92c3-fb3e4715bbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_11b7212c-25da-4ca5-b20b-7a1285e226be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76549522-3e09-4755-92c3-fb3e4715bbfa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_11b7212c-25da-4ca5-b20b-7a1285e226be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_682d0810-c9a0-4497-96a9-9595c504fd65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76549522-3e09-4755-92c3-fb3e4715bbfa" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_682d0810-c9a0-4497-96a9-9595c504fd65" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_95a07e29-f023-44ef-ad19-9b82a65daa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a79752fc-cf25-4d1c-9aa6-a1a3707dfb95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_95a07e29-f023-44ef-ad19-9b82a65daa2c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a79752fc-cf25-4d1c-9aa6-a1a3707dfb95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f3d13cd7-b724-47b1-b534-dd23bdce8e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_95a07e29-f023-44ef-ad19-9b82a65daa2c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f3d13cd7-b724-47b1-b534-dd23bdce8e3c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cah-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:537b797f-b836-409a-bf04-ad11625945c4,g:bd28f3d8-0395-4523-ae63-79ccc2df931a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="simple" xlink:href="cah-20240930.xsd#CondensedConsolidatedStatementofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_618d2ae4-3abc-4de6-937f-459db6128311" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a8e44fdc-6c99-44ef-b843-f00a9c0a1aff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_618d2ae4-3abc-4de6-937f-459db6128311" xlink:to="loc_us-gaap_StatementTable_a8e44fdc-6c99-44ef-b843-f00a9c0a1aff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_af1991d3-59cf-44d9-88df-a06f7460e54e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a8e44fdc-6c99-44ef-b843-f00a9c0a1aff" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_af1991d3-59cf-44d9-88df-a06f7460e54e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_af1991d3-59cf-44d9-88df-a06f7460e54e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af1991d3-59cf-44d9-88df-a06f7460e54e" xlink:to="loc_us-gaap_EquityComponentDomain_af1991d3-59cf-44d9-88df-a06f7460e54e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af1991d3-59cf-44d9-88df-a06f7460e54e" xlink:to="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_559cf914-4588-4819-8d1b-06827251f0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:to="loc_us-gaap_CommonStockMember_559cf914-4588-4819-8d1b-06827251f0d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4d567f3e-691f-4041-96d9-eeab03778e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:to="loc_us-gaap_RetainedEarningsMember_4d567f3e-691f-4041-96d9-eeab03778e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_daaf5ceb-7f60-428f-bb5a-511f7bd7cc95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:to="loc_us-gaap_TreasuryStockCommonMember_daaf5ceb-7f60-428f-bb5a-511f7bd7cc95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45e1f79f-092e-4de6-9acc-2443fb53bc29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45e1f79f-092e-4de6-9acc-2443fb53bc29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_08c5de25-9baf-4a26-b181-0f3e22146e98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_08c5de25-9baf-4a26-b181-0f3e22146e98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_618d2ae4-3abc-4de6-937f-459db6128311" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_23138350-9419-4e9e-a615-888cdc96b14b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_CommonStockSharesIssued_23138350-9419-4e9e-a615-888cdc96b14b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50a71afc-6bda-41f8-9df0-3ae04150fa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50a71afc-6bda-41f8-9df0-3ae04150fa2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_e01d097e-b927-41e7-87ac-01af8f24e0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_e01d097e-b927-41e7-87ac-01af8f24e0e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_8e28dca9-ce77-4ca7-a8ee-a1c9d3ed00ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_TreasuryStockValue_8e28dca9-ce77-4ca7-a8ee-a1c9d3ed00ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e29e8d9-eff7-4cc3-a43a-c44938ec638c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_NetIncomeLoss_9e29e8d9-eff7-4cc3-a43a-c44938ec638c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d47a3d06-15b6-46f4-85ee-86856e733b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_ProfitLoss_d47a3d06-15b6-46f4-85ee-86856e733b7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c5de8a6d-22bd-459b-829e-f4d051f1d40d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c5de8a6d-22bd-459b-829e-f4d051f1d40d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_77f8f120-b0e7-4cfd-acd9-fbbfe1aabcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_77f8f120-b0e7-4cfd-acd9-fbbfe1aabcf2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_df47069c-0014-4c8f-84a2-e60522da10c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_df47069c-0014-4c8f-84a2-e60522da10c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e65a82a6-8029-48ee-85af-ee437be47e37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e65a82a6-8029-48ee-85af-ee437be47e37" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_f2c9f498-91f2-4790-a908-e03edaee42b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_f2c9f498-91f2-4790-a908-e03edaee42b9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_64bc7820-163e-49c7-a88e-2ed61e77443a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_64bc7820-163e-49c7-a88e-2ed61e77443a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_7e2c5e77-d037-471d-b75c-c0f15fccf534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_Dividends_7e2c5e77-d037-471d-b75c-c0f15fccf534" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_6395a1b5-18ad-433d-8220-1c7b99603066" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_StockholdersEquityOther_6395a1b5-18ad-433d-8220-1c7b99603066" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e168c046-b71c-4526-a89a-71b1eb2ba7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_24426541-bc4a-4b87-95de-3dd0b1e751fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_7bd9970a-503f-4455-a132-9910125e7ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_9ed73385-62d0-4d45-a35e-ec8362b2a4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_2abafa6b-6175-4b32-a1ae-6fb124ef34df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2abafa6b-6175-4b32-a1ae-6fb124ef34df" xlink:to="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_91057e86-2d57-430e-b71a-5606b195081b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:to="loc_srt_MajorCustomersAxis_91057e86-2d57-430e-b71a-5606b195081b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_91057e86-2d57-430e-b71a-5606b195081b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_91057e86-2d57-430e-b71a-5606b195081b" xlink:to="loc_srt_NameOfMajorCustomerDomain_91057e86-2d57-430e-b71a-5606b195081b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f529c8c0-efed-484f-84f2-f1641618810a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_91057e86-2d57-430e-b71a-5606b195081b" xlink:to="loc_srt_NameOfMajorCustomerDomain_f529c8c0-efed-484f-84f2-f1641618810a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OptumRxMember_8c685898-de4d-4c79-b935-9941bac4e72e" xlink:href="cah-20240930.xsd#cah_OptumRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f529c8c0-efed-484f-84f2-f1641618810a" xlink:to="loc_cah_OptumRxMember_8c685898-de4d-4c79-b935-9941bac4e72e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_29440fd7-9b67-41af-adb8-4dc66d68f041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_29440fd7-9b67-41af-adb8-4dc66d68f041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29440fd7-9b67-41af-adb8-4dc66d68f041_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_29440fd7-9b67-41af-adb8-4dc66d68f041" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29440fd7-9b67-41af-adb8-4dc66d68f041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b709c242-00d1-46c7-bfb5-5aaff31163c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_29440fd7-9b67-41af-adb8-4dc66d68f041" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b709c242-00d1-46c7-bfb5-5aaff31163c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6475c895-aafe-4751-bb47-1d589084459c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b709c242-00d1-46c7-bfb5-5aaff31163c8" xlink:to="loc_us-gaap_SalesRevenueNetMember_6475c895-aafe-4751-bb47-1d589084459c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4bd59dd3-6b80-4087-85b3-e31c95dc94b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4bd59dd3-6b80-4087-85b3-e31c95dc94b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4bd59dd3-6b80-4087-85b3-e31c95dc94b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4bd59dd3-6b80-4087-85b3-e31c95dc94b2" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4bd59dd3-6b80-4087-85b3-e31c95dc94b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b177cd7a-ff08-4cc0-ae8d-32294cb024eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4bd59dd3-6b80-4087-85b3-e31c95dc94b2" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b177cd7a-ff08-4cc0-ae8d-32294cb024eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_307287d3-aea8-4f9c-a3e9-7877f4692ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b177cd7a-ff08-4cc0-ae8d-32294cb024eb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_307287d3-aea8-4f9c-a3e9-7877f4692ec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1c7a7a76-17b2-463e-a8fd-609ed05a307e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1c7a7a76-17b2-463e-a8fd-609ed05a307e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1c7a7a76-17b2-463e-a8fd-609ed05a307e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1c7a7a76-17b2-463e-a8fd-609ed05a307e" xlink:to="loc_us-gaap_SegmentDomain_1c7a7a76-17b2-463e-a8fd-609ed05a307e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c9a88151-0925-4d16-9170-f99e11e4425d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1c7a7a76-17b2-463e-a8fd-609ed05a307e" xlink:to="loc_us-gaap_SegmentDomain_c9a88151-0925-4d16-9170-f99e11e4425d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_240f9df6-62fd-48bd-83ff-f45cf0344953" xlink:href="cah-20240930.xsd#cah_PharmaceuticalAndSpecialtySolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c9a88151-0925-4d16-9170-f99e11e4425d" xlink:to="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_240f9df6-62fd-48bd-83ff-f45cf0344953" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_eaf43324-9a44-49e5-a498-185dc0c4fffa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2abafa6b-6175-4b32-a1ae-6fb124ef34df" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_eaf43324-9a44-49e5-a498-185dc0c4fffa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/AcquisitionsDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#AcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/AcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_72c0eca2-a6f1-4e97-a9f6-583f9f3f533a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8187579-84be-4a8e-88b1-28642c807a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_72c0eca2-a6f1-4e97-a9f6-583f9f3f533a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8187579-84be-4a8e-88b1-28642c807a48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1cb105c1-5386-4c4c-9387-a095414c346f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8187579-84be-4a8e-88b1-28642c807a48" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1cb105c1-5386-4c4c-9387-a095414c346f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cb105c1-5386-4c4c-9387-a095414c346f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1cb105c1-5386-4c4c-9387-a095414c346f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cb105c1-5386-4c4c-9387-a095414c346f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8dd7fe1c-42e8-4275-b5b2-b5823ab117d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1cb105c1-5386-4c4c-9387-a095414c346f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8dd7fe1c-42e8-4275-b5b2-b5823ab117d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IntegratedOncologyNetworkMember_ceecd7a9-476f-46ff-bbc3-8f2fe06023c3" xlink:href="cah-20240930.xsd#cah_IntegratedOncologyNetworkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8dd7fe1c-42e8-4275-b5b2-b5823ab117d6" xlink:to="loc_cah_IntegratedOncologyNetworkMember_ceecd7a9-476f-46ff-bbc3-8f2fe06023c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SpecialtyNetworksMember_7ae13970-52ec-4f7b-a700-ba138a425075" xlink:href="cah-20240930.xsd#cah_SpecialtyNetworksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8dd7fe1c-42e8-4275-b5b2-b5823ab117d6" xlink:to="loc_cah_SpecialtyNetworksMember_7ae13970-52ec-4f7b-a700-ba138a425075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationPriceOfAcquisitionExpected_4da47cbe-d2da-4859-bec8-708b3dd3675c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationPriceOfAcquisitionExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_72c0eca2-a6f1-4e97-a9f6-583f9f3f533a" xlink:to="loc_us-gaap_BusinessCombinationPriceOfAcquisitionExpected_4da47cbe-d2da-4859-bec8-708b3dd3675c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a1a00dd9-590c-425a-902e-ecaa2a7fcfac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_72c0eca2-a6f1-4e97-a9f6-583f9f3f533a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a1a00dd9-590c-425a-902e-ecaa2a7fcfac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DivestituresDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#DivestituresDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/DivestituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_81dbf425-8132-49d3-9aa6-d35f18a742f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_d7a14a91-45d4-4ab9-a0ce-0ec5adec3e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_81dbf425-8132-49d3-9aa6-d35f18a742f2" xlink:to="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_d7a14a91-45d4-4ab9-a0ce-0ec5adec3e6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OutcomesDivestitureAxis_4b8e7bb2-27f1-492b-8f37-b14c5da0b559" xlink:href="cah-20240930.xsd#cah_OutcomesDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_d7a14a91-45d4-4ab9-a0ce-0ec5adec3e6a" xlink:to="loc_cah_OutcomesDivestitureAxis_4b8e7bb2-27f1-492b-8f37-b14c5da0b559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OutcomesDivestitureDomain_4b8e7bb2-27f1-492b-8f37-b14c5da0b559_default" xlink:href="cah-20240930.xsd#cah_OutcomesDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OutcomesDivestitureAxis_4b8e7bb2-27f1-492b-8f37-b14c5da0b559" xlink:to="loc_cah_OutcomesDivestitureDomain_4b8e7bb2-27f1-492b-8f37-b14c5da0b559_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OutcomesDivestitureDomain_88cec384-7bd5-4155-ac2e-15e9fb33c0fb" xlink:href="cah-20240930.xsd#cah_OutcomesDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OutcomesDivestitureAxis_4b8e7bb2-27f1-492b-8f37-b14c5da0b559" xlink:to="loc_cah_OutcomesDivestitureDomain_88cec384-7bd5-4155-ac2e-15e9fb33c0fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OutcomesDivestitureMember_284b21b7-b06a-4e92-b04e-b12fdb759dbc" xlink:href="cah-20240930.xsd#cah_OutcomesDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OutcomesDivestitureDomain_88cec384-7bd5-4155-ac2e-15e9fb33c0fb" xlink:to="loc_cah_OutcomesDivestitureMember_284b21b7-b06a-4e92-b04e-b12fdb759dbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4254e273-1351-47fa-ba16-1f2b346fd1ce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_d7a14a91-45d4-4ab9-a0ce-0ec5adec3e6a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4254e273-1351-47fa-ba16-1f2b346fd1ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4254e273-1351-47fa-ba16-1f2b346fd1ce_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4254e273-1351-47fa-ba16-1f2b346fd1ce" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4254e273-1351-47fa-ba16-1f2b346fd1ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7b2d9601-b5c6-484d-8c0e-52380f79bd64" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4254e273-1351-47fa-ba16-1f2b346fd1ce" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7b2d9601-b5c6-484d-8c0e-52380f79bd64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TransactionDataSystemInvestmentMember_8d33b28c-4b94-4fc8-b752-29b33e5875b5" xlink:href="cah-20240930.xsd#cah_TransactionDataSystemInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7b2d9601-b5c6-484d-8c0e-52380f79bd64" xlink:to="loc_cah_TransactionDataSystemInvestmentMember_8d33b28c-4b94-4fc8-b752-29b33e5875b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_bc125d0f-44ac-4ffd-8c06-2d63cb45242f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_81dbf425-8132-49d3-9aa6-d35f18a742f2" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_bc125d0f-44ac-4ffd-8c06-2d63cb45242f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_550a1647-b908-4ee2-a8ef-14d5d9320769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_81dbf425-8132-49d3-9aa6-d35f18a742f2" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_550a1647-b908-4ee2-a8ef-14d5d9320769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_0a366a9c-8ca4-4262-add5-0c149a123672" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_81dbf425-8132-49d3-9aa6-d35f18a742f2" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_0a366a9c-8ca4-4262-add5-0c149a123672" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e1d413bb-dc8a-4d54-ad18-0abc2dca4375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_81dbf425-8132-49d3-9aa6-d35f18a742f2" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e1d413bb-dc8a-4d54-ad18-0abc2dca4375" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2e88bfc3-969b-4e56-a553-f378e4d3e8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bd9099c-865a-4dd7-af08-d200f0865c28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2e88bfc3-969b-4e56-a553-f378e4d3e8ea" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bd9099c-865a-4dd7-af08-d200f0865c28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_617ba065-5bf8-4c58-a59b-f17fc29659ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bd9099c-865a-4dd7-af08-d200f0865c28" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_617ba065-5bf8-4c58-a59b-f17fc29659ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_617ba065-5bf8-4c58-a59b-f17fc29659ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_617ba065-5bf8-4c58-a59b-f17fc29659ff" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_617ba065-5bf8-4c58-a59b-f17fc29659ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d9f341d0-a8e9-4988-9a33-366fd1605527" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_617ba065-5bf8-4c58-a59b-f17fc29659ff" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d9f341d0-a8e9-4988-9a33-366fd1605527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_367ae227-e7f9-41fa-8f1a-3472a6c8b688" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d9f341d0-a8e9-4988-9a33-366fd1605527" xlink:to="loc_us-gaap_EmployeeSeveranceMember_367ae227-e7f9-41fa-8f1a-3472a6c8b688" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_134166eb-6815-422a-9311-011e15a6e102" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d9f341d0-a8e9-4988-9a33-366fd1605527" xlink:to="loc_us-gaap_FacilityClosingMember_134166eb-6815-422a-9311-011e15a6e102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_898e25c5-3119-4eeb-9bc7-368245e21375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2e88bfc3-969b-4e56-a553-f378e4d3e8ea" xlink:to="loc_us-gaap_RestructuringReserveRollForward_898e25c5-3119-4eeb-9bc7-368245e21375" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_328cdf98-de02-4761-ada2-b98b2411452f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898e25c5-3119-4eeb-9bc7-368245e21375" xlink:to="loc_us-gaap_RestructuringReserve_328cdf98-de02-4761-ada2-b98b2411452f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_3e22f739-d2f2-4553-bfbb-1b3674cb872c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898e25c5-3119-4eeb-9bc7-368245e21375" xlink:to="loc_us-gaap_RestructuringCosts_3e22f739-d2f2-4553-bfbb-1b3674cb872c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_0b6b795d-51f9-4e7b-a3bc-6f9afea4d7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898e25c5-3119-4eeb-9bc7-368245e21375" xlink:to="loc_us-gaap_PaymentsForRestructuring_0b6b795d-51f9-4e7b-a3bc-6f9afea4d7e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_dc2d142d-6200-4b93-b01a-4f1c1d9b618b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#RestructuringandEmployeeSeveranceNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9a189dda-e98d-4dc2-9996-7c640f568180" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6176f066-993a-47f6-bec3-2b0b8e543c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9a189dda-e98d-4dc2-9996-7c640f568180" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6176f066-993a-47f6-bec3-2b0b8e543c7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_e620b9ea-0001-4c0c-a31b-6a92e43a3f12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6176f066-993a-47f6-bec3-2b0b8e543c7d" xlink:to="loc_us-gaap_RestructuringPlanAxis_e620b9ea-0001-4c0c-a31b-6a92e43a3f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e620b9ea-0001-4c0c-a31b-6a92e43a3f12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_e620b9ea-0001-4c0c-a31b-6a92e43a3f12" xlink:to="loc_us-gaap_RestructuringPlanDomain_e620b9ea-0001-4c0c-a31b-6a92e43a3f12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_1f60a54f-76b3-437b-bca2-67afe5e41412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_e620b9ea-0001-4c0c-a31b-6a92e43a3f12" xlink:to="loc_us-gaap_RestructuringPlanDomain_1f60a54f-76b3-437b-bca2-67afe5e41412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_3a98c484-5078-4070-8517-bbbb7e1e7d68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9a189dda-e98d-4dc2-9996-7c640f568180" xlink:to="loc_us-gaap_SeveranceCosts1_3a98c484-5078-4070-8517-bbbb7e1e7d68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_f82faa6f-969e-4865-9de0-bcddf7559301" xlink:href="cah-20240930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9a189dda-e98d-4dc2-9996-7c640f568180" xlink:to="loc_cah_FacilityExitAndOtherCosts_f82faa6f-969e-4865-9de0-bcddf7559301" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_938f4f5c-62f1-4dc9-8244-cedb3b4bea82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_428ef3f6-16a9-4d61-8090-826fffd6800b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_938f4f5c-62f1-4dc9-8244-cedb3b4bea82" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_428ef3f6-16a9-4d61-8090-826fffd6800b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_51e744a3-62c7-4155-9bd6-747b7c10451a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_428ef3f6-16a9-4d61-8090-826fffd6800b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_51e744a3-62c7-4155-9bd6-747b7c10451a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_51e744a3-62c7-4155-9bd6-747b7c10451a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_51e744a3-62c7-4155-9bd6-747b7c10451a" xlink:to="loc_us-gaap_SegmentDomain_51e744a3-62c7-4155-9bd6-747b7c10451a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8bc68510-1660-4f6f-9a1c-5f91bf95fd83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_51e744a3-62c7-4155-9bd6-747b7c10451a" xlink:to="loc_us-gaap_SegmentDomain_8bc68510-1660-4f6f-9a1c-5f91bf95fd83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_4ac6c11d-2992-484d-9576-50904639028e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8bc68510-1660-4f6f-9a1c-5f91bf95fd83" xlink:to="loc_us-gaap_AllOtherSegmentsMember_4ac6c11d-2992-484d-9576-50904639028e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_2e86bd09-624f-4f1f-bb2d-f7ea31d9263a" xlink:href="cah-20240930.xsd#cah_PharmaceuticalAndSpecialtySolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8bc68510-1660-4f6f-9a1c-5f91bf95fd83" xlink:to="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_2e86bd09-624f-4f1f-bb2d-f7ea31d9263a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_68902cd3-ca74-4dfa-b13e-e555db8fab0a" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8bc68510-1660-4f6f-9a1c-5f91bf95fd83" xlink:to="loc_cah_GMPDMember_68902cd3-ca74-4dfa-b13e-e555db8fab0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_3b4a14c3-11a7-4f11-963c-a70cb79f618e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_938f4f5c-62f1-4dc9-8244-cedb3b4bea82" xlink:to="loc_us-gaap_GoodwillRollForward_3b4a14c3-11a7-4f11-963c-a70cb79f618e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dbe1e086-0962-4fdd-977c-45cb04c53fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_3b4a14c3-11a7-4f11-963c-a70cb79f618e" xlink:to="loc_us-gaap_Goodwill_dbe1e086-0962-4fdd-977c-45cb04c53fa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_397626fb-5113-42d3-b699-7ddd0d52d2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_3b4a14c3-11a7-4f11-963c-a70cb79f618e" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_397626fb-5113-42d3-b699-7ddd0d52d2bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_19958502-a211-4347-afa2-475a7add5dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d87dafdb-260c-4733-b5cd-2ce5f24df622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_3b4a14c3-11a7-4f11-963c-a70cb79f618e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d87dafdb-260c-4733-b5cd-2ce5f24df622" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_cc6bcbb0-2442-4b1b-a01e-58749cbd3455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a89854f9-94a8-477a-af08-18bf99481e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_cc6bcbb0-2442-4b1b-a01e-58749cbd3455" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a89854f9-94a8-477a-af08-18bf99481e1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9fcc2feb-1575-4874-9b15-2315ddcbcfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a89854f9-94a8-477a-af08-18bf99481e1f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9fcc2feb-1575-4874-9b15-2315ddcbcfb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9fcc2feb-1575-4874-9b15-2315ddcbcfb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9fcc2feb-1575-4874-9b15-2315ddcbcfb4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9fcc2feb-1575-4874-9b15-2315ddcbcfb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e4bbda8-0e79-427f-bd69-15ac88315dce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9fcc2feb-1575-4874-9b15-2315ddcbcfb4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e4bbda8-0e79-427f-bd69-15ac88315dce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_13d75365-561a-4748-99f7-7545ae757e45" xlink:href="cah-20240930.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e4bbda8-0e79-427f-bd69-15ac88315dce" xlink:to="loc_cah_IPRDTrademarksandOtherMember_13d75365-561a-4748-99f7-7545ae757e45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4c5b3350-32b1-487f-9a5b-c11b0cecf57c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_cc6bcbb0-2442-4b1b-a01e-58749cbd3455" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4c5b3350-32b1-487f-9a5b-c11b0cecf57c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_de932e1d-dbf9-4d37-a94f-607fc3be8aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e260a0e9-4cfe-4cf9-8543-22579f08bf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_de932e1d-dbf9-4d37-a94f-607fc3be8aa5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e260a0e9-4cfe-4cf9-8543-22579f08bf8b" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ebef25-fc9c-419c-b4ed-5cd783e03bee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e260a0e9-4cfe-4cf9-8543-22579f08bf8b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ebef25-fc9c-419c-b4ed-5cd783e03bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27ebef25-fc9c-419c-b4ed-5cd783e03bee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ebef25-fc9c-419c-b4ed-5cd783e03bee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27ebef25-fc9c-419c-b4ed-5cd783e03bee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9cb8829e-8a6e-4455-82c2-74c5c8a2e00f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ebef25-fc9c-419c-b4ed-5cd783e03bee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9cb8829e-8a6e-4455-82c2-74c5c8a2e00f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_f26cc821-fe6b-45c0-b706-cd5203c3b604" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9cb8829e-8a6e-4455-82c2-74c5c8a2e00f" xlink:to="loc_us-gaap_CustomerRelationshipsMember_f26cc821-fe6b-45c0-b706-cd5203c3b604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_84e694b6-edb5-4cf9-be61-bdf9f19be60e" xlink:href="cah-20240930.xsd#cah_TrademarksAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9cb8829e-8a6e-4455-82c2-74c5c8a2e00f" xlink:to="loc_cah_TrademarksAndPatentsMember_84e694b6-edb5-4cf9-be61-bdf9f19be60e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_e6cf83f4-8225-482b-8862-99d240d1ef53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9cb8829e-8a6e-4455-82c2-74c5c8a2e00f" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_e6cf83f4-8225-482b-8862-99d240d1ef53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9a389657-0c22-4013-8e63-5ff53495654e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_de932e1d-dbf9-4d37-a94f-607fc3be8aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9a389657-0c22-4013-8e63-5ff53495654e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_758d023f-0dd8-4aca-8e23-28c3bb042a53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_de932e1d-dbf9-4d37-a94f-607fc3be8aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_758d023f-0dd8-4aca-8e23-28c3bb042a53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cff852e6-0506-4058-b34a-8bf7e103fe80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_de932e1d-dbf9-4d37-a94f-607fc3be8aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cff852e6-0506-4058-b34a-8bf7e103fe80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_0c1b5397-ce9b-4254-a6a6-fbe698ccb112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_de932e1d-dbf9-4d37-a94f-607fc3be8aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_0c1b5397-ce9b-4254-a6a6-fbe698ccb112" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_59feee1d-c237-4faa-ba22-923b10efd60e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_ebe88830-5501-4246-ba15-e1cd3ec36982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_59feee1d-c237-4faa-ba22-923b10efd60e" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_ebe88830-5501-4246-ba15-e1cd3ec36982" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_adb075aa-436a-43b4-a175-d8d7540525a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ebe88830-5501-4246-ba15-e1cd3ec36982" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_adb075aa-436a-43b4-a175-d8d7540525a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_adb075aa-436a-43b4-a175-d8d7540525a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_adb075aa-436a-43b4-a175-d8d7540525a8" xlink:to="loc_us-gaap_SegmentDomain_adb075aa-436a-43b4-a175-d8d7540525a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2e808d03-76ab-4625-85a1-2744dc4177a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_adb075aa-436a-43b4-a175-d8d7540525a8" xlink:to="loc_us-gaap_SegmentDomain_2e808d03-76ab-4625-85a1-2744dc4177a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_6207a22e-0928-4c07-af23-c88a84370bfb" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2e808d03-76ab-4625-85a1-2744dc4177a1" xlink:to="loc_cah_GMPDMember_6207a22e-0928-4c07-af23-c88a84370bfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_a9e3153b-0e48-4188-993d-4cd499bb94f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ebe88830-5501-4246-ba15-e1cd3ec36982" xlink:to="loc_us-gaap_ReportingUnitAxis_a9e3153b-0e48-4188-993d-4cd499bb94f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_a9e3153b-0e48-4188-993d-4cd499bb94f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_a9e3153b-0e48-4188-993d-4cd499bb94f4" xlink:to="loc_us-gaap_ReportingUnitDomain_a9e3153b-0e48-4188-993d-4cd499bb94f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_b164fa03-0e36-4663-9876-0da77dedb037" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_a9e3153b-0e48-4188-993d-4cd499bb94f4" xlink:to="loc_us-gaap_ReportingUnitDomain_b164fa03-0e36-4663-9876-0da77dedb037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b03d5999-f285-477e-872c-b1f4a7e1aaab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_59feee1d-c237-4faa-ba22-923b10efd60e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b03d5999-f285-477e-872c-b1f4a7e1aaab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0f111200-9e88-4507-bea9-1f7642cce2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_59feee1d-c237-4faa-ba22-923b10efd60e" xlink:to="loc_us-gaap_Goodwill_0f111200-9e88-4507-bea9-1f7642cce2fe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:to="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d8b06b8b-1c35-41ad-8d9c-3cb3cd02e4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_CreditFacilityAxis_d8b06b8b-1c35-41ad-8d9c-3cb3cd02e4f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d8b06b8b-1c35-41ad-8d9c-3cb3cd02e4f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_d8b06b8b-1c35-41ad-8d9c-3cb3cd02e4f1" xlink:to="loc_us-gaap_CreditFacilityDomain_d8b06b8b-1c35-41ad-8d9c-3cb3cd02e4f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_abf6b103-5eb5-4e6f-856c-6bca7732b84d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_d8b06b8b-1c35-41ad-8d9c-3cb3cd02e4f1" xlink:to="loc_us-gaap_CreditFacilityDomain_abf6b103-5eb5-4e6f-856c-6bca7732b84d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2ee1ce14-1771-447e-a577-82319043141c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_abf6b103-5eb5-4e6f-856c-6bca7732b84d" xlink:to="loc_us-gaap_CommercialPaperMember_2ee1ce14-1771-447e-a577-82319043141c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_27a9774f-a5ed-4d71-8fec-696798d7c34b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_abf6b103-5eb5-4e6f-856c-6bca7732b84d" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_27a9774f-a5ed-4d71-8fec-696798d7c34b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_d10833dc-c305-4113-b821-4bf4ece59ab4" xlink:href="cah-20240930.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_abf6b103-5eb5-4e6f-856c-6bca7732b84d" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_d10833dc-c305-4113-b821-4bf4ece59ab4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_16c0d766-766d-49c3-8947-050f46fd2944" xlink:href="cah-20240930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShortTermCreditFacilitiesMember_d10833dc-c305-4113-b821-4bf4ece59ab4" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_16c0d766-766d-49c3-8947-050f46fd2944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bf04792c-8e4e-4931-ae85-12b959cf75d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bf04792c-8e4e-4931-ae85-12b959cf75d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bf04792c-8e4e-4931-ae85-12b959cf75d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bf04792c-8e4e-4931-ae85-12b959cf75d2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bf04792c-8e4e-4931-ae85-12b959cf75d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ce536dc1-4da5-4870-8299-6cb7f19aaa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bf04792c-8e4e-4931-ae85-12b959cf75d2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ce536dc1-4da5-4870-8299-6cb7f19aaa8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cf1dd1fe-c643-4c6e-83a6-7df0d8f04ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_DebtInstrumentAxis_cf1dd1fe-c643-4c6e-83a6-7df0d8f04ec1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cf1dd1fe-c643-4c6e-83a6-7df0d8f04ec1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf1dd1fe-c643-4c6e-83a6-7df0d8f04ec1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cf1dd1fe-c643-4c6e-83a6-7df0d8f04ec1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d668fe1-8d1d-47ec-8470-72ea793fef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf1dd1fe-c643-4c6e-83a6-7df0d8f04ec1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d668fe1-8d1d-47ec-8470-72ea793fef3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_da18a13e-cb24-4b0a-93e7-9ab721874385" xlink:href="cah-20240930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2d668fe1-8d1d-47ec-8470-72ea793fef3f" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_da18a13e-cb24-4b0a-93e7-9ab721874385" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_dafcc721-833f-4ac2-9c21-925b71696929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_VariableRateAxis_dafcc721-833f-4ac2-9c21-925b71696929" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_dafcc721-833f-4ac2-9c21-925b71696929_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_dafcc721-833f-4ac2-9c21-925b71696929" xlink:to="loc_us-gaap_VariableRateDomain_dafcc721-833f-4ac2-9c21-925b71696929_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3b9c0286-fdc6-4b3f-8c80-5c7d0c0d7460" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_dafcc721-833f-4ac2-9c21-925b71696929" xlink:to="loc_us-gaap_VariableRateDomain_3b9c0286-fdc6-4b3f-8c80-5c7d0c0d7460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e35aec8c-e2a6-4228-abed-bcf677261ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e35aec8c-e2a6-4228-abed-bcf677261ff0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e35aec8c-e2a6-4228-abed-bcf677261ff0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e35aec8c-e2a6-4228-abed-bcf677261ff0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e35aec8c-e2a6-4228-abed-bcf677261ff0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_fa9e81f0-91c5-4268-bb70-0279efce3171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e35aec8c-e2a6-4228-abed-bcf677261ff0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_fa9e81f0-91c5-4268-bb70-0279efce3171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_26e76dd6-d2f0-403f-852b-d78b1e8fbbe6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_srt_RangeAxis_26e76dd6-d2f0-403f-852b-d78b1e8fbbe6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_26e76dd6-d2f0-403f-852b-d78b1e8fbbe6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_26e76dd6-d2f0-403f-852b-d78b1e8fbbe6" xlink:to="loc_srt_RangeMember_26e76dd6-d2f0-403f-852b-d78b1e8fbbe6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3d3cf76d-9bad-4e9b-af63-19f6dd4d65e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_26e76dd6-d2f0-403f-852b-d78b1e8fbbe6" xlink:to="loc_srt_RangeMember_3d3cf76d-9bad-4e9b-af63-19f6dd4d65e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ab6598ea-5682-4934-85e8-ff78daf16ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ab6598ea-5682-4934-85e8-ff78daf16ea9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ab6598ea-5682-4934-85e8-ff78daf16ea9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ab6598ea-5682-4934-85e8-ff78daf16ea9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ab6598ea-5682-4934-85e8-ff78daf16ea9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a58df437-0794-4ba1-a343-8d35bd7ad982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ab6598ea-5682-4934-85e8-ff78daf16ea9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a58df437-0794-4ba1-a343-8d35bd7ad982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_43980bd0-0065-458d-b3d8-48d72337e725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a58df437-0794-4ba1-a343-8d35bd7ad982" xlink:to="loc_us-gaap_SubsequentEventMember_43980bd0-0065-458d-b3d8-48d72337e725" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_3a6eccba-4552-4469-bcf1-3dbb196d6bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_3a6eccba-4552-4469-bcf1-3dbb196d6bd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_03950aed-6be6-4f43-b42e-821bafa1c3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_03950aed-6be6-4f43-b42e-821bafa1c3b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8cdff853-0b8b-4df1-9169-e9f0fda61df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8cdff853-0b8b-4df1-9169-e9f0fda61df3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_4a7b4248-4fd4-48eb-ae4c-4f2ab0919d02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:to="loc_us-gaap_OtherShortTermBorrowings_4a7b4248-4fd4-48eb-ae4c-4f2ab0919d02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_6a441b92-46d4-452f-82c5-f05b81d23ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_6a441b92-46d4-452f-82c5-f05b81d23ac5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3050664f-760d-4109-8629-d12ce4f60260" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_srt_MajorCustomersAxis_3050664f-760d-4109-8629-d12ce4f60260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3050664f-760d-4109-8629-d12ce4f60260_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3050664f-760d-4109-8629-d12ce4f60260" xlink:to="loc_srt_NameOfMajorCustomerDomain_3050664f-760d-4109-8629-d12ce4f60260_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e24a1aae-4d74-4475-8e33-bac34143b678" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3050664f-760d-4109-8629-d12ce4f60260" xlink:to="loc_srt_NameOfMajorCustomerDomain_e24a1aae-4d74-4475-8e33-bac34143b678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_4f84b1b4-a3e9-4094-8011-4eb5f9aeac15" xlink:href="cah-20240930.xsd#cah_CVSHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e24a1aae-4d74-4475-8e33-bac34143b678" xlink:to="loc_cah_CVSHealthMember_4f84b1b4-a3e9-4094-8011-4eb5f9aeac15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_40d4ee69-0391-4302-ad2b-ea49b92bbde2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_srt_LitigationCaseAxis_40d4ee69-0391-4302-ad2b-ea49b92bbde2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_40d4ee69-0391-4302-ad2b-ea49b92bbde2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_40d4ee69-0391-4302-ad2b-ea49b92bbde2" xlink:to="loc_srt_LitigationCaseTypeDomain_40d4ee69-0391-4302-ad2b-ea49b92bbde2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3c123b2c-090d-48ae-ba40-4dda3aa9744f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_40d4ee69-0391-4302-ad2b-ea49b92bbde2" xlink:to="loc_srt_LitigationCaseTypeDomain_3c123b2c-090d-48ae-ba40-4dda3aa9744f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_9a39fe70-7a9c-4cc3-8546-ae15ff975348" xlink:href="cah-20240930.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3c123b2c-090d-48ae-ba40-4dda3aa9744f" xlink:to="loc_cah_OpioidLawsuitsMember_9a39fe70-7a9c-4cc3-8546-ae15ff975348" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_6b6da89f-26fb-45e3-a3e0-9f8d6eba979c" xlink:href="cah-20240930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3c123b2c-090d-48ae-ba40-4dda3aa9744f" xlink:to="loc_cah_ClassActionLawsuitsMember_6b6da89f-26fb-45e3-a3e0-9f8d6eba979c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_be03021a-a021-4b99-9f73-75dd04bb3c80" xlink:href="cah-20240930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3c123b2c-090d-48ae-ba40-4dda3aa9744f" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_be03021a-a021-4b99-9f73-75dd04bb3c80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_645fd19f-d237-4a6b-804a-49d96045d14a" xlink:href="cah-20240930.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3c123b2c-090d-48ae-ba40-4dda3aa9744f" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_645fd19f-d237-4a6b-804a-49d96045d14a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_4191f741-a84a-4e94-8731-15074f6310f0" xlink:href="cah-20240930.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_cah_OpioidLitigationAxis_4191f741-a84a-4e94-8731-15074f6310f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_4191f741-a84a-4e94-8731-15074f6310f0_default" xlink:href="cah-20240930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_4191f741-a84a-4e94-8731-15074f6310f0" xlink:to="loc_cah_OpioidLitigationDomain_4191f741-a84a-4e94-8731-15074f6310f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_38f7a918-80f0-4a33-8fe7-c6685d5eb619" xlink:href="cah-20240930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_4191f741-a84a-4e94-8731-15074f6310f0" xlink:to="loc_cah_OpioidLitigationDomain_38f7a918-80f0-4a33-8fe7-c6685d5eb619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_7ae95fc9-6f85-4b9a-88f2-4db4f496c0f3" xlink:href="cah-20240930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_38f7a918-80f0-4a33-8fe7-c6685d5eb619" xlink:to="loc_cah_TotalOpioidLitigationMember_7ae95fc9-6f85-4b9a-88f2-4db4f496c0f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_a7a8a02a-b106-4245-80b2-fd1d833a753c" xlink:href="cah-20240930.xsd#cah_LawsuitTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_cah_LawsuitTypeAxis_a7a8a02a-b106-4245-80b2-fd1d833a753c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain_a7a8a02a-b106-4245-80b2-fd1d833a753c_default" xlink:href="cah-20240930.xsd#cah_LitigationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_LawsuitTypeAxis_a7a8a02a-b106-4245-80b2-fd1d833a753c" xlink:to="loc_cah_LitigationTypeDomain_a7a8a02a-b106-4245-80b2-fd1d833a753c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain_929dba9d-4a4a-416e-86ab-22b94d26e773" xlink:href="cah-20240930.xsd#cah_LitigationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_LawsuitTypeAxis_a7a8a02a-b106-4245-80b2-fd1d833a753c" xlink:to="loc_cah_LitigationTypeDomain_929dba9d-4a4a-416e-86ab-22b94d26e773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_08a2345b-e9e3-4c07-ab0c-b0a53f680104" xlink:href="cah-20240930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LitigationTypeDomain_929dba9d-4a4a-416e-86ab-22b94d26e773" xlink:to="loc_cah_ClassActionLawsuitsMember_08a2345b-e9e3-4c07-ab0c-b0a53f680104" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_8ddc6371-0988-439d-b40e-cab37caac430" xlink:href="cah-20240930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LitigationTypeDomain_929dba9d-4a4a-416e-86ab-22b94d26e773" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_8ddc6371-0988-439d-b40e-cab37caac430" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_9bd5f043-3b3c-483f-b941-2c03af313cb3" xlink:href="cah-20240930.xsd#cah_PlaintiffTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_cah_PlaintiffTypeAxis_9bd5f043-3b3c-483f-b941-2c03af313cb3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_9bd5f043-3b3c-483f-b941-2c03af313cb3_default" xlink:href="cah-20240930.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PlaintiffTypeAxis_9bd5f043-3b3c-483f-b941-2c03af313cb3" xlink:to="loc_cah_PlaintiffTypeDomain_9bd5f043-3b3c-483f-b941-2c03af313cb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_23e1e552-a048-4ed6-bf64-928b25973206" xlink:href="cah-20240930.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PlaintiffTypeAxis_9bd5f043-3b3c-483f-b941-2c03af313cb3" xlink:to="loc_cah_PlaintiffTypeDomain_23e1e552-a048-4ed6-bf64-928b25973206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_e14a38f5-a505-41e1-ade2-06a2ad89f3df" xlink:href="cah-20240930.xsd#cah_PrivatePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_23e1e552-a048-4ed6-bf64-928b25973206" xlink:to="loc_cah_PrivatePartiesMember_e14a38f5-a505-41e1-ade2-06a2ad89f3df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_9dee80ad-8533-4383-af70-43d8e09a7caa" xlink:href="cah-20240930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_23e1e552-a048-4ed6-bf64-928b25973206" xlink:to="loc_cah_ClassActionLawsuitsMember_9dee80ad-8533-4383-af70-43d8e09a7caa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4f3a2385-d948-4648-b65b-c4e2cc8a749f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_srt_StatementGeographicalAxis_4f3a2385-d948-4648-b65b-c4e2cc8a749f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4f3a2385-d948-4648-b65b-c4e2cc8a749f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4f3a2385-d948-4648-b65b-c4e2cc8a749f" xlink:to="loc_srt_SegmentGeographicalDomain_4f3a2385-d948-4648-b65b-c4e2cc8a749f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4f3a2385-d948-4648-b65b-c4e2cc8a749f" xlink:to="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_565093ad-fb1e-445d-a120-ac3eb9177657" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_WV"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:to="loc_stpr_WV_565093ad-fb1e-445d-a120-ac3eb9177657" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_35805117-48a5-4885-846e-12769663359e" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_GA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:to="loc_stpr_GA_35805117-48a5-4885-846e-12769663359e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_naics_ZZ921150_61343496-e1fd-4501-bbe7-6f0c75e89225" xlink:href="https://xbrl.sec.gov/naics/2024/naics-2024.xsd#naics_ZZ921150"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:to="loc_naics_ZZ921150_61343496-e1fd-4501-bbe7-6f0c75e89225" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AL_b88b6462-6842-4713-93dc-6db0fb9f9b40" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_AL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:to="loc_stpr_AL_b88b6462-6842-4713-93dc-6db0fb9f9b40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CityOfBaltimoreMember_e5d07896-85c6-440d-aa1b-f5918c76c628" xlink:href="cah-20240930.xsd#cah_CityOfBaltimoreMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:to="loc_cah_CityOfBaltimoreMember_e5d07896-85c6-440d-aa1b-f5918c76c628" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_03164129-99d2-4645-b3ae-d20becb566bd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_srt_RangeAxis_03164129-99d2-4645-b3ae-d20becb566bd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03164129-99d2-4645-b3ae-d20becb566bd_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_03164129-99d2-4645-b3ae-d20becb566bd" xlink:to="loc_srt_RangeMember_03164129-99d2-4645-b3ae-d20becb566bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e054a341-5665-4097-8759-6fdd14acb7be" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_03164129-99d2-4645-b3ae-d20becb566bd" xlink:to="loc_srt_RangeMember_e054a341-5665-4097-8759-6fdd14acb7be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1b4950a1-5810-4964-ba6a-cf3e315158ff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e054a341-5665-4097-8759-6fdd14acb7be" xlink:to="loc_srt_MinimumMember_1b4950a1-5810-4964-ba6a-cf3e315158ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_72759b48-266c-4f3a-b11b-505679f45412" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e054a341-5665-4097-8759-6fdd14acb7be" xlink:to="loc_srt_MaximumMember_72759b48-266c-4f3a-b11b-505679f45412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_62eb9b84-b16e-4910-84ce-01c1be9cb41d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_62eb9b84-b16e-4910-84ce-01c1be9cb41d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_62eb9b84-b16e-4910-84ce-01c1be9cb41d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_62eb9b84-b16e-4910-84ce-01c1be9cb41d" xlink:to="loc_us-gaap_LossContingencyNatureDomain_62eb9b84-b16e-4910-84ce-01c1be9cb41d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_97e3371e-d3a7-4410-adfd-55af3d5a3cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_62eb9b84-b16e-4910-84ce-01c1be9cb41d" xlink:to="loc_us-gaap_LossContingencyNatureDomain_97e3371e-d3a7-4410-adfd-55af3d5a3cb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_56a72527-7a40-4e0b-b715-9b39dda187b1" xlink:href="cah-20240930.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_97e3371e-d3a7-4410-adfd-55af3d5a3cb9" xlink:to="loc_cah_OpioidLawsuitsMember_56a72527-7a40-4e0b-b715-9b39dda187b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_2e600ac9-6ff9-40e0-bd1e-4837989575b6" xlink:href="cah-20240930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_97e3371e-d3a7-4410-adfd-55af3d5a3cb9" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_2e600ac9-6ff9-40e0-bd1e-4837989575b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_06a84746-dd64-43ba-96bd-8cf47ac4bce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_06a84746-dd64-43ba-96bd-8cf47ac4bce7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_06a84746-dd64-43ba-96bd-8cf47ac4bce7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_06a84746-dd64-43ba-96bd-8cf47ac4bce7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_06a84746-dd64-43ba-96bd-8cf47ac4bce7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a1ebf7d3-cb6b-44bf-81f8-4bebf6a8843f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_06a84746-dd64-43ba-96bd-8cf47ac4bce7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a1ebf7d3-cb6b-44bf-81f8-4bebf6a8843f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4c483626-27e0-43fd-aede-517380432079" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a1ebf7d3-cb6b-44bf-81f8-4bebf6a8843f" xlink:to="loc_us-gaap_SubsequentEventMember_4c483626-27e0-43fd-aede-517380432079" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsAxis_3fcdde0f-9cd9-46c7-9faa-803ff78b8b47" xlink:href="cah-20240930.xsd#cah_AgreementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_cah_AgreementsAxis_3fcdde0f-9cd9-46c7-9faa-803ff78b8b47" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsDomain_3fcdde0f-9cd9-46c7-9faa-803ff78b8b47_default" xlink:href="cah-20240930.xsd#cah_AgreementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_AgreementsAxis_3fcdde0f-9cd9-46c7-9faa-803ff78b8b47" xlink:to="loc_cah_AgreementsDomain_3fcdde0f-9cd9-46c7-9faa-803ff78b8b47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsDomain_9d351771-447e-406e-ae60-7ad2cdc9b1c3" xlink:href="cah-20240930.xsd#cah_AgreementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_AgreementsAxis_3fcdde0f-9cd9-46c7-9faa-803ff78b8b47" xlink:to="loc_cah_AgreementsDomain_9d351771-447e-406e-ae60-7ad2cdc9b1c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IVCApril2023AgreementMember_33cac6bb-99b2-4ba1-84f9-d64b391fe7a8" xlink:href="cah-20240930.xsd#cah_IVCApril2023AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_AgreementsDomain_9d351771-447e-406e-ae60-7ad2cdc9b1c3" xlink:to="loc_cah_IVCApril2023AgreementMember_33cac6bb-99b2-4ba1-84f9-d64b391fe7a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_9654def9-b146-4e9a-bdf6-0b916a4e01d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_9654def9-b146-4e9a-bdf6-0b916a4e01d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_c69fa39d-f9fa-4d8c-b18e-5011db42eccc" xlink:href="cah-20240930.xsd#cah_AggregateAnnualAssessment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_AggregateAnnualAssessment_c69fa39d-f9fa-4d8c-b18e-5011db42eccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_0d4ff948-4543-4397-ae6f-156474497ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LitigationReserve_0d4ff948-4543-4397-ae6f-156474497ad4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_bec2f3c1-86bb-49d1-940d-f904231a827e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LitigationReserveCurrent_bec2f3c1-86bb-49d1-940d-f904231a827e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss_c5a3c70b-f61d-4ac5-a824-00bd92214d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LitigationSettlementLoss_c5a3c70b-f61d-4ac5-a824-00bd92214d76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomeAsAResultOfPrepayments_15560ea5-5676-4c33-bc91-c98c86c29d07" xlink:href="cah-20240930.xsd#cah_IncomeAsAResultOfPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_IncomeAsAResultOfPrepayments_15560ea5-5676-4c33-bc91-c98c86c29d07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_8d58d064-a9c6-4ee6-b152-ab1421ba7287" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_8d58d064-a9c6-4ee6-b152-ab1421ba7287" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates_83cb171c-3f81-4e67-a36c-521f90e58a4e" xlink:href="cah-20240930.xsd#cah_SettlingStates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_SettlingStates_83cb171c-3f81-4e67-a36c-521f90e58a4e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories_b2aa3363-4514-4b45-ac61-6b8eec321a2b" xlink:href="cah-20240930.xsd#cah_SettlingUSTerritories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_SettlingUSTerritories_b2aa3363-4514-4b45-ac61-6b8eec321a2b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PercentageSettlingSubdivisions_a4d9d1a2-95dc-49a9-bdbe-091c313a03ad" xlink:href="cah-20240930.xsd#cah_PercentageSettlingSubdivisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_PercentageSettlingSubdivisions_a4d9d1a2-95dc-49a9-bdbe-091c313a03ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1277e037-c15e-4535-ad14-08d53b0478ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1277e037-c15e-4535-ad14-08d53b0478ab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_4a2e8649-38d4-4cc8-9745-64e2f92d511e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_4a2e8649-38d4-4cc8-9745-64e2f92d511e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_97692ebf-3263-42a5-bb87-7243a499d195" xlink:href="cah-20240930.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_LossContingencyLawsuitsNumber_97692ebf-3263-42a5-bb87-7243a499d195" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_08100a52-40e2-4b13-a202-e24ba275bdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_08100a52-40e2-4b13-a202-e24ba275bdb9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries_7cd3b5d6-ddac-44b4-8839-306e7f6f9a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_InsuranceRecoveries_7cd3b5d6-ddac-44b4-8839-306e7f6f9a5b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_f663aacd-5e18-4e32-9c47-4e0498fd5111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_f663aacd-5e18-4e32-9c47-4e0498fd5111" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_5f4a8bdb-99fe-48f2-8245-b3b8aa367704" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_5f4a8bdb-99fe-48f2-8245-b3b8aa367704" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7b0a26ad-796a-4578-9134-0cf8e378afa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7b0a26ad-796a-4578-9134-0cf8e378afa6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_4197e0f9-5465-4119-9372-e6139d8a6088" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_4197e0f9-5465-4119-9372-e6139d8a6088" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomefromSettlementsofClassActionLawsuits_edd0fe00-69c7-449b-bbda-a3bb88b743b2" xlink:href="cah-20240930.xsd#cah_IncomefromSettlementsofClassActionLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_IncomefromSettlementsofClassActionLawsuits_edd0fe00-69c7-449b-bbda-a3bb88b743b2" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_8acebd40-542a-4e91-8bd1-db736ec8c75c" xlink:href="cah-20240930.xsd#cah_TaxMatterAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_cah_TaxMatterAxis_8acebd40-542a-4e91-8bd1-db736ec8c75c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_8acebd40-542a-4e91-8bd1-db736ec8c75c_default" xlink:href="cah-20240930.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMatterAxis_8acebd40-542a-4e91-8bd1-db736ec8c75c" xlink:to="loc_cah_TaxMatterDomain_8acebd40-542a-4e91-8bd1-db736ec8c75c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_a5462458-f8d4-4f70-a352-0bd2699121dd" xlink:href="cah-20240930.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMatterAxis_8acebd40-542a-4e91-8bd1-db736ec8c75c" xlink:to="loc_cah_TaxMatterDomain_a5462458-f8d4-4f70-a352-0bd2699121dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_6e4f1bd2-ad99-46b4-87a4-3df1462350bf" xlink:href="cah-20240930.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_cah_OpioidLitigationAxis_6e4f1bd2-ad99-46b4-87a4-3df1462350bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_6e4f1bd2-ad99-46b4-87a4-3df1462350bf_default" xlink:href="cah-20240930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_6e4f1bd2-ad99-46b4-87a4-3df1462350bf" xlink:to="loc_cah_OpioidLitigationDomain_6e4f1bd2-ad99-46b4-87a4-3df1462350bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_013a79ed-4f73-4747-bf97-d98a17b51abc" xlink:href="cah-20240930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_6e4f1bd2-ad99-46b4-87a4-3df1462350bf" xlink:to="loc_cah_OpioidLitigationDomain_013a79ed-4f73-4747-bf97-d98a17b51abc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_486075ab-c676-4202-8f41-59f12968056f" xlink:href="cah-20240930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_013a79ed-4f73-4747-bf97-d98a17b51abc" xlink:to="loc_cah_TotalOpioidLitigationMember_486075ab-c676-4202-8f41-59f12968056f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_315f1c90-116f-46a2-b7a8-d27b7ee19bad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_315f1c90-116f-46a2-b7a8-d27b7ee19bad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_315f1c90-116f-46a2-b7a8-d27b7ee19bad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_315f1c90-116f-46a2-b7a8-d27b7ee19bad" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_315f1c90-116f-46a2-b7a8-d27b7ee19bad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ec22a63d-f6f8-471c-ae05-437774ba373b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_315f1c90-116f-46a2-b7a8-d27b7ee19bad" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ec22a63d-f6f8-471c-ae05-437774ba373b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a8129abb-2246-4e6f-a1c3-ed6bedbe33cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a8129abb-2246-4e6f-a1c3-ed6bedbe33cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a8129abb-2246-4e6f-a1c3-ed6bedbe33cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a8129abb-2246-4e6f-a1c3-ed6bedbe33cd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a8129abb-2246-4e6f-a1c3-ed6bedbe33cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9341c44d-30b6-4705-979e-6f0cfed3b9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a8129abb-2246-4e6f-a1c3-ed6bedbe33cd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9341c44d-30b6-4705-979e-6f0cfed3b9d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_63e57ca3-594e-4bb7-9db8-23234227b9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9341c44d-30b6-4705-979e-6f0cfed3b9d9" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_63e57ca3-594e-4bb7-9db8-23234227b9b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cc17e493-ba4a-47cd-b125-943809590c66" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_srt_RangeAxis_cc17e493-ba4a-47cd-b125-943809590c66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cc17e493-ba4a-47cd-b125-943809590c66_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cc17e493-ba4a-47cd-b125-943809590c66" xlink:to="loc_srt_RangeMember_cc17e493-ba4a-47cd-b125-943809590c66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d237ba6-bc75-4afd-96c3-098f28ab095e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cc17e493-ba4a-47cd-b125-943809590c66" xlink:to="loc_srt_RangeMember_5d237ba6-bc75-4afd-96c3-098f28ab095e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6232d968-166d-4fec-946b-619bb43425f4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5d237ba6-bc75-4afd-96c3-098f28ab095e" xlink:to="loc_srt_MinimumMember_6232d968-166d-4fec-946b-619bb43425f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_105f8949-fd20-45b5-94c2-f2d589468fdb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5d237ba6-bc75-4afd-96c3-098f28ab095e" xlink:to="loc_srt_MaximumMember_105f8949-fd20-45b5-94c2-f2d589468fdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_36a61bce-22e9-4b18-8e90-26e81ab79f19" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_srt_StatementScenarioAxis_36a61bce-22e9-4b18-8e90-26e81ab79f19" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_36a61bce-22e9-4b18-8e90-26e81ab79f19_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_36a61bce-22e9-4b18-8e90-26e81ab79f19" xlink:to="loc_srt_ScenarioUnspecifiedDomain_36a61bce-22e9-4b18-8e90-26e81ab79f19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9519de84-1fd8-474e-9c87-8d37c493f9ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_36a61bce-22e9-4b18-8e90-26e81ab79f19" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9519de84-1fd8-474e-9c87-8d37c493f9ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_77182b29-4140-47b9-8f44-13245f47c957" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9519de84-1fd8-474e-9c87-8d37c493f9ca" xlink:to="loc_srt_ScenarioForecastMember_77182b29-4140-47b9-8f44-13245f47c957" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4a4483c6-a508-4b89-98fb-96a591e91443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4a4483c6-a508-4b89-98fb-96a591e91443" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4a4483c6-a508-4b89-98fb-96a591e91443_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4a4483c6-a508-4b89-98fb-96a591e91443" xlink:to="loc_us-gaap_SegmentDomain_4a4483c6-a508-4b89-98fb-96a591e91443_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fcfba54a-e414-4794-8a85-373490de9adb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4a4483c6-a508-4b89-98fb-96a591e91443" xlink:to="loc_us-gaap_SegmentDomain_fcfba54a-e414-4794-8a85-373490de9adb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_ac93d5f5-956e-43e1-980a-b3256832b366" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fcfba54a-e414-4794-8a85-373490de9adb" xlink:to="loc_cah_GMPDMember_ac93d5f5-956e-43e1-980a-b3256832b366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_b64f1181-7927-4dde-9a88-b32709d1ac63" xlink:href="cah-20240930.xsd#cah_GoodwillImpairmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_cah_GoodwillImpairmentAxis_b64f1181-7927-4dde-9a88-b32709d1ac63" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_b64f1181-7927-4dde-9a88-b32709d1ac63_default" xlink:href="cah-20240930.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_GoodwillImpairmentAxis_b64f1181-7927-4dde-9a88-b32709d1ac63" xlink:to="loc_cah_GoodwillImpairmentDomain_b64f1181-7927-4dde-9a88-b32709d1ac63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_c131e694-6946-431d-991d-41683e4b9551" xlink:href="cah-20240930.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_GoodwillImpairmentAxis_b64f1181-7927-4dde-9a88-b32709d1ac63" xlink:to="loc_cah_GoodwillImpairmentDomain_c131e694-6946-431d-991d-41683e4b9551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FY24Q1GoodwillImpairmentGMPDMember_b40807ff-d19f-4600-81b2-c2a89be0e54e" xlink:href="cah-20240930.xsd#cah_FY24Q1GoodwillImpairmentGMPDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_c131e694-6946-431d-991d-41683e4b9551" xlink:to="loc_cah_FY24Q1GoodwillImpairmentGMPDMember_b40807ff-d19f-4600-81b2-c2a89be0e54e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_339b10c6-6782-47ca-a5ea-4f366a857090" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_339b10c6-6782-47ca-a5ea-4f366a857090" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_339b10c6-6782-47ca-a5ea-4f366a857090_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_339b10c6-6782-47ca-a5ea-4f366a857090" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_339b10c6-6782-47ca-a5ea-4f366a857090_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_11d493eb-e0a7-4f5a-b22c-7c919b0e7b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_339b10c6-6782-47ca-a5ea-4f366a857090" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_11d493eb-e0a7-4f5a-b22c-7c919b0e7b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f13d66f3-32ac-413c-bdcf-e48e3eb25bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_11d493eb-e0a7-4f5a-b22c-7c919b0e7b0c" xlink:to="loc_us-gaap_SubsequentEventMember_f13d66f3-32ac-413c-bdcf-e48e3eb25bfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5ef6c877-5cdc-442d-ab32-ebc91fddbd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5ef6c877-5cdc-442d-ab32-ebc91fddbd7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b1b837f4-0e36-4f8c-a915-bd9cbb4aaec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b1b837f4-0e36-4f8c-a915-bd9cbb4aaec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_28ec2044-109f-4ba7-8d1b-8f6c21f6b084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_28ec2044-109f-4ba7-8d1b-8f6c21f6b084" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2dac0162-da54-4de5-9c84-75a50a1a24e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2dac0162-da54-4de5-9c84-75a50a1a24e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a34a6738-3efb-411b-84cf-43cffd7d9528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a34a6738-3efb-411b-84cf-43cffd7d9528" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_ef17b2b7-0e0d-4b58-b26d-f7f3500b6ded" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_ef17b2b7-0e0d-4b58-b26d-f7f3500b6ded" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_4ec04e5a-5aac-484e-833f-7b259692e942" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_OpenTaxYear_4ec04e5a-5aac-484e-833f-7b259692e942" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_99723caf-b0c9-4ddc-a0b9-fa387948dc39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_99723caf-b0c9-4ddc-a0b9-fa387948dc39" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b1baf2e5-fb9c-45e4-aa92-954db41e0b57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b1baf2e5-fb9c-45e4-aa92-954db41e0b57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77dbdac2-0431-482e-8652-8fd618e6f27b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b1baf2e5-fb9c-45e4-aa92-954db41e0b57" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77dbdac2-0431-482e-8652-8fd618e6f27b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_77dbdac2-0431-482e-8652-8fd618e6f27b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77dbdac2-0431-482e-8652-8fd618e6f27b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_77dbdac2-0431-482e-8652-8fd618e6f27b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e234d404-d0f3-4d81-864c-9ea09687975c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77dbdac2-0431-482e-8652-8fd618e6f27b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e234d404-d0f3-4d81-864c-9ea09687975c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5aaa5dcc-a67d-4137-91df-fc7ecb5dd8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e234d404-d0f3-4d81-864c-9ea09687975c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5aaa5dcc-a67d-4137-91df-fc7ecb5dd8a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98fa7068-dc97-4c37-88cd-67157c17adb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b1baf2e5-fb9c-45e4-aa92-954db41e0b57" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98fa7068-dc97-4c37-88cd-67157c17adb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98fa7068-dc97-4c37-88cd-67157c17adb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98fa7068-dc97-4c37-88cd-67157c17adb3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98fa7068-dc97-4c37-88cd-67157c17adb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae8127ca-3068-4485-9025-e5e8f9c0541c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98fa7068-dc97-4c37-88cd-67157c17adb3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae8127ca-3068-4485-9025-e5e8f9c0541c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2c497f51-87d3-434b-99e9-f648d49935ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae8127ca-3068-4485-9025-e5e8f9c0541c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2c497f51-87d3-434b-99e9-f648d49935ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0984e45f-fdd6-419b-95ff-8419c27d6361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae8127ca-3068-4485-9025-e5e8f9c0541c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0984e45f-fdd6-419b-95ff-8419c27d6361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_378a3fd6-d4a1-4c3d-9487-be0161450d43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae8127ca-3068-4485-9025-e5e8f9c0541c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_378a3fd6-d4a1-4c3d-9487-be0161450d43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member_0b4e72d8-892e-4e9d-9881-89aba592531d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae8127ca-3068-4485-9025-e5e8f9c0541c" xlink:to="loc_us-gaap_FairValueInputsLevel12And3Member_0b4e72d8-892e-4e9d-9881-89aba592531d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3a54a59f-3104-4347-a0be-d08ad0afc030" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b1baf2e5-fb9c-45e4-aa92-954db41e0b57" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3a54a59f-3104-4347-a0be-d08ad0afc030" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3a54a59f-3104-4347-a0be-d08ad0afc030_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3a54a59f-3104-4347-a0be-d08ad0afc030" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3a54a59f-3104-4347-a0be-d08ad0afc030_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0591424b-55b8-475e-8974-9f7896f3d786" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3a54a59f-3104-4347-a0be-d08ad0afc030" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0591424b-55b8-475e-8974-9f7896f3d786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TransactionDataSystemInvestmentMember_00160ae1-b0d7-4581-a3a8-5d6464916bf3" xlink:href="cah-20240930.xsd#cah_TransactionDataSystemInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0591424b-55b8-475e-8974-9f7896f3d786" xlink:to="loc_cah_TransactionDataSystemInvestmentMember_00160ae1-b0d7-4581-a3a8-5d6464916bf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1a6c8ea5-b432-4d1a-af6c-ae6ed1fb106a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1a6c8ea5-b432-4d1a-af6c-ae6ed1fb106a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ddd64fda-d719-4e88-9533-4aac6ae953c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ddd64fda-d719-4e88-9533-4aac6ae953c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_48029c02-6452-4e01-b1b6-1485e41829fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_48029c02-6452-4e01-b1b6-1485e41829fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_8e82d5df-7592-4ccb-ba08-870d67d3a2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_8e82d5df-7592-4ccb-ba08-870d67d3a2c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_223ec661-9e70-4d9c-a589-dd3b26f19e20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_223ec661-9e70-4d9c-a589-dd3b26f19e20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_0e270d1b-87d7-4478-99b3-3f2635864ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_19128b3a-8064-4d30-85d3-0e33666c11c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_19128b3a-8064-4d30-85d3-0e33666c11c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19128b3a-8064-4d30-85d3-0e33666c11c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19128b3a-8064-4d30-85d3-0e33666c11c6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19128b3a-8064-4d30-85d3-0e33666c11c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_16478c0f-abe7-483f-88fe-1d4ddc3cbccd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19128b3a-8064-4d30-85d3-0e33666c11c6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_16478c0f-abe7-483f-88fe-1d4ddc3cbccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_e7a828e2-bd64-464c-940c-6c8c8666ead0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_16478c0f-abe7-483f-88fe-1d4ddc3cbccd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_e7a828e2-bd64-464c-940c-6c8c8666ead0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_79426e41-84a7-46cc-9405-32b19544581d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_us-gaap_HedgingDesignationAxis_79426e41-84a7-46cc-9405-32b19544581d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_79426e41-84a7-46cc-9405-32b19544581d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_79426e41-84a7-46cc-9405-32b19544581d" xlink:to="loc_us-gaap_HedgingDesignationDomain_79426e41-84a7-46cc-9405-32b19544581d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d9683714-0795-436a-8c47-36a016d70eea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_79426e41-84a7-46cc-9405-32b19544581d" xlink:to="loc_us-gaap_HedgingDesignationDomain_d9683714-0795-436a-8c47-36a016d70eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d3ce4609-61ad-472e-b689-5d291e7b1a74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_d9683714-0795-436a-8c47-36a016d70eea" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d3ce4609-61ad-472e-b689-5d291e7b1a74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_64c5013f-0840-4859-8906-d688ceb10405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_d9683714-0795-436a-8c47-36a016d70eea" xlink:to="loc_us-gaap_NondesignatedMember_64c5013f-0840-4859-8906-d688ceb10405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8df6a09a-5e98-45b3-93c4-dad2bb40dac9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8df6a09a-5e98-45b3-93c4-dad2bb40dac9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8df6a09a-5e98-45b3-93c4-dad2bb40dac9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8df6a09a-5e98-45b3-93c4-dad2bb40dac9" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8df6a09a-5e98-45b3-93c4-dad2bb40dac9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f6babc92-5217-4c91-893e-ec546399bd98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8df6a09a-5e98-45b3-93c4-dad2bb40dac9" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f6babc92-5217-4c91-893e-ec546399bd98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_18375c45-7652-47f5-bbc5-107d7705ef77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f6babc92-5217-4c91-893e-ec546399bd98" xlink:to="loc_us-gaap_FairValueHedgingMember_18375c45-7652-47f5-bbc5-107d7705ef77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_8b5b1cee-d91a-4a55-97ea-e793b15cc8da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f6babc92-5217-4c91-893e-ec546399bd98" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_8b5b1cee-d91a-4a55-97ea-e793b15cc8da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2d79f38b-3ecb-485e-862b-55d0b20e169a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f6babc92-5217-4c91-893e-ec546399bd98" xlink:to="loc_us-gaap_CashFlowHedgingMember_2d79f38b-3ecb-485e-862b-55d0b20e169a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bd4716d9-f5a5-4842-9bea-a80716d2db0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bd4716d9-f5a5-4842-9bea-a80716d2db0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bd4716d9-f5a5-4842-9bea-a80716d2db0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bd4716d9-f5a5-4842-9bea-a80716d2db0f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bd4716d9-f5a5-4842-9bea-a80716d2db0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4f36bdbe-c115-4859-a7e5-b48083ce6367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bd4716d9-f5a5-4842-9bea-a80716d2db0f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4f36bdbe-c115-4859-a7e5-b48083ce6367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_c0805226-3678-44b3-a207-51b3e01c6bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4f36bdbe-c115-4859-a7e5-b48083ce6367" xlink:to="loc_us-gaap_ForeignExchangeContractMember_c0805226-3678-44b3-a207-51b3e01c6bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_4872678d-a87c-460b-af00-41fb8da970b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4f36bdbe-c115-4859-a7e5-b48083ce6367" xlink:to="loc_us-gaap_InterestRateSwapMember_4872678d-a87c-460b-af00-41fb8da970b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_ecfe7fb7-2476-44be-a4ac-60bca3829917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4f36bdbe-c115-4859-a7e5-b48083ce6367" xlink:to="loc_us-gaap_CashFlowHedgingMember_ecfe7fb7-2476-44be-a4ac-60bca3829917" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_ba9f5cd5-8cf9-417f-aba7-2e4ad07eecb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4f36bdbe-c115-4859-a7e5-b48083ce6367" xlink:to="loc_us-gaap_CurrencySwapMember_ba9f5cd5-8cf9-417f-aba7-2e4ad07eecb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateAxis_77845deb-2afe-453e-95aa-b63a49846c89" xlink:href="cah-20240930.xsd#cah_MaturityDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_cah_MaturityDateAxis_77845deb-2afe-453e-95aa-b63a49846c89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain_77845deb-2afe-453e-95aa-b63a49846c89_default" xlink:href="cah-20240930.xsd#cah_MaturityDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_MaturityDateAxis_77845deb-2afe-453e-95aa-b63a49846c89" xlink:to="loc_cah_MaturityDateDomain_77845deb-2afe-453e-95aa-b63a49846c89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain_66fcd75c-c99b-4e2d-933d-e7823009061f" xlink:href="cah-20240930.xsd#cah_MaturityDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_MaturityDateAxis_77845deb-2afe-453e-95aa-b63a49846c89" xlink:to="loc_cah_MaturityDateDomain_66fcd75c-c99b-4e2d-933d-e7823009061f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_September2025Member_89d76aee-2957-4092-ae03-06b0ef2e44d3" xlink:href="cah-20240930.xsd#cah_September2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_MaturityDateDomain_66fcd75c-c99b-4e2d-933d-e7823009061f" xlink:to="loc_cah_September2025Member_89d76aee-2957-4092-ae03-06b0ef2e44d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_June2027Member_da2a7e75-d361-42d4-817b-6823b804e63f" xlink:href="cah-20240930.xsd#cah_June2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_MaturityDateDomain_66fcd75c-c99b-4e2d-933d-e7823009061f" xlink:to="loc_cah_June2027Member_da2a7e75-d361-42d4-817b-6823b804e63f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedAxis_86beb5ca-2d54-4f9a-92d5-5a60ff557bc2" xlink:href="cah-20240930.xsd#cah_DateInitiatedAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_cah_DateInitiatedAxis_86beb5ca-2d54-4f9a-92d5-5a60ff557bc2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedDomain_86beb5ca-2d54-4f9a-92d5-5a60ff557bc2_default" xlink:href="cah-20240930.xsd#cah_DateInitiatedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_DateInitiatedAxis_86beb5ca-2d54-4f9a-92d5-5a60ff557bc2" xlink:to="loc_cah_DateInitiatedDomain_86beb5ca-2d54-4f9a-92d5-5a60ff557bc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedDomain_32f08784-47aa-4067-8860-a9865c856a87" xlink:href="cah-20240930.xsd#cah_DateInitiatedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_DateInitiatedAxis_86beb5ca-2d54-4f9a-92d5-5a60ff557bc2" xlink:to="loc_cah_DateInitiatedDomain_32f08784-47aa-4067-8860-a9865c856a87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_January2023Member_9d4ed951-8e8e-42d2-a78c-d9815e2263fa" xlink:href="cah-20240930.xsd#cah_January2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_DateInitiatedDomain_32f08784-47aa-4067-8860-a9865c856a87" xlink:to="loc_cah_January2023Member_9d4ed951-8e8e-42d2-a78c-d9815e2263fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_28c7b9ab-a7b7-411b-b9bf-51bb7550b870" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_srt_StatementScenarioAxis_28c7b9ab-a7b7-411b-b9bf-51bb7550b870" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_28c7b9ab-a7b7-411b-b9bf-51bb7550b870_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_28c7b9ab-a7b7-411b-b9bf-51bb7550b870" xlink:to="loc_srt_ScenarioUnspecifiedDomain_28c7b9ab-a7b7-411b-b9bf-51bb7550b870_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5266ceb4-ab60-4cfe-ad2c-be83e419458a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_28c7b9ab-a7b7-411b-b9bf-51bb7550b870" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5266ceb4-ab60-4cfe-ad2c-be83e419458a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6e9ebaf8-9666-4e34-bb1d-3e828e4b89dc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_5266ceb4-ab60-4cfe-ad2c-be83e419458a" xlink:to="loc_srt_ScenarioForecastMember_6e9ebaf8-9666-4e34-bb1d-3e828e4b89dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_549e56b6-8610-491a-9c3e-1025bf1d98ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_549e56b6-8610-491a-9c3e-1025bf1d98ff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_549e56b6-8610-491a-9c3e-1025bf1d98ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_549e56b6-8610-491a-9c3e-1025bf1d98ff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_549e56b6-8610-491a-9c3e-1025bf1d98ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5e81a9c5-0078-43c9-a207-44a77f92467a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_549e56b6-8610-491a-9c3e-1025bf1d98ff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5e81a9c5-0078-43c9-a207-44a77f92467a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6e407951-76c5-440e-a501-a8c57fbf710d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5e81a9c5-0078-43c9-a207-44a77f92467a" xlink:to="loc_us-gaap_SubsequentEventMember_6e407951-76c5-440e-a501-a8c57fbf710d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f65832a1-b95a-4ed1-9c2a-cef8315b090d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f65832a1-b95a-4ed1-9c2a-cef8315b090d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_010cc312-ea64-47cc-8db3-3213e704c38e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_010cc312-ea64-47cc-8db3-3213e704c38e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c6dc29b4-67f5-43c4-962e-709c3d73f343" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c6dc29b4-67f5-43c4-962e-709c3d73f343" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_579f7683-e919-4058-87cc-97c41a87e6af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_579f7683-e919-4058-87cc-97c41a87e6af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_4b8817a2-0bcb-4dae-819a-9ad6db275e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_4b8817a2-0bcb-4dae-819a-9ad6db275e1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_07b08003-071b-44a1-80a0-4372a38eae88" xlink:href="cah-20240930.xsd#cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_07b08003-071b-44a1-80a0-4372a38eae88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_bb2e380e-587f-47d4-9dde-efbffcb4660b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_bb2e380e-587f-47d4-9dde-efbffcb4660b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_341981b6-4bed-4394-b54b-69423c436a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_341981b6-4bed-4394-b54b-69423c436a9c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_b68ae645-79f7-4a77-a158-a6724097d56a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_b68ae645-79f7-4a77-a158-a6724097d56a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_9b2e9635-ad63-4f87-b234-83e79c90dad7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_9b2e9635-ad63-4f87-b234-83e79c90dad7" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f9ee3e5-fd02-43e4-a078-6ea5b2d5b4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd602c1f-2356-4e5c-b142-0d63339cd488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f9ee3e5-fd02-43e4-a078-6ea5b2d5b4d5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd602c1f-2356-4e5c-b142-0d63339cd488" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e1ce468-9f83-4b57-9bf8-6d8dee7b36b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd602c1f-2356-4e5c-b142-0d63339cd488" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e1ce468-9f83-4b57-9bf8-6d8dee7b36b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e1ce468-9f83-4b57-9bf8-6d8dee7b36b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e1ce468-9f83-4b57-9bf8-6d8dee7b36b9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e1ce468-9f83-4b57-9bf8-6d8dee7b36b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_72a2e674-413b-4eae-91e2-bbfe22cd9d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e1ce468-9f83-4b57-9bf8-6d8dee7b36b9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_72a2e674-413b-4eae-91e2-bbfe22cd9d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a0058822-fa37-440c-9c60-c8c652237b26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_72a2e674-413b-4eae-91e2-bbfe22cd9d2d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a0058822-fa37-440c-9c60-c8c652237b26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4654529b-e056-48ac-8663-94a2ec7e313f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f9ee3e5-fd02-43e4-a078-6ea5b2d5b4d5" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4654529b-e056-48ac-8663-94a2ec7e313f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_2e24bcdb-6f49-4550-b496-a057ae220928" xlink:href="cah-20240930.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f9ee3e5-fd02-43e4-a078-6ea5b2d5b4d5" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_2e24bcdb-6f49-4550-b496-a057ae220928" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_01a64422-2338-44c5-b11d-e6b4b0a339b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_01a64422-2338-44c5-b11d-e6b4b0a339b3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_984ddb11-6008-40f8-9c3f-329b16030bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_984ddb11-6008-40f8-9c3f-329b16030bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_984ddb11-6008-40f8-9c3f-329b16030bc2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_984ddb11-6008-40f8-9c3f-329b16030bc2" xlink:to="loc_us-gaap_LossContingencyNatureDomain_984ddb11-6008-40f8-9c3f-329b16030bc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b524c5a9-1e4d-4f9b-9341-d85e30b8536e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_984ddb11-6008-40f8-9c3f-329b16030bc2" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b524c5a9-1e4d-4f9b-9341-d85e30b8536e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_35e16f3a-5269-4615-ac4a-9c3440a1c09b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_35e16f3a-5269-4615-ac4a-9c3440a1c09b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_35e16f3a-5269-4615-ac4a-9c3440a1c09b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_35e16f3a-5269-4615-ac4a-9c3440a1c09b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_35e16f3a-5269-4615-ac4a-9c3440a1c09b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6ba9a259-8693-46df-8589-90bf2f223b11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_35e16f3a-5269-4615-ac4a-9c3440a1c09b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6ba9a259-8693-46df-8589-90bf2f223b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ebc4e5ed-42ee-4485-a901-3ff75d770356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6ba9a259-8693-46df-8589-90bf2f223b11" xlink:to="loc_us-gaap_SubsequentEventMember_ebc4e5ed-42ee-4485-a901-3ff75d770356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_557e3a44-f875-498a-953e-e11eca1776f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_557e3a44-f875-498a-953e-e11eca1776f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_557e3a44-f875-498a-953e-e11eca1776f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_557e3a44-f875-498a-953e-e11eca1776f2" xlink:to="loc_us-gaap_EquityComponentDomain_557e3a44-f875-498a-953e-e11eca1776f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_14f81433-8b1a-41e4-bf92-7775b63aa30d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_557e3a44-f875-498a-953e-e11eca1776f2" xlink:to="loc_us-gaap_EquityComponentDomain_14f81433-8b1a-41e4-bf92-7775b63aa30d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_0d413207-c184-4c05-8799-9aceaea96d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14f81433-8b1a-41e4-bf92-7775b63aa30d" xlink:to="loc_us-gaap_TreasuryStockCommonMember_0d413207-c184-4c05-8799-9aceaea96d4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c4e2227-4f03-404f-9a5d-ae52441b3d56" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_srt_RangeAxis_0c4e2227-4f03-404f-9a5d-ae52441b3d56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c4e2227-4f03-404f-9a5d-ae52441b3d56_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0c4e2227-4f03-404f-9a5d-ae52441b3d56" xlink:to="loc_srt_RangeMember_0c4e2227-4f03-404f-9a5d-ae52441b3d56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_29d73e7f-9f42-461f-807b-97a4ed799075" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0c4e2227-4f03-404f-9a5d-ae52441b3d56" xlink:to="loc_srt_RangeMember_29d73e7f-9f42-461f-807b-97a4ed799075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1143a1a4-cf88-4233-a26c-ed1a025b48c1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_29d73e7f-9f42-461f-807b-97a4ed799075" xlink:to="loc_srt_MinimumMember_1143a1a4-cf88-4233-a26c-ed1a025b48c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cf23b282-c07f-4fee-8da8-5bcdce755a02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_us-gaap_AwardTypeAxis_cf23b282-c07f-4fee-8da8-5bcdce755a02" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf23b282-c07f-4fee-8da8-5bcdce755a02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cf23b282-c07f-4fee-8da8-5bcdce755a02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf23b282-c07f-4fee-8da8-5bcdce755a02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b18e2f84-2918-42e3-898a-470ee2781d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cf23b282-c07f-4fee-8da8-5bcdce755a02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b18e2f84-2918-42e3-898a-470ee2781d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_db753767-f29a-4d49-8bbf-43453da0fd66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b18e2f84-2918-42e3-898a-470ee2781d4b" xlink:to="loc_us-gaap_PerformanceSharesMember_db753767-f29a-4d49-8bbf-43453da0fd66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_3398dbf6-71f9-4e07-a6cc-3135c6676c06" xlink:href="cah-20240930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_3398dbf6-71f9-4e07-a6cc-3135c6676c06" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_3398dbf6-71f9-4e07-a6cc-3135c6676c06_default" xlink:href="cah-20240930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_3398dbf6-71f9-4e07-a6cc-3135c6676c06" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_3398dbf6-71f9-4e07-a6cc-3135c6676c06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_5ceccd5c-faeb-4796-b3d0-c7ed98f51aac" xlink:href="cah-20240930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_3398dbf6-71f9-4e07-a6cc-3135c6676c06" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_5ceccd5c-faeb-4796-b3d0-c7ed98f51aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_21250471-2bec-45da-a4f9-c1d5cbe55ef9" xlink:href="cah-20240930.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_5ceccd5c-faeb-4796-b3d0-c7ed98f51aac" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_21250471-2bec-45da-a4f9-c1d5cbe55ef9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A375MillionShareRepurchaseProgramMember_2fb90bc7-00d8-4dc2-8bb6-3f35e666a90b" xlink:href="cah-20240930.xsd#cah_A375MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_5ceccd5c-faeb-4796-b3d0-c7ed98f51aac" xlink:to="loc_cah_A375MillionShareRepurchaseProgramMember_2fb90bc7-00d8-4dc2-8bb6-3f35e666a90b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_472b8395-939d-4be5-97b1-987d89519128" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_srt_ShareRepurchaseProgramAxis_472b8395-939d-4be5-97b1-987d89519128" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_472b8395-939d-4be5-97b1-987d89519128_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_472b8395-939d-4be5-97b1-987d89519128" xlink:to="loc_srt_ShareRepurchaseProgramDomain_472b8395-939d-4be5-97b1-987d89519128_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_2f80e4fd-a51d-4dd0-874b-d0963faa9802" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_472b8395-939d-4be5-97b1-987d89519128" xlink:to="loc_srt_ShareRepurchaseProgramDomain_2f80e4fd-a51d-4dd0-874b-d0963faa9802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_7a10a30c-35a3-45d7-8c84-782c36f99cb0" xlink:href="cah-20240930.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_2f80e4fd-a51d-4dd0-874b-d0963faa9802" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_7a10a30c-35a3-45d7-8c84-782c36f99cb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A375MillionShareRepurchaseProgramMember_ed95c258-eab6-4efb-bfd3-aa6531750e74" xlink:href="cah-20240930.xsd#cah_A375MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_2f80e4fd-a51d-4dd0-874b-d0963faa9802" xlink:to="loc_cah_A375MillionShareRepurchaseProgramMember_ed95c258-eab6-4efb-bfd3-aa6531750e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_be750d49-7807-4352-99eb-d603045586ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01a64422-2338-44c5-b11d-e6b4b0a339b3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_be750d49-7807-4352-99eb-d603045586ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_23c69a65-caf1-4dd8-8f54-f1fda5e9f2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01a64422-2338-44c5-b11d-e6b4b0a339b3" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_23c69a65-caf1-4dd8-8f54-f1fda5e9f2e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_78e7c835-e120-413a-b861-7e410b24b0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_01a64422-2338-44c5-b11d-e6b4b0a339b3" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_78e7c835-e120-413a-b861-7e410b24b0e9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_1dc336f7-8498-4000-81f9-2ee0e00655fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3619070-a05b-4c9e-bd38-c453bc1fa601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_1dc336f7-8498-4000-81f9-2ee0e00655fd" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3619070-a05b-4c9e-bd38-c453bc1fa601" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_19c7f2ff-5228-40a7-a10b-2320590791e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3619070-a05b-4c9e-bd38-c453bc1fa601" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_19c7f2ff-5228-40a7-a10b-2320590791e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_19c7f2ff-5228-40a7-a10b-2320590791e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19c7f2ff-5228-40a7-a10b-2320590791e8" xlink:to="loc_us-gaap_EquityComponentDomain_19c7f2ff-5228-40a7-a10b-2320590791e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d744fbc0-4fe3-4c07-9348-64ded95901bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19c7f2ff-5228-40a7-a10b-2320590791e8" xlink:to="loc_us-gaap_EquityComponentDomain_d744fbc0-4fe3-4c07-9348-64ded95901bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_25788739-7df0-4ca1-9ffc-e12d2d136113" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d744fbc0-4fe3-4c07-9348-64ded95901bc" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_25788739-7df0-4ca1-9ffc-e12d2d136113" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_a219473f-9ec5-4b35-90ac-1a659e1f77a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d744fbc0-4fe3-4c07-9348-64ded95901bc" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_a219473f-9ec5-4b35-90ac-1a659e1f77a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_4311d6fa-f816-4666-9906-880a51796e28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d744fbc0-4fe3-4c07-9348-64ded95901bc" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_4311d6fa-f816-4666-9906-880a51796e28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_444e0c4e-2229-4e33-a0d7-9da61482902a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d744fbc0-4fe3-4c07-9348-64ded95901bc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_444e0c4e-2229-4e33-a0d7-9da61482902a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_1dc336f7-8498-4000-81f9-2ee0e00655fd" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95bcfbfc-d334-44f6-bc6a-6d4c3f720e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95bcfbfc-d334-44f6-bc6a-6d4c3f720e2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6a40d92b-2786-47bf-b89d-4821e33c19f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6a40d92b-2786-47bf-b89d-4821e33c19f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d06cda34-3090-4c2e-b9b7-688f44870a21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d06cda34-3090-4c2e-b9b7-688f44870a21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0b77cbfa-92d4-4ef3-b032-8f8423e35521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0b77cbfa-92d4-4ef3-b032-8f8423e35521" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_86560a1d-b42b-47bb-9339-0d4d6c898511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_86560a1d-b42b-47bb-9339-0d4d6c898511" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7463db72-480f-47df-9d1f-5669150198b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#SegmentInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f5a5b1a9-c18e-42ee-b807-24edda2e8c59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a510339e-c520-4747-8ca6-4fdd71dde5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f5a5b1a9-c18e-42ee-b807-24edda2e8c59" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a510339e-c520-4747-8ca6-4fdd71dde5f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3dc6f6df-cd45-43fa-bde6-eef8faa7a6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a510339e-c520-4747-8ca6-4fdd71dde5f0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3dc6f6df-cd45-43fa-bde6-eef8faa7a6b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3dc6f6df-cd45-43fa-bde6-eef8faa7a6b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3dc6f6df-cd45-43fa-bde6-eef8faa7a6b0" xlink:to="loc_us-gaap_SegmentDomain_3dc6f6df-cd45-43fa-bde6-eef8faa7a6b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_af93582c-104c-4fb9-a091-04a2deac5069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3dc6f6df-cd45-43fa-bde6-eef8faa7a6b0" xlink:to="loc_us-gaap_SegmentDomain_af93582c-104c-4fb9-a091-04a2deac5069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_8176be35-4249-4b6b-98cd-3d7401eff1a6" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_af93582c-104c-4fb9-a091-04a2deac5069" xlink:to="loc_cah_GMPDMember_8176be35-4249-4b6b-98cd-3d7401eff1a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_2b7c98fe-9fca-424e-ae92-274a6aba1d74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_af93582c-104c-4fb9-a091-04a2deac5069" xlink:to="loc_us-gaap_AllOtherSegmentsMember_2b7c98fe-9fca-424e-ae92-274a6aba1d74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_cf81af55-8fe9-45b6-a763-2aa195fe33a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f5a5b1a9-c18e-42ee-b807-24edda2e8c59" xlink:to="loc_us-gaap_NumberOfReportableSegments_cf81af55-8fe9-45b6-a763-2aa195fe33a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_33f6249e-1d97-47b0-aa37-5484891ea81e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f5a5b1a9-c18e-42ee-b807-24edda2e8c59" xlink:to="loc_us-gaap_NumberOfOperatingSegments_33f6249e-1d97-47b0-aa37-5484891ea81e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e026cf1f-6f87-48dc-80b0-6c3a56cbc99e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f5a5b1a9-c18e-42ee-b807-24edda2e8c59" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e026cf1f-6f87-48dc-80b0-6c3a56cbc99e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_d3b11069-f805-4494-8642-a693c3a71d0a" xlink:href="cah-20240930.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f5a5b1a9-c18e-42ee-b807-24edda2e8c59" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_d3b11069-f805-4494-8642-a693c3a71d0a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_698f1d8d-1cd2-4348-8d14-b6e3b72370f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_5d2c6458-5b46-4b0f-9e4a-b01bd400b96c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_698f1d8d-1cd2-4348-8d14-b6e3b72370f4" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_5d2c6458-5b46-4b0f-9e4a-b01bd400b96c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_81ae65f7-268e-4c9b-a34e-439a9248d74a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_5d2c6458-5b46-4b0f-9e4a-b01bd400b96c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_81ae65f7-268e-4c9b-a34e-439a9248d74a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_81ae65f7-268e-4c9b-a34e-439a9248d74a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_81ae65f7-268e-4c9b-a34e-439a9248d74a" xlink:to="loc_us-gaap_SegmentDomain_81ae65f7-268e-4c9b-a34e-439a9248d74a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_63be7a8c-cad8-4b58-b76d-e6cb1511cde3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_81ae65f7-268e-4c9b-a34e-439a9248d74a" xlink:to="loc_us-gaap_SegmentDomain_63be7a8c-cad8-4b58-b76d-e6cb1511cde3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_2fde1ce2-0f60-4806-b6b3-325885eafa56" xlink:href="cah-20240930.xsd#cah_PharmaceuticalAndSpecialtySolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_63be7a8c-cad8-4b58-b76d-e6cb1511cde3" xlink:to="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_2fde1ce2-0f60-4806-b6b3-325885eafa56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_6bb40dff-a8f7-4df3-8384-7a815cde04e3" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_63be7a8c-cad8-4b58-b76d-e6cb1511cde3" xlink:to="loc_cah_GMPDMember_6bb40dff-a8f7-4df3-8384-7a815cde04e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_f9eafcde-27a3-45d6-99f6-bc30f688eb15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_63be7a8c-cad8-4b58-b76d-e6cb1511cde3" xlink:to="loc_us-gaap_AllOtherSegmentsMember_f9eafcde-27a3-45d6-99f6-bc30f688eb15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_523df5aa-9ca2-469b-be1f-46b33e40bc06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_5d2c6458-5b46-4b0f-9e4a-b01bd400b96c" xlink:to="loc_us-gaap_SubsegmentsAxis_523df5aa-9ca2-469b-be1f-46b33e40bc06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_523df5aa-9ca2-469b-be1f-46b33e40bc06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_523df5aa-9ca2-469b-be1f-46b33e40bc06" xlink:to="loc_us-gaap_SubsegmentsDomain_523df5aa-9ca2-469b-be1f-46b33e40bc06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_f07dfe46-c65d-486d-9684-02e523daef37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_523df5aa-9ca2-469b-be1f-46b33e40bc06" xlink:to="loc_us-gaap_SubsegmentsDomain_f07dfe46-c65d-486d-9684-02e523daef37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearAndPrecisionHealthSolutionsMember_8a0b2a18-6833-4d5f-a030-9c8f8f81cce4" xlink:href="cah-20240930.xsd#cah_NuclearAndPrecisionHealthSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_f07dfe46-c65d-486d-9684-02e523daef37" xlink:to="loc_cah_NuclearAndPrecisionHealthSolutionsMember_8a0b2a18-6833-4d5f-a030-9c8f8f81cce4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AtHomeSolutionsMember_72d920c0-cc9b-48e4-8c95-709a158c87ac" xlink:href="cah-20240930.xsd#cah_AtHomeSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_f07dfe46-c65d-486d-9684-02e523daef37" xlink:to="loc_cah_AtHomeSolutionsMember_72d920c0-cc9b-48e4-8c95-709a158c87ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OptiFreightMember_da4f2eb6-1414-4316-8768-9d0ae8231823" xlink:href="cah-20240930.xsd#cah_OptiFreightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_f07dfe46-c65d-486d-9684-02e523daef37" xlink:to="loc_cah_OptiFreightMember_da4f2eb6-1414-4316-8768-9d0ae8231823" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_fc873152-c5c1-49c9-8b86-bba2051fc063" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_5d2c6458-5b46-4b0f-9e4a-b01bd400b96c" xlink:to="loc_srt_ConsolidationItemsAxis_fc873152-c5c1-49c9-8b86-bba2051fc063" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fc873152-c5c1-49c9-8b86-bba2051fc063_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_fc873152-c5c1-49c9-8b86-bba2051fc063" xlink:to="loc_srt_ConsolidationItemsDomain_fc873152-c5c1-49c9-8b86-bba2051fc063_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ecf6be3c-4971-4744-85ab-a4bb25f130ba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_fc873152-c5c1-49c9-8b86-bba2051fc063" xlink:to="loc_srt_ConsolidationItemsDomain_ecf6be3c-4971-4744-85ab-a4bb25f130ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_b031960d-6646-4ac6-a793-75fd1b16378c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ecf6be3c-4971-4744-85ab-a4bb25f130ba" xlink:to="loc_us-gaap_OperatingSegmentsMember_b031960d-6646-4ac6-a793-75fd1b16378c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_3a854225-aea5-4835-a92f-276f2545c883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ecf6be3c-4971-4744-85ab-a4bb25f130ba" xlink:to="loc_us-gaap_CorporateNonSegmentMember_3a854225-aea5-4835-a92f-276f2545c883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_42cc7670-5e13-4808-ab19-e19245721eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_698f1d8d-1cd2-4348-8d14-b6e3b72370f4" xlink:to="loc_us-gaap_Revenues_42cc7670-5e13-4808-ab19-e19245721eb9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#SegmentInformationRevenuebyGeographicalSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicLineItems_e60dbfef-5f2d-4654-9cce-db11206997a6" xlink:href="cah-20240930.xsd#cah_SegmentRevenuebyGeographicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicTable_5b1705a2-a0d5-4401-bbd8-5fb4ea4c60f9" xlink:href="cah-20240930.xsd#cah_SegmentRevenuebyGeographicTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems_e60dbfef-5f2d-4654-9cce-db11206997a6" xlink:to="loc_cah_SegmentRevenuebyGeographicTable_5b1705a2-a0d5-4401-bbd8-5fb4ea4c60f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_014e151d-e008-420f-8711-f9e384b185f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_5b1705a2-a0d5-4401-bbd8-5fb4ea4c60f9" xlink:to="loc_srt_ConsolidationItemsAxis_014e151d-e008-420f-8711-f9e384b185f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_014e151d-e008-420f-8711-f9e384b185f9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_014e151d-e008-420f-8711-f9e384b185f9" xlink:to="loc_srt_ConsolidationItemsDomain_014e151d-e008-420f-8711-f9e384b185f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b11b56f1-d65b-4e1d-97eb-70a15e2a1cd3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_014e151d-e008-420f-8711-f9e384b185f9" xlink:to="loc_srt_ConsolidationItemsDomain_b11b56f1-d65b-4e1d-97eb-70a15e2a1cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_b3de8c9e-52a7-402a-bbff-8881aec3773f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_b11b56f1-d65b-4e1d-97eb-70a15e2a1cd3" xlink:to="loc_us-gaap_OperatingSegmentsMember_b3de8c9e-52a7-402a-bbff-8881aec3773f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c2876879-5780-403f-a6ac-7fe2f8fbb495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_b11b56f1-d65b-4e1d-97eb-70a15e2a1cd3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c2876879-5780-403f-a6ac-7fe2f8fbb495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8f224dbc-43c6-48e9-8a27-fb4cc45e9362" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_5b1705a2-a0d5-4401-bbd8-5fb4ea4c60f9" xlink:to="loc_srt_StatementGeographicalAxis_8f224dbc-43c6-48e9-8a27-fb4cc45e9362" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8f224dbc-43c6-48e9-8a27-fb4cc45e9362_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8f224dbc-43c6-48e9-8a27-fb4cc45e9362" xlink:to="loc_srt_SegmentGeographicalDomain_8f224dbc-43c6-48e9-8a27-fb4cc45e9362_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_729d68c5-c364-4acc-9617-eec63eb6de3f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8f224dbc-43c6-48e9-8a27-fb4cc45e9362" xlink:to="loc_srt_SegmentGeographicalDomain_729d68c5-c364-4acc-9617-eec63eb6de3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_aad5f735-0f04-46d9-960f-77046d26127f" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_729d68c5-c364-4acc-9617-eec63eb6de3f" xlink:to="loc_country_US_aad5f735-0f04-46d9-960f-77046d26127f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_802d9e0d-5171-4711-a34b-276226e5f030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_729d68c5-c364-4acc-9617-eec63eb6de3f" xlink:to="loc_us-gaap_NonUsMember_802d9e0d-5171-4711-a34b-276226e5f030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ba3834be-fa20-41ba-a57c-33c9da927f02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems_e60dbfef-5f2d-4654-9cce-db11206997a6" xlink:to="loc_us-gaap_Revenues_ba3834be-fa20-41ba-a57c-33c9da927f02" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a5c11a1e-162d-46e8-bb0e-a23f77ce9594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4f37fd54-6968-47cf-9949-16175f6e758c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a5c11a1e-162d-46e8-bb0e-a23f77ce9594" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4f37fd54-6968-47cf-9949-16175f6e758c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_603e7915-bd55-4e6e-ad45-1a90c1b6ae8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4f37fd54-6968-47cf-9949-16175f6e758c" xlink:to="loc_srt_ConsolidationItemsAxis_603e7915-bd55-4e6e-ad45-1a90c1b6ae8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_603e7915-bd55-4e6e-ad45-1a90c1b6ae8c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_603e7915-bd55-4e6e-ad45-1a90c1b6ae8c" xlink:to="loc_srt_ConsolidationItemsDomain_603e7915-bd55-4e6e-ad45-1a90c1b6ae8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_af54813d-d94c-4965-90b3-4ad055a5d8f7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_603e7915-bd55-4e6e-ad45-1a90c1b6ae8c" xlink:to="loc_srt_ConsolidationItemsDomain_af54813d-d94c-4965-90b3-4ad055a5d8f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9a14853d-9c3a-43df-a52f-8b07ecd5c2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_af54813d-d94c-4965-90b3-4ad055a5d8f7" xlink:to="loc_us-gaap_OperatingSegmentsMember_9a14853d-9c3a-43df-a52f-8b07ecd5c2a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_3945d3f6-11dc-4ccf-9b99-96e478eebae4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_af54813d-d94c-4965-90b3-4ad055a5d8f7" xlink:to="loc_us-gaap_CorporateNonSegmentMember_3945d3f6-11dc-4ccf-9b99-96e478eebae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a05b0e82-ae04-4601-9eb4-3442f4d05a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4f37fd54-6968-47cf-9949-16175f6e758c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a05b0e82-ae04-4601-9eb4-3442f4d05a2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a05b0e82-ae04-4601-9eb4-3442f4d05a2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a05b0e82-ae04-4601-9eb4-3442f4d05a2e" xlink:to="loc_us-gaap_SegmentDomain_a05b0e82-ae04-4601-9eb4-3442f4d05a2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d4bb644d-56bb-4a45-8808-1efea2493492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a05b0e82-ae04-4601-9eb4-3442f4d05a2e" xlink:to="loc_us-gaap_SegmentDomain_d4bb644d-56bb-4a45-8808-1efea2493492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_881ce644-4967-4f3b-8d4c-909783c64e2b" xlink:href="cah-20240930.xsd#cah_PharmaceuticalAndSpecialtySolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d4bb644d-56bb-4a45-8808-1efea2493492" xlink:to="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_881ce644-4967-4f3b-8d4c-909783c64e2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_43cc051f-b5fd-444a-be5f-db494f453dd6" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d4bb644d-56bb-4a45-8808-1efea2493492" xlink:to="loc_cah_GMPDMember_43cc051f-b5fd-444a-be5f-db494f453dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_528f7360-8b0e-41b9-b560-020c5dff0785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d4bb644d-56bb-4a45-8808-1efea2493492" xlink:to="loc_us-gaap_AllOtherSegmentsMember_528f7360-8b0e-41b9-b560-020c5dff0785" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_38de1a36-64b3-4a73-a67a-290135334e27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a5c11a1e-162d-46e8-bb0e-a23f77ce9594" xlink:to="loc_us-gaap_OperatingIncomeLoss_38de1a36-64b3-4a73-a67a-290135334e27" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8ab929a4-3e84-4cc8-9fbd-b1dd55b83dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_680b2c3a-d5fa-45ff-92f3-8fa1349853e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8ab929a4-3e84-4cc8-9fbd-b1dd55b83dc9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_680b2c3a-d5fa-45ff-92f3-8fa1349853e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2ccf875b-d0c3-4054-aa0c-c1b22b720d55" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_680b2c3a-d5fa-45ff-92f3-8fa1349853e3" xlink:to="loc_srt_ConsolidationItemsAxis_2ccf875b-d0c3-4054-aa0c-c1b22b720d55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2ccf875b-d0c3-4054-aa0c-c1b22b720d55_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_2ccf875b-d0c3-4054-aa0c-c1b22b720d55" xlink:to="loc_srt_ConsolidationItemsDomain_2ccf875b-d0c3-4054-aa0c-c1b22b720d55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e11d1c21-7611-4791-8300-e963390e62ff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_2ccf875b-d0c3-4054-aa0c-c1b22b720d55" xlink:to="loc_srt_ConsolidationItemsDomain_e11d1c21-7611-4791-8300-e963390e62ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_aed8fccc-033c-4090-8d42-2aea645c632d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e11d1c21-7611-4791-8300-e963390e62ff" xlink:to="loc_us-gaap_OperatingSegmentsMember_aed8fccc-033c-4090-8d42-2aea645c632d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e0a4d579-ae1c-484a-a5db-1e572ae5cc24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e11d1c21-7611-4791-8300-e963390e62ff" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e0a4d579-ae1c-484a-a5db-1e572ae5cc24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8890f9ee-ebd9-48d5-ab4b-af9687be3de5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_680b2c3a-d5fa-45ff-92f3-8fa1349853e3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8890f9ee-ebd9-48d5-ab4b-af9687be3de5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8890f9ee-ebd9-48d5-ab4b-af9687be3de5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8890f9ee-ebd9-48d5-ab4b-af9687be3de5" xlink:to="loc_us-gaap_SegmentDomain_8890f9ee-ebd9-48d5-ab4b-af9687be3de5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_67bddde4-a936-4d8e-9fe5-0b5d51823230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8890f9ee-ebd9-48d5-ab4b-af9687be3de5" xlink:to="loc_us-gaap_SegmentDomain_67bddde4-a936-4d8e-9fe5-0b5d51823230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_339dfd05-b0c9-4bcc-b4cc-27746674b209" xlink:href="cah-20240930.xsd#cah_PharmaceuticalAndSpecialtySolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_67bddde4-a936-4d8e-9fe5-0b5d51823230" xlink:to="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_339dfd05-b0c9-4bcc-b4cc-27746674b209" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_9dc2dd56-155c-479c-a0b1-b7fb7207e929" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_67bddde4-a936-4d8e-9fe5-0b5d51823230" xlink:to="loc_cah_GMPDMember_9dc2dd56-155c-479c-a0b1-b7fb7207e929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_0d4ecd2e-25c1-4508-93cc-811d6c9c3c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_67bddde4-a936-4d8e-9fe5-0b5d51823230" xlink:to="loc_us-gaap_AllOtherSegmentsMember_0d4ecd2e-25c1-4508-93cc-811d6c9c3c5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d6e251b3-ff3a-4579-8822-1326654b595b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8ab929a4-3e84-4cc8-9fbd-b1dd55b83dc9" xlink:to="loc_us-gaap_Assets_d6e251b3-ff3a-4579-8822-1326654b595b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3e3f4db-fa71-4096-887a-3e7ba56931ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3e3f4db-fa71-4096-887a-3e7ba56931ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_90d0ee7d-48d9-49f6-bb72-4116bcbb86ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3e3f4db-fa71-4096-887a-3e7ba56931ef" xlink:to="loc_us-gaap_AwardTypeAxis_90d0ee7d-48d9-49f6-bb72-4116bcbb86ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90d0ee7d-48d9-49f6-bb72-4116bcbb86ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_90d0ee7d-48d9-49f6-bb72-4116bcbb86ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90d0ee7d-48d9-49f6-bb72-4116bcbb86ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98d02db2-56ac-43b4-8f18-a2267ef6c525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_90d0ee7d-48d9-49f6-bb72-4116bcbb86ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98d02db2-56ac-43b4-8f18-a2267ef6c525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d51658fa-be96-462b-aca6-0ccd3886b4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98d02db2-56ac-43b4-8f18-a2267ef6c525" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d51658fa-be96-462b-aca6-0ccd3886b4ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3ee10bbc-3aab-4977-819f-aad626648708" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98d02db2-56ac-43b4-8f18-a2267ef6c525" xlink:to="loc_us-gaap_PerformanceSharesMember_3ee10bbc-3aab-4977-819f-aad626648708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fcd6b5e5-353d-4495-a41e-c1952f7beb7d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3e3f4db-fa71-4096-887a-3e7ba56931ef" xlink:to="loc_srt_RangeAxis_fcd6b5e5-353d-4495-a41e-c1952f7beb7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fcd6b5e5-353d-4495-a41e-c1952f7beb7d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fcd6b5e5-353d-4495-a41e-c1952f7beb7d" xlink:to="loc_srt_RangeMember_fcd6b5e5-353d-4495-a41e-c1952f7beb7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5df6be7c-d820-4d28-9ef1-5e0dce25dbce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fcd6b5e5-353d-4495-a41e-c1952f7beb7d" xlink:to="loc_srt_RangeMember_5df6be7c-d820-4d28-9ef1-5e0dce25dbce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4d05d453-5c37-4cfe-bdbb-285ce7b23cf4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5df6be7c-d820-4d28-9ef1-5e0dce25dbce" xlink:to="loc_srt_MinimumMember_4d05d453-5c37-4cfe-bdbb-285ce7b23cf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f2d52c20-eb5c-4094-ab05-72f3318734b0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5df6be7c-d820-4d28-9ef1-5e0dce25dbce" xlink:to="loc_srt_MaximumMember_f2d52c20-eb5c-4094-ab05-72f3318734b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ef1cdd15-fa4f-4586-8545-2de244803e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ef1cdd15-fa4f-4586-8545-2de244803e56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_882bc1cf-7b63-4605-8f74-8cddbedd2315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_882bc1cf-7b63-4605-8f74-8cddbedd2315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_709bda32-af3a-484a-a3f8-927f3597a831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_709bda32-af3a-484a-a3f8-927f3597a831" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f29062d-3625-4249-a980-5b29b51104b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f29062d-3625-4249-a980-5b29b51104b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_b85e4d0a-89c6-4cb2-831f-41bb79ae71d7" xlink:href="cah-20240930.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_cah_VestingPeriodinyearsforShares_b85e4d0a-89c6-4cb2-831f-41bb79ae71d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b7c2b442-f57a-4cda-9f9e-82e9e941da80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b7c2b442-f57a-4cda-9f9e-82e9e941da80" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b544a5d2-3b57-4c08-aa17-ec3949beaa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_031174d3-cf68-4e47-87cc-8bb3cc80e85c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b544a5d2-3b57-4c08-aa17-ec3949beaa0f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_031174d3-cf68-4e47-87cc-8bb3cc80e85c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_586afb49-d199-4bd8-80eb-b20907cd6d94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_031174d3-cf68-4e47-87cc-8bb3cc80e85c" xlink:to="loc_us-gaap_AwardTypeAxis_586afb49-d199-4bd8-80eb-b20907cd6d94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_586afb49-d199-4bd8-80eb-b20907cd6d94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_586afb49-d199-4bd8-80eb-b20907cd6d94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_586afb49-d199-4bd8-80eb-b20907cd6d94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ec9e754-ff64-4646-af0f-6e8b0ba085fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_586afb49-d199-4bd8-80eb-b20907cd6d94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ec9e754-ff64-4646-af0f-6e8b0ba085fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_92ea641d-d8c0-4248-9eee-b5a1417433da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ec9e754-ff64-4646-af0f-6e8b0ba085fe" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_92ea641d-d8c0-4248-9eee-b5a1417433da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_502e5e10-d56d-46b0-9785-1a5e6e0f832d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ec9e754-ff64-4646-af0f-6e8b0ba085fe" xlink:to="loc_us-gaap_PerformanceSharesMember_502e5e10-d56d-46b0-9785-1a5e6e0f832d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f909aa01-3e9a-4a0e-a4c4-3a3d212b7ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b544a5d2-3b57-4c08-aa17-ec3949beaa0f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f909aa01-3e9a-4a0e-a4c4-3a3d212b7ad0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6229eefc-b9bd-4ec5-9ee6-7b9738ca9dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d7e78b6-ab49-4dcf-9c8d-719ae6022e30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6229eefc-b9bd-4ec5-9ee6-7b9738ca9dc7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d7e78b6-ab49-4dcf-9c8d-719ae6022e30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b6d6ed00-0e80-4b4c-bc91-73a7a96a57d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d7e78b6-ab49-4dcf-9c8d-719ae6022e30" xlink:to="loc_us-gaap_AwardTypeAxis_b6d6ed00-0e80-4b4c-bc91-73a7a96a57d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6d6ed00-0e80-4b4c-bc91-73a7a96a57d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b6d6ed00-0e80-4b4c-bc91-73a7a96a57d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6d6ed00-0e80-4b4c-bc91-73a7a96a57d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_361c70a1-cf39-48b2-a802-be57220d0187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b6d6ed00-0e80-4b4c-bc91-73a7a96a57d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_361c70a1-cf39-48b2-a802-be57220d0187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_326e4c1e-a38f-4392-b285-787c096278bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_361c70a1-cf39-48b2-a802-be57220d0187" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_326e4c1e-a38f-4392-b285-787c096278bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ca14b744-859d-4974-9136-299274a12903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6229eefc-b9bd-4ec5-9ee6-7b9738ca9dc7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ca14b744-859d-4974-9136-299274a12903" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6229eefc-b9bd-4ec5-9ee6-7b9738ca9dc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7fc0cdf2-47b5-4578-9203-669b90dcdcef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7fc0cdf2-47b5-4578-9203-669b90dcdcef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a39f54f9-3d1e-419f-b7b5-df6b57914fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a39f54f9-3d1e-419f-b7b5-df6b57914fc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_26fb3764-eaac-4959-92f8-40e359cf5664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_26fb3764-eaac-4959-92f8-40e359cf5664" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a4aaee0d-4b10-482c-8d12-f32afba6a014" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a4aaee0d-4b10-482c-8d12-f32afba6a014" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_56f40162-988c-4786-8138-1721593fde13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6229eefc-b9bd-4ec5-9ee6-7b9738ca9dc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6fa8b0b-34d1-4686-935e-ffe1743750ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6fa8b0b-34d1-4686-935e-ffe1743750ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc757527-ae29-4ceb-baff-4a8b5922a0db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc757527-ae29-4ceb-baff-4a8b5922a0db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_18c7d7b5-e892-4fd2-a4d8-5dbbdb9f1a60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_18c7d7b5-e892-4fd2-a4d8-5dbbdb9f1a60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02a1cf93-3f86-496e-ac5b-be26352eac34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02a1cf93-3f86-496e-ac5b-be26352eac34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_868b3416-1cc8-4ea9-8fd8-0578993e6a57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3008565e-29e4-44ca-bd1a-3539ea93419f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3008565e-29e4-44ca-bd1a-3539ea93419f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_44be3fed-3b6f-4e7e-8577-85c404f28dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3008565e-29e4-44ca-bd1a-3539ea93419f" xlink:to="loc_us-gaap_AwardTypeAxis_44be3fed-3b6f-4e7e-8577-85c404f28dd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44be3fed-3b6f-4e7e-8577-85c404f28dd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_44be3fed-3b6f-4e7e-8577-85c404f28dd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44be3fed-3b6f-4e7e-8577-85c404f28dd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fccfb54b-e56f-4902-9443-a89d40e697ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_44be3fed-3b6f-4e7e-8577-85c404f28dd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fccfb54b-e56f-4902-9443-a89d40e697ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3e0f8827-7c94-4ae6-8b59-0f5cb32f1896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fccfb54b-e56f-4902-9443-a89d40e697ad" xlink:to="loc_us-gaap_PerformanceSharesMember_3e0f8827-7c94-4ae6-8b59-0f5cb32f1896" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fc7a357f-7f26-45d5-ab38-0afc4150ab2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fc7a357f-7f26-45d5-ab38-0afc4150ab2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5624d3a2-e200-4797-af96-087dbd91e560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5624d3a2-e200-4797-af96-087dbd91e560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cbe49d32-5910-4f16-ac02-9286826258da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cbe49d32-5910-4f16-ac02-9286826258da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b7218c43-378b-4a76-a279-6317ff08d8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b7218c43-378b-4a76-a279-6317ff08d8cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f4cddf27-dba7-41d6-ba41-24c3b9cf7b28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f4cddf27-dba7-41d6-ba41-24c3b9cf7b28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_932b7a34-6f74-4554-ad5d-e1cc14c5636d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0aa3668a-a55b-4b97-bd85-421fae6da8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0aa3668a-a55b-4b97-bd85-421fae6da8b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d31a164-63cd-41a2-b756-6a99c2fec8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d31a164-63cd-41a2-b756-6a99c2fec8f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_399b337f-2f71-40e5-8030-ab548dabd971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_399b337f-2f71-40e5-8030-ab548dabd971" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_304775b2-2e72-4052-86ae-84ccfe8dfe7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_304775b2-2e72-4052-86ae-84ccfe8dfe7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_06c9e88a-a463-4493-9df4-902a28c37f39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_75e1be5e-04ac-4879-a2af-619c402e1e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_75e1be5e-04ac-4879-a2af-619c402e1e56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_64a35d32-07e5-4157-b03a-617385cdbf24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_64a35d32-07e5-4157-b03a-617385cdbf24" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cah-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:537b797f-b836-409a-bf04-ad11625945c4,g:bd28f3d8-0395-4523-ae63-79ccc2df931a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_58fc8e02-87e1-45a0-9626-b2b6036b6060_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_5c5a100c-0a7a-452a-be46-e42acbd23551_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill acquired, net of purchase price adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_92f42e60-64e9-4717-a9bd-676865f33e43_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ce10edc6-38a4-4b79-af8b-1d5a13bc5b1f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reduction of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_1ca4f47c-9277-4023-8e57-f81aa52c2c4a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b5f3b9f4-12e9-4c9e-942d-cc6604a7c254_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6a393ad4-ae54-4e7c-9531-26bf3b21cbfd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_92d21a23-a911-48b1-b2b9-fbd79ca27fd5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_2818b44a-e87b-4082-a049-bd8fa9187979_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_865e04cb-dde6-48ab-8f59-7cde86f736c5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_b9e61083-9e07-4a65-aaa7-0e84d49bf100_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_91ae5622-dac4-47ff-9099-67b2695bc1c8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_e34e923b-560c-40b2-af8c-4823728f1e16_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8a546839-3fcc-4d50-b017-81089201ac8c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_c745b50e-7d10-4c51-bfb7-6a848709fe8a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_938fef40-2e63-40ea-b1e3-e64a3e160fa7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ac6e4eaf-1b81-429e-a1f3-bb61c02a5890_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a1f7175c-ad31-4f38-9000-ef4fa0eef665_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_7b8810e8-0fc5-41f0-9abb-5a853b263ec8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash dividends declared per common share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_8a716cd8-f22c-45e5-9395-5de0786d987b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_548b793c-ea0a-4a75-bb60-15a2693c8a21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Total Share-based Compensation Expense by Type of Award</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_6b59e198-f0da-4d24-9b4b-57d4cc7a41f0_terseLabel_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_label_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_documentation_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares" xlink:href="cah-20240930.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_VestingPeriodinyearsforShares" xlink:to="lab_cah_VestingPeriodinyearsforShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PercentageSettlingSubdivisions_42276bdd-9c3a-4fb0-a795-bc86754c397a_terseLabel_en-US" xlink:label="lab_cah_PercentageSettlingSubdivisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Settling Subdivisions [Line Items]</link:label>
    <link:label id="lab_cah_PercentageSettlingSubdivisions_label_en-US" xlink:label="lab_cah_PercentageSettlingSubdivisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Settling Subdivisions</link:label>
    <link:label id="lab_cah_PercentageSettlingSubdivisions_documentation_en-US" xlink:label="lab_cah_PercentageSettlingSubdivisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Settling Subdivisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PercentageSettlingSubdivisions" xlink:href="cah-20240930.xsd#cah_PercentageSettlingSubdivisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PercentageSettlingSubdivisions" xlink:to="lab_cah_PercentageSettlingSubdivisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_5e3b2331-a16d-43ab-a755-d1c8c9f67c4d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_d9d873ca-0bd5-48fc-93e6-e04224bcceac_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_68c531c9-91ce-4a93-b27e-fb10cb6b5aaa_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_02dc1136-6c9d-4f5d-b51a-59c169b644a8_terseLabel_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_label_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember" xlink:href="cah-20240930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProductLiabilityLawsuitsMember" xlink:to="lab_cah_ProductLiabilityLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_db15e660-2253-4e00-b4a7-dd22aa9de81c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ClassActionLawsuitsMember_c7da456e-b18c-4223-8768-61195840ecf0_terseLabel_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_label_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember" xlink:href="cah-20240930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ClassActionLawsuitsMember" xlink:to="lab_cah_ClassActionLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_fc2f56c7-5642-4a07-8208-9017a0eff830_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_5d57bb6d-6409-4cd9-a15e-f0d39e54177a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_54499747-6dcf-40a7-99bf-cab3e484991f_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_777e675e-e786-4562-90e7-b6f2db7b7a4e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities and operating items, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_176afb88-55f0-4cc4-a193-ff227d603761_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, without par value:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_93f68d29-b631-4044-b9ba-373e38fd1539_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_342fec3e-71c4-4417-86c1-0284f60234d4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_a4f288d4-a13f-46dc-9672-636c945fc3ff_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_ad837112-edf2-48fe-83e7-faf516c7a025_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_97142f78-330c-4ad9-9432-cd1140236290_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MaturityDateAxis_34b02268-dfbc-4a5a-b0ea-71fbe8c0489c_terseLabel_en-US" xlink:label="lab_cah_MaturityDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Date [Axis]</link:label>
    <link:label id="lab_cah_MaturityDateAxis_label_en-US" xlink:label="lab_cah_MaturityDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity Date [Axis]</link:label>
    <link:label id="lab_cah_MaturityDateAxis_documentation_en-US" xlink:label="lab_cah_MaturityDateAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateAxis" xlink:href="cah-20240930.xsd#cah_MaturityDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MaturityDateAxis" xlink:to="lab_cah_MaturityDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_357cf624-0354-4366-8c6b-58353d7a2561_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7735dc72-b8c3-4f52-be16-80acdf256947_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ac566f45-7f0b-4520-9b88-f0022978df60_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0b930fe3-3609-4628-a6ab-59b49a28dfe3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OutcomesDivestitureAxis_2c7a426d-0549-40e1-aab8-ce6a2e87cd2d_terseLabel_en-US" xlink:label="lab_cah_OutcomesDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outcomes Divestiture [Axis]</link:label>
    <link:label id="lab_cah_OutcomesDivestitureAxis_label_en-US" xlink:label="lab_cah_OutcomesDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outcomes Divestiture [Axis]</link:label>
    <link:label id="lab_cah_OutcomesDivestitureAxis_documentation_en-US" xlink:label="lab_cah_OutcomesDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Outcomes Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OutcomesDivestitureAxis" xlink:href="cah-20240930.xsd#cah_OutcomesDivestitureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OutcomesDivestitureAxis" xlink:to="lab_cah_OutcomesDivestitureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_989f398b-c3b1-41d3-ac10-cc703935836b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1daa9393-d83c-4c53-8d08-f08901fcf7fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_4842ad32-4c5f-4c81-924f-18938352cb11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program activity (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_b2d717fd-f616-4172-88c9-9ea87df8f511_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares acquired (using cost method), shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_420457e1-83cb-41a4-9b6e-0c197c0e8436_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b6f826ca-9b89-4f6e-b04d-ffb6764cba1a_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_cc80ffd4-3d48-48f9-a42c-4c061ff31c04_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_June2027Member_6c787aaf-8ae5-4c42-98f3-6d43556823a2_terseLabel_en-US" xlink:label="lab_cah_June2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">June 2027</link:label>
    <link:label id="lab_cah_June2027Member_label_en-US" xlink:label="lab_cah_June2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">June 2027 [Member]</link:label>
    <link:label id="lab_cah_June2027Member_documentation_en-US" xlink:label="lab_cah_June2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">June 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_June2027Member" xlink:href="cah-20240930.xsd#cah_June2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_June2027Member" xlink:to="lab_cah_June2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_78037a7a-548a-45a9-9d83-39eb0049673c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_27165348-17ec-4ee6-bcb9-cf725c2e54d7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_1e8d5a20-3430-4aa7-b3f3-8a525ea357e1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f67c4b2c-3074-49e8-b549-7051688acf47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_a51b991d-7dda-4e2a-99b5-f43ba055f774_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7d0b0c3b-bc3d-4dee-91af-3af376d3fb6e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_e30dd2a6-2ac2-4a13-8a0d-b84ed20a1dbb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_c57b6545-8cf6-4704-8f4a-a132f30c5be4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_a6ee89e4-b3fa-4758-b5c4-98c4f8a4466b_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_362d26e4-5cce-418a-9cfd-4b00edbc20b6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_b77ae511-76bf-4eae-96d2-b36b180fc991_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_3272b3fa-b6dc-4baa-9495-786ed65dcfa1_terseLabel_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_label_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_documentation_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:href="cah-20240930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:to="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2dd7bfaf-b8ef-4e75-985d-3e4798dd6d99_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_f059b4f0-95b0-4a4a-8c50-f794dbdd9905_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_0a8a9d00-8c9b-4ef7-8200-13102bd8c629_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from divestitures, net of cash sold</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5b31ac24-e94a-491d-8767-4abcaea3078e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_a845a766-3e38-4b6b-836b-2ef98099671f_terseLabel_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_label_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_documentation_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:href="cah-20240930.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:to="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_September2025Member_b36da357-7e88-4b5d-8ff2-a670ed5d2fff_terseLabel_en-US" xlink:label="lab_cah_September2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 2025</link:label>
    <link:label id="lab_cah_September2025Member_label_en-US" xlink:label="lab_cah_September2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">September 2025 [Member]</link:label>
    <link:label id="lab_cah_September2025Member_documentation_en-US" xlink:label="lab_cah_September2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">September 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_September2025Member" xlink:href="cah-20240930.xsd#cah_September2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_September2025Member" xlink:to="lab_cah_September2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f8b3ed18-bbf1-4072-a163-e24d2c85f582_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_4fe3cd6a-0e1e-42b2-9f2e-1afd0d212d66_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_3741af69-7c11-4ad4-af45-8dba11090e2b_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_5527cd4d-ab64-4b8a-a4fc-840965b0e10e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9e68f29e-9889-447f-bcbd-450f2fec9824_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62c51e8c-79e0-4624-a23d-efb45e61bed4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_74be8e38-9ab8-4077-8205-410d5502e446_terseLabel_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net tax withholding from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_label_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_documentation_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:href="cah-20240930.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:to="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_a7d97ccd-4545-4e4a-9116-f8da4296e834_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_ce3e0277-63ef-42bd-9c47-fb017b1fc660_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ce75d1e8-6364-40da-bc55-ef5f8288b4aa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_14397300-2bd3-4d15-8468-cbdb7fdc45c4_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">litigation settlement liability recorded</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeDomain_92b9ae2e-982e-41e0-95fd-3c6a8680193f_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_label_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain" xlink:href="cah-20240930.xsd#cah_PlaintiffTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeDomain" xlink:to="lab_cah_PlaintiffTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_f17bc961-4f1f-421f-803d-f5f3798e4ede_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WV_172acaf2-13f4-4ef8-9c50-e6b2f91cfe6f_terseLabel_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:label id="lab_stpr_WV_label_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_WV"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WV" xlink:to="lab_stpr_WV" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_f46810f5-cfcc-43e1-bf0f-805be4bfd64d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9d8623c-003b-4f5c-b811-2377ee225c6e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0dbb5d64-ff45-4a41-a359-fbe3fa2113dd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4e769595-b6e0-4056-b10d-16e6ec532742_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ec3490aa-c7d4-4ffa-b051-982c16fe656e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_03469df7-918e-42a1-8373-1838587ea9ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at June 30, 2024</link:label>
    <link:label id="lab_us-gaap_Goodwill_543738c1-2afd-450d-9fd2-0311344ba671_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_c5589817-9980-4af1-95dd-799e94ef8d2a_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalAndSpecialtySolutionsMember_6056ad26-cece-4839-b5b8-c586384b32be_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalAndSpecialtySolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmaceutical and Specialty Solutions</link:label>
    <link:label id="lab_cah_PharmaceuticalAndSpecialtySolutionsMember_label_en-US" xlink:label="lab_cah_PharmaceuticalAndSpecialtySolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmaceutical and Specialty Solutions [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalAndSpecialtySolutionsMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalAndSpecialtySolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmaceutical and Specialty Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalAndSpecialtySolutionsMember" xlink:href="cah-20240930.xsd#cah_PharmaceuticalAndSpecialtySolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalAndSpecialtySolutionsMember" xlink:to="lab_cah_PharmaceuticalAndSpecialtySolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_6608b5d3-4134-4fdd-b881-16b8e663bb33_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9249dd8a-4607-4e50-b86e-312d1186c1e9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fdad3009-536e-48ba-9182-5fd55806f53c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SettlingUSTerritories_375193c3-2708-4ae7-90af-6562c1608743_terseLabel_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:label id="lab_cah_SettlingUSTerritories_label_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:label id="lab_cah_SettlingUSTerritories_documentation_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories" xlink:href="cah-20240930.xsd#cah_SettlingUSTerritories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SettlingUSTerritories" xlink:to="lab_cah_SettlingUSTerritories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_ce20b043-9e2f-4c80-b390-560689e1abe9_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_938e8175-3610-4390-9a93-6f00123b99f8_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Treasury, balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_6a34f303-6ffd-4195-ae34-1e8ac13fcbd5_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Treasury, balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_cee0d1bd-e720-49ff-ba65-fbe1587269d4_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_2a097494-4336-4b9e-8cf8-07e83de486d4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_da958b5a-f721-4eb4-bcac-959398283951_verboseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0e530f18-7061-4b2b-9cfd-7e1542525ee3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_1aa09f1d-9aab-4ba5-8456-dfde36905b26_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e0ba289b-8534-4393-a34b-15d5676fdd12_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_701acbe8-d2d1-44fe-9c31-a78a358b6488_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_524ecf44-5719-43ba-beac-29c0793f369c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_da7a02d0-6e1b-49c0-834e-a359d3aee210_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_5706ea0c-19f0-4a08-bbfc-3ef2f1014f76_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings/(loss) per common share attributable to Cardinal Health, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OutcomesDivestitureDomain_e95ab9c6-a139-42ce-a2bd-8a4383b3c7af_terseLabel_en-US" xlink:label="lab_cah_OutcomesDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outcomes Divestiture [Domain]</link:label>
    <link:label id="lab_cah_OutcomesDivestitureDomain_label_en-US" xlink:label="lab_cah_OutcomesDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outcomes Divestiture [Domain]</link:label>
    <link:label id="lab_cah_OutcomesDivestitureDomain_documentation_en-US" xlink:label="lab_cah_OutcomesDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Outcomes Divestiture [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OutcomesDivestitureDomain" xlink:href="cah-20240930.xsd#cah_OutcomesDivestitureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OutcomesDivestitureDomain" xlink:to="lab_cah_OutcomesDivestitureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_21876f33-a863-4905-9ffd-32cd020b44e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e8570588-f5ae-4a4d-b561-20bb33ae483e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_fef99605-0c62-4afe-951e-597a5ae1a654_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_a79f9b79-a54a-4c2e-9dd8-2ed405480b8b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_e5ef0c94-ffe3-4b92-9524-e1198ab7017d_terseLabel_en-US" xlink:label="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Definite and Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="cah-20240930.xsd#cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98c10499-4f88-4bfb-9e87-ad2bfb28ea4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_baa7b81f-8293-4d94-b086-604937e197f3_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c40afbf6-e2aa-4c4d-a2f6-d453524877ab_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_7ec8979b-dab2-422f-b96b-9f460f81b625_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Loss [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_ce1424ca-7feb-4725-b1f6-0cfb5a7cb843_terseLabel_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_label_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_documentation_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts" xlink:href="cah-20240930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FacilityExitAndOtherCosts" xlink:to="lab_cah_FacilityExitAndOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_6324fe1f-e7ab-4d44-8988-129fde6b6c7a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_46867afb-72a8-4061-bf09-a4f9c32d8f67_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_0c1203be-971a-4da8-9263-86dc9b99d107_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuebyGeographicTable_c89e037b-d395-4c56-90af-207da86ebcf2_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Revenue by Geographic [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicTable_label_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Revenue by Geographic [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicTable_documentation_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment Revenue by Geographic [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicTable" xlink:href="cah-20240930.xsd#cah_SegmentRevenuebyGeographicTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuebyGeographicTable" xlink:to="lab_cah_SegmentRevenuebyGeographicTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IncomeAsAResultOfPrepayments_b5a169d0-b057-4d4b-858c-6499f630d81b_terseLabel_en-US" xlink:label="lab_cah_IncomeAsAResultOfPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income As A Result Of Prepayments</link:label>
    <link:label id="lab_cah_IncomeAsAResultOfPrepayments_label_en-US" xlink:label="lab_cah_IncomeAsAResultOfPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income As A Result Of Prepayments</link:label>
    <link:label id="lab_cah_IncomeAsAResultOfPrepayments_documentation_en-US" xlink:label="lab_cah_IncomeAsAResultOfPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income as a result of prepayments at a pre-negotiated discount certain future payment amounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomeAsAResultOfPrepayments" xlink:href="cah-20240930.xsd#cah_IncomeAsAResultOfPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IncomeAsAResultOfPrepayments" xlink:to="lab_cah_IncomeAsAResultOfPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8b2d9985-9219-4bdc-8922-2d42347b0d81_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1f1cb1ff-18ce-46ec-a7c5-7edddd568932_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1cce9dd1-c35a-4376-8317-4ad18b88a20b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f565f0dc-f5e8-48a2-aa32-621f0212aa15_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_d123ac3d-08aa-4374-8928-ca3dd139ade9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_feded695-4702-4cc2-9824-f3ed56c54153_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8d9e2ecc-b192-4de9-9107-0746e421b385_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_3724bb57-c857-4dc8-a04f-d6286b894259_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0f3d9f9a-66b6-4c4b-887a-bb068fbefd8b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3b0300fd-86ed-4092-a584-f154ce34d984_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_a036da62-ad1b-41c8-a7ca-cddf9208c118_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward Contract</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_daf359e7-bacf-4adb-9f92-5e03aa5e36e4_terseLabel_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_label_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_documentation_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:href="cah-20240930.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:to="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d2ceedc5-9d80-43f0-8a25-17140699200f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8bf6956c-7ac9-4e62-948e-74b9b88416a2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68c60106-c2b9-4a64-9136-9d19c3a8d57b_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares&#8211;diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AgreementsAxis_c4412b22-f3e9-494a-9960-7efdedf57712_terseLabel_en-US" xlink:label="lab_cah_AgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreements [Axis]</link:label>
    <link:label id="lab_cah_AgreementsAxis_label_en-US" xlink:label="lab_cah_AgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreements [Axis]</link:label>
    <link:label id="lab_cah_AgreementsAxis_documentation_en-US" xlink:label="lab_cah_AgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsAxis" xlink:href="cah-20240930.xsd#cah_AgreementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AgreementsAxis" xlink:to="lab_cah_AgreementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_8623eea5-5810-4843-9360-cc0db76984a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain/(Loss) on Derivatives, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_b9c4150b-0eaf-4110-b8ee-1bb76c83db1a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentAxis_de5d95f7-58ca-401a-b921-ec126411402c_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill Impairment [Axis]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentAxis_label_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Impairment [Axis]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentAxis_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis" xlink:href="cah-20240930.xsd#cah_GoodwillImpairmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentAxis" xlink:to="lab_cah_GoodwillImpairmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_9769f557-f629-4f76-a4bb-e160895c9e0f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_547e0f2b-f9be-4eb2-a0fb-6d1feb56a96f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_305170fb-d9c0-4cf5-9bd5-07484f3fd213_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_3ee0506e-237a-488f-aad6-25d552339af0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_94fa1bfd-9700-4bc6-8800-2c5a90ec37d6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Cardinal Health, Inc. shareholders' deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_44e41c9c-2122-4792-823b-6c6cc1f634a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_5d9acaa0-da01-487c-84f9-cca8c7563e4d_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Treasury, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_dc5349c2-c85f-4c96-9425-9f600df97af8_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Treasury, balance at end of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_68faaad3-8048-4456-ab2b-021ae06df73a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_9cf25420-fec5-407d-aeed-f8598fae444e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NuclearAndPrecisionHealthSolutionsMember_16d3eb38-6140-45b9-83c3-648f7594d958_terseLabel_en-US" xlink:label="lab_cah_NuclearAndPrecisionHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nuclear and Precision Health Solutions [Member]</link:label>
    <link:label id="lab_cah_NuclearAndPrecisionHealthSolutionsMember_label_en-US" xlink:label="lab_cah_NuclearAndPrecisionHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nuclear and Precision Health Solutions [Member]</link:label>
    <link:label id="lab_cah_NuclearAndPrecisionHealthSolutionsMember_documentation_en-US" xlink:label="lab_cah_NuclearAndPrecisionHealthSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nuclear and Precision Health Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearAndPrecisionHealthSolutionsMember" xlink:href="cah-20240930.xsd#cah_NuclearAndPrecisionHealthSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NuclearAndPrecisionHealthSolutionsMember" xlink:to="lab_cah_NuclearAndPrecisionHealthSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_c6ab2d84-3657-4dab-808d-4e33c221b0ca_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_3a444070-d673-4fe6-a296-922eaf47b1f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_b6db3b2f-5844-4769-becd-bdd7ef89216e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_18d90a24-68f1-42ed-9d35-283d8c764a74_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution, selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_2c34534b-c9e5-483d-a75e-d3e990a506d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2b05b529-be0e-4744-937d-fc850960af3c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_e8db459c-043b-49e6-891e-80f3e52d03bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_063e8da7-3878-4c45-b7a5-03a11e0c937f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_ad4453cd-aa14-40ab-9f75-7afab54d47e5_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OptumRxMember_c353aa56-2e9a-4ee3-a04b-874131d5f301_terseLabel_en-US" xlink:label="lab_cah_OptumRxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OptumRx</link:label>
    <link:label id="lab_cah_OptumRxMember_label_en-US" xlink:label="lab_cah_OptumRxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OptumRx [Member]</link:label>
    <link:label id="lab_cah_OptumRxMember_documentation_en-US" xlink:label="lab_cah_OptumRxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OptumRx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OptumRxMember" xlink:href="cah-20240930.xsd#cah_OptumRxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OptumRxMember" xlink:to="lab_cah_OptumRxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_4ef7f611-9f46-4f5c-bf18-b641c8e34baf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_92e8fe03-5847-4492-9d55-70621169c163_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_79cc79d6-e0ca-460d-8129-1435d688d62b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_58cca2c8-0e66-4695-8768-f068117c114e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_f308892f-6f3c-4529-b6df-69829700956a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b9972576-eff7-40d3-ad15-8e932b7d04e5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_96aa7707-d033-4535-b398-6ce24dafd3d0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_971c5f73-02c0-4abe-915e-d0094a039ca5_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_ea2392ce-6241-4888-b5df-27f9b9a71ce2_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares acquired, average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OutcomesDivestitureMember_bf170218-c893-4186-9f2f-f1eb64956e18_terseLabel_en-US" xlink:label="lab_cah_OutcomesDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outcomes Divestiture</link:label>
    <link:label id="lab_cah_OutcomesDivestitureMember_label_en-US" xlink:label="lab_cah_OutcomesDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outcomes Divestiture [Member]</link:label>
    <link:label id="lab_cah_OutcomesDivestitureMember_documentation_en-US" xlink:label="lab_cah_OutcomesDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Outcomes Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OutcomesDivestitureMember" xlink:href="cah-20240930.xsd#cah_OutcomesDivestitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OutcomesDivestitureMember" xlink:to="lab_cah_OutcomesDivestitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8300d356-bfc3-449e-8a8b-fee56b1d2d97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_18e5362f-0885-4dfb-9b3c-23d237eab765_terseLabel_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_label_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_documentation_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other short-term credit facilities and an unsecured line of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember" xlink:href="cah-20240930.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShortTermCreditFacilitiesMember" xlink:to="lab_cah_ShortTermCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1a1f614c-27b5-4810-9519-8e210f7d3859_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6fe95e9e-3a6d-4b1f-9801-ca1c9e6d9353_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_593d36db-452f-4c08-947c-44688459eed5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2450bff3-301e-4b50-8201-bbeeaa87e7c4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_80981746-e97c-4c6e-8860-840ab4773e0d_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_561db51b-26fa-4085-9de6-aa13e87a6364_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0da186c0-1c34-43a2-ac90-269d92f9fb8e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_7226e287-f707-4c22-afc0-cdfc3c2716bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Litigation (recoveries)/charges, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_fd061bab-5aa2-4719-9064-512e422c3f57_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) from Litigation Settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) from Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CityOfBaltimoreMember_6167de6c-e566-4cd7-b540-4fd5ba6cc658_terseLabel_en-US" xlink:label="lab_cah_CityOfBaltimoreMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City of Baltimore</link:label>
    <link:label id="lab_cah_CityOfBaltimoreMember_label_en-US" xlink:label="lab_cah_CityOfBaltimoreMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City of Baltimore [Member]</link:label>
    <link:label id="lab_cah_CityOfBaltimoreMember_documentation_en-US" xlink:label="lab_cah_CityOfBaltimoreMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">City of Baltimore</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CityOfBaltimoreMember" xlink:href="cah-20240930.xsd#cah_CityOfBaltimoreMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CityOfBaltimoreMember" xlink:to="lab_cah_CityOfBaltimoreMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_07ade3f6-9778-471a-8128-73038a0111f2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d54d3741-5ca3-4efc-9276-9f9c28ae4f83_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_c1164173-f112-4bf0-8b91-9a8e55201b0e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e732673a-253e-4659-a7e1-b98a7a6246f1_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_08298246-3afe-4fb2-8ab9-f1f1655f40d6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Earnings/(loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cca79122-c3a3-4d47-9736-a1fa0bcdc650_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4f3521be-31e2-495e-b96c-4754ef185b5b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock plans activity, net of shares withheld for employee taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_48725cab-202a-4a6a-9078-5f0aac48f230_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_08c52d5f-2a2d-413d-bfe1-dd629dc55ff3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TrademarksAndPatentsMember_38386af0-724b-4cbc-b2d8-f6d0f835271c_terseLabel_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks, trade names and patents</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_label_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks And Patents Member</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_documentation_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember" xlink:href="cah-20240930.xsd#cah_TrademarksAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TrademarksAndPatentsMember" xlink:to="lab_cah_TrademarksAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_5a7c4a77-f0e3-4a1a-b8ac-956696072939_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1d945779-c6df-42c1-954b-c4cecb95aa22_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_7565ef5d-7b09-445a-80fd-4b031d932145_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_8e19d631-fc38-4957-8bc2-a32c2d6fcbcd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends on common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_58322eb5-f15f-4a96-adff-efb9c5176bb8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ad7a90bc-a7e2-424f-9675-d508043a3663_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_14686e94-1aa7-482e-befb-677f1ef6c1a9_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_785249b6-c186-46dc-a0c1-42bc30e19f04_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_7a92a045-c53d-4a89-a977-6d399f8165d6_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5dfd536b-7465-499f-8319-b2aa29a0314a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68fcc0f5-8f1c-497f-bd89-64d533cd3c90_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_56aa0b17-adec-4ed3-a935-fe4cd69a650b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_c3ea3a32-9cca-428f-be1c-21754a806510_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1a82aa30-cdc9-448c-804d-d7d1b420775e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_a880a86f-d37a-45fa-a0c5-1967ff944110_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_12bec74a-2012-44f9-ae4a-cff9b4f5d39b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Transactions Related to Performance Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Performance-Based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_715c223e-9389-4dd2-80d0-671a1d429bc1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Target performance goal (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2ee1704a-13a6-4c23-b3f7-01cdd65dc464_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c40f0298-d977-4e50-911c-6c3e0b03fe5c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_e4c293a5-800f-44e3-b428-dc989bb77a8e_terseLabel_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and patents</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_label_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPR&amp;D,TrademarksandOther [Member]</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_documentation_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember" xlink:href="cah-20240930.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IPRDTrademarksandOtherMember" xlink:to="lab_cah_IPRDTrademarksandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_85b7133c-7c3d-484b-99ba-db0364799bca_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_aa95f60f-3193-4b46-aff1-c6349c779c57_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d63b3c5a-3c28-4809-b971-7d6a4fd1af2f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_5dbaae81-dbc8-4723-96d0-a08fabb491aa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee- Related Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_636eccc8-81dd-4f46-9f2d-661e2286d80c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TransactionDataSystemInvestmentMember_fef3b1d2-414d-4104-ad53-5fdb7d04a840_terseLabel_en-US" xlink:label="lab_cah_TransactionDataSystemInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Data System Investment [Member]</link:label>
    <link:label id="lab_cah_TransactionDataSystemInvestmentMember_label_en-US" xlink:label="lab_cah_TransactionDataSystemInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Data System Investment [Member]</link:label>
    <link:label id="lab_cah_TransactionDataSystemInvestmentMember_documentation_en-US" xlink:label="lab_cah_TransactionDataSystemInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction Data System Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TransactionDataSystemInvestmentMember" xlink:href="cah-20240930.xsd#cah_TransactionDataSystemInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TransactionDataSystemInvestmentMember" xlink:to="lab_cah_TransactionDataSystemInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7b6189fc-8ed9-4deb-b99a-81e41b10a742_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_d1f03ddc-d812-4098-8ad9-c23e2ab1d857_terseLabel_en-US" xlink:label="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:href="cah-20240930.xsd#cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:to="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_02908d12-3da0-4c2f-9a7f-423e37ad2e57_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_77d1e42a-f1bc-4bfc-abb5-32430497f49c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_48f52c76-c760-4363-8b1d-23f573eff168_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_4b2b6497-cb30-494b-8efb-1287552f13ca_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_5f99dc33-bbfb-424c-b72d-e1bb08b3d879_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ada4711e-a3d9-400d-81c7-ae177e7899a0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d8ecdbf8-36e9-4ba7-8c84-949bb89efac7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_ff8f6775-96a6-48f8-8279-2d721be5f211_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IncomefromSettlementsofClassActionLawsuits_18edefce-9647-4609-b4f1-58ab8e42b722_terseLabel_en-US" xlink:label="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:label id="lab_cah_IncomefromSettlementsofClassActionLawsuits_label_en-US" xlink:label="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:label id="lab_cah_IncomefromSettlementsofClassActionLawsuits_documentation_en-US" xlink:label="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomefromSettlementsofClassActionLawsuits" xlink:href="cah-20240930.xsd#cah_IncomefromSettlementsofClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IncomefromSettlementsofClassActionLawsuits" xlink:to="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5b6d8565-6a7a-48eb-b5e7-b1c6ef1af03d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for/(benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_779bdbe4-3e51-4349-8386-0669157449d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision for/(benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_d697f840-a930-46f7-adb4-1cf452b7910f_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_5cc83e71-84e7-4273-b9ac-e2a2321dbefd_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e3ebd143-4672-4315-a3c2-5ff9481aac34_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterDomain_418ff53d-d775-49cb-9ff9-b0337d2a6348_terseLabel_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_label_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_documentation_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain" xlink:href="cah-20240930.xsd#cah_TaxMatterDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterDomain" xlink:to="lab_cah_TaxMatterDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8d004e09-f13a-4a12-b762-811566d55f37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_bcd68ad8-6ac4-4125-99a3-30c4cf641e92_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e317bf20-8e79-417e-a5e0-4f3b10d9c8ee_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a20c7caa-cade-429d-9d6d-f2e2894e86b6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1c53199a-223c-4b3c-84ee-c3c30b8eaf0d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5f70a03c-f400-4cc8-b1ad-107cbad1cdf0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_510ec414-5d76-4eeb-a9e4-9cb8d555c727_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_596981d1-138b-45a0-a4b4-eece87974d42_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SettlingStates_899322ef-fb5b-492d-8a70-2b698e9d0569_terseLabel_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settling States</link:label>
    <link:label id="lab_cah_SettlingStates_label_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settling States</link:label>
    <link:label id="lab_cah_SettlingStates_documentation_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settling States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates" xlink:href="cah-20240930.xsd#cah_SettlingStates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SettlingStates" xlink:to="lab_cah_SettlingStates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_e791a3dc-f9b1-4d0a-af6e-d7263bffe0bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_3fee6fc6-08ba-4bb6-b595-864060f220dc_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_92babfa4-5f91-4f50-a347-aa1fd421421f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_304fe816-11a9-4954-920a-65feb916011a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f2960f5d-4cb1-443a-b287-2253a09ab771_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_52034955-9048-422e-ad67-15dc69b25aae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8cf56fac-e1fb-421a-89a8-0f72b8b2c164_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_891ec92d-31ad-44c9-bea5-f7fdd34f1aef_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_217e64d8-aaa8-4592-b6ed-b7465a6fee1a_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_2580d8b1-669d-4cad-9f14-326f78c852f5_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d3ddb3ee-acaf-448b-84d1-de354d9b0145_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0c20a5fe-d819-45e0-b520-b1eabf84c398_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_132d23b3-6f25-41c3-abf1-5f060d265ad4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_abd37581-8bc7-4452-8af3-310a68d9c6be_terseLabel_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program aggregate purchase price [Domain]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_label_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share repurchase program aggregate purchase price [Domain]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_documentation_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share repurchase program aggregate purchase price [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:href="cah-20240930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:to="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae4f2d02-4826-4951-b683-0823a401e940_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6f717c73-343a-48b9-93f3-0ec4eba97102_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term obligations and other short-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8e79afd0-face-4458-af39-e41634610091_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long Lived Assets Held-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Asset, Held-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:to="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_218e005d-db98-4fd2-9eca-130fa928a7ee_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_d4b5ed37-e4a9-4d9d-9c66-6067a1912990_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from net investment hedge terminations</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ee4d9a19-bea8-40bd-a650-54e820bf5947_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_0d9ebfb1-a999-42bc-87ea-7a6232593871_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_146e3bb8-4eee-43b6-9cf2-3f6ec92ca47b_terseLabel_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_label_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_documentation_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:href="cah-20240930.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:to="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1bbc4889-f3d4-4e38-a22b-79ff41fce7b0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f74f48c1-fb17-4a57-a099-e3103362b329_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0b18d357-e7ee-49c5-a1e4-23521fba1b79_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_44bbbc31-de8d-4a8d-bc2b-10575a3baedc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b201949d-855d-4fd4-9060-b4cafc90215a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationDomain_3d6b533c-7924-42bd-8994-6d9bc645f675_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_label_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_documentation_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain" xlink:href="cah-20240930.xsd#cah_OpioidLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationDomain" xlink:to="lab_cah_OpioidLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_0aef2bcb-130c-42a8-a82c-0e4216c2efe8_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Profit by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_59f5c085-cebe-4c33-8747-ab6af8e688f3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_632bf076-15f7-4c44-8c96-f7a7805f9b66_terseLabel_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$500 million share repurchase program</link:label>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$500 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$500 million share repurchase program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember" xlink:href="cah-20240930.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A500MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DateInitiatedDomain_02a8f4c0-896e-4f7b-8a83-28f3dd35ccb5_terseLabel_en-US" xlink:label="lab_cah_DateInitiatedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Date Initiated [Domain]</link:label>
    <link:label id="lab_cah_DateInitiatedDomain_label_en-US" xlink:label="lab_cah_DateInitiatedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Date Initiated [Domain]</link:label>
    <link:label id="lab_cah_DateInitiatedDomain_documentation_en-US" xlink:label="lab_cah_DateInitiatedDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Date Initiated [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedDomain" xlink:href="cah-20240930.xsd#cah_DateInitiatedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DateInitiatedDomain" xlink:to="lab_cah_DateInitiatedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_January2023Member_f2cd4f33-0eb9-4029-8bc0-0aaf195d8e6d_terseLabel_en-US" xlink:label="lab_cah_January2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">January 2023</link:label>
    <link:label id="lab_cah_January2023Member_label_en-US" xlink:label="lab_cah_January2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">January 2023 [Member]</link:label>
    <link:label id="lab_cah_January2023Member_documentation_en-US" xlink:label="lab_cah_January2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">January 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_January2023Member" xlink:href="cah-20240930.xsd#cah_January2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_January2023Member" xlink:to="lab_cah_January2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentDomain_86c27364-b204-4787-afbe-87393dc05661_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentDomain_label_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentDomain_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain" xlink:href="cah-20240930.xsd#cah_GoodwillImpairmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentDomain" xlink:to="lab_cah_GoodwillImpairmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_465816eb-0ba4-4a2c-bc48-2d8982adeae5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3fa29148-9ae2-4e2a-b2d5-f09b23a55bba_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_478cbd01-cef5-4961-973d-0b5e21aaf217_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Shareholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LitigationTypeDomain_bc9eb20d-ebae-4fce-8d5e-8f90f2af585d_terseLabel_en-US" xlink:label="lab_cah_LitigationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Type [Domain]</link:label>
    <link:label id="lab_cah_LitigationTypeDomain_label_en-US" xlink:label="lab_cah_LitigationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Type [Domain]</link:label>
    <link:label id="lab_cah_LitigationTypeDomain_documentation_en-US" xlink:label="lab_cah_LitigationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Litigation Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain" xlink:href="cah-20240930.xsd#cah_LitigationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LitigationTypeDomain" xlink:to="lab_cah_LitigationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_eac59b5a-57f0-4987-8ca1-b724319a4853_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_3fad1508-1f62-4432-a59e-feebd003314c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_9e28e438-dae6-405e-b1fc-b24383f5e2bc_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_51ae5a7d-eff7-4563-82cc-ece995102cca_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_408fb5f2-727a-45c2-9d98-4d740347c409_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_7b72e3bd-a4fc-45bb-b180-ef9c2d6c06ef_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_6d464d59-95c7-4091-9020-27a24e5fad00_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating and Reportable Segment</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_12ca283b-7385-485a-82ab-f81ed173251e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_794e4b8a-8431-49b5-8d36-e186937dc73a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share Attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_d8a6ad83-2aea-422d-aece-da5a8c42caec_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_2c1bf478-e137-463c-8191-963c002466c3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod_cc00722c-c5f0-4584-8285-be86f6ea4e5d_terseLabel_en-US" xlink:label="lab_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from computation of EPS as a result of the net loss during the period</link:label>
    <link:label id="lab_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod_label_en-US" xlink:label="lab_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from computation of EPS as a result of the net loss during the period</link:label>
    <link:label id="lab_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod_documentation_en-US" xlink:label="lab_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from computation of EPS as a result of the net loss during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod" xlink:href="cah-20240930.xsd#cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod" xlink:to="lab_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_aa2e91ae-50a8-4dab-be3d-d44af86796e8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6057e3ef-8993-4eeb-9702-851cdf434fea_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4e1d8abc-252d-4201-8d60-1ee689301a48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_1bcdeab6-ad92-4ad1-9249-efcce0475f0b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_f6eaa335-dfdf-4c00-9250-500a48e17019_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_510e4062-c881-4e3a-8fa5-b4474d6499d2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_bef842dd-72a0-4ec8-96f4-045a6340c511_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MaturityDateDomain_212c3522-3370-4f98-86ac-8dc2f487598a_terseLabel_en-US" xlink:label="lab_cah_MaturityDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Date [Domain]</link:label>
    <link:label id="lab_cah_MaturityDateDomain_label_en-US" xlink:label="lab_cah_MaturityDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity Date [Domain]</link:label>
    <link:label id="lab_cah_MaturityDateDomain_documentation_en-US" xlink:label="lab_cah_MaturityDateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain" xlink:href="cah-20240930.xsd#cah_MaturityDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MaturityDateDomain" xlink:to="lab_cah_MaturityDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c171d218-3a37-4fd0-a067-c2c53e308791_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_2b9844f6-9a64-4531-b2c0-2c6a5cd0e644_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes and other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationPriceOfAcquisitionExpected_b1e53c39-b338-4c81-b87f-36dbbae82a44_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationPriceOfAcquisitionExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Price of Acquisition, Expected</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationPriceOfAcquisitionExpected_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationPriceOfAcquisitionExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Price of Acquisition, Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationPriceOfAcquisitionExpected" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationPriceOfAcquisitionExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationPriceOfAcquisitionExpected" xlink:to="lab_us-gaap_BusinessCombinationPriceOfAcquisitionExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_42c07251-0f2f-4284-8452-625aac09cb5f_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_538409f5-888f-4a12-bdea-f413b233d41f_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_a6654488-9eec-4b56-941f-bf619c4487da_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d4c8c4f8-09bd-4314-b04b-ab075eb9e1ec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_e18c2740-8f3d-47e6-9802-3a0b5b442486_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1f5dbf52-015c-4816-8f6c-193fa2812397_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other (income)/expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_46af614d-2300-4f5d-b6be-48aa7a45d550_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_833361dd-1d3a-43b4-bdfb-5be75a417567_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_df6986c6-35cb-4de5-bc25-c78003e7eade_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairments and (gain)/loss on disposal of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_c0cd22a9-634a-4a68-a497-cdd23ed51f27_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_AL_8de84060-11d0-46ab-970b-1505c6a4ba57_terseLabel_en-US" xlink:label="lab_stpr_AL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALABAMA</link:label>
    <link:label id="lab_stpr_AL_label_en-US" xlink:label="lab_stpr_AL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALABAMA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AL" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_AL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_AL" xlink:to="lab_stpr_AL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_a27f5809-162d-467e-a1f7-1d674239e1ec_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Operating Segment</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7f866a4e-b18a-4116-8e16-d49236474b8e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8177d7b2-8e0f-4127-8d5e-fc9c61aff7ff_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_d46a295c-239d-43d2-b454-ee1e1aa12e49_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated range of decrease in unrecognized tax benefits within the next 12 months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_7ad5dfdc-aa33-4358-95ee-c42bc6f068ee_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DateInitiatedAxis_74ffcbea-58a8-4ddf-a04e-62b820ffe73f_terseLabel_en-US" xlink:label="lab_cah_DateInitiatedAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Date Initiated [Axis]</link:label>
    <link:label id="lab_cah_DateInitiatedAxis_label_en-US" xlink:label="lab_cah_DateInitiatedAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Date Initiated [Axis]</link:label>
    <link:label id="lab_cah_DateInitiatedAxis_documentation_en-US" xlink:label="lab_cah_DateInitiatedAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Date Initiated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedAxis" xlink:href="cah-20240930.xsd#cah_DateInitiatedAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DateInitiatedAxis" xlink:to="lab_cah_DateInitiatedAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e063dda3-16bf-4d36-89bc-689ad67c84d7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b658c0db-d9df-465d-8dce-0c03ec2d538b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_c800973b-e39a-4135-bdee-0a4102763167_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_3c1f258e-0200-4094-a14f-2d681344117d_terseLabel_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program aggregate purchase price [Axis]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_label_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share repurchase program aggregate purchase price [Axis]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_documentation_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share repurchase program aggregate purchase price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:href="cah-20240930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:to="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_0e1cafb8-2588-49b6-a349-f6bfd3ea41a2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalOpioidLitigationMember_61eb60e0-9feb-499f-938a-94b7872ae00b_terseLabel_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_label_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_documentation_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember" xlink:href="cah-20240930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalOpioidLitigationMember" xlink:to="lab_cah_TotalOpioidLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_a775c212-61b1-4282-a2e8-e3a5a6907966_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Transactions Related to Restricted Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_cbe5970d-5766-4200-b3e7-d18213b4befe_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_naics_ZZ921150_26897f89-c4fe-4aeb-a2ac-6179c1afa02c_terseLabel_en-US" xlink:label="lab_naics_ZZ921150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">921150 American Indian and Alaska Native Tribal Governments</link:label>
    <link:label id="lab_naics_ZZ921150_label_en-US" xlink:label="lab_naics_ZZ921150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">921150 American Indian and Alaska Native Tribal Governments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_naics_ZZ921150" xlink:href="https://xbrl.sec.gov/naics/2024/naics-2024.xsd#naics_ZZ921150"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_naics_ZZ921150" xlink:to="lab_naics_ZZ921150" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ecb6866-40ef-4086-a3dd-3900872ad919_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_0c02c1c3-0083-4e93-9d87-003079c9cea2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Increase (Decrease), Net</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Increase (Decrease), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:to="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ea6e1803-a831-4688-b875-2d798d991dcd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SpecialtyNetworksMember_1ba05e91-ebc4-496c-a7f9-fc9d10a0a4cd_terseLabel_en-US" xlink:label="lab_cah_SpecialtyNetworksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Specialty Networks</link:label>
    <link:label id="lab_cah_SpecialtyNetworksMember_label_en-US" xlink:label="lab_cah_SpecialtyNetworksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Specialty Networks [Member]</link:label>
    <link:label id="lab_cah_SpecialtyNetworksMember_documentation_en-US" xlink:label="lab_cah_SpecialtyNetworksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Specialty Networks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SpecialtyNetworksMember" xlink:href="cah-20240930.xsd#cah_SpecialtyNetworksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SpecialtyNetworksMember" xlink:to="lab_cah_SpecialtyNetworksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_891f4f96-1fc8-467a-bb18-4b9d953da8fb_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramDomain" xlink:to="lab_srt_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeAxis_e257abf9-f7b3-4dda-9fbe-268e8df5773a_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_label_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_documentation_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis" xlink:href="cah-20240930.xsd#cah_LawsuitTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeAxis" xlink:to="lab_cah_LawsuitTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5020c126-4cf8-47fc-894f-8cfee8ee33bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments, Contingent Liabilities and Litigation</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_a8f2e9a4-68d5-47c1-a72d-6760422515cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_aabcce22-75e3-4c6b-82bc-984a8a40e62a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ad792a06-5861-441e-801f-c3b9c82b0c25_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock plans activity, net of shares withheld for employee taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuebyGeographicLineItems_4cfe0553-f803-41c2-9316-2912e9de0e7d_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Revenue by Geographic [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicLineItems_label_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Revenue by Geographic [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicLineItems_documentation_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Segment Revenue by Geographic [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicLineItems" xlink:href="cah-20240930.xsd#cah_SegmentRevenuebyGeographicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems" xlink:to="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d78f341a-80ae-447c-9109-91d53bcb7afc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5a0046e0-3a78-4fe0-9686-6c2d500cc22b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_664b2edb-b735-4ed4-a7ba-50fdcd57d420_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ae0e45c2-c5dd-4f7e-a1af-409fbb235f34_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenTaxYear_3d10b15a-b108-4538-b3a1-04a48adf0ca1_terseLabel_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:label id="lab_us-gaap_OpenTaxYear_label_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_c40f5076-5b34-4018-b839-72c7ca188a03_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OptiFreightMember_aa17bca7-69ed-4ff6-b305-e2c6f216594e_terseLabel_en-US" xlink:label="lab_cah_OptiFreightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OptiFreight [Member]</link:label>
    <link:label id="lab_cah_OptiFreightMember_label_en-US" xlink:label="lab_cah_OptiFreightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OptiFreight [Member]</link:label>
    <link:label id="lab_cah_OptiFreightMember_documentation_en-US" xlink:label="lab_cah_OptiFreightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OptiFreight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OptiFreightMember" xlink:href="cah-20240930.xsd#cah_OptiFreightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OptiFreightMember" xlink:to="lab_cah_OptiFreightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c8ca8940-e831-49a0-a792-bc169b45323a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_14ec9fb5-f4ca-482a-aef9-2ab257492537_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_904786d6-9f46-4989-9d82-20eae92808a4_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers, Policy</link:label>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Customers, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:to="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c632a98c-55ef-4623-9cc4-525d104a1afc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2b3ecc2c-6f53-410f-a282-d61eef90d02c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_aeae0232-12b3-42af-b8f3-2aa8aa48dd08_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_721635a4-ee25-4853-97cc-515041697689_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel12And3Member_1b5dc043-12fa-48a2-a5fa-1e13c5e09d81_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1, 2 and 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel12And3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member" xlink:to="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_e77ab365-16a2-4017-8272-5daf3f8c188b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified to earnings</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ca55c841-b031-4aab-877b-4dde6fa9d4f2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8566989c-e615-47ca-9e7f-e521c8fa4c88_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d74fe2ea-e708-454e-8a44-7b315f1598d4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ca25460c-a77c-4e13-95b0-a59056075b71_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_45916cd5-7366-44f7-823c-d412d786bdef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_cd236473-788b-46e1-a8a3-97261602c866_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_9483268d-8383-47df-83dc-993c66f7dd85_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_96bae74c-674a-4b15-b177-4a187c728df3_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d7e0a77b-ff13-44fa-a2ab-961bd3a42611_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a04bea09-fac4-4260-9cda-2843d0062fa2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_66cf1165-a640-415e-9546-38e9d2b48681_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_388bfe2a-5881-485d-9e78-203ef04a64b3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4d891eee-caec-4ec2-a6d2-9a1ac2321450_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9cfe0e44-f8b5-4a62-be1e-77d9d97f2f08_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b6b14785-c848-47d9-a212-e90d0a844720_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_GA_8490b56e-e52b-4b14-8947-044a2574aca6_terseLabel_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GEORGIA</link:label>
    <link:label id="lab_stpr_GA_label_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GEORGIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_GA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_GA" xlink:to="lab_stpr_GA" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GMPDMember_42cee110-1aa4-4b2d-9d11-fb25368e401d_terseLabel_en-US" xlink:label="lab_cah_GMPDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GMPD</link:label>
    <link:label id="lab_cah_GMPDMember_label_en-US" xlink:label="lab_cah_GMPDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GMPD [Member]</link:label>
    <link:label id="lab_cah_GMPDMember_documentation_en-US" xlink:label="lab_cah_GMPDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GMPDMember" xlink:to="lab_cah_GMPDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CVSHealthMember_d09d28eb-876e-4e26-a4d0-c57a8d178363_terseLabel_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CVS Health</link:label>
    <link:label id="lab_cah_CVSHealthMember_label_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:label id="lab_cah_CVSHealthMember_documentation_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember" xlink:href="cah-20240930.xsd#cah_CVSHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CVSHealthMember" xlink:to="lab_cah_CVSHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_71a47517-acc2-400d-9e50-5653589c26f4_terseLabel_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_label_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_documentation_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember" xlink:href="cah-20240930.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NewYorkOpioidStewardshipActMember" xlink:to="lab_cah_NewYorkOpioidStewardshipActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_c17d2de7-fb62-4fb2-a6d3-41322944afae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_2ae74774-0c1d-4851-a811-6547b79f8ff0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program activity</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_c9661847-b2ba-4269-bb96-e79e99e09b4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c064aacf-7c05-417e-9d9b-a43f120c7c8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_0d970ca7-7bcb-4328-98d8-49456a5c2bc3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings" xlink:to="lab_us-gaap_OtherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5dd223e0-f817-4d6c-bbd2-43f997eb31ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_894f1176-d1dd-4428-91e2-07f7199faec3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AtHomeSolutionsMember_f110d691-6e25-4edb-bd78-7736c96d9c6b_terseLabel_en-US" xlink:label="lab_cah_AtHomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">at-Home Solutions [Member]</link:label>
    <link:label id="lab_cah_AtHomeSolutionsMember_label_en-US" xlink:label="lab_cah_AtHomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">at-Home Solutions [Member]</link:label>
    <link:label id="lab_cah_AtHomeSolutionsMember_documentation_en-US" xlink:label="lab_cah_AtHomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">at-Home Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AtHomeSolutionsMember" xlink:href="cah-20240930.xsd#cah_AtHomeSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AtHomeSolutionsMember" xlink:to="lab_cah_AtHomeSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_cacb35af-ecba-44cc-a329-1b20cd780a1c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3dbc1f41-cff6-4d0f-9fe9-9eeffda3f563_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_140e163f-c341-4c8a-8c5c-80968d0efe13_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1de5f5ce-cc01-4903-b2bc-f48809ab3eb3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_58d29dc5-1178-485b-9c1f-8c65dca03889_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c1e68092-d8b0-4fd9-a5f9-b62f26aec452_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings/(accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_6ad58e84-6390-49d2-9fc3-5e4e8be1c49b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a43dd246-ea31-4b0c-b0f9-84eec20fb1f8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_54fc7a0a-a4ee-4e8d-becc-9dcce45a08e5_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_8d20c447-aef6-49c7-9856-1c251f90d938_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Performance Share Unit</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_fc89164c-4f94-49ef-b0fd-148eadc9bb40_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_a28e9050-425c-4415-8626-6a9f897ac198_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares, without par value:</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_13d87d37-0252-409e-8bec-949825026420_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_8ddc1f7d-4174-49ed-aea6-f08241717f06_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7a86d573-ddaf-4e71-88be-5e59f592d74d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_a1eb526d-cae4-4b1c-a368-4e63bc53be0a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e0473fe8-14da-470c-82d2-b97673eb9412_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_bf55c4f9-6047-4b81-b7a1-9dfb9c91a42f_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_79f63132-09c9-497c-b2d1-da10d4dad003_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_16cd945c-e8fd-4160-bda0-29a5a7ad141d_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Lived Assets Held-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets Held-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_6bb7cf37-3006-4aab-80ac-d1e2cf333023_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_4f1c0126-e79a-4c76-8423-edf77ff95dfe_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income, before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_45178a9a-7177-4136-8b04-4ec970b04547_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_fd2a6272-46d2-4fcc-92f0-f508ed20291f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8efb922-5463-415e-b00e-12a91fe0cf82_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_de3011ca-4eff-44fb-a10e-18c9176f8c96_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_9de0f8af-adc0-4bb6-9b75-c24b10f38421_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AgreementsDomain_47bdb22e-268b-4017-be51-da7c9312adbf_terseLabel_en-US" xlink:label="lab_cah_AgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreements [Domain]</link:label>
    <link:label id="lab_cah_AgreementsDomain_label_en-US" xlink:label="lab_cah_AgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreements [Domain]</link:label>
    <link:label id="lab_cah_AgreementsDomain_documentation_en-US" xlink:label="lab_cah_AgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreements [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsDomain" xlink:href="cah-20240930.xsd#cah_AgreementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AgreementsDomain" xlink:to="lab_cah_AgreementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_2fe4243d-6586-4369-9614-d0c44f20cfa3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_773eb4bb-141c-4039-ad5f-1d7e55bfcbd1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_9763a98c-ec16-4646-ab35-2876f32e38f6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_427e2f44-ada8-4bfb-9fb1-1fe439637a0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9d4120d9-65fa-40a3-85b2-a229f8f59c9c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_e33ed1c4-e46e-4bbe-8ff7-a80f7359059d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6461000f-8890-4224-8a4c-b47fa778a692_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_012a700f-f03e-44f3-9aa9-cdd176102345_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeAxis_f9f1d392-0f20-4163-ae09-ecfa61224c4a_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_label_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis" xlink:href="cah-20240930.xsd#cah_PlaintiffTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeAxis" xlink:to="lab_cah_PlaintiffTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_03906a97-68e5-4f1e-bb75-fb5f7417d6e3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A375MillionShareRepurchaseProgramMember_400a65b7-3a0a-44f6-9bf7-2717bd925f79_terseLabel_en-US" xlink:label="lab_cah_A375MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">#375 million share repurchase program</link:label>
    <link:label id="lab_cah_A375MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A375MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$375 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A375MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A375MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$375 million share repurchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A375MillionShareRepurchaseProgramMember" xlink:href="cah-20240930.xsd#cah_A375MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A375MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A375MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1b8f2a-c725-4bc2-88e5-d37a2a09f60c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6b8623b0-a245-42c9-9d07-c928e7e71ea7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_abd82760-07b6-4360-89c0-6e2e98ac799e_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8fda5e4-3bc8-4f90-b673-174af411e69e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_b34b5bb4-80d9-4da2-8f4a-4abf05dc265b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a6430794-a43b-41d1-8f22-f974318b76e5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_10d8fd16-1d14-40c3-9ce1-665c74553759_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a7508e23-ba21-4cf7-8666-38935d429021_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_bcca42fe-c020-42bf-a3df-8f8d207c9302_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase/(decrease) in accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterAxis_c57e8a0c-cdeb-4e5c-a078-a8759f58c009_terseLabel_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_label_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_documentation_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis" xlink:href="cah-20240930.xsd#cah_TaxMatterAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterAxis" xlink:to="lab_cah_TaxMatterAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsMember_13967d09-cc36-4247-86ad-4f4827bc8a65_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_label_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember" xlink:href="cah-20240930.xsd#cah_OpioidLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsMember" xlink:to="lab_cah_OpioidLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PrivatePartiesMember_d1ded2a5-313f-4ab4-a217-f9cc65540e15_terseLabel_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_label_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_documentation_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember" xlink:href="cah-20240930.xsd#cah_PrivatePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PrivatePartiesMember" xlink:to="lab_cah_PrivatePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_830529a2-bed9-44df-ab8c-2d4bd11dc61a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_d59ebab7-5c8f-454f-89a2-4dcccaf21b51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_70da91de-d452-42ed-a64c-f235c200640f_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_77e48247-88c5-48f2-b4d4-7d302aad85fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d89ff903-f99f-45f7-880b-72eaa9823659_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_a46f31e5-ed02-4fb2-bcae-a4b6608dc993_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramAxis" xlink:to="lab_srt_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e42897f4-2cc0-40fd-bdeb-1074e21d0d14_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_a2f81fdc-01d3-4b5c-9506-eaf305e72269_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_87deeb07-a0a8-468b-8666-93ecbadd35d2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_fddb9886-ff88-47b1-873b-74a922d83693_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FY24Q1GoodwillImpairmentGMPDMember_c4e4d645-36e4-4006-8ef3-e94b7f51140c_terseLabel_en-US" xlink:label="lab_cah_FY24Q1GoodwillImpairmentGMPDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FY24 Q1 GMPD Goodwill Impairment [Member]</link:label>
    <link:label id="lab_cah_FY24Q1GoodwillImpairmentGMPDMember_label_en-US" xlink:label="lab_cah_FY24Q1GoodwillImpairmentGMPDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FY24 Q1 Goodwill Impairment - GMPD [Member]</link:label>
    <link:label id="lab_cah_FY24Q1GoodwillImpairmentGMPDMember_documentation_en-US" xlink:label="lab_cah_FY24Q1GoodwillImpairmentGMPDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FY24 Q1 Goodwill Impairment - GMPD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FY24Q1GoodwillImpairmentGMPDMember" xlink:href="cah-20240930.xsd#cah_FY24Q1GoodwillImpairmentGMPDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FY24Q1GoodwillImpairmentGMPDMember" xlink:to="lab_cah_FY24Q1GoodwillImpairmentGMPDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b824fb0a-0a70-4f89-8248-8c8c44103554_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_219542b6-80da-4b86-9a70-c6cc96196a1b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_3fa6a3c6-8dd6-4564-8ef4-ed29f9ab3079_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationAxis_5f611ad0-2da7-4fe0-8356-35c0e20510e0_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opioid Litigation</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_label_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_documentation_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis" xlink:href="cah-20240930.xsd#cah_OpioidLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationAxis" xlink:to="lab_cah_OpioidLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83f3a65d-a5cf-4753-a8e4-2406fa652625_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_2873acc4-90e4-47db-8145-d37b7b9ef9b0_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_fdfd10dc-5383-441c-bd9a-2ae7ca12ee7e_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_36c671d1-806e-4aba-8e31-112c462d00ab_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_0d846014-8e20-4522-808f-5e52341bccb3_terseLabel_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</link:label>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_label_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</link:label>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_documentation_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:href="cah-20240930.xsd#cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:to="lab_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AggregateAnnualAssessment_6a07e5c5-436f-4c1b-9086-2091f05728f5_terseLabel_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_label_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_documentation_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment" xlink:href="cah-20240930.xsd#cah_AggregateAnnualAssessment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AggregateAnnualAssessment" xlink:to="lab_cah_AggregateAnnualAssessment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_065246b6-edb8-4857-9937-95f57a788767_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_be5913b2-e382-43c3-a0b8-f1a08fb83852_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_61195912-fbbf-4c5d-85d9-0e209b97e2d5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6954261f-fac1-4c37-bfb5-186840c967b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8650c20f-15ba-43a8-a389-2db17b91edfa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ad0c40dc-d770-4b43-9dd8-2e48a846ce5c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_90d93364-df28-4958-b8fa-53803130f8c4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6bd3eb9a-8cad-4a61-a805-9db300222169_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net earnings/(loss) attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9d34939f-6264-4117-8109-96c84ab467ba_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IntegratedOncologyNetworkMember_59131be5-7d29-4ece-bf3a-6b03fdbddd88_terseLabel_en-US" xlink:label="lab_cah_IntegratedOncologyNetworkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Integrated Oncology Network</link:label>
    <link:label id="lab_cah_IntegratedOncologyNetworkMember_label_en-US" xlink:label="lab_cah_IntegratedOncologyNetworkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Integrated Oncology Network [Member]</link:label>
    <link:label id="lab_cah_IntegratedOncologyNetworkMember_documentation_en-US" xlink:label="lab_cah_IntegratedOncologyNetworkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Integrated Oncology Network [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IntegratedOncologyNetworkMember" xlink:href="cah-20240930.xsd#cah_IntegratedOncologyNetworkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IntegratedOncologyNetworkMember" xlink:to="lab_cah_IntegratedOncologyNetworkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_a6f84ce3-033a-432b-8208-b62ecade9e84_terseLabel_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_label_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_documentation_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber" xlink:href="cah-20240930.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossContingencyLawsuitsNumber" xlink:to="lab_cah_LossContingencyLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b00b4ab1-5edb-4a49-98fd-d73723d04dcf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_cc58a31a-10e2-4e28-92bf-5e4f00dd9fa7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_41cb6282-8a79-4e75-84e1-f82be916c53a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ff5ee639-1a9f-425d-a1b0-f9d52bf45aa7_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceRecoveries_8dc41efd-9c79-4e56-a2ce-b76a832b5ade_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:label id="lab_us-gaap_InsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceRecoveries" xlink:to="lab_us-gaap_InsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_cab36833-6a4c-4772-99a1-5324f290c989_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_422911b4-f927-42af-8d8f-f8ae97552c43_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain/(loss) on derivative instruments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b39e2355-0036-48f2-a1be-a75f00fdc142_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_18f3f1e9-3525-4884-ab8d-8ea3f4e0f633_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_892ae0ae-51d7-4cae-9f6c-686ed76b3489_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7e930fd4-c5e5-4a59-aec3-d178e63c8125_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_45da9b5b-db0b-4956-8ef5-464c56065db0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program activity</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_632b3864-bb32-46e0-ad04-2188f41d2d20_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_64a6cf72-80d6-453e-a5cc-8563ae863e28_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc60805e-eef4-4a2b-a3f7-ade3e5479170_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates changes on cash and equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_49843823-bbb6-4fb2-b2df-742a8c4763c4_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee-related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_de66759a-4b38-4b6b-8d2f-771ec891f908_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_5e933ffe-09aa-473b-981a-aac2f09f740c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2fd0d5db-b6d9-4b25-90ce-36bdc397fd08_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b540fe9b-c05b-49d3-88cb-4f97aad7921e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IVCApril2023AgreementMember_8010ecfa-ba23-4747-9c40-e1c1b6ff6c9a_terseLabel_en-US" xlink:label="lab_cah_IVCApril2023AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IVC April 2023 Agreement</link:label>
    <link:label id="lab_cah_IVCApril2023AgreementMember_label_en-US" xlink:label="lab_cah_IVCApril2023AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IVC April 2023 Agreement [Member]</link:label>
    <link:label id="lab_cah_IVCApril2023AgreementMember_documentation_en-US" xlink:label="lab_cah_IVCApril2023AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IVC April 2023 Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IVCApril2023AgreementMember" xlink:href="cah-20240930.xsd#cah_IVCApril2023AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IVCApril2023AgreementMember" xlink:to="lab_cah_IVCApril2023AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_85281bd4-b7e7-4fe9-a607-7f592bd39539_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_042c1c48-aff5-47b0-90ed-186ed4dc71fc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3382249c-a1e5-4880-acca-52bcfcf233a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2734005a-5a13-4f34-b59f-bf2fb6f09ba5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Net earnings attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a47484b0-1aab-4b6f-b4d0-ba8454412598_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_1b658d8c-194d-4c54-b270-f25133257690_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ecfea75d-2b04-4efa-805d-36bc366e55f6_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_c70d8798-086c-4057-b6ee-84469fba3344_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_004ad392-d10e-4cb5-849f-066a0341d99e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case Type</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d4345fd8-1ba1-40d1-b949-75061cc0f3c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_50e54496-c107-4247-b000-7a004f9baabc_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e60ef36c-bd57-4948-9c0e-f017c1db8d23_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4f4e3d14-8f9c-419b-8ee5-1569523b2f1f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_92a81932-6af0-446a-af5a-5cb2483076a6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings/(Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_10c1cace-0c88-4f26-9923-f165ed600e5d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_94e2bb85-eb23-4b0d-b9fd-55bdbd243372_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares&#8211;basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ae6d7bd-87f1-4581-980a-2b7d8d0ccc58_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eaa0cb83-bcef-4d8d-ace0-4b7498016383_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2dffbc59-e314-47da-bbc4-bf234a7222eb_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3ee8d171-f67e-4543-a6dd-f9f2edd38784_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_66bb4513-f691-462a-8d7b-f0f58db4c9f0_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Share Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95afe837-f73f-42c8-b5e6-18b15647b6e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_b8fa6589-b95c-4477-a091-f265be1f3888_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_f32d6485-50ea-4f1d-8a91-1c205805e4a1_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementLoss_e491370e-41d4-4a99-9332-2fd5e9800663_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Loss</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementLoss_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementLoss" xlink:to="lab_us-gaap_LitigationSettlementLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_db7e6288-134c-49d5-86bc-23a1934447ee_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_89e03b93-9bcb-4abb-a070-e3d3f5832fe8_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_7121c204-2908-42c8-b04e-27763ba900cf_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a4c84510-8719-45a5-b9d6-5454ab6e91f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_38415e8f-78ba-4fe0-8ae9-a1a9af87a767_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cah-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:537b797f-b836-409a-bf04-ad11625945c4,g:bd28f3d8-0395-4523-ae63-79ccc2df931a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20240930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e87f808e-68e4-448f-a084-1fbe2797af06" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_DocumentType_e87f808e-68e4-448f-a084-1fbe2797af06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b15a1726-d385-4754-8509-ac69de98dc7d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_DocumentQuarterlyReport_b15a1726-d385-4754-8509-ac69de98dc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_88a9e12b-0310-450a-81c4-e315be8b1cdd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_DocumentPeriodEndDate_88a9e12b-0310-450a-81c4-e315be8b1cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_2e4f5fb3-df42-4f30-888a-da67dfaed562" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_DocumentTransitionReport_2e4f5fb3-df42-4f30-888a-da67dfaed562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_773cb278-ee55-46df-ade6-4e7625decd95" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityFileNumber_773cb278-ee55-46df-ade6-4e7625decd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_47bca284-409d-4852-b6b4-dfff5143bb90" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityRegistrantName_47bca284-409d-4852-b6b4-dfff5143bb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_aa796599-f0d9-4b6a-ac02-63fd10f914fc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityCentralIndexKey_aa796599-f0d9-4b6a-ac02-63fd10f914fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_76198ed5-4db4-43f0-873d-440718db1942" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_CurrentFiscalYearEndDate_76198ed5-4db4-43f0-873d-440718db1942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a7c60e84-e10f-45b4-88eb-7156e597b61c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_DocumentFiscalYearFocus_a7c60e84-e10f-45b4-88eb-7156e597b61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b2df74b1-ba92-4d61-b79d-5f2a317159d0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b2df74b1-ba92-4d61-b79d-5f2a317159d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_66d7477c-9351-41fc-b906-c71664144482" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_AmendmentFlag_66d7477c-9351-41fc-b906-c71664144482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a63b6ccb-7a33-49e0-b574-f27d14889a71" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a63b6ccb-7a33-49e0-b574-f27d14889a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3b7f183c-f51c-4063-9835-14f2a6df60d5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityTaxIdentificationNumber_3b7f183c-f51c-4063-9835-14f2a6df60d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b225f3d3-6d87-4c8e-89af-be21661cbf73" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityAddressAddressLine1_b225f3d3-6d87-4c8e-89af-be21661cbf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f50f2612-6ae1-4266-9707-cec53af815ed" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityAddressCityOrTown_f50f2612-6ae1-4266-9707-cec53af815ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_87ad4ecd-617f-4e1e-bafc-effd5e27d8eb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityAddressStateOrProvince_87ad4ecd-617f-4e1e-bafc-effd5e27d8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1a682d3e-bac4-4737-8508-a3698b8d1d4c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityAddressPostalZipCode_1a682d3e-bac4-4737-8508-a3698b8d1d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_69f3ae91-83fb-4524-a687-62c0e6c3e288" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_CityAreaCode_69f3ae91-83fb-4524-a687-62c0e6c3e288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_899cf05a-da34-4008-b1ae-5e5bb7c2aaad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_LocalPhoneNumber_899cf05a-da34-4008-b1ae-5e5bb7c2aaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_70e3e7a5-912f-42ca-9e66-4723ebb44d9a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityCurrentReportingStatus_70e3e7a5-912f-42ca-9e66-4723ebb44d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f7f3451d-592c-412c-8b68-4936f5372fc9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityInteractiveDataCurrent_f7f3451d-592c-412c-8b68-4936f5372fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ee5c8386-87eb-4d06-b84e-e8276c272ac4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityFilerCategory_ee5c8386-87eb-4d06-b84e-e8276c272ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f5e2ed28-fa50-475a-9020-19a6a0577a75" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntitySmallBusiness_f5e2ed28-fa50-475a-9020-19a6a0577a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_89489a1e-a98d-4d58-afbd-e8eeab43f5e6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityEmergingGrowthCompany_89489a1e-a98d-4d58-afbd-e8eeab43f5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a8a32dc2-fb61-4c0a-bd79-d21735cbaafd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityShellCompany_a8a32dc2-fb61-4c0a-bd79-d21735cbaafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7a1b6fea-c5cf-42a9-928a-19e22a4cbe86" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_Security12bTitle_7a1b6fea-c5cf-42a9-928a-19e22a4cbe86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7fd2931c-ca61-4039-b260-2bdb66533d05" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_TradingSymbol_7fd2931c-ca61-4039-b260-2bdb66533d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_50eefe7c-ee13-4d0a-901d-09cae456266f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_SecurityExchangeName_50eefe7c-ee13-4d0a-901d-09cae456266f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_06165454-15a5-4126-8cb6-ffaab27621f8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_65f92426-ca1e-43da-b272-ea82087076b5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_06165454-15a5-4126-8cb6-ffaab27621f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20240930.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_987da686-ef76-4eaf-accd-b7a880a40ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_Revenues_987da686-ef76-4eaf-accd-b7a880a40ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e90446a3-50e8-4c0f-a999-4bbaf50d198f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e90446a3-50e8-4c0f-a999-4bbaf50d198f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_34b92fb9-4bab-45b3-93aa-6465d5bdfdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_GrossProfit_34b92fb9-4bab-45b3-93aa-6465d5bdfdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3763d29a-fde3-4d1b-b14a-277c1e407c05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3763d29a-fde3-4d1b-b14a-277c1e407c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8315c834-c68e-4537-af7b-1aa3ec8afbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3763d29a-fde3-4d1b-b14a-277c1e407c05" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8315c834-c68e-4537-af7b-1aa3ec8afbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b74aa819-1c6f-4317-884a-5a73a755f041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3763d29a-fde3-4d1b-b14a-277c1e407c05" xlink:to="loc_us-gaap_RestructuringCharges_b74aa819-1c6f-4317-884a-5a73a755f041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_7b3c7ff2-67ff-44fa-b0b9-b0f26b75c142" xlink:href="cah-20240930.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3763d29a-fde3-4d1b-b14a-277c1e407c05" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_7b3c7ff2-67ff-44fa-b0b9-b0f26b75c142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_4bcc3b70-51d1-40b2-b64e-5fd0c793abe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3763d29a-fde3-4d1b-b14a-277c1e407c05" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_4bcc3b70-51d1-40b2-b64e-5fd0c793abe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_ad327b09-ccd1-468a-bbbd-674bf2b97a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3763d29a-fde3-4d1b-b14a-277c1e407c05" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_ad327b09-ccd1-468a-bbbd-674bf2b97a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_13db79e5-03aa-47ca-baed-e4942a74f4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_OperatingIncomeLoss_13db79e5-03aa-47ca-baed-e4942a74f4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cfe54a4a-ff05-47cb-893a-a434fdb0f5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cfe54a4a-ff05-47cb-893a-a434fdb0f5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_02d8ce32-9173-47bd-8add-3da24f38c6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_InterestExpense_02d8ce32-9173-47bd-8add-3da24f38c6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b105c022-f0bb-497a-af82-3519706e214c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b105c022-f0bb-497a-af82-3519706e214c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4f7da0ce-7bdd-40f8-acae-d221993dcf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4f7da0ce-7bdd-40f8-acae-d221993dcf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ee9bdd4a-f592-47a4-9e3b-0ea9828420b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_ProfitLoss_ee9bdd4a-f592-47a4-9e3b-0ea9828420b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b5128bde-bf57-45e6-9210-5070c7791fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b5128bde-bf57-45e6-9210-5070c7791fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d0da78a4-fe6d-48c2-bc3f-a2803a67f12d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_NetIncomeLoss_d0da78a4-fe6d-48c2-bc3f-a2803a67f12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_f0684704-c297-4c8c-83ad-b5c29ebfc6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_f0684704-c297-4c8c-83ad-b5c29ebfc6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b06b89ce-0317-4822-804c-73c0f3f52106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_f0684704-c297-4c8c-83ad-b5c29ebfc6b8" xlink:to="loc_us-gaap_EarningsPerShareBasic_b06b89ce-0317-4822-804c-73c0f3f52106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_076cf217-a6e5-4ac2-be00-a036c21ac017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_f0684704-c297-4c8c-83ad-b5c29ebfc6b8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_076cf217-a6e5-4ac2-be00-a036c21ac017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_88ee56be-14c5-437e-a588-785eb1e1c039" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_88ee56be-14c5-437e-a588-785eb1e1c039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c8ef4243-61ee-4bb0-8acc-03886a7c7473" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_88ee56be-14c5-437e-a588-785eb1e1c039" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c8ef4243-61ee-4bb0-8acc-03886a7c7473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b93b94d-a2eb-49b8-9e7d-bbde85206359" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_88ee56be-14c5-437e-a588-785eb1e1c039" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b93b94d-a2eb-49b8-9e7d-bbde85206359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_59c69048-2675-4543-a17c-3de0d356959c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59ecb170-dcfa-4e5d-bc1f-603e8f9de427" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_59c69048-2675-4543-a17c-3de0d356959c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20240930.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ab49a82e-ee27-404a-92d9-b7221649c4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f13bd387-22eb-4a15-8aff-cdfa685dc0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ab49a82e-ee27-404a-92d9-b7221649c4a7" xlink:to="loc_us-gaap_ProfitLoss_f13bd387-22eb-4a15-8aff-cdfa685dc0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a27de3df-7e98-41f4-8a8e-60ba26f0cd46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ab49a82e-ee27-404a-92d9-b7221649c4a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a27de3df-7e98-41f4-8a8e-60ba26f0cd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b4912c38-b105-4392-9344-84fbde4df091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a27de3df-7e98-41f4-8a8e-60ba26f0cd46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b4912c38-b105-4392-9344-84fbde4df091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8d748dbe-28db-4d3f-9c51-0d4321146b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a27de3df-7e98-41f4-8a8e-60ba26f0cd46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8d748dbe-28db-4d3f-9c51-0d4321146b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_00d0355e-36b1-49a8-9e1d-5608d049481d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a27de3df-7e98-41f4-8a8e-60ba26f0cd46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_00d0355e-36b1-49a8-9e1d-5608d049481d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c84aa785-7d3a-494e-8f66-8295a3770216" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ab49a82e-ee27-404a-92d9-b7221649c4a7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c84aa785-7d3a-494e-8f66-8295a3770216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fcf2b317-a566-492e-8094-25feac7ef4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ab49a82e-ee27-404a-92d9-b7221649c4a7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fcf2b317-a566-492e-8094-25feac7ef4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e1db6aad-f43c-4123-823a-7ceea05ccc24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ab49a82e-ee27-404a-92d9-b7221649c4a7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e1db6aad-f43c-4123-823a-7ceea05ccc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20240930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_72e7b73c-cca9-4a39-a41e-0951429b056c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d80631af-7900-49e2-8968-b5ba9bd60dee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72e7b73c-cca9-4a39-a41e-0951429b056c" xlink:to="loc_us-gaap_AssetsAbstract_d80631af-7900-49e2-8968-b5ba9bd60dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_50729aa4-c3cf-44c2-a8a2-435ab94ef181" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d80631af-7900-49e2-8968-b5ba9bd60dee" xlink:to="loc_us-gaap_AssetsCurrentAbstract_50729aa4-c3cf-44c2-a8a2-435ab94ef181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0faa6e8-5c23-4421-966e-5be7cf172932" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50729aa4-c3cf-44c2-a8a2-435ab94ef181" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0faa6e8-5c23-4421-966e-5be7cf172932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_7bbd18e2-bcf4-4d2d-9461-7839fc320507" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50729aa4-c3cf-44c2-a8a2-435ab94ef181" xlink:to="loc_us-gaap_ReceivablesNetCurrent_7bbd18e2-bcf4-4d2d-9461-7839fc320507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a8bf60f0-fced-4a4f-a01f-6a25b3140dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50729aa4-c3cf-44c2-a8a2-435ab94ef181" xlink:to="loc_us-gaap_InventoryNet_a8bf60f0-fced-4a4f-a01f-6a25b3140dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e13c7ca5-a5eb-495a-95e3-9828b131a5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50729aa4-c3cf-44c2-a8a2-435ab94ef181" xlink:to="loc_us-gaap_OtherAssetsCurrent_e13c7ca5-a5eb-495a-95e3-9828b131a5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_335e3f19-35c2-4348-a473-dec3a3a6ea13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50729aa4-c3cf-44c2-a8a2-435ab94ef181" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_335e3f19-35c2-4348-a473-dec3a3a6ea13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d9b4d2bb-48ee-4d45-a0aa-7647ebaa39e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50729aa4-c3cf-44c2-a8a2-435ab94ef181" xlink:to="loc_us-gaap_AssetsCurrent_d9b4d2bb-48ee-4d45-a0aa-7647ebaa39e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cbb04d20-1a5f-4f2a-ac3c-cef27e733cda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d80631af-7900-49e2-8968-b5ba9bd60dee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cbb04d20-1a5f-4f2a-ac3c-cef27e733cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7b8f7721-1384-414c-9101-80f5135f783c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d80631af-7900-49e2-8968-b5ba9bd60dee" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_7b8f7721-1384-414c-9101-80f5135f783c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cfee4ecc-afab-4ad9-9a62-e70b8036b696" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d80631af-7900-49e2-8968-b5ba9bd60dee" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cfee4ecc-afab-4ad9-9a62-e70b8036b696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_45cf9799-80b3-4dbe-87dd-4810afdc8952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d80631af-7900-49e2-8968-b5ba9bd60dee" xlink:to="loc_us-gaap_Assets_45cf9799-80b3-4dbe-87dd-4810afdc8952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a8b0837-a24b-4bcd-9251-3cd976797df2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72e7b73c-cca9-4a39-a41e-0951429b056c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a8b0837-a24b-4bcd-9251-3cd976797df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1c6bb000-a9fc-42d3-a453-e1766642e4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a8b0837-a24b-4bcd-9251-3cd976797df2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1c6bb000-a9fc-42d3-a453-e1766642e4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1625c5cc-0dd1-4876-9e2f-e81f25328301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1c6bb000-a9fc-42d3-a453-e1766642e4b1" xlink:to="loc_us-gaap_AccountsPayableCurrent_1625c5cc-0dd1-4876-9e2f-e81f25328301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c1c46ea0-56bf-40d5-9d9e-b0a37535de6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1c6bb000-a9fc-42d3-a453-e1766642e4b1" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c1c46ea0-56bf-40d5-9d9e-b0a37535de6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1580ae7d-3876-4207-a077-36e8ae9276ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1c6bb000-a9fc-42d3-a453-e1766642e4b1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1580ae7d-3876-4207-a077-36e8ae9276ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_20d6bb8a-bb83-4895-a183-88f719bd79b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1c6bb000-a9fc-42d3-a453-e1766642e4b1" xlink:to="loc_us-gaap_LiabilitiesCurrent_20d6bb8a-bb83-4895-a183-88f719bd79b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_af45d92d-d554-4b7f-8b70-a1c14b292e87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a8b0837-a24b-4bcd-9251-3cd976797df2" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_af45d92d-d554-4b7f-8b70-a1c14b292e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_73fd0746-a3d7-4243-893e-e1f17b374deb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a8b0837-a24b-4bcd-9251-3cd976797df2" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_73fd0746-a3d7-4243-893e-e1f17b374deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a8b0837-a24b-4bcd-9251-3cd976797df2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8b5e321e-85fb-4219-b3ab-c72ac45bd42c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8b5e321e-85fb-4219-b3ab-c72ac45bd42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_eb8ca177-77ad-4d3c-a0c0-e03f4a30aef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_eb8ca177-77ad-4d3c-a0c0-e03f4a30aef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_13afde61-ed0d-4f8f-b83f-904cd3a65764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_PreferredStockSharesIssued_13afde61-ed0d-4f8f-b83f-904cd3a65764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_98b10ea0-9d7e-4d64-80d3-bb97ddbee19a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_PreferredStockValue_98b10ea0-9d7e-4d64-80d3-bb97ddbee19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30cbae25-1b4f-47a3-a2f6-f43e830a5270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30cbae25-1b4f-47a3-a2f6-f43e830a5270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c6daca5e-2582-4d0f-828d-406008b3d4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c6daca5e-2582-4d0f-828d-406008b3d4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_50b68a35-a6e9-44a2-8821-02f2264dff91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_CommonStockSharesIssued_50b68a35-a6e9-44a2-8821-02f2264dff91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e11f5f9b-6f8e-4a3f-826d-0c14e6dc0328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_CommonStockValue_e11f5f9b-6f8e-4a3f-826d-0c14e6dc0328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_027579ae-3ac7-444f-9c9b-2c86b35ee586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_027579ae-3ac7-444f-9c9b-2c86b35ee586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_df7ef570-e2bb-47aa-830f-e2d7f3ba55f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_TreasuryStockValue_df7ef570-e2bb-47aa-830f-e2d7f3ba55f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b8df3f0e-9943-44d5-8c7a-1944af84b10d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_TreasuryStockCommonShares_b8df3f0e-9943-44d5-8c7a-1944af84b10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7d9ccc91-5a9e-40b0-9dc9-c52dc0b2ed37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7d9ccc91-5a9e-40b0-9dc9-c52dc0b2ed37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a2e44da-a5fa-4edd-a828-07ea1035d051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_StockholdersEquity_1a2e44da-a5fa-4edd-a828-07ea1035d051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_76c4d307-3f8a-42de-b08c-8de6fd1fd88e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_MinorityInterest_76c4d307-3f8a-42de-b08c-8de6fd1fd88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b83b53e3-2475-4eae-b0ee-efb0eafd38e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f25d8c6b-986d-450d-8304-87234c7e85bf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b83b53e3-2475-4eae-b0ee-efb0eafd38e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_38ad8f3d-e901-4eba-8d27-7ce5bbea02aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a8b0837-a24b-4bcd-9251-3cd976797df2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_38ad8f3d-e901-4eba-8d27-7ce5bbea02aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="simple" xlink:href="cah-20240930.xsd#CondensedConsolidatedStatementofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b4970e1b-6963-40df-86f4-d1443ec04635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a8e44fdc-6c99-44ef-b843-f00a9c0a1aff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b4970e1b-6963-40df-86f4-d1443ec04635" xlink:to="loc_us-gaap_StatementTable_a8e44fdc-6c99-44ef-b843-f00a9c0a1aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_af1991d3-59cf-44d9-88df-a06f7460e54e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a8e44fdc-6c99-44ef-b843-f00a9c0a1aff" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_af1991d3-59cf-44d9-88df-a06f7460e54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af1991d3-59cf-44d9-88df-a06f7460e54e" xlink:to="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_559cf914-4588-4819-8d1b-06827251f0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:to="loc_us-gaap_CommonStockMember_559cf914-4588-4819-8d1b-06827251f0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4d567f3e-691f-4041-96d9-eeab03778e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:to="loc_us-gaap_RetainedEarningsMember_4d567f3e-691f-4041-96d9-eeab03778e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_daaf5ceb-7f60-428f-bb5a-511f7bd7cc95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:to="loc_us-gaap_TreasuryStockCommonMember_daaf5ceb-7f60-428f-bb5a-511f7bd7cc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45e1f79f-092e-4de6-9acc-2443fb53bc29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45e1f79f-092e-4de6-9acc-2443fb53bc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_08c5de25-9baf-4a26-b181-0f3e22146e98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98211701-1f5f-45b0-997b-ca0b0bca389f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_08c5de25-9baf-4a26-b181-0f3e22146e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_618d2ae4-3abc-4de6-937f-459db6128311" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a8e44fdc-6c99-44ef-b843-f00a9c0a1aff" xlink:to="loc_us-gaap_StatementLineItems_618d2ae4-3abc-4de6-937f-459db6128311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_618d2ae4-3abc-4de6-937f-459db6128311" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_23138350-9419-4e9e-a615-888cdc96b14b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_CommonStockSharesIssued_23138350-9419-4e9e-a615-888cdc96b14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50a71afc-6bda-41f8-9df0-3ae04150fa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50a71afc-6bda-41f8-9df0-3ae04150fa2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_e01d097e-b927-41e7-87ac-01af8f24e0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_e01d097e-b927-41e7-87ac-01af8f24e0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_8e28dca9-ce77-4ca7-a8ee-a1c9d3ed00ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_TreasuryStockValue_8e28dca9-ce77-4ca7-a8ee-a1c9d3ed00ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e29e8d9-eff7-4cc3-a43a-c44938ec638c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_NetIncomeLoss_9e29e8d9-eff7-4cc3-a43a-c44938ec638c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d47a3d06-15b6-46f4-85ee-86856e733b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_ProfitLoss_d47a3d06-15b6-46f4-85ee-86856e733b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c5de8a6d-22bd-459b-829e-f4d051f1d40d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c5de8a6d-22bd-459b-829e-f4d051f1d40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_77f8f120-b0e7-4cfd-acd9-fbbfe1aabcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_77f8f120-b0e7-4cfd-acd9-fbbfe1aabcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_df47069c-0014-4c8f-84a2-e60522da10c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_df47069c-0014-4c8f-84a2-e60522da10c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e65a82a6-8029-48ee-85af-ee437be47e37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e65a82a6-8029-48ee-85af-ee437be47e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_f2c9f498-91f2-4790-a908-e03edaee42b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_f2c9f498-91f2-4790-a908-e03edaee42b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_64bc7820-163e-49c7-a88e-2ed61e77443a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_64bc7820-163e-49c7-a88e-2ed61e77443a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_7e2c5e77-d037-471d-b75c-c0f15fccf534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_Dividends_7e2c5e77-d037-471d-b75c-c0f15fccf534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_6395a1b5-18ad-433d-8220-1c7b99603066" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_StockholdersEquityOther_6395a1b5-18ad-433d-8220-1c7b99603066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e168c046-b71c-4526-a89a-71b1eb2ba7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_CommonStockSharesIssued_e168c046-b71c-4526-a89a-71b1eb2ba7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_24426541-bc4a-4b87-95de-3dd0b1e751fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_24426541-bc4a-4b87-95de-3dd0b1e751fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_7bd9970a-503f-4455-a132-9910125e7ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_7bd9970a-503f-4455-a132-9910125e7ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_9ed73385-62d0-4d45-a35e-ec8362b2a4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50122336-266c-4c14-ab39-f3b2b7edca1b" xlink:to="loc_us-gaap_TreasuryStockValue_9ed73385-62d0-4d45-a35e-ec8362b2a4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20240930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b6977deb-81ae-4e22-8dc2-e6300633f732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_95b8c2b0-224b-4230-a19c-e7e29e9de0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6977deb-81ae-4e22-8dc2-e6300633f732" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_95b8c2b0-224b-4230-a19c-e7e29e9de0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c3fdf7eb-e8f9-4806-b2e4-4f994b53a254" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_95b8c2b0-224b-4230-a19c-e7e29e9de0ea" xlink:to="loc_us-gaap_ProfitLoss_c3fdf7eb-e8f9-4806-b2e4-4f994b53a254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f11efddb-e287-4883-ae0e-c40b692aed41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_95b8c2b0-224b-4230-a19c-e7e29e9de0ea" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f11efddb-e287-4883-ae0e-c40b692aed41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e2d8c2c2-e474-45e4-ab15-9303b3969b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f11efddb-e287-4883-ae0e-c40b692aed41" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e2d8c2c2-e474-45e4-ab15-9303b3969b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_a82291f8-f6f0-4c4b-8ea6-33fb92c0c4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f11efddb-e287-4883-ae0e-c40b692aed41" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_a82291f8-f6f0-4c4b-8ea6-33fb92c0c4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b0deaf96-6d34-4aba-8c7a-2e51f8a62e83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f11efddb-e287-4883-ae0e-c40b692aed41" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b0deaf96-6d34-4aba-8c7a-2e51f8a62e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3c0a6a88-71fb-486a-bfb4-2c97e0a86702" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f11efddb-e287-4883-ae0e-c40b692aed41" xlink:to="loc_us-gaap_ShareBasedCompensation_3c0a6a88-71fb-486a-bfb4-2c97e0a86702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_6d75668e-a195-447e-b4ef-90ea5d57f3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f11efddb-e287-4883-ae0e-c40b692aed41" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_6d75668e-a195-447e-b4ef-90ea5d57f3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2caf5cb-b38f-4215-b696-c2422730a90e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f11efddb-e287-4883-ae0e-c40b692aed41" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2caf5cb-b38f-4215-b696-c2422730a90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_3dbe3f8d-50ae-4d57-a181-2f1b7728b65f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2caf5cb-b38f-4215-b696-c2422730a90e" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_3dbe3f8d-50ae-4d57-a181-2f1b7728b65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_59495888-fd1a-4838-9480-26f9e638a209" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2caf5cb-b38f-4215-b696-c2422730a90e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_59495888-fd1a-4838-9480-26f9e638a209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3f668fdb-bb65-4677-8a32-0b02fbbc07d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2caf5cb-b38f-4215-b696-c2422730a90e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3f668fdb-bb65-4677-8a32-0b02fbbc07d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1a157710-a59b-478b-be46-d88837bc5828" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2caf5cb-b38f-4215-b696-c2422730a90e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1a157710-a59b-478b-be46-d88837bc5828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c6b08ca8-1b28-4ecc-b992-3d2a8f47629e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_95b8c2b0-224b-4230-a19c-e7e29e9de0ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c6b08ca8-1b28-4ecc-b992-3d2a8f47629e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_080825b2-0beb-4825-a038-447546cc52c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6977deb-81ae-4e22-8dc2-e6300633f732" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_080825b2-0beb-4825-a038-447546cc52c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22ccd702-1e6e-4178-8f94-d476b24a61fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_080825b2-0beb-4825-a038-447546cc52c4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22ccd702-1e6e-4178-8f94-d476b24a61fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_6cd20ad4-e87d-4d61-9542-5772f13443ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_080825b2-0beb-4825-a038-447546cc52c4" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_6cd20ad4-e87d-4d61-9542-5772f13443ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f0c57987-2d59-4274-8fad-747760684933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_080825b2-0beb-4825-a038-447546cc52c4" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f0c57987-2d59-4274-8fad-747760684933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_0bd320c3-fb2d-45e9-ad95-a183de385e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_080825b2-0beb-4825-a038-447546cc52c4" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_0bd320c3-fb2d-45e9-ad95-a183de385e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_006bcf24-7e12-4add-987d-19486c970c25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_080825b2-0beb-4825-a038-447546cc52c4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_006bcf24-7e12-4add-987d-19486c970c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_012a53fa-9ddc-4dee-b893-d5a8a09ff342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6977deb-81ae-4e22-8dc2-e6300633f732" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_012a53fa-9ddc-4dee-b893-d5a8a09ff342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2b8807ca-6ded-4565-8b92-78e8aa7b21d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_012a53fa-9ddc-4dee-b893-d5a8a09ff342" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2b8807ca-6ded-4565-8b92-78e8aa7b21d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_b94aa520-7408-43ce-8284-c1b45582029d" xlink:href="cah-20240930.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_012a53fa-9ddc-4dee-b893-d5a8a09ff342" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_b94aa520-7408-43ce-8284-c1b45582029d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_32ffd521-aa07-490a-9708-ffb5a40b3d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_012a53fa-9ddc-4dee-b893-d5a8a09ff342" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_32ffd521-aa07-490a-9708-ffb5a40b3d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_db12df35-9f31-4eca-8c25-af239abcb12a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_012a53fa-9ddc-4dee-b893-d5a8a09ff342" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_db12df35-9f31-4eca-8c25-af239abcb12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cc53738-086f-40ef-8a1b-147cc87f8740" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_012a53fa-9ddc-4dee-b893-d5a8a09ff342" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cc53738-086f-40ef-8a1b-147cc87f8740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6476e1bc-8631-43cd-8b94-9956192bfb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6977deb-81ae-4e22-8dc2-e6300633f732" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6476e1bc-8631-43cd-8b94-9956192bfb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a04633ba-54af-4e7c-89c1-479ce9fbd455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6977deb-81ae-4e22-8dc2-e6300633f732" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a04633ba-54af-4e7c-89c1-479ce9fbd455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8cca7511-8e60-4fa8-988d-6ee4a5baf79d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6977deb-81ae-4e22-8dc2-e6300633f732" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8cca7511-8e60-4fa8-988d-6ee4a5baf79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6cdad456-0006-46f6-8684-2a2291f3f324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6977deb-81ae-4e22-8dc2-e6300633f732" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6cdad456-0006-46f6-8684-2a2291f3f324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20240930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_52ed22f9-8b41-4a42-8530-9ce35fc15097" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_7ae95361-7146-4686-995d-24f7e62ff406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_52ed22f9-8b41-4a42-8530-9ce35fc15097" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_7ae95361-7146-4686-995d-24f7e62ff406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/Acquisitions" xlink:type="simple" xlink:href="cah-20240930.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ed5d9760-df1c-4dde-9c1b-918fcd8ee6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_a2aa80a6-7266-4fb0-889f-a78c8e9f1dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ed5d9760-df1c-4dde-9c1b-918fcd8ee6b7" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_a2aa80a6-7266-4fb0-889f-a78c8e9f1dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/Divestitures" xlink:type="simple" xlink:href="cah-20240930.xsd#Divestitures"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/Divestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5a6cc4ba-7544-46cc-9327-173ae6134532" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_84948c98-7dcc-4e83-8187-eb43c70a0efc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5a6cc4ba-7544-46cc-9327-173ae6134532" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_84948c98-7dcc-4e83-8187-eb43c70a0efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20240930.xsd#RestructuringandEmployeeSeverance"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_751aecd4-0599-43b4-8714-251048ef1239" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_13a91e6e-d839-44f3-ac16-a1154333d4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_751aecd4-0599-43b4-8714-251048ef1239" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_13a91e6e-d839-44f3-ac16-a1154333d4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20240930.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_18e845a8-feff-4fc5-a894-22f6fd299f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6d5c0aec-0793-4500-a591-124a57479787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_18e845a8-feff-4fc5-a894-22f6fd299f4c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6d5c0aec-0793-4500-a591-124a57479787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20240930.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1251afa7-431e-4ef5-87cc-56b48199f4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_927a8f48-fe93-4fa7-a813-4cac5549fa82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1251afa7-431e-4ef5-87cc-56b48199f4e3" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_927a8f48-fe93-4fa7-a813-4cac5549fa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20240930.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e8e45229-9631-4251-860b-9d71b4030231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_164ab8c8-b4c9-4667-822d-f8eab4373946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e8e45229-9631-4251-860b-9d71b4030231" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_164ab8c8-b4c9-4667-822d-f8eab4373946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20240930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9a3698d9-c964-4e84-8a93-fcf8e0f02fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3f916979-8dd9-44b6-8769-d1d1c93affe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9a3698d9-c964-4e84-8a93-fcf8e0f02fe1" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3f916979-8dd9-44b6-8769-d1d1c93affe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20240930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d6d94825-74ae-4281-a46c-3a80ff1f3290" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_53569c6a-30ca-43c7-aecb-5ebdc3c07842" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d6d94825-74ae-4281-a46c-3a80ff1f3290" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_53569c6a-30ca-43c7-aecb-5ebdc3c07842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20240930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_919b5d9f-0999-445d-8be5-e57b5782ae6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6d878ab0-b733-4861-b826-aa2117cfcb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_919b5d9f-0999-445d-8be5-e57b5782ae6f" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6d878ab0-b733-4861-b826-aa2117cfcb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3e325c68-c67e-415c-b198-39cb28e0fb88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c4d66930-06f1-41a1-9cca-804721d1e488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3e325c68-c67e-415c-b198-39cb28e0fb88" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c4d66930-06f1-41a1-9cca-804721d1e488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20240930.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3e30b5b3-2a8a-40e5-806f-4c883c2b91c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9d9dad33-63a0-4de2-9fdf-9a084f8678b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3e30b5b3-2a8a-40e5-806f-4c883c2b91c2" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9d9dad33-63a0-4de2-9fdf-9a084f8678b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20240930.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0d18e9e1-0761-4fd7-9914-2fedee8a1868" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_45d30528-52be-4012-9ce5-694b93fbe735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0d18e9e1-0761-4fd7-9914-2fedee8a1868" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_45d30528-52be-4012-9ce5-694b93fbe735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07a987e1-7bfa-408d-85c7-f196244877df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5711385f-2fce-43eb-aeba-bde66ffb91ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07a987e1-7bfa-408d-85c7-f196244877df" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5711385f-2fce-43eb-aeba-bde66ffb91ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20240930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2d5b31a3-6237-499b-b9f5-5eb2b329bce3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_530d70be-8df6-4566-b1b5-41fe9fd481fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2d5b31a3-6237-499b-b9f5-5eb2b329bce3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_530d70be-8df6-4566-b1b5-41fe9fd481fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_01df680f-ef76-47cb-8495-fb8f5b74cf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2d5b31a3-6237-499b-b9f5-5eb2b329bce3" xlink:to="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_01df680f-ef76-47cb-8495-fb8f5b74cf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ac5b5982-850f-4e68-a6ab-34b08ecaa56e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2d5b31a3-6237-499b-b9f5-5eb2b329bce3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ac5b5982-850f-4e68-a6ab-34b08ecaa56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="cah-20240930.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b24d5042-c614-4b1a-b0a2-a995765871bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DivestituresTables" xlink:type="simple" xlink:href="cah-20240930.xsd#DivestituresTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_35cb4a5a-8852-4e54-925d-8528818f8d15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20240930.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_8d3b789f-bc3d-44ed-9cb8-519b9d18a6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_bfacde4a-9a27-4614-9d1b-9898c82dc3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_8d3b789f-bc3d-44ed-9cb8-519b9d18a6a9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_bfacde4a-9a27-4614-9d1b-9898c82dc3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6bb124e1-2f19-4c59-a129-5f0ebfad426b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_8d3b789f-bc3d-44ed-9cb8-519b9d18a6a9" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6bb124e1-2f19-4c59-a129-5f0ebfad426b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20240930.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5fad1662-97ab-4f9c-87e8-90f8e309944a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_0a8144e4-4d52-4f42-9cc9-4c079c6b0bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5fad1662-97ab-4f9c-87e8-90f8e309944a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_0a8144e4-4d52-4f42-9cc9-4c079c6b0bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_d1a445d7-50cb-423f-8cd7-0f9af9aa993a" xlink:href="cah-20240930.xsd#cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5fad1662-97ab-4f9c-87e8-90f8e309944a" xlink:to="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_d1a445d7-50cb-423f-8cd7-0f9af9aa993a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20240930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0ab33df4-34d7-4ce3-9f5a-4fb58d71959c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a388e03c-ec9c-4376-b5bc-9a32de8e2f57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0ab33df4-34d7-4ce3-9f5a-4fb58d71959c" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a388e03c-ec9c-4376-b5bc-9a32de8e2f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20240930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2920ad82-2069-4f53-8d0c-f8c55cd0f1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_7f2a5874-631c-4907-80e2-3720a5752e35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2920ad82-2069-4f53-8d0c-f8c55cd0f1d8" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_7f2a5874-631c-4907-80e2-3720a5752e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_924641a5-7d84-45d4-807e-c0e3fc06bf21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ea5a1cc1-ff49-4a5d-a903-903fb12b854d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_924641a5-7d84-45d4-807e-c0e3fc06bf21" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ea5a1cc1-ff49-4a5d-a903-903fb12b854d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20240930.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a64a1fea-f469-452f-820d-236b13a4b7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_c9c65a03-7ede-4269-922c-912da4a1314d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a64a1fea-f469-452f-820d-236b13a4b7eb" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_c9c65a03-7ede-4269-922c-912da4a1314d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20240930.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2c49db09-6407-4f6d-b6b9-62cee6c91641" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_994b5d75-1e81-4ad9-a344-f0f6f1cb1c34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2c49db09-6407-4f6d-b6b9-62cee6c91641" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_994b5d75-1e81-4ad9-a344-f0f6f1cb1c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_b860f7e0-6e8c-426b-9f24-315374acc7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2c49db09-6407-4f6d-b6b9-62cee6c91641" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_b860f7e0-6e8c-426b-9f24-315374acc7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_59a7db2e-7195-48ee-a99c-94e37a747212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2c49db09-6407-4f6d-b6b9-62cee6c91641" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_59a7db2e-7195-48ee-a99c-94e37a747212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_d40ae377-67ea-40b2-8fcd-5508291c84b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2c49db09-6407-4f6d-b6b9-62cee6c91641" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_d40ae377-67ea-40b2-8fcd-5508291c84b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11298cdf-e00c-4b46-8740-ef185966975e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_94ddcd2e-22dd-4f2e-a60a-9f8e882262ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11298cdf-e00c-4b46-8740-ef185966975e" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_94ddcd2e-22dd-4f2e-a60a-9f8e882262ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e5b70524-1454-4291-a2bb-8aedeac96dff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11298cdf-e00c-4b46-8740-ef185966975e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e5b70524-1454-4291-a2bb-8aedeac96dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_34a437f6-8909-4266-9364-b9222fcf8254" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11298cdf-e00c-4b46-8740-ef185966975e" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_34a437f6-8909-4266-9364-b9222fcf8254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_999df002-e1df-4a38-9b36-2580624bbdf2" xlink:href="cah-20240930.xsd#cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_999df002-e1df-4a38-9b36-2580624bbdf2" xlink:to="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_91057e86-2d57-430e-b71a-5606b195081b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:to="loc_srt_MajorCustomersAxis_91057e86-2d57-430e-b71a-5606b195081b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f529c8c0-efed-484f-84f2-f1641618810a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_91057e86-2d57-430e-b71a-5606b195081b" xlink:to="loc_srt_NameOfMajorCustomerDomain_f529c8c0-efed-484f-84f2-f1641618810a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OptumRxMember_8c685898-de4d-4c79-b935-9941bac4e72e" xlink:href="cah-20240930.xsd#cah_OptumRxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f529c8c0-efed-484f-84f2-f1641618810a" xlink:to="loc_cah_OptumRxMember_8c685898-de4d-4c79-b935-9941bac4e72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_29440fd7-9b67-41af-adb8-4dc66d68f041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_29440fd7-9b67-41af-adb8-4dc66d68f041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b709c242-00d1-46c7-bfb5-5aaff31163c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_29440fd7-9b67-41af-adb8-4dc66d68f041" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b709c242-00d1-46c7-bfb5-5aaff31163c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6475c895-aafe-4751-bb47-1d589084459c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b709c242-00d1-46c7-bfb5-5aaff31163c8" xlink:to="loc_us-gaap_SalesRevenueNetMember_6475c895-aafe-4751-bb47-1d589084459c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4bd59dd3-6b80-4087-85b3-e31c95dc94b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4bd59dd3-6b80-4087-85b3-e31c95dc94b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b177cd7a-ff08-4cc0-ae8d-32294cb024eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4bd59dd3-6b80-4087-85b3-e31c95dc94b2" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b177cd7a-ff08-4cc0-ae8d-32294cb024eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_307287d3-aea8-4f9c-a3e9-7877f4692ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b177cd7a-ff08-4cc0-ae8d-32294cb024eb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_307287d3-aea8-4f9c-a3e9-7877f4692ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1c7a7a76-17b2-463e-a8fd-609ed05a307e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1c7a7a76-17b2-463e-a8fd-609ed05a307e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c9a88151-0925-4d16-9170-f99e11e4425d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1c7a7a76-17b2-463e-a8fd-609ed05a307e" xlink:to="loc_us-gaap_SegmentDomain_c9a88151-0925-4d16-9170-f99e11e4425d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_240f9df6-62fd-48bd-83ff-f45cf0344953" xlink:href="cah-20240930.xsd#cah_PharmaceuticalAndSpecialtySolutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c9a88151-0925-4d16-9170-f99e11e4425d" xlink:to="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_240f9df6-62fd-48bd-83ff-f45cf0344953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_2abafa6b-6175-4b32-a1ae-6fb124ef34df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_b8db06b8-58c4-4fc5-a603-3f2c708175b0" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_2abafa6b-6175-4b32-a1ae-6fb124ef34df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_eaf43324-9a44-49e5-a498-185dc0c4fffa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2abafa6b-6175-4b32-a1ae-6fb124ef34df" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_eaf43324-9a44-49e5-a498-185dc0c4fffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/AcquisitionsDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#AcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/AcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_01495a22-235e-4899-9d85-e9052acbb8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8187579-84be-4a8e-88b1-28642c807a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_01495a22-235e-4899-9d85-e9052acbb8b6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8187579-84be-4a8e-88b1-28642c807a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1cb105c1-5386-4c4c-9387-a095414c346f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8187579-84be-4a8e-88b1-28642c807a48" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1cb105c1-5386-4c4c-9387-a095414c346f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8dd7fe1c-42e8-4275-b5b2-b5823ab117d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1cb105c1-5386-4c4c-9387-a095414c346f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8dd7fe1c-42e8-4275-b5b2-b5823ab117d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IntegratedOncologyNetworkMember_ceecd7a9-476f-46ff-bbc3-8f2fe06023c3" xlink:href="cah-20240930.xsd#cah_IntegratedOncologyNetworkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8dd7fe1c-42e8-4275-b5b2-b5823ab117d6" xlink:to="loc_cah_IntegratedOncologyNetworkMember_ceecd7a9-476f-46ff-bbc3-8f2fe06023c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SpecialtyNetworksMember_7ae13970-52ec-4f7b-a700-ba138a425075" xlink:href="cah-20240930.xsd#cah_SpecialtyNetworksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8dd7fe1c-42e8-4275-b5b2-b5823ab117d6" xlink:to="loc_cah_SpecialtyNetworksMember_7ae13970-52ec-4f7b-a700-ba138a425075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_72c0eca2-a6f1-4e97-a9f6-583f9f3f533a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8187579-84be-4a8e-88b1-28642c807a48" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_72c0eca2-a6f1-4e97-a9f6-583f9f3f533a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationPriceOfAcquisitionExpected_4da47cbe-d2da-4859-bec8-708b3dd3675c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationPriceOfAcquisitionExpected"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_72c0eca2-a6f1-4e97-a9f6-583f9f3f533a" xlink:to="loc_us-gaap_BusinessCombinationPriceOfAcquisitionExpected_4da47cbe-d2da-4859-bec8-708b3dd3675c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a1a00dd9-590c-425a-902e-ecaa2a7fcfac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_72c0eca2-a6f1-4e97-a9f6-583f9f3f533a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a1a00dd9-590c-425a-902e-ecaa2a7fcfac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DivestituresDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#DivestituresDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DivestituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_194f8791-e184-4c99-996a-6751b3cdd685" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_d7a14a91-45d4-4ab9-a0ce-0ec5adec3e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_194f8791-e184-4c99-996a-6751b3cdd685" xlink:to="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_d7a14a91-45d4-4ab9-a0ce-0ec5adec3e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OutcomesDivestitureAxis_4b8e7bb2-27f1-492b-8f37-b14c5da0b559" xlink:href="cah-20240930.xsd#cah_OutcomesDivestitureAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_d7a14a91-45d4-4ab9-a0ce-0ec5adec3e6a" xlink:to="loc_cah_OutcomesDivestitureAxis_4b8e7bb2-27f1-492b-8f37-b14c5da0b559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OutcomesDivestitureDomain_88cec384-7bd5-4155-ac2e-15e9fb33c0fb" xlink:href="cah-20240930.xsd#cah_OutcomesDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OutcomesDivestitureAxis_4b8e7bb2-27f1-492b-8f37-b14c5da0b559" xlink:to="loc_cah_OutcomesDivestitureDomain_88cec384-7bd5-4155-ac2e-15e9fb33c0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OutcomesDivestitureMember_284b21b7-b06a-4e92-b04e-b12fdb759dbc" xlink:href="cah-20240930.xsd#cah_OutcomesDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OutcomesDivestitureDomain_88cec384-7bd5-4155-ac2e-15e9fb33c0fb" xlink:to="loc_cah_OutcomesDivestitureMember_284b21b7-b06a-4e92-b04e-b12fdb759dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4254e273-1351-47fa-ba16-1f2b346fd1ce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_d7a14a91-45d4-4ab9-a0ce-0ec5adec3e6a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4254e273-1351-47fa-ba16-1f2b346fd1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7b2d9601-b5c6-484d-8c0e-52380f79bd64" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4254e273-1351-47fa-ba16-1f2b346fd1ce" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7b2d9601-b5c6-484d-8c0e-52380f79bd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TransactionDataSystemInvestmentMember_8d33b28c-4b94-4fc8-b752-29b33e5875b5" xlink:href="cah-20240930.xsd#cah_TransactionDataSystemInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7b2d9601-b5c6-484d-8c0e-52380f79bd64" xlink:to="loc_cah_TransactionDataSystemInvestmentMember_8d33b28c-4b94-4fc8-b752-29b33e5875b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_81dbf425-8132-49d3-9aa6-d35f18a742f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_d7a14a91-45d4-4ab9-a0ce-0ec5adec3e6a" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_81dbf425-8132-49d3-9aa6-d35f18a742f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_bc125d0f-44ac-4ffd-8c06-2d63cb45242f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_81dbf425-8132-49d3-9aa6-d35f18a742f2" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_bc125d0f-44ac-4ffd-8c06-2d63cb45242f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_550a1647-b908-4ee2-a8ef-14d5d9320769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_81dbf425-8132-49d3-9aa6-d35f18a742f2" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_550a1647-b908-4ee2-a8ef-14d5d9320769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_0a366a9c-8ca4-4262-add5-0c149a123672" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_81dbf425-8132-49d3-9aa6-d35f18a742f2" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_0a366a9c-8ca4-4262-add5-0c149a123672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e1d413bb-dc8a-4d54-ad18-0abc2dca4375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_81dbf425-8132-49d3-9aa6-d35f18a742f2" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e1d413bb-dc8a-4d54-ad18-0abc2dca4375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_e16fe673-725b-454a-a83c-a85a9b37b2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_ed6b2662-e126-471e-b499-1de8ae060e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_e16fe673-725b-454a-a83c-a85a9b37b2d1" xlink:to="loc_us-gaap_SeveranceCosts1_ed6b2662-e126-471e-b499-1de8ae060e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_9731eaed-a73d-483b-a829-847ef9434b17" xlink:href="cah-20240930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_e16fe673-725b-454a-a83c-a85a9b37b2d1" xlink:to="loc_cah_FacilityExitAndOtherCosts_9731eaed-a73d-483b-a829-847ef9434b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_25558b14-3d6e-4c5e-90f2-99c681d340e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_e16fe673-725b-454a-a83c-a85a9b37b2d1" xlink:to="loc_us-gaap_RestructuringCharges_25558b14-3d6e-4c5e-90f2-99c681d340e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_041d29e6-72c9-44a0-94af-36a4bf8dc925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bd9099c-865a-4dd7-af08-d200f0865c28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_041d29e6-72c9-44a0-94af-36a4bf8dc925" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bd9099c-865a-4dd7-af08-d200f0865c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_617ba065-5bf8-4c58-a59b-f17fc29659ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bd9099c-865a-4dd7-af08-d200f0865c28" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_617ba065-5bf8-4c58-a59b-f17fc29659ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d9f341d0-a8e9-4988-9a33-366fd1605527" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_617ba065-5bf8-4c58-a59b-f17fc29659ff" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d9f341d0-a8e9-4988-9a33-366fd1605527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_367ae227-e7f9-41fa-8f1a-3472a6c8b688" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d9f341d0-a8e9-4988-9a33-366fd1605527" xlink:to="loc_us-gaap_EmployeeSeveranceMember_367ae227-e7f9-41fa-8f1a-3472a6c8b688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_134166eb-6815-422a-9311-011e15a6e102" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d9f341d0-a8e9-4988-9a33-366fd1605527" xlink:to="loc_us-gaap_FacilityClosingMember_134166eb-6815-422a-9311-011e15a6e102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2e88bfc3-969b-4e56-a553-f378e4d3e8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bd9099c-865a-4dd7-af08-d200f0865c28" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_2e88bfc3-969b-4e56-a553-f378e4d3e8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_898e25c5-3119-4eeb-9bc7-368245e21375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2e88bfc3-969b-4e56-a553-f378e4d3e8ea" xlink:to="loc_us-gaap_RestructuringReserveRollForward_898e25c5-3119-4eeb-9bc7-368245e21375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_328cdf98-de02-4761-ada2-b98b2411452f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898e25c5-3119-4eeb-9bc7-368245e21375" xlink:to="loc_us-gaap_RestructuringReserve_328cdf98-de02-4761-ada2-b98b2411452f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_3e22f739-d2f2-4553-bfbb-1b3674cb872c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898e25c5-3119-4eeb-9bc7-368245e21375" xlink:to="loc_us-gaap_RestructuringCosts_3e22f739-d2f2-4553-bfbb-1b3674cb872c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_0b6b795d-51f9-4e7b-a3bc-6f9afea4d7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898e25c5-3119-4eeb-9bc7-368245e21375" xlink:to="loc_us-gaap_PaymentsForRestructuring_0b6b795d-51f9-4e7b-a3bc-6f9afea4d7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_dc2d142d-6200-4b93-b01a-4f1c1d9b618b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_898e25c5-3119-4eeb-9bc7-368245e21375" xlink:to="loc_us-gaap_RestructuringReserve_dc2d142d-6200-4b93-b01a-4f1c1d9b618b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#RestructuringandEmployeeSeveranceNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_958f2cdf-23e2-49de-9679-8d57ebcbebc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6176f066-993a-47f6-bec3-2b0b8e543c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_958f2cdf-23e2-49de-9679-8d57ebcbebc8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6176f066-993a-47f6-bec3-2b0b8e543c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_e620b9ea-0001-4c0c-a31b-6a92e43a3f12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6176f066-993a-47f6-bec3-2b0b8e543c7d" xlink:to="loc_us-gaap_RestructuringPlanAxis_e620b9ea-0001-4c0c-a31b-6a92e43a3f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_1f60a54f-76b3-437b-bca2-67afe5e41412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_e620b9ea-0001-4c0c-a31b-6a92e43a3f12" xlink:to="loc_us-gaap_RestructuringPlanDomain_1f60a54f-76b3-437b-bca2-67afe5e41412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9a189dda-e98d-4dc2-9996-7c640f568180" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6176f066-993a-47f6-bec3-2b0b8e543c7d" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_9a189dda-e98d-4dc2-9996-7c640f568180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_3a98c484-5078-4070-8517-bbbb7e1e7d68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9a189dda-e98d-4dc2-9996-7c640f568180" xlink:to="loc_us-gaap_SeveranceCosts1_3a98c484-5078-4070-8517-bbbb7e1e7d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_f82faa6f-969e-4865-9de0-bcddf7559301" xlink:href="cah-20240930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9a189dda-e98d-4dc2-9996-7c640f568180" xlink:to="loc_cah_FacilityExitAndOtherCosts_f82faa6f-969e-4865-9de0-bcddf7559301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b3f22cb9-e2cb-4eb9-a565-448bfc34a728" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_428ef3f6-16a9-4d61-8090-826fffd6800b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b3f22cb9-e2cb-4eb9-a565-448bfc34a728" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_428ef3f6-16a9-4d61-8090-826fffd6800b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_51e744a3-62c7-4155-9bd6-747b7c10451a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_428ef3f6-16a9-4d61-8090-826fffd6800b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_51e744a3-62c7-4155-9bd6-747b7c10451a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8bc68510-1660-4f6f-9a1c-5f91bf95fd83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_51e744a3-62c7-4155-9bd6-747b7c10451a" xlink:to="loc_us-gaap_SegmentDomain_8bc68510-1660-4f6f-9a1c-5f91bf95fd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_4ac6c11d-2992-484d-9576-50904639028e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8bc68510-1660-4f6f-9a1c-5f91bf95fd83" xlink:to="loc_us-gaap_AllOtherSegmentsMember_4ac6c11d-2992-484d-9576-50904639028e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_2e86bd09-624f-4f1f-bb2d-f7ea31d9263a" xlink:href="cah-20240930.xsd#cah_PharmaceuticalAndSpecialtySolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8bc68510-1660-4f6f-9a1c-5f91bf95fd83" xlink:to="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_2e86bd09-624f-4f1f-bb2d-f7ea31d9263a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_68902cd3-ca74-4dfa-b13e-e555db8fab0a" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8bc68510-1660-4f6f-9a1c-5f91bf95fd83" xlink:to="loc_cah_GMPDMember_68902cd3-ca74-4dfa-b13e-e555db8fab0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_938f4f5c-62f1-4dc9-8244-cedb3b4bea82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_428ef3f6-16a9-4d61-8090-826fffd6800b" xlink:to="loc_us-gaap_GoodwillLineItems_938f4f5c-62f1-4dc9-8244-cedb3b4bea82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_3b4a14c3-11a7-4f11-963c-a70cb79f618e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_938f4f5c-62f1-4dc9-8244-cedb3b4bea82" xlink:to="loc_us-gaap_GoodwillRollForward_3b4a14c3-11a7-4f11-963c-a70cb79f618e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dbe1e086-0962-4fdd-977c-45cb04c53fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3b4a14c3-11a7-4f11-963c-a70cb79f618e" xlink:to="loc_us-gaap_Goodwill_dbe1e086-0962-4fdd-977c-45cb04c53fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_397626fb-5113-42d3-b699-7ddd0d52d2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3b4a14c3-11a7-4f11-963c-a70cb79f618e" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_397626fb-5113-42d3-b699-7ddd0d52d2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_19958502-a211-4347-afa2-475a7add5dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3b4a14c3-11a7-4f11-963c-a70cb79f618e" xlink:to="loc_us-gaap_Goodwill_19958502-a211-4347-afa2-475a7add5dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d87dafdb-260c-4733-b5cd-2ce5f24df622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3b4a14c3-11a7-4f11-963c-a70cb79f618e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d87dafdb-260c-4733-b5cd-2ce5f24df622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8e8e743a-ac3d-4f15-9ccc-c6f86ec0bc68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a89854f9-94a8-477a-af08-18bf99481e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8e8e743a-ac3d-4f15-9ccc-c6f86ec0bc68" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a89854f9-94a8-477a-af08-18bf99481e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9fcc2feb-1575-4874-9b15-2315ddcbcfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a89854f9-94a8-477a-af08-18bf99481e1f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9fcc2feb-1575-4874-9b15-2315ddcbcfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e4bbda8-0e79-427f-bd69-15ac88315dce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9fcc2feb-1575-4874-9b15-2315ddcbcfb4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e4bbda8-0e79-427f-bd69-15ac88315dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_13d75365-561a-4748-99f7-7545ae757e45" xlink:href="cah-20240930.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e4bbda8-0e79-427f-bd69-15ac88315dce" xlink:to="loc_cah_IPRDTrademarksandOtherMember_13d75365-561a-4748-99f7-7545ae757e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_cc6bcbb0-2442-4b1b-a01e-58749cbd3455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a89854f9-94a8-477a-af08-18bf99481e1f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_cc6bcbb0-2442-4b1b-a01e-58749cbd3455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4c5b3350-32b1-487f-9a5b-c11b0cecf57c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_cc6bcbb0-2442-4b1b-a01e-58749cbd3455" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4c5b3350-32b1-487f-9a5b-c11b0cecf57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e260a0e9-4cfe-4cf9-8543-22579f08bf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8e8e743a-ac3d-4f15-9ccc-c6f86ec0bc68" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e260a0e9-4cfe-4cf9-8543-22579f08bf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ebef25-fc9c-419c-b4ed-5cd783e03bee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e260a0e9-4cfe-4cf9-8543-22579f08bf8b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ebef25-fc9c-419c-b4ed-5cd783e03bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9cb8829e-8a6e-4455-82c2-74c5c8a2e00f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ebef25-fc9c-419c-b4ed-5cd783e03bee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9cb8829e-8a6e-4455-82c2-74c5c8a2e00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_f26cc821-fe6b-45c0-b706-cd5203c3b604" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9cb8829e-8a6e-4455-82c2-74c5c8a2e00f" xlink:to="loc_us-gaap_CustomerRelationshipsMember_f26cc821-fe6b-45c0-b706-cd5203c3b604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_84e694b6-edb5-4cf9-be61-bdf9f19be60e" xlink:href="cah-20240930.xsd#cah_TrademarksAndPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9cb8829e-8a6e-4455-82c2-74c5c8a2e00f" xlink:to="loc_cah_TrademarksAndPatentsMember_84e694b6-edb5-4cf9-be61-bdf9f19be60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_e6cf83f4-8225-482b-8862-99d240d1ef53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9cb8829e-8a6e-4455-82c2-74c5c8a2e00f" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_e6cf83f4-8225-482b-8862-99d240d1ef53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_de932e1d-dbf9-4d37-a94f-607fc3be8aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e260a0e9-4cfe-4cf9-8543-22579f08bf8b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_de932e1d-dbf9-4d37-a94f-607fc3be8aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9a389657-0c22-4013-8e63-5ff53495654e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_de932e1d-dbf9-4d37-a94f-607fc3be8aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9a389657-0c22-4013-8e63-5ff53495654e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_758d023f-0dd8-4aca-8e23-28c3bb042a53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_de932e1d-dbf9-4d37-a94f-607fc3be8aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_758d023f-0dd8-4aca-8e23-28c3bb042a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cff852e6-0506-4058-b34a-8bf7e103fe80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_de932e1d-dbf9-4d37-a94f-607fc3be8aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cff852e6-0506-4058-b34a-8bf7e103fe80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_0c1b5397-ce9b-4254-a6a6-fbe698ccb112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_de932e1d-dbf9-4d37-a94f-607fc3be8aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_0c1b5397-ce9b-4254-a6a6-fbe698ccb112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3d4bf2c3-836a-4b1f-b5e7-35018853d9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8e8e743a-ac3d-4f15-9ccc-c6f86ec0bc68" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3d4bf2c3-836a-4b1f-b5e7-35018853d9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4ff09405-ad85-4922-8a05-cacfc6718e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8e8e743a-ac3d-4f15-9ccc-c6f86ec0bc68" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4ff09405-ad85-4922-8a05-cacfc6718e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_66bb64a9-7d92-403a-a8ed-1e69f8fdd440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1e14b993-398d-4d3d-87eb-faa66fb78705" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_66bb64a9-7d92-403a-a8ed-1e69f8fdd440" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1e14b993-398d-4d3d-87eb-faa66fb78705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_649e8e05-10e8-41b0-bb75-42390638e953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_66bb64a9-7d92-403a-a8ed-1e69f8fdd440" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_649e8e05-10e8-41b0-bb75-42390638e953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5a1d7655-36bc-45b6-a20a-d74bcc4783d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_66bb64a9-7d92-403a-a8ed-1e69f8fdd440" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5a1d7655-36bc-45b6-a20a-d74bcc4783d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bbfeed6c-3038-4ca6-990c-a3709361e881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_66bb64a9-7d92-403a-a8ed-1e69f8fdd440" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bbfeed6c-3038-4ca6-990c-a3709361e881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bd8b227b-1704-462e-8240-d1114b9ea402" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_66bb64a9-7d92-403a-a8ed-1e69f8fdd440" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bd8b227b-1704-462e-8240-d1114b9ea402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ee47fd2a-82c9-42b8-b6e5-1d8b1bb74ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_66bb64a9-7d92-403a-a8ed-1e69f8fdd440" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ee47fd2a-82c9-42b8-b6e5-1d8b1bb74ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_ebe88830-5501-4246-ba15-e1cd3ec36982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_66bb64a9-7d92-403a-a8ed-1e69f8fdd440" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_ebe88830-5501-4246-ba15-e1cd3ec36982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_adb075aa-436a-43b4-a175-d8d7540525a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ebe88830-5501-4246-ba15-e1cd3ec36982" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_adb075aa-436a-43b4-a175-d8d7540525a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2e808d03-76ab-4625-85a1-2744dc4177a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_adb075aa-436a-43b4-a175-d8d7540525a8" xlink:to="loc_us-gaap_SegmentDomain_2e808d03-76ab-4625-85a1-2744dc4177a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_6207a22e-0928-4c07-af23-c88a84370bfb" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2e808d03-76ab-4625-85a1-2744dc4177a1" xlink:to="loc_cah_GMPDMember_6207a22e-0928-4c07-af23-c88a84370bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_a9e3153b-0e48-4188-993d-4cd499bb94f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ebe88830-5501-4246-ba15-e1cd3ec36982" xlink:to="loc_us-gaap_ReportingUnitAxis_a9e3153b-0e48-4188-993d-4cd499bb94f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_b164fa03-0e36-4663-9876-0da77dedb037" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_a9e3153b-0e48-4188-993d-4cd499bb94f4" xlink:to="loc_us-gaap_ReportingUnitDomain_b164fa03-0e36-4663-9876-0da77dedb037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_59feee1d-c237-4faa-ba22-923b10efd60e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ebe88830-5501-4246-ba15-e1cd3ec36982" xlink:to="loc_us-gaap_GoodwillLineItems_59feee1d-c237-4faa-ba22-923b10efd60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b03d5999-f285-477e-872c-b1f4a7e1aaab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_59feee1d-c237-4faa-ba22-923b10efd60e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b03d5999-f285-477e-872c-b1f4a7e1aaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0f111200-9e88-4507-bea9-1f7642cce2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_59feee1d-c237-4faa-ba22-923b10efd60e" xlink:to="loc_us-gaap_Goodwill_0f111200-9e88-4507-bea9-1f7642cce2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_637b3e86-0a88-432d-af41-172f5720d58d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_637b3e86-0a88-432d-af41-172f5720d58d" xlink:to="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d8b06b8b-1c35-41ad-8d9c-3cb3cd02e4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_CreditFacilityAxis_d8b06b8b-1c35-41ad-8d9c-3cb3cd02e4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_abf6b103-5eb5-4e6f-856c-6bca7732b84d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_d8b06b8b-1c35-41ad-8d9c-3cb3cd02e4f1" xlink:to="loc_us-gaap_CreditFacilityDomain_abf6b103-5eb5-4e6f-856c-6bca7732b84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2ee1ce14-1771-447e-a577-82319043141c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_abf6b103-5eb5-4e6f-856c-6bca7732b84d" xlink:to="loc_us-gaap_CommercialPaperMember_2ee1ce14-1771-447e-a577-82319043141c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_27a9774f-a5ed-4d71-8fec-696798d7c34b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_abf6b103-5eb5-4e6f-856c-6bca7732b84d" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_27a9774f-a5ed-4d71-8fec-696798d7c34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_d10833dc-c305-4113-b821-4bf4ece59ab4" xlink:href="cah-20240930.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_abf6b103-5eb5-4e6f-856c-6bca7732b84d" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_d10833dc-c305-4113-b821-4bf4ece59ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_16c0d766-766d-49c3-8947-050f46fd2944" xlink:href="cah-20240930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShortTermCreditFacilitiesMember_d10833dc-c305-4113-b821-4bf4ece59ab4" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_16c0d766-766d-49c3-8947-050f46fd2944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bf04792c-8e4e-4931-ae85-12b959cf75d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bf04792c-8e4e-4931-ae85-12b959cf75d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ce536dc1-4da5-4870-8299-6cb7f19aaa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bf04792c-8e4e-4931-ae85-12b959cf75d2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ce536dc1-4da5-4870-8299-6cb7f19aaa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cf1dd1fe-c643-4c6e-83a6-7df0d8f04ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_DebtInstrumentAxis_cf1dd1fe-c643-4c6e-83a6-7df0d8f04ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d668fe1-8d1d-47ec-8470-72ea793fef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf1dd1fe-c643-4c6e-83a6-7df0d8f04ec1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d668fe1-8d1d-47ec-8470-72ea793fef3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_da18a13e-cb24-4b0a-93e7-9ab721874385" xlink:href="cah-20240930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2d668fe1-8d1d-47ec-8470-72ea793fef3f" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_da18a13e-cb24-4b0a-93e7-9ab721874385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_dafcc721-833f-4ac2-9c21-925b71696929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_VariableRateAxis_dafcc721-833f-4ac2-9c21-925b71696929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3b9c0286-fdc6-4b3f-8c80-5c7d0c0d7460" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_dafcc721-833f-4ac2-9c21-925b71696929" xlink:to="loc_us-gaap_VariableRateDomain_3b9c0286-fdc6-4b3f-8c80-5c7d0c0d7460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e35aec8c-e2a6-4228-abed-bcf677261ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e35aec8c-e2a6-4228-abed-bcf677261ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_fa9e81f0-91c5-4268-bb70-0279efce3171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e35aec8c-e2a6-4228-abed-bcf677261ff0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_fa9e81f0-91c5-4268-bb70-0279efce3171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_26e76dd6-d2f0-403f-852b-d78b1e8fbbe6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_srt_RangeAxis_26e76dd6-d2f0-403f-852b-d78b1e8fbbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3d3cf76d-9bad-4e9b-af63-19f6dd4d65e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_26e76dd6-d2f0-403f-852b-d78b1e8fbbe6" xlink:to="loc_srt_RangeMember_3d3cf76d-9bad-4e9b-af63-19f6dd4d65e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ab6598ea-5682-4934-85e8-ff78daf16ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ab6598ea-5682-4934-85e8-ff78daf16ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a58df437-0794-4ba1-a343-8d35bd7ad982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ab6598ea-5682-4934-85e8-ff78daf16ea9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a58df437-0794-4ba1-a343-8d35bd7ad982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_43980bd0-0065-458d-b3d8-48d72337e725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a58df437-0794-4ba1-a343-8d35bd7ad982" xlink:to="loc_us-gaap_SubsequentEventMember_43980bd0-0065-458d-b3d8-48d72337e725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ade2b256-f04c-4157-b9c7-3916a398445b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_3a6eccba-4552-4469-bcf1-3dbb196d6bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_3a6eccba-4552-4469-bcf1-3dbb196d6bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_03950aed-6be6-4f43-b42e-821bafa1c3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_03950aed-6be6-4f43-b42e-821bafa1c3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8cdff853-0b8b-4df1-9169-e9f0fda61df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8cdff853-0b8b-4df1-9169-e9f0fda61df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_4a7b4248-4fd4-48eb-ae4c-4f2ab0919d02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:to="loc_us-gaap_OtherShortTermBorrowings_4a7b4248-4fd4-48eb-ae4c-4f2ab0919d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_6a441b92-46d4-452f-82c5-f05b81d23ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d7f1da-33ca-4ec7-a460-3634d0247ac5" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_6a441b92-46d4-452f-82c5-f05b81d23ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7e6e316-8595-4576-99bd-6817bdaa14d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7e6e316-8595-4576-99bd-6817bdaa14d8" xlink:to="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3050664f-760d-4109-8629-d12ce4f60260" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_srt_MajorCustomersAxis_3050664f-760d-4109-8629-d12ce4f60260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e24a1aae-4d74-4475-8e33-bac34143b678" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3050664f-760d-4109-8629-d12ce4f60260" xlink:to="loc_srt_NameOfMajorCustomerDomain_e24a1aae-4d74-4475-8e33-bac34143b678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_4f84b1b4-a3e9-4094-8011-4eb5f9aeac15" xlink:href="cah-20240930.xsd#cah_CVSHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e24a1aae-4d74-4475-8e33-bac34143b678" xlink:to="loc_cah_CVSHealthMember_4f84b1b4-a3e9-4094-8011-4eb5f9aeac15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_40d4ee69-0391-4302-ad2b-ea49b92bbde2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_srt_LitigationCaseAxis_40d4ee69-0391-4302-ad2b-ea49b92bbde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3c123b2c-090d-48ae-ba40-4dda3aa9744f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_40d4ee69-0391-4302-ad2b-ea49b92bbde2" xlink:to="loc_srt_LitigationCaseTypeDomain_3c123b2c-090d-48ae-ba40-4dda3aa9744f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_9a39fe70-7a9c-4cc3-8546-ae15ff975348" xlink:href="cah-20240930.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3c123b2c-090d-48ae-ba40-4dda3aa9744f" xlink:to="loc_cah_OpioidLawsuitsMember_9a39fe70-7a9c-4cc3-8546-ae15ff975348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_6b6da89f-26fb-45e3-a3e0-9f8d6eba979c" xlink:href="cah-20240930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3c123b2c-090d-48ae-ba40-4dda3aa9744f" xlink:to="loc_cah_ClassActionLawsuitsMember_6b6da89f-26fb-45e3-a3e0-9f8d6eba979c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_be03021a-a021-4b99-9f73-75dd04bb3c80" xlink:href="cah-20240930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3c123b2c-090d-48ae-ba40-4dda3aa9744f" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_be03021a-a021-4b99-9f73-75dd04bb3c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_645fd19f-d237-4a6b-804a-49d96045d14a" xlink:href="cah-20240930.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3c123b2c-090d-48ae-ba40-4dda3aa9744f" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_645fd19f-d237-4a6b-804a-49d96045d14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_4191f741-a84a-4e94-8731-15074f6310f0" xlink:href="cah-20240930.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_cah_OpioidLitigationAxis_4191f741-a84a-4e94-8731-15074f6310f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_38f7a918-80f0-4a33-8fe7-c6685d5eb619" xlink:href="cah-20240930.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_4191f741-a84a-4e94-8731-15074f6310f0" xlink:to="loc_cah_OpioidLitigationDomain_38f7a918-80f0-4a33-8fe7-c6685d5eb619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_7ae95fc9-6f85-4b9a-88f2-4db4f496c0f3" xlink:href="cah-20240930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_38f7a918-80f0-4a33-8fe7-c6685d5eb619" xlink:to="loc_cah_TotalOpioidLitigationMember_7ae95fc9-6f85-4b9a-88f2-4db4f496c0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_a7a8a02a-b106-4245-80b2-fd1d833a753c" xlink:href="cah-20240930.xsd#cah_LawsuitTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_cah_LawsuitTypeAxis_a7a8a02a-b106-4245-80b2-fd1d833a753c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain_929dba9d-4a4a-416e-86ab-22b94d26e773" xlink:href="cah-20240930.xsd#cah_LitigationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeAxis_a7a8a02a-b106-4245-80b2-fd1d833a753c" xlink:to="loc_cah_LitigationTypeDomain_929dba9d-4a4a-416e-86ab-22b94d26e773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_08a2345b-e9e3-4c07-ab0c-b0a53f680104" xlink:href="cah-20240930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LitigationTypeDomain_929dba9d-4a4a-416e-86ab-22b94d26e773" xlink:to="loc_cah_ClassActionLawsuitsMember_08a2345b-e9e3-4c07-ab0c-b0a53f680104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_8ddc6371-0988-439d-b40e-cab37caac430" xlink:href="cah-20240930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LitigationTypeDomain_929dba9d-4a4a-416e-86ab-22b94d26e773" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_8ddc6371-0988-439d-b40e-cab37caac430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_9bd5f043-3b3c-483f-b941-2c03af313cb3" xlink:href="cah-20240930.xsd#cah_PlaintiffTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_cah_PlaintiffTypeAxis_9bd5f043-3b3c-483f-b941-2c03af313cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_23e1e552-a048-4ed6-bf64-928b25973206" xlink:href="cah-20240930.xsd#cah_PlaintiffTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeAxis_9bd5f043-3b3c-483f-b941-2c03af313cb3" xlink:to="loc_cah_PlaintiffTypeDomain_23e1e552-a048-4ed6-bf64-928b25973206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_e14a38f5-a505-41e1-ade2-06a2ad89f3df" xlink:href="cah-20240930.xsd#cah_PrivatePartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_23e1e552-a048-4ed6-bf64-928b25973206" xlink:to="loc_cah_PrivatePartiesMember_e14a38f5-a505-41e1-ade2-06a2ad89f3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_9dee80ad-8533-4383-af70-43d8e09a7caa" xlink:href="cah-20240930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_23e1e552-a048-4ed6-bf64-928b25973206" xlink:to="loc_cah_ClassActionLawsuitsMember_9dee80ad-8533-4383-af70-43d8e09a7caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4f3a2385-d948-4648-b65b-c4e2cc8a749f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_srt_StatementGeographicalAxis_4f3a2385-d948-4648-b65b-c4e2cc8a749f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4f3a2385-d948-4648-b65b-c4e2cc8a749f" xlink:to="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_565093ad-fb1e-445d-a120-ac3eb9177657" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_WV"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:to="loc_stpr_WV_565093ad-fb1e-445d-a120-ac3eb9177657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_35805117-48a5-4885-846e-12769663359e" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_GA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:to="loc_stpr_GA_35805117-48a5-4885-846e-12769663359e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_naics_ZZ921150_61343496-e1fd-4501-bbe7-6f0c75e89225" xlink:href="https://xbrl.sec.gov/naics/2024/naics-2024.xsd#naics_ZZ921150"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:to="loc_naics_ZZ921150_61343496-e1fd-4501-bbe7-6f0c75e89225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AL_b88b6462-6842-4713-93dc-6db0fb9f9b40" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_AL"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:to="loc_stpr_AL_b88b6462-6842-4713-93dc-6db0fb9f9b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CityOfBaltimoreMember_e5d07896-85c6-440d-aa1b-f5918c76c628" xlink:href="cah-20240930.xsd#cah_CityOfBaltimoreMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_98488bac-9fef-4828-b0a0-4cf3d8bf0026" xlink:to="loc_cah_CityOfBaltimoreMember_e5d07896-85c6-440d-aa1b-f5918c76c628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_03164129-99d2-4645-b3ae-d20becb566bd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_srt_RangeAxis_03164129-99d2-4645-b3ae-d20becb566bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e054a341-5665-4097-8759-6fdd14acb7be" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_03164129-99d2-4645-b3ae-d20becb566bd" xlink:to="loc_srt_RangeMember_e054a341-5665-4097-8759-6fdd14acb7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1b4950a1-5810-4964-ba6a-cf3e315158ff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e054a341-5665-4097-8759-6fdd14acb7be" xlink:to="loc_srt_MinimumMember_1b4950a1-5810-4964-ba6a-cf3e315158ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_72759b48-266c-4f3a-b11b-505679f45412" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e054a341-5665-4097-8759-6fdd14acb7be" xlink:to="loc_srt_MaximumMember_72759b48-266c-4f3a-b11b-505679f45412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_62eb9b84-b16e-4910-84ce-01c1be9cb41d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_62eb9b84-b16e-4910-84ce-01c1be9cb41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_97e3371e-d3a7-4410-adfd-55af3d5a3cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_62eb9b84-b16e-4910-84ce-01c1be9cb41d" xlink:to="loc_us-gaap_LossContingencyNatureDomain_97e3371e-d3a7-4410-adfd-55af3d5a3cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_56a72527-7a40-4e0b-b715-9b39dda187b1" xlink:href="cah-20240930.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_97e3371e-d3a7-4410-adfd-55af3d5a3cb9" xlink:to="loc_cah_OpioidLawsuitsMember_56a72527-7a40-4e0b-b715-9b39dda187b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_2e600ac9-6ff9-40e0-bd1e-4837989575b6" xlink:href="cah-20240930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_97e3371e-d3a7-4410-adfd-55af3d5a3cb9" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_2e600ac9-6ff9-40e0-bd1e-4837989575b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_06a84746-dd64-43ba-96bd-8cf47ac4bce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_06a84746-dd64-43ba-96bd-8cf47ac4bce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a1ebf7d3-cb6b-44bf-81f8-4bebf6a8843f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_06a84746-dd64-43ba-96bd-8cf47ac4bce7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a1ebf7d3-cb6b-44bf-81f8-4bebf6a8843f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4c483626-27e0-43fd-aede-517380432079" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a1ebf7d3-cb6b-44bf-81f8-4bebf6a8843f" xlink:to="loc_us-gaap_SubsequentEventMember_4c483626-27e0-43fd-aede-517380432079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsAxis_3fcdde0f-9cd9-46c7-9faa-803ff78b8b47" xlink:href="cah-20240930.xsd#cah_AgreementsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_cah_AgreementsAxis_3fcdde0f-9cd9-46c7-9faa-803ff78b8b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AgreementsDomain_9d351771-447e-406e-ae60-7ad2cdc9b1c3" xlink:href="cah-20240930.xsd#cah_AgreementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_AgreementsAxis_3fcdde0f-9cd9-46c7-9faa-803ff78b8b47" xlink:to="loc_cah_AgreementsDomain_9d351771-447e-406e-ae60-7ad2cdc9b1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IVCApril2023AgreementMember_33cac6bb-99b2-4ba1-84f9-d64b391fe7a8" xlink:href="cah-20240930.xsd#cah_IVCApril2023AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_AgreementsDomain_9d351771-447e-406e-ae60-7ad2cdc9b1c3" xlink:to="loc_cah_IVCApril2023AgreementMember_33cac6bb-99b2-4ba1-84f9-d64b391fe7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_55dfeaa4-842e-4c87-a770-122899d61b7b" xlink:to="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_9654def9-b146-4e9a-bdf6-0b916a4e01d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_9654def9-b146-4e9a-bdf6-0b916a4e01d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_c69fa39d-f9fa-4d8c-b18e-5011db42eccc" xlink:href="cah-20240930.xsd#cah_AggregateAnnualAssessment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_AggregateAnnualAssessment_c69fa39d-f9fa-4d8c-b18e-5011db42eccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_0d4ff948-4543-4397-ae6f-156474497ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LitigationReserve_0d4ff948-4543-4397-ae6f-156474497ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_bec2f3c1-86bb-49d1-940d-f904231a827e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LitigationReserveCurrent_bec2f3c1-86bb-49d1-940d-f904231a827e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementLoss_c5a3c70b-f61d-4ac5-a824-00bd92214d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LitigationSettlementLoss_c5a3c70b-f61d-4ac5-a824-00bd92214d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomeAsAResultOfPrepayments_15560ea5-5676-4c33-bc91-c98c86c29d07" xlink:href="cah-20240930.xsd#cah_IncomeAsAResultOfPrepayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_IncomeAsAResultOfPrepayments_15560ea5-5676-4c33-bc91-c98c86c29d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_8d58d064-a9c6-4ee6-b152-ab1421ba7287" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_8d58d064-a9c6-4ee6-b152-ab1421ba7287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates_83cb171c-3f81-4e67-a36c-521f90e58a4e" xlink:href="cah-20240930.xsd#cah_SettlingStates"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_SettlingStates_83cb171c-3f81-4e67-a36c-521f90e58a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories_b2aa3363-4514-4b45-ac61-6b8eec321a2b" xlink:href="cah-20240930.xsd#cah_SettlingUSTerritories"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_SettlingUSTerritories_b2aa3363-4514-4b45-ac61-6b8eec321a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PercentageSettlingSubdivisions_a4d9d1a2-95dc-49a9-bdbe-091c313a03ad" xlink:href="cah-20240930.xsd#cah_PercentageSettlingSubdivisions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_PercentageSettlingSubdivisions_a4d9d1a2-95dc-49a9-bdbe-091c313a03ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1277e037-c15e-4535-ad14-08d53b0478ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1277e037-c15e-4535-ad14-08d53b0478ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_4a2e8649-38d4-4cc8-9745-64e2f92d511e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_4a2e8649-38d4-4cc8-9745-64e2f92d511e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_97692ebf-3263-42a5-bb87-7243a499d195" xlink:href="cah-20240930.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_LossContingencyLawsuitsNumber_97692ebf-3263-42a5-bb87-7243a499d195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_08100a52-40e2-4b13-a202-e24ba275bdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_08100a52-40e2-4b13-a202-e24ba275bdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries_7cd3b5d6-ddac-44b4-8839-306e7f6f9a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_InsuranceRecoveries_7cd3b5d6-ddac-44b4-8839-306e7f6f9a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_f663aacd-5e18-4e32-9c47-4e0498fd5111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_f663aacd-5e18-4e32-9c47-4e0498fd5111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_5f4a8bdb-99fe-48f2-8245-b3b8aa367704" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_5f4a8bdb-99fe-48f2-8245-b3b8aa367704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7b0a26ad-796a-4578-9134-0cf8e378afa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7b0a26ad-796a-4578-9134-0cf8e378afa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_4197e0f9-5465-4119-9372-e6139d8a6088" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_4197e0f9-5465-4119-9372-e6139d8a6088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomefromSettlementsofClassActionLawsuits_edd0fe00-69c7-449b-bbda-a3bb88b743b2" xlink:href="cah-20240930.xsd#cah_IncomefromSettlementsofClassActionLawsuits"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_77c284cc-0425-49a8-9fda-5480acfd9ab8" xlink:to="loc_cah_IncomefromSettlementsofClassActionLawsuits_edd0fe00-69c7-449b-bbda-a3bb88b743b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_46b55dc3-e0ed-4ace-a562-5cda7e1e9ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46b55dc3-e0ed-4ace-a562-5cda7e1e9ae2" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_8acebd40-542a-4e91-8bd1-db736ec8c75c" xlink:href="cah-20240930.xsd#cah_TaxMatterAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_cah_TaxMatterAxis_8acebd40-542a-4e91-8bd1-db736ec8c75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_a5462458-f8d4-4f70-a352-0bd2699121dd" xlink:href="cah-20240930.xsd#cah_TaxMatterDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterAxis_8acebd40-542a-4e91-8bd1-db736ec8c75c" xlink:to="loc_cah_TaxMatterDomain_a5462458-f8d4-4f70-a352-0bd2699121dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_6e4f1bd2-ad99-46b4-87a4-3df1462350bf" xlink:href="cah-20240930.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_cah_OpioidLitigationAxis_6e4f1bd2-ad99-46b4-87a4-3df1462350bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_013a79ed-4f73-4747-bf97-d98a17b51abc" xlink:href="cah-20240930.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_6e4f1bd2-ad99-46b4-87a4-3df1462350bf" xlink:to="loc_cah_OpioidLitigationDomain_013a79ed-4f73-4747-bf97-d98a17b51abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_486075ab-c676-4202-8f41-59f12968056f" xlink:href="cah-20240930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_013a79ed-4f73-4747-bf97-d98a17b51abc" xlink:to="loc_cah_TotalOpioidLitigationMember_486075ab-c676-4202-8f41-59f12968056f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_315f1c90-116f-46a2-b7a8-d27b7ee19bad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_315f1c90-116f-46a2-b7a8-d27b7ee19bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ec22a63d-f6f8-471c-ae05-437774ba373b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_315f1c90-116f-46a2-b7a8-d27b7ee19bad" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ec22a63d-f6f8-471c-ae05-437774ba373b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a8129abb-2246-4e6f-a1c3-ed6bedbe33cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a8129abb-2246-4e6f-a1c3-ed6bedbe33cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9341c44d-30b6-4705-979e-6f0cfed3b9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a8129abb-2246-4e6f-a1c3-ed6bedbe33cd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9341c44d-30b6-4705-979e-6f0cfed3b9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_63e57ca3-594e-4bb7-9db8-23234227b9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9341c44d-30b6-4705-979e-6f0cfed3b9d9" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_63e57ca3-594e-4bb7-9db8-23234227b9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cc17e493-ba4a-47cd-b125-943809590c66" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_srt_RangeAxis_cc17e493-ba4a-47cd-b125-943809590c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d237ba6-bc75-4afd-96c3-098f28ab095e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cc17e493-ba4a-47cd-b125-943809590c66" xlink:to="loc_srt_RangeMember_5d237ba6-bc75-4afd-96c3-098f28ab095e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6232d968-166d-4fec-946b-619bb43425f4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5d237ba6-bc75-4afd-96c3-098f28ab095e" xlink:to="loc_srt_MinimumMember_6232d968-166d-4fec-946b-619bb43425f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_105f8949-fd20-45b5-94c2-f2d589468fdb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5d237ba6-bc75-4afd-96c3-098f28ab095e" xlink:to="loc_srt_MaximumMember_105f8949-fd20-45b5-94c2-f2d589468fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_36a61bce-22e9-4b18-8e90-26e81ab79f19" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_srt_StatementScenarioAxis_36a61bce-22e9-4b18-8e90-26e81ab79f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9519de84-1fd8-474e-9c87-8d37c493f9ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_36a61bce-22e9-4b18-8e90-26e81ab79f19" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9519de84-1fd8-474e-9c87-8d37c493f9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_77182b29-4140-47b9-8f44-13245f47c957" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9519de84-1fd8-474e-9c87-8d37c493f9ca" xlink:to="loc_srt_ScenarioForecastMember_77182b29-4140-47b9-8f44-13245f47c957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4a4483c6-a508-4b89-98fb-96a591e91443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4a4483c6-a508-4b89-98fb-96a591e91443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fcfba54a-e414-4794-8a85-373490de9adb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4a4483c6-a508-4b89-98fb-96a591e91443" xlink:to="loc_us-gaap_SegmentDomain_fcfba54a-e414-4794-8a85-373490de9adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_ac93d5f5-956e-43e1-980a-b3256832b366" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fcfba54a-e414-4794-8a85-373490de9adb" xlink:to="loc_cah_GMPDMember_ac93d5f5-956e-43e1-980a-b3256832b366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_b64f1181-7927-4dde-9a88-b32709d1ac63" xlink:href="cah-20240930.xsd#cah_GoodwillImpairmentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_cah_GoodwillImpairmentAxis_b64f1181-7927-4dde-9a88-b32709d1ac63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_c131e694-6946-431d-991d-41683e4b9551" xlink:href="cah-20240930.xsd#cah_GoodwillImpairmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentAxis_b64f1181-7927-4dde-9a88-b32709d1ac63" xlink:to="loc_cah_GoodwillImpairmentDomain_c131e694-6946-431d-991d-41683e4b9551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FY24Q1GoodwillImpairmentGMPDMember_b40807ff-d19f-4600-81b2-c2a89be0e54e" xlink:href="cah-20240930.xsd#cah_FY24Q1GoodwillImpairmentGMPDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_c131e694-6946-431d-991d-41683e4b9551" xlink:to="loc_cah_FY24Q1GoodwillImpairmentGMPDMember_b40807ff-d19f-4600-81b2-c2a89be0e54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_339b10c6-6782-47ca-a5ea-4f366a857090" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_339b10c6-6782-47ca-a5ea-4f366a857090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_11d493eb-e0a7-4f5a-b22c-7c919b0e7b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_339b10c6-6782-47ca-a5ea-4f366a857090" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_11d493eb-e0a7-4f5a-b22c-7c919b0e7b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f13d66f3-32ac-413c-bdcf-e48e3eb25bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_11d493eb-e0a7-4f5a-b22c-7c919b0e7b0c" xlink:to="loc_us-gaap_SubsequentEventMember_f13d66f3-32ac-413c-bdcf-e48e3eb25bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e6baa164-b75c-4910-bc18-ec04198e582b" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5ef6c877-5cdc-442d-ab32-ebc91fddbd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5ef6c877-5cdc-442d-ab32-ebc91fddbd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b1b837f4-0e36-4f8c-a915-bd9cbb4aaec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b1b837f4-0e36-4f8c-a915-bd9cbb4aaec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_28ec2044-109f-4ba7-8d1b-8f6c21f6b084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_28ec2044-109f-4ba7-8d1b-8f6c21f6b084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2dac0162-da54-4de5-9c84-75a50a1a24e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2dac0162-da54-4de5-9c84-75a50a1a24e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a34a6738-3efb-411b-84cf-43cffd7d9528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a34a6738-3efb-411b-84cf-43cffd7d9528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_ef17b2b7-0e0d-4b58-b26d-f7f3500b6ded" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_ef17b2b7-0e0d-4b58-b26d-f7f3500b6ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_4ec04e5a-5aac-484e-833f-7b259692e942" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_OpenTaxYear_4ec04e5a-5aac-484e-833f-7b259692e942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_99723caf-b0c9-4ddc-a0b9-fa387948dc39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_c066bb02-a293-48e9-b417-a4773eef99d2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_99723caf-b0c9-4ddc-a0b9-fa387948dc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_64b3f887-90e5-4a0b-a0c8-0662db87fc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b1baf2e5-fb9c-45e4-aa92-954db41e0b57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_64b3f887-90e5-4a0b-a0c8-0662db87fc3d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b1baf2e5-fb9c-45e4-aa92-954db41e0b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77dbdac2-0431-482e-8652-8fd618e6f27b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b1baf2e5-fb9c-45e4-aa92-954db41e0b57" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77dbdac2-0431-482e-8652-8fd618e6f27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e234d404-d0f3-4d81-864c-9ea09687975c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77dbdac2-0431-482e-8652-8fd618e6f27b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e234d404-d0f3-4d81-864c-9ea09687975c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5aaa5dcc-a67d-4137-91df-fc7ecb5dd8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e234d404-d0f3-4d81-864c-9ea09687975c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5aaa5dcc-a67d-4137-91df-fc7ecb5dd8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98fa7068-dc97-4c37-88cd-67157c17adb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b1baf2e5-fb9c-45e4-aa92-954db41e0b57" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98fa7068-dc97-4c37-88cd-67157c17adb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae8127ca-3068-4485-9025-e5e8f9c0541c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98fa7068-dc97-4c37-88cd-67157c17adb3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae8127ca-3068-4485-9025-e5e8f9c0541c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2c497f51-87d3-434b-99e9-f648d49935ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae8127ca-3068-4485-9025-e5e8f9c0541c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2c497f51-87d3-434b-99e9-f648d49935ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0984e45f-fdd6-419b-95ff-8419c27d6361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae8127ca-3068-4485-9025-e5e8f9c0541c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0984e45f-fdd6-419b-95ff-8419c27d6361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_378a3fd6-d4a1-4c3d-9487-be0161450d43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae8127ca-3068-4485-9025-e5e8f9c0541c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_378a3fd6-d4a1-4c3d-9487-be0161450d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member_0b4e72d8-892e-4e9d-9881-89aba592531d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae8127ca-3068-4485-9025-e5e8f9c0541c" xlink:to="loc_us-gaap_FairValueInputsLevel12And3Member_0b4e72d8-892e-4e9d-9881-89aba592531d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3a54a59f-3104-4347-a0be-d08ad0afc030" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b1baf2e5-fb9c-45e4-aa92-954db41e0b57" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3a54a59f-3104-4347-a0be-d08ad0afc030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0591424b-55b8-475e-8974-9f7896f3d786" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3a54a59f-3104-4347-a0be-d08ad0afc030" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0591424b-55b8-475e-8974-9f7896f3d786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TransactionDataSystemInvestmentMember_00160ae1-b0d7-4581-a3a8-5d6464916bf3" xlink:href="cah-20240930.xsd#cah_TransactionDataSystemInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0591424b-55b8-475e-8974-9f7896f3d786" xlink:to="loc_cah_TransactionDataSystemInvestmentMember_00160ae1-b0d7-4581-a3a8-5d6464916bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b1baf2e5-fb9c-45e4-aa92-954db41e0b57" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1a6c8ea5-b432-4d1a-af6c-ae6ed1fb106a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1a6c8ea5-b432-4d1a-af6c-ae6ed1fb106a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ddd64fda-d719-4e88-9533-4aac6ae953c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ddd64fda-d719-4e88-9533-4aac6ae953c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_48029c02-6452-4e01-b1b6-1485e41829fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_48029c02-6452-4e01-b1b6-1485e41829fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_8e82d5df-7592-4ccb-ba08-870d67d3a2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_8e82d5df-7592-4ccb-ba08-870d67d3a2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_223ec661-9e70-4d9c-a589-dd3b26f19e20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037c897f-37f6-400d-b3ce-d9f2c77a0d33" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_223ec661-9e70-4d9c-a589-dd3b26f19e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_0e270d1b-87d7-4478-99b3-3f2635864ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_42e898d2-3522-4501-bfb9-367522881ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_42e898d2-3522-4501-bfb9-367522881ee8" xlink:to="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_19128b3a-8064-4d30-85d3-0e33666c11c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_19128b3a-8064-4d30-85d3-0e33666c11c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_16478c0f-abe7-483f-88fe-1d4ddc3cbccd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19128b3a-8064-4d30-85d3-0e33666c11c6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_16478c0f-abe7-483f-88fe-1d4ddc3cbccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_e7a828e2-bd64-464c-940c-6c8c8666ead0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_16478c0f-abe7-483f-88fe-1d4ddc3cbccd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_e7a828e2-bd64-464c-940c-6c8c8666ead0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_79426e41-84a7-46cc-9405-32b19544581d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_us-gaap_HedgingDesignationAxis_79426e41-84a7-46cc-9405-32b19544581d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d9683714-0795-436a-8c47-36a016d70eea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_79426e41-84a7-46cc-9405-32b19544581d" xlink:to="loc_us-gaap_HedgingDesignationDomain_d9683714-0795-436a-8c47-36a016d70eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d3ce4609-61ad-472e-b689-5d291e7b1a74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_d9683714-0795-436a-8c47-36a016d70eea" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d3ce4609-61ad-472e-b689-5d291e7b1a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_64c5013f-0840-4859-8906-d688ceb10405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_d9683714-0795-436a-8c47-36a016d70eea" xlink:to="loc_us-gaap_NondesignatedMember_64c5013f-0840-4859-8906-d688ceb10405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8df6a09a-5e98-45b3-93c4-dad2bb40dac9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8df6a09a-5e98-45b3-93c4-dad2bb40dac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f6babc92-5217-4c91-893e-ec546399bd98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8df6a09a-5e98-45b3-93c4-dad2bb40dac9" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f6babc92-5217-4c91-893e-ec546399bd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_18375c45-7652-47f5-bbc5-107d7705ef77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f6babc92-5217-4c91-893e-ec546399bd98" xlink:to="loc_us-gaap_FairValueHedgingMember_18375c45-7652-47f5-bbc5-107d7705ef77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_8b5b1cee-d91a-4a55-97ea-e793b15cc8da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f6babc92-5217-4c91-893e-ec546399bd98" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_8b5b1cee-d91a-4a55-97ea-e793b15cc8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2d79f38b-3ecb-485e-862b-55d0b20e169a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f6babc92-5217-4c91-893e-ec546399bd98" xlink:to="loc_us-gaap_CashFlowHedgingMember_2d79f38b-3ecb-485e-862b-55d0b20e169a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bd4716d9-f5a5-4842-9bea-a80716d2db0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bd4716d9-f5a5-4842-9bea-a80716d2db0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4f36bdbe-c115-4859-a7e5-b48083ce6367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bd4716d9-f5a5-4842-9bea-a80716d2db0f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4f36bdbe-c115-4859-a7e5-b48083ce6367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_c0805226-3678-44b3-a207-51b3e01c6bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4f36bdbe-c115-4859-a7e5-b48083ce6367" xlink:to="loc_us-gaap_ForeignExchangeContractMember_c0805226-3678-44b3-a207-51b3e01c6bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_4872678d-a87c-460b-af00-41fb8da970b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4f36bdbe-c115-4859-a7e5-b48083ce6367" xlink:to="loc_us-gaap_InterestRateSwapMember_4872678d-a87c-460b-af00-41fb8da970b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_ecfe7fb7-2476-44be-a4ac-60bca3829917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4f36bdbe-c115-4859-a7e5-b48083ce6367" xlink:to="loc_us-gaap_CashFlowHedgingMember_ecfe7fb7-2476-44be-a4ac-60bca3829917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_ba9f5cd5-8cf9-417f-aba7-2e4ad07eecb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4f36bdbe-c115-4859-a7e5-b48083ce6367" xlink:to="loc_us-gaap_CurrencySwapMember_ba9f5cd5-8cf9-417f-aba7-2e4ad07eecb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateAxis_77845deb-2afe-453e-95aa-b63a49846c89" xlink:href="cah-20240930.xsd#cah_MaturityDateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_cah_MaturityDateAxis_77845deb-2afe-453e-95aa-b63a49846c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaturityDateDomain_66fcd75c-c99b-4e2d-933d-e7823009061f" xlink:href="cah-20240930.xsd#cah_MaturityDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MaturityDateAxis_77845deb-2afe-453e-95aa-b63a49846c89" xlink:to="loc_cah_MaturityDateDomain_66fcd75c-c99b-4e2d-933d-e7823009061f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_September2025Member_89d76aee-2957-4092-ae03-06b0ef2e44d3" xlink:href="cah-20240930.xsd#cah_September2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MaturityDateDomain_66fcd75c-c99b-4e2d-933d-e7823009061f" xlink:to="loc_cah_September2025Member_89d76aee-2957-4092-ae03-06b0ef2e44d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_June2027Member_da2a7e75-d361-42d4-817b-6823b804e63f" xlink:href="cah-20240930.xsd#cah_June2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MaturityDateDomain_66fcd75c-c99b-4e2d-933d-e7823009061f" xlink:to="loc_cah_June2027Member_da2a7e75-d361-42d4-817b-6823b804e63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedAxis_86beb5ca-2d54-4f9a-92d5-5a60ff557bc2" xlink:href="cah-20240930.xsd#cah_DateInitiatedAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_cah_DateInitiatedAxis_86beb5ca-2d54-4f9a-92d5-5a60ff557bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DateInitiatedDomain_32f08784-47aa-4067-8860-a9865c856a87" xlink:href="cah-20240930.xsd#cah_DateInitiatedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_DateInitiatedAxis_86beb5ca-2d54-4f9a-92d5-5a60ff557bc2" xlink:to="loc_cah_DateInitiatedDomain_32f08784-47aa-4067-8860-a9865c856a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_January2023Member_9d4ed951-8e8e-42d2-a78c-d9815e2263fa" xlink:href="cah-20240930.xsd#cah_January2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_DateInitiatedDomain_32f08784-47aa-4067-8860-a9865c856a87" xlink:to="loc_cah_January2023Member_9d4ed951-8e8e-42d2-a78c-d9815e2263fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_28c7b9ab-a7b7-411b-b9bf-51bb7550b870" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_srt_StatementScenarioAxis_28c7b9ab-a7b7-411b-b9bf-51bb7550b870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5266ceb4-ab60-4cfe-ad2c-be83e419458a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_28c7b9ab-a7b7-411b-b9bf-51bb7550b870" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5266ceb4-ab60-4cfe-ad2c-be83e419458a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6e9ebaf8-9666-4e34-bb1d-3e828e4b89dc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_5266ceb4-ab60-4cfe-ad2c-be83e419458a" xlink:to="loc_srt_ScenarioForecastMember_6e9ebaf8-9666-4e34-bb1d-3e828e4b89dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_549e56b6-8610-491a-9c3e-1025bf1d98ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_549e56b6-8610-491a-9c3e-1025bf1d98ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5e81a9c5-0078-43c9-a207-44a77f92467a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_549e56b6-8610-491a-9c3e-1025bf1d98ff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5e81a9c5-0078-43c9-a207-44a77f92467a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6e407951-76c5-440e-a501-a8c57fbf710d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5e81a9c5-0078-43c9-a207-44a77f92467a" xlink:to="loc_us-gaap_SubsequentEventMember_6e407951-76c5-440e-a501-a8c57fbf710d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2d0d34ee-860a-4023-934d-636cf36387c2" xlink:to="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f65832a1-b95a-4ed1-9c2a-cef8315b090d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f65832a1-b95a-4ed1-9c2a-cef8315b090d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_010cc312-ea64-47cc-8db3-3213e704c38e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_010cc312-ea64-47cc-8db3-3213e704c38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c6dc29b4-67f5-43c4-962e-709c3d73f343" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c6dc29b4-67f5-43c4-962e-709c3d73f343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_579f7683-e919-4058-87cc-97c41a87e6af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_579f7683-e919-4058-87cc-97c41a87e6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_4b8817a2-0bcb-4dae-819a-9ad6db275e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_4b8817a2-0bcb-4dae-819a-9ad6db275e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_07b08003-071b-44a1-80a0-4372a38eae88" xlink:href="cah-20240930.xsd#cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount_07b08003-071b-44a1-80a0-4372a38eae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_bb2e380e-587f-47d4-9dde-efbffcb4660b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_bb2e380e-587f-47d4-9dde-efbffcb4660b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_341981b6-4bed-4394-b54b-69423c436a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_341981b6-4bed-4394-b54b-69423c436a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_b68ae645-79f7-4a77-a158-a6724097d56a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_b68ae645-79f7-4a77-a158-a6724097d56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_9b2e9635-ad63-4f87-b234-83e79c90dad7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_cfe40312-f2e2-4fcb-83f7-cdf7ea01486d" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_9b2e9635-ad63-4f87-b234-83e79c90dad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0052ff0d-0056-475f-9ea7-1322a5f161ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd602c1f-2356-4e5c-b142-0d63339cd488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0052ff0d-0056-475f-9ea7-1322a5f161ca" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd602c1f-2356-4e5c-b142-0d63339cd488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e1ce468-9f83-4b57-9bf8-6d8dee7b36b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd602c1f-2356-4e5c-b142-0d63339cd488" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e1ce468-9f83-4b57-9bf8-6d8dee7b36b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_72a2e674-413b-4eae-91e2-bbfe22cd9d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e1ce468-9f83-4b57-9bf8-6d8dee7b36b9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_72a2e674-413b-4eae-91e2-bbfe22cd9d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a0058822-fa37-440c-9c60-c8c652237b26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_72a2e674-413b-4eae-91e2-bbfe22cd9d2d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a0058822-fa37-440c-9c60-c8c652237b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f9ee3e5-fd02-43e4-a078-6ea5b2d5b4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd602c1f-2356-4e5c-b142-0d63339cd488" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f9ee3e5-fd02-43e4-a078-6ea5b2d5b4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4654529b-e056-48ac-8663-94a2ec7e313f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f9ee3e5-fd02-43e4-a078-6ea5b2d5b4d5" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4654529b-e056-48ac-8663-94a2ec7e313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_2e24bcdb-6f49-4550-b496-a057ae220928" xlink:href="cah-20240930.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f9ee3e5-fd02-43e4-a078-6ea5b2d5b4d5" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_2e24bcdb-6f49-4550-b496-a057ae220928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_76d8565f-d164-40b6-8880-d020c074a1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_76d8565f-d164-40b6-8880-d020c074a1e7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_984ddb11-6008-40f8-9c3f-329b16030bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_984ddb11-6008-40f8-9c3f-329b16030bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b524c5a9-1e4d-4f9b-9341-d85e30b8536e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_984ddb11-6008-40f8-9c3f-329b16030bc2" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b524c5a9-1e4d-4f9b-9341-d85e30b8536e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_35e16f3a-5269-4615-ac4a-9c3440a1c09b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_35e16f3a-5269-4615-ac4a-9c3440a1c09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6ba9a259-8693-46df-8589-90bf2f223b11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_35e16f3a-5269-4615-ac4a-9c3440a1c09b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6ba9a259-8693-46df-8589-90bf2f223b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ebc4e5ed-42ee-4485-a901-3ff75d770356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6ba9a259-8693-46df-8589-90bf2f223b11" xlink:to="loc_us-gaap_SubsequentEventMember_ebc4e5ed-42ee-4485-a901-3ff75d770356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_557e3a44-f875-498a-953e-e11eca1776f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_557e3a44-f875-498a-953e-e11eca1776f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_14f81433-8b1a-41e4-bf92-7775b63aa30d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_557e3a44-f875-498a-953e-e11eca1776f2" xlink:to="loc_us-gaap_EquityComponentDomain_14f81433-8b1a-41e4-bf92-7775b63aa30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_0d413207-c184-4c05-8799-9aceaea96d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14f81433-8b1a-41e4-bf92-7775b63aa30d" xlink:to="loc_us-gaap_TreasuryStockCommonMember_0d413207-c184-4c05-8799-9aceaea96d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c4e2227-4f03-404f-9a5d-ae52441b3d56" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_srt_RangeAxis_0c4e2227-4f03-404f-9a5d-ae52441b3d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_29d73e7f-9f42-461f-807b-97a4ed799075" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0c4e2227-4f03-404f-9a5d-ae52441b3d56" xlink:to="loc_srt_RangeMember_29d73e7f-9f42-461f-807b-97a4ed799075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1143a1a4-cf88-4233-a26c-ed1a025b48c1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_29d73e7f-9f42-461f-807b-97a4ed799075" xlink:to="loc_srt_MinimumMember_1143a1a4-cf88-4233-a26c-ed1a025b48c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cf23b282-c07f-4fee-8da8-5bcdce755a02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_us-gaap_AwardTypeAxis_cf23b282-c07f-4fee-8da8-5bcdce755a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b18e2f84-2918-42e3-898a-470ee2781d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cf23b282-c07f-4fee-8da8-5bcdce755a02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b18e2f84-2918-42e3-898a-470ee2781d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_db753767-f29a-4d49-8bbf-43453da0fd66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b18e2f84-2918-42e3-898a-470ee2781d4b" xlink:to="loc_us-gaap_PerformanceSharesMember_db753767-f29a-4d49-8bbf-43453da0fd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_3398dbf6-71f9-4e07-a6cc-3135c6676c06" xlink:href="cah-20240930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_3398dbf6-71f9-4e07-a6cc-3135c6676c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_5ceccd5c-faeb-4796-b3d0-c7ed98f51aac" xlink:href="cah-20240930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_3398dbf6-71f9-4e07-a6cc-3135c6676c06" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_5ceccd5c-faeb-4796-b3d0-c7ed98f51aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_21250471-2bec-45da-a4f9-c1d5cbe55ef9" xlink:href="cah-20240930.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_5ceccd5c-faeb-4796-b3d0-c7ed98f51aac" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_21250471-2bec-45da-a4f9-c1d5cbe55ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A375MillionShareRepurchaseProgramMember_2fb90bc7-00d8-4dc2-8bb6-3f35e666a90b" xlink:href="cah-20240930.xsd#cah_A375MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_5ceccd5c-faeb-4796-b3d0-c7ed98f51aac" xlink:to="loc_cah_A375MillionShareRepurchaseProgramMember_2fb90bc7-00d8-4dc2-8bb6-3f35e666a90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_472b8395-939d-4be5-97b1-987d89519128" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_srt_ShareRepurchaseProgramAxis_472b8395-939d-4be5-97b1-987d89519128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_2f80e4fd-a51d-4dd0-874b-d0963faa9802" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_472b8395-939d-4be5-97b1-987d89519128" xlink:to="loc_srt_ShareRepurchaseProgramDomain_2f80e4fd-a51d-4dd0-874b-d0963faa9802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_7a10a30c-35a3-45d7-8c84-782c36f99cb0" xlink:href="cah-20240930.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_2f80e4fd-a51d-4dd0-874b-d0963faa9802" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_7a10a30c-35a3-45d7-8c84-782c36f99cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A375MillionShareRepurchaseProgramMember_ed95c258-eab6-4efb-bfd3-aa6531750e74" xlink:href="cah-20240930.xsd#cah_A375MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_2f80e4fd-a51d-4dd0-874b-d0963faa9802" xlink:to="loc_cah_A375MillionShareRepurchaseProgramMember_ed95c258-eab6-4efb-bfd3-aa6531750e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_01a64422-2338-44c5-b11d-e6b4b0a339b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8c573533-160c-41ed-b47e-2822c7230183" xlink:to="loc_us-gaap_ClassOfStockLineItems_01a64422-2338-44c5-b11d-e6b4b0a339b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_be750d49-7807-4352-99eb-d603045586ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01a64422-2338-44c5-b11d-e6b4b0a339b3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_be750d49-7807-4352-99eb-d603045586ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_23c69a65-caf1-4dd8-8f54-f1fda5e9f2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01a64422-2338-44c5-b11d-e6b4b0a339b3" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_23c69a65-caf1-4dd8-8f54-f1fda5e9f2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_78e7c835-e120-413a-b861-7e410b24b0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_01a64422-2338-44c5-b11d-e6b4b0a339b3" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_78e7c835-e120-413a-b861-7e410b24b0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bd9149cf-c583-4cc1-aabb-97a2e6182ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3619070-a05b-4c9e-bd38-c453bc1fa601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bd9149cf-c583-4cc1-aabb-97a2e6182ce5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3619070-a05b-4c9e-bd38-c453bc1fa601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_19c7f2ff-5228-40a7-a10b-2320590791e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3619070-a05b-4c9e-bd38-c453bc1fa601" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_19c7f2ff-5228-40a7-a10b-2320590791e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d744fbc0-4fe3-4c07-9348-64ded95901bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19c7f2ff-5228-40a7-a10b-2320590791e8" xlink:to="loc_us-gaap_EquityComponentDomain_d744fbc0-4fe3-4c07-9348-64ded95901bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_25788739-7df0-4ca1-9ffc-e12d2d136113" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d744fbc0-4fe3-4c07-9348-64ded95901bc" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_25788739-7df0-4ca1-9ffc-e12d2d136113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_a219473f-9ec5-4b35-90ac-1a659e1f77a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d744fbc0-4fe3-4c07-9348-64ded95901bc" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_a219473f-9ec5-4b35-90ac-1a659e1f77a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_4311d6fa-f816-4666-9906-880a51796e28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d744fbc0-4fe3-4c07-9348-64ded95901bc" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_4311d6fa-f816-4666-9906-880a51796e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_444e0c4e-2229-4e33-a0d7-9da61482902a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d744fbc0-4fe3-4c07-9348-64ded95901bc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_444e0c4e-2229-4e33-a0d7-9da61482902a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_1dc336f7-8498-4000-81f9-2ee0e00655fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3619070-a05b-4c9e-bd38-c453bc1fa601" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_1dc336f7-8498-4000-81f9-2ee0e00655fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_1dc336f7-8498-4000-81f9-2ee0e00655fd" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95bcfbfc-d334-44f6-bc6a-6d4c3f720e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95bcfbfc-d334-44f6-bc6a-6d4c3f720e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6a40d92b-2786-47bf-b89d-4821e33c19f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6a40d92b-2786-47bf-b89d-4821e33c19f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d06cda34-3090-4c2e-b9b7-688f44870a21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d06cda34-3090-4c2e-b9b7-688f44870a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0b77cbfa-92d4-4ef3-b032-8f8423e35521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0b77cbfa-92d4-4ef3-b032-8f8423e35521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_86560a1d-b42b-47bb-9339-0d4d6c898511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_86560a1d-b42b-47bb-9339-0d4d6c898511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7463db72-480f-47df-9d1f-5669150198b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_158d31eb-c403-436a-87ad-81e3eb9dc9f8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7463db72-480f-47df-9d1f-5669150198b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_957642d4-e067-4f97-a482-ecad27b4ebc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9bb17a05-4c29-4993-a2a3-8f5c9fac336a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_957642d4-e067-4f97-a482-ecad27b4ebc8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9bb17a05-4c29-4993-a2a3-8f5c9fac336a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_12c53929-a99b-493d-a940-2559ea42e450" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_957642d4-e067-4f97-a482-ecad27b4ebc8" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_12c53929-a99b-493d-a940-2559ea42e450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6a0c2119-be4e-432d-b326-bb34b390794b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_957642d4-e067-4f97-a482-ecad27b4ebc8" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6a0c2119-be4e-432d-b326-bb34b390794b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1097bc13-1bbb-4476-8f0a-5b42de809499" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_957642d4-e067-4f97-a482-ecad27b4ebc8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1097bc13-1bbb-4476-8f0a-5b42de809499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_389f1078-111b-4701-927e-64e2b3267c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0c6787f1-683d-45ad-bc6e-0d88e8f1093c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_389f1078-111b-4701-927e-64e2b3267c84" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0c6787f1-683d-45ad-bc6e-0d88e8f1093c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod_a9f7a349-b0e5-4c83-9e30-69e4f47e6bfe" xlink:href="cah-20240930.xsd#cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_389f1078-111b-4701-927e-64e2b3267c84" xlink:to="loc_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod_a9f7a349-b0e5-4c83-9e30-69e4f47e6bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ce64fe7c-67e8-43b8-832f-2e711318cbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a510339e-c520-4747-8ca6-4fdd71dde5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ce64fe7c-67e8-43b8-832f-2e711318cbf2" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a510339e-c520-4747-8ca6-4fdd71dde5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3dc6f6df-cd45-43fa-bde6-eef8faa7a6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a510339e-c520-4747-8ca6-4fdd71dde5f0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3dc6f6df-cd45-43fa-bde6-eef8faa7a6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_af93582c-104c-4fb9-a091-04a2deac5069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3dc6f6df-cd45-43fa-bde6-eef8faa7a6b0" xlink:to="loc_us-gaap_SegmentDomain_af93582c-104c-4fb9-a091-04a2deac5069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_8176be35-4249-4b6b-98cd-3d7401eff1a6" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_af93582c-104c-4fb9-a091-04a2deac5069" xlink:to="loc_cah_GMPDMember_8176be35-4249-4b6b-98cd-3d7401eff1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_2b7c98fe-9fca-424e-ae92-274a6aba1d74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_af93582c-104c-4fb9-a091-04a2deac5069" xlink:to="loc_us-gaap_AllOtherSegmentsMember_2b7c98fe-9fca-424e-ae92-274a6aba1d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f5a5b1a9-c18e-42ee-b807-24edda2e8c59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a510339e-c520-4747-8ca6-4fdd71dde5f0" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_f5a5b1a9-c18e-42ee-b807-24edda2e8c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_cf81af55-8fe9-45b6-a763-2aa195fe33a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f5a5b1a9-c18e-42ee-b807-24edda2e8c59" xlink:to="loc_us-gaap_NumberOfReportableSegments_cf81af55-8fe9-45b6-a763-2aa195fe33a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_33f6249e-1d97-47b0-aa37-5484891ea81e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f5a5b1a9-c18e-42ee-b807-24edda2e8c59" xlink:to="loc_us-gaap_NumberOfOperatingSegments_33f6249e-1d97-47b0-aa37-5484891ea81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e026cf1f-6f87-48dc-80b0-6c3a56cbc99e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f5a5b1a9-c18e-42ee-b807-24edda2e8c59" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e026cf1f-6f87-48dc-80b0-6c3a56cbc99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_d3b11069-f805-4494-8642-a693c3a71d0a" xlink:href="cah-20240930.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f5a5b1a9-c18e-42ee-b807-24edda2e8c59" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_d3b11069-f805-4494-8642-a693c3a71d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e6352de0-4913-4b47-93d1-20b59b4cb221" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_5d2c6458-5b46-4b0f-9e4a-b01bd400b96c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e6352de0-4913-4b47-93d1-20b59b4cb221" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_5d2c6458-5b46-4b0f-9e4a-b01bd400b96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_81ae65f7-268e-4c9b-a34e-439a9248d74a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_5d2c6458-5b46-4b0f-9e4a-b01bd400b96c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_81ae65f7-268e-4c9b-a34e-439a9248d74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_63be7a8c-cad8-4b58-b76d-e6cb1511cde3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_81ae65f7-268e-4c9b-a34e-439a9248d74a" xlink:to="loc_us-gaap_SegmentDomain_63be7a8c-cad8-4b58-b76d-e6cb1511cde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_2fde1ce2-0f60-4806-b6b3-325885eafa56" xlink:href="cah-20240930.xsd#cah_PharmaceuticalAndSpecialtySolutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_63be7a8c-cad8-4b58-b76d-e6cb1511cde3" xlink:to="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_2fde1ce2-0f60-4806-b6b3-325885eafa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_6bb40dff-a8f7-4df3-8384-7a815cde04e3" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_63be7a8c-cad8-4b58-b76d-e6cb1511cde3" xlink:to="loc_cah_GMPDMember_6bb40dff-a8f7-4df3-8384-7a815cde04e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_f9eafcde-27a3-45d6-99f6-bc30f688eb15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_63be7a8c-cad8-4b58-b76d-e6cb1511cde3" xlink:to="loc_us-gaap_AllOtherSegmentsMember_f9eafcde-27a3-45d6-99f6-bc30f688eb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_523df5aa-9ca2-469b-be1f-46b33e40bc06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_5d2c6458-5b46-4b0f-9e4a-b01bd400b96c" xlink:to="loc_us-gaap_SubsegmentsAxis_523df5aa-9ca2-469b-be1f-46b33e40bc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_f07dfe46-c65d-486d-9684-02e523daef37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_523df5aa-9ca2-469b-be1f-46b33e40bc06" xlink:to="loc_us-gaap_SubsegmentsDomain_f07dfe46-c65d-486d-9684-02e523daef37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearAndPrecisionHealthSolutionsMember_8a0b2a18-6833-4d5f-a030-9c8f8f81cce4" xlink:href="cah-20240930.xsd#cah_NuclearAndPrecisionHealthSolutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_f07dfe46-c65d-486d-9684-02e523daef37" xlink:to="loc_cah_NuclearAndPrecisionHealthSolutionsMember_8a0b2a18-6833-4d5f-a030-9c8f8f81cce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AtHomeSolutionsMember_72d920c0-cc9b-48e4-8c95-709a158c87ac" xlink:href="cah-20240930.xsd#cah_AtHomeSolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_f07dfe46-c65d-486d-9684-02e523daef37" xlink:to="loc_cah_AtHomeSolutionsMember_72d920c0-cc9b-48e4-8c95-709a158c87ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OptiFreightMember_da4f2eb6-1414-4316-8768-9d0ae8231823" xlink:href="cah-20240930.xsd#cah_OptiFreightMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_f07dfe46-c65d-486d-9684-02e523daef37" xlink:to="loc_cah_OptiFreightMember_da4f2eb6-1414-4316-8768-9d0ae8231823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_fc873152-c5c1-49c9-8b86-bba2051fc063" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_5d2c6458-5b46-4b0f-9e4a-b01bd400b96c" xlink:to="loc_srt_ConsolidationItemsAxis_fc873152-c5c1-49c9-8b86-bba2051fc063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ecf6be3c-4971-4744-85ab-a4bb25f130ba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_fc873152-c5c1-49c9-8b86-bba2051fc063" xlink:to="loc_srt_ConsolidationItemsDomain_ecf6be3c-4971-4744-85ab-a4bb25f130ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_b031960d-6646-4ac6-a793-75fd1b16378c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ecf6be3c-4971-4744-85ab-a4bb25f130ba" xlink:to="loc_us-gaap_OperatingSegmentsMember_b031960d-6646-4ac6-a793-75fd1b16378c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_3a854225-aea5-4835-a92f-276f2545c883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ecf6be3c-4971-4744-85ab-a4bb25f130ba" xlink:to="loc_us-gaap_CorporateNonSegmentMember_3a854225-aea5-4835-a92f-276f2545c883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_698f1d8d-1cd2-4348-8d14-b6e3b72370f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_5d2c6458-5b46-4b0f-9e4a-b01bd400b96c" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_698f1d8d-1cd2-4348-8d14-b6e3b72370f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_42cc7670-5e13-4808-ab19-e19245721eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_698f1d8d-1cd2-4348-8d14-b6e3b72370f4" xlink:to="loc_us-gaap_Revenues_42cc7670-5e13-4808-ab19-e19245721eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#SegmentInformationRevenuebyGeographicalSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7ad3f32e-b939-4f98-b762-c78bdc3124ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicTable_5b1705a2-a0d5-4401-bbd8-5fb4ea4c60f9" xlink:href="cah-20240930.xsd#cah_SegmentRevenuebyGeographicTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7ad3f32e-b939-4f98-b762-c78bdc3124ce" xlink:to="loc_cah_SegmentRevenuebyGeographicTable_5b1705a2-a0d5-4401-bbd8-5fb4ea4c60f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_014e151d-e008-420f-8711-f9e384b185f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_5b1705a2-a0d5-4401-bbd8-5fb4ea4c60f9" xlink:to="loc_srt_ConsolidationItemsAxis_014e151d-e008-420f-8711-f9e384b185f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b11b56f1-d65b-4e1d-97eb-70a15e2a1cd3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_014e151d-e008-420f-8711-f9e384b185f9" xlink:to="loc_srt_ConsolidationItemsDomain_b11b56f1-d65b-4e1d-97eb-70a15e2a1cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_b3de8c9e-52a7-402a-bbff-8881aec3773f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_b11b56f1-d65b-4e1d-97eb-70a15e2a1cd3" xlink:to="loc_us-gaap_OperatingSegmentsMember_b3de8c9e-52a7-402a-bbff-8881aec3773f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c2876879-5780-403f-a6ac-7fe2f8fbb495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_b11b56f1-d65b-4e1d-97eb-70a15e2a1cd3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c2876879-5780-403f-a6ac-7fe2f8fbb495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8f224dbc-43c6-48e9-8a27-fb4cc45e9362" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_5b1705a2-a0d5-4401-bbd8-5fb4ea4c60f9" xlink:to="loc_srt_StatementGeographicalAxis_8f224dbc-43c6-48e9-8a27-fb4cc45e9362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_729d68c5-c364-4acc-9617-eec63eb6de3f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8f224dbc-43c6-48e9-8a27-fb4cc45e9362" xlink:to="loc_srt_SegmentGeographicalDomain_729d68c5-c364-4acc-9617-eec63eb6de3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_aad5f735-0f04-46d9-960f-77046d26127f" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_729d68c5-c364-4acc-9617-eec63eb6de3f" xlink:to="loc_country_US_aad5f735-0f04-46d9-960f-77046d26127f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_802d9e0d-5171-4711-a34b-276226e5f030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_729d68c5-c364-4acc-9617-eec63eb6de3f" xlink:to="loc_us-gaap_NonUsMember_802d9e0d-5171-4711-a34b-276226e5f030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicLineItems_e60dbfef-5f2d-4654-9cce-db11206997a6" xlink:href="cah-20240930.xsd#cah_SegmentRevenuebyGeographicLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_5b1705a2-a0d5-4401-bbd8-5fb4ea4c60f9" xlink:to="loc_cah_SegmentRevenuebyGeographicLineItems_e60dbfef-5f2d-4654-9cce-db11206997a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ba3834be-fa20-41ba-a57c-33c9da927f02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems_e60dbfef-5f2d-4654-9cce-db11206997a6" xlink:to="loc_us-gaap_Revenues_ba3834be-fa20-41ba-a57c-33c9da927f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5dff8ec9-cf52-4d71-b455-502dd3b55ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4f37fd54-6968-47cf-9949-16175f6e758c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5dff8ec9-cf52-4d71-b455-502dd3b55ba5" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4f37fd54-6968-47cf-9949-16175f6e758c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_603e7915-bd55-4e6e-ad45-1a90c1b6ae8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4f37fd54-6968-47cf-9949-16175f6e758c" xlink:to="loc_srt_ConsolidationItemsAxis_603e7915-bd55-4e6e-ad45-1a90c1b6ae8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_af54813d-d94c-4965-90b3-4ad055a5d8f7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_603e7915-bd55-4e6e-ad45-1a90c1b6ae8c" xlink:to="loc_srt_ConsolidationItemsDomain_af54813d-d94c-4965-90b3-4ad055a5d8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9a14853d-9c3a-43df-a52f-8b07ecd5c2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_af54813d-d94c-4965-90b3-4ad055a5d8f7" xlink:to="loc_us-gaap_OperatingSegmentsMember_9a14853d-9c3a-43df-a52f-8b07ecd5c2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_3945d3f6-11dc-4ccf-9b99-96e478eebae4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_af54813d-d94c-4965-90b3-4ad055a5d8f7" xlink:to="loc_us-gaap_CorporateNonSegmentMember_3945d3f6-11dc-4ccf-9b99-96e478eebae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a05b0e82-ae04-4601-9eb4-3442f4d05a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4f37fd54-6968-47cf-9949-16175f6e758c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a05b0e82-ae04-4601-9eb4-3442f4d05a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d4bb644d-56bb-4a45-8808-1efea2493492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a05b0e82-ae04-4601-9eb4-3442f4d05a2e" xlink:to="loc_us-gaap_SegmentDomain_d4bb644d-56bb-4a45-8808-1efea2493492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_881ce644-4967-4f3b-8d4c-909783c64e2b" xlink:href="cah-20240930.xsd#cah_PharmaceuticalAndSpecialtySolutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d4bb644d-56bb-4a45-8808-1efea2493492" xlink:to="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_881ce644-4967-4f3b-8d4c-909783c64e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_43cc051f-b5fd-444a-be5f-db494f453dd6" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d4bb644d-56bb-4a45-8808-1efea2493492" xlink:to="loc_cah_GMPDMember_43cc051f-b5fd-444a-be5f-db494f453dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_528f7360-8b0e-41b9-b560-020c5dff0785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d4bb644d-56bb-4a45-8808-1efea2493492" xlink:to="loc_us-gaap_AllOtherSegmentsMember_528f7360-8b0e-41b9-b560-020c5dff0785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a5c11a1e-162d-46e8-bb0e-a23f77ce9594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4f37fd54-6968-47cf-9949-16175f6e758c" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a5c11a1e-162d-46e8-bb0e-a23f77ce9594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_38de1a36-64b3-4a73-a67a-290135334e27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a5c11a1e-162d-46e8-bb0e-a23f77ce9594" xlink:to="loc_us-gaap_OperatingIncomeLoss_38de1a36-64b3-4a73-a67a-290135334e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c61f83c2-e221-4869-bc23-a88ec046f946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_680b2c3a-d5fa-45ff-92f3-8fa1349853e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c61f83c2-e221-4869-bc23-a88ec046f946" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_680b2c3a-d5fa-45ff-92f3-8fa1349853e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2ccf875b-d0c3-4054-aa0c-c1b22b720d55" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_680b2c3a-d5fa-45ff-92f3-8fa1349853e3" xlink:to="loc_srt_ConsolidationItemsAxis_2ccf875b-d0c3-4054-aa0c-c1b22b720d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e11d1c21-7611-4791-8300-e963390e62ff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_2ccf875b-d0c3-4054-aa0c-c1b22b720d55" xlink:to="loc_srt_ConsolidationItemsDomain_e11d1c21-7611-4791-8300-e963390e62ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_aed8fccc-033c-4090-8d42-2aea645c632d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e11d1c21-7611-4791-8300-e963390e62ff" xlink:to="loc_us-gaap_OperatingSegmentsMember_aed8fccc-033c-4090-8d42-2aea645c632d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e0a4d579-ae1c-484a-a5db-1e572ae5cc24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e11d1c21-7611-4791-8300-e963390e62ff" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e0a4d579-ae1c-484a-a5db-1e572ae5cc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8890f9ee-ebd9-48d5-ab4b-af9687be3de5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_680b2c3a-d5fa-45ff-92f3-8fa1349853e3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8890f9ee-ebd9-48d5-ab4b-af9687be3de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_67bddde4-a936-4d8e-9fe5-0b5d51823230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8890f9ee-ebd9-48d5-ab4b-af9687be3de5" xlink:to="loc_us-gaap_SegmentDomain_67bddde4-a936-4d8e-9fe5-0b5d51823230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_339dfd05-b0c9-4bcc-b4cc-27746674b209" xlink:href="cah-20240930.xsd#cah_PharmaceuticalAndSpecialtySolutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_67bddde4-a936-4d8e-9fe5-0b5d51823230" xlink:to="loc_cah_PharmaceuticalAndSpecialtySolutionsMember_339dfd05-b0c9-4bcc-b4cc-27746674b209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GMPDMember_9dc2dd56-155c-479c-a0b1-b7fb7207e929" xlink:href="cah-20240930.xsd#cah_GMPDMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_67bddde4-a936-4d8e-9fe5-0b5d51823230" xlink:to="loc_cah_GMPDMember_9dc2dd56-155c-479c-a0b1-b7fb7207e929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_0d4ecd2e-25c1-4508-93cc-811d6c9c3c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_67bddde4-a936-4d8e-9fe5-0b5d51823230" xlink:to="loc_us-gaap_AllOtherSegmentsMember_0d4ecd2e-25c1-4508-93cc-811d6c9c3c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8ab929a4-3e84-4cc8-9fbd-b1dd55b83dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_680b2c3a-d5fa-45ff-92f3-8fa1349853e3" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_8ab929a4-3e84-4cc8-9fbd-b1dd55b83dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d6e251b3-ff3a-4579-8822-1326654b595b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8ab929a4-3e84-4cc8-9fbd-b1dd55b83dc9" xlink:to="loc_us-gaap_Assets_d6e251b3-ff3a-4579-8822-1326654b595b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d862f1bb-e48a-41bb-9f4e-fc57a7595b21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3e3f4db-fa71-4096-887a-3e7ba56931ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d862f1bb-e48a-41bb-9f4e-fc57a7595b21" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3e3f4db-fa71-4096-887a-3e7ba56931ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_90d0ee7d-48d9-49f6-bb72-4116bcbb86ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3e3f4db-fa71-4096-887a-3e7ba56931ef" xlink:to="loc_us-gaap_AwardTypeAxis_90d0ee7d-48d9-49f6-bb72-4116bcbb86ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98d02db2-56ac-43b4-8f18-a2267ef6c525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_90d0ee7d-48d9-49f6-bb72-4116bcbb86ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98d02db2-56ac-43b4-8f18-a2267ef6c525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d51658fa-be96-462b-aca6-0ccd3886b4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98d02db2-56ac-43b4-8f18-a2267ef6c525" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d51658fa-be96-462b-aca6-0ccd3886b4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3ee10bbc-3aab-4977-819f-aad626648708" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98d02db2-56ac-43b4-8f18-a2267ef6c525" xlink:to="loc_us-gaap_PerformanceSharesMember_3ee10bbc-3aab-4977-819f-aad626648708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fcd6b5e5-353d-4495-a41e-c1952f7beb7d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3e3f4db-fa71-4096-887a-3e7ba56931ef" xlink:to="loc_srt_RangeAxis_fcd6b5e5-353d-4495-a41e-c1952f7beb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5df6be7c-d820-4d28-9ef1-5e0dce25dbce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fcd6b5e5-353d-4495-a41e-c1952f7beb7d" xlink:to="loc_srt_RangeMember_5df6be7c-d820-4d28-9ef1-5e0dce25dbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4d05d453-5c37-4cfe-bdbb-285ce7b23cf4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5df6be7c-d820-4d28-9ef1-5e0dce25dbce" xlink:to="loc_srt_MinimumMember_4d05d453-5c37-4cfe-bdbb-285ce7b23cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f2d52c20-eb5c-4094-ab05-72f3318734b0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5df6be7c-d820-4d28-9ef1-5e0dce25dbce" xlink:to="loc_srt_MaximumMember_f2d52c20-eb5c-4094-ab05-72f3318734b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3e3f4db-fa71-4096-887a-3e7ba56931ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ef1cdd15-fa4f-4586-8545-2de244803e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ef1cdd15-fa4f-4586-8545-2de244803e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_882bc1cf-7b63-4605-8f74-8cddbedd2315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_882bc1cf-7b63-4605-8f74-8cddbedd2315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_709bda32-af3a-484a-a3f8-927f3597a831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_709bda32-af3a-484a-a3f8-927f3597a831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f29062d-3625-4249-a980-5b29b51104b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f29062d-3625-4249-a980-5b29b51104b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_b85e4d0a-89c6-4cb2-831f-41bb79ae71d7" xlink:href="cah-20240930.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_cah_VestingPeriodinyearsforShares_b85e4d0a-89c6-4cb2-831f-41bb79ae71d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b7c2b442-f57a-4cda-9f9e-82e9e941da80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f07ea1-ec70-4834-b8e3-5934f317df68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b7c2b442-f57a-4cda-9f9e-82e9e941da80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5c7f16a-12b1-4422-9561-6756579f9abd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_031174d3-cf68-4e47-87cc-8bb3cc80e85c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5c7f16a-12b1-4422-9561-6756579f9abd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_031174d3-cf68-4e47-87cc-8bb3cc80e85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_586afb49-d199-4bd8-80eb-b20907cd6d94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_031174d3-cf68-4e47-87cc-8bb3cc80e85c" xlink:to="loc_us-gaap_AwardTypeAxis_586afb49-d199-4bd8-80eb-b20907cd6d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ec9e754-ff64-4646-af0f-6e8b0ba085fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_586afb49-d199-4bd8-80eb-b20907cd6d94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ec9e754-ff64-4646-af0f-6e8b0ba085fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_92ea641d-d8c0-4248-9eee-b5a1417433da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ec9e754-ff64-4646-af0f-6e8b0ba085fe" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_92ea641d-d8c0-4248-9eee-b5a1417433da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_502e5e10-d56d-46b0-9785-1a5e6e0f832d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ec9e754-ff64-4646-af0f-6e8b0ba085fe" xlink:to="loc_us-gaap_PerformanceSharesMember_502e5e10-d56d-46b0-9785-1a5e6e0f832d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b544a5d2-3b57-4c08-aa17-ec3949beaa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_031174d3-cf68-4e47-87cc-8bb3cc80e85c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b544a5d2-3b57-4c08-aa17-ec3949beaa0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f909aa01-3e9a-4a0e-a4c4-3a3d212b7ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b544a5d2-3b57-4c08-aa17-ec3949beaa0f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f909aa01-3e9a-4a0e-a4c4-3a3d212b7ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b5798789-2726-4850-8b09-57823e173ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d7e78b6-ab49-4dcf-9c8d-719ae6022e30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b5798789-2726-4850-8b09-57823e173ec1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d7e78b6-ab49-4dcf-9c8d-719ae6022e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b6d6ed00-0e80-4b4c-bc91-73a7a96a57d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d7e78b6-ab49-4dcf-9c8d-719ae6022e30" xlink:to="loc_us-gaap_AwardTypeAxis_b6d6ed00-0e80-4b4c-bc91-73a7a96a57d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_361c70a1-cf39-48b2-a802-be57220d0187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b6d6ed00-0e80-4b4c-bc91-73a7a96a57d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_361c70a1-cf39-48b2-a802-be57220d0187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_326e4c1e-a38f-4392-b285-787c096278bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_361c70a1-cf39-48b2-a802-be57220d0187" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_326e4c1e-a38f-4392-b285-787c096278bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6229eefc-b9bd-4ec5-9ee6-7b9738ca9dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d7e78b6-ab49-4dcf-9c8d-719ae6022e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6229eefc-b9bd-4ec5-9ee6-7b9738ca9dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ca14b744-859d-4974-9136-299274a12903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6229eefc-b9bd-4ec5-9ee6-7b9738ca9dc7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ca14b744-859d-4974-9136-299274a12903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6229eefc-b9bd-4ec5-9ee6-7b9738ca9dc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7fc0cdf2-47b5-4578-9203-669b90dcdcef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7fc0cdf2-47b5-4578-9203-669b90dcdcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a39f54f9-3d1e-419f-b7b5-df6b57914fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a39f54f9-3d1e-419f-b7b5-df6b57914fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_26fb3764-eaac-4959-92f8-40e359cf5664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_26fb3764-eaac-4959-92f8-40e359cf5664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a4aaee0d-4b10-482c-8d12-f32afba6a014" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a4aaee0d-4b10-482c-8d12-f32afba6a014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_56f40162-988c-4786-8138-1721593fde13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a94452fe-9dc4-484b-805a-9b592091ca87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_56f40162-988c-4786-8138-1721593fde13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6229eefc-b9bd-4ec5-9ee6-7b9738ca9dc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6fa8b0b-34d1-4686-935e-ffe1743750ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6fa8b0b-34d1-4686-935e-ffe1743750ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc757527-ae29-4ceb-baff-4a8b5922a0db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc757527-ae29-4ceb-baff-4a8b5922a0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_18c7d7b5-e892-4fd2-a4d8-5dbbdb9f1a60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_18c7d7b5-e892-4fd2-a4d8-5dbbdb9f1a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02a1cf93-3f86-496e-ac5b-be26352eac34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02a1cf93-3f86-496e-ac5b-be26352eac34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_868b3416-1cc8-4ea9-8fd8-0578993e6a57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f463e7e9-d559-41a0-85ed-0069bf7c0452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_868b3416-1cc8-4ea9-8fd8-0578993e6a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20240930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5bfa360-ee4d-4479-80f6-8c7f5965890c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3008565e-29e4-44ca-bd1a-3539ea93419f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5bfa360-ee4d-4479-80f6-8c7f5965890c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3008565e-29e4-44ca-bd1a-3539ea93419f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_44be3fed-3b6f-4e7e-8577-85c404f28dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3008565e-29e4-44ca-bd1a-3539ea93419f" xlink:to="loc_us-gaap_AwardTypeAxis_44be3fed-3b6f-4e7e-8577-85c404f28dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fccfb54b-e56f-4902-9443-a89d40e697ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_44be3fed-3b6f-4e7e-8577-85c404f28dd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fccfb54b-e56f-4902-9443-a89d40e697ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3e0f8827-7c94-4ae6-8b59-0f5cb32f1896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fccfb54b-e56f-4902-9443-a89d40e697ad" xlink:to="loc_us-gaap_PerformanceSharesMember_3e0f8827-7c94-4ae6-8b59-0f5cb32f1896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3008565e-29e4-44ca-bd1a-3539ea93419f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fc7a357f-7f26-45d5-ab38-0afc4150ab2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fc7a357f-7f26-45d5-ab38-0afc4150ab2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5624d3a2-e200-4797-af96-087dbd91e560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5624d3a2-e200-4797-af96-087dbd91e560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cbe49d32-5910-4f16-ac02-9286826258da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cbe49d32-5910-4f16-ac02-9286826258da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b7218c43-378b-4a76-a279-6317ff08d8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b7218c43-378b-4a76-a279-6317ff08d8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f4cddf27-dba7-41d6-ba41-24c3b9cf7b28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f4cddf27-dba7-41d6-ba41-24c3b9cf7b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_932b7a34-6f74-4554-ad5d-e1cc14c5636d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_50955fda-98a2-4ee3-a7ca-dd89b7f47b9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_932b7a34-6f74-4554-ad5d-e1cc14c5636d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0aa3668a-a55b-4b97-bd85-421fae6da8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0aa3668a-a55b-4b97-bd85-421fae6da8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d31a164-63cd-41a2-b756-6a99c2fec8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d31a164-63cd-41a2-b756-6a99c2fec8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_399b337f-2f71-40e5-8030-ab548dabd971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_399b337f-2f71-40e5-8030-ab548dabd971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_304775b2-2e72-4052-86ae-84ccfe8dfe7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_304775b2-2e72-4052-86ae-84ccfe8dfe7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_06c9e88a-a463-4493-9df4-902a28c37f39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_40403c79-a090-46dc-85c6-09d9624ad39e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_06c9e88a-a463-4493-9df4-902a28c37f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_75e1be5e-04ac-4879-a2af-619c402e1e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_75e1be5e-04ac-4879-a2af-619c402e1e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_64a35d32-07e5-4157-b03a-617385cdbf24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9e1d14c-e7ee-458a-a30f-f134b07984f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_64a35d32-07e5-4157-b03a-617385cdbf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cah-20240930_g1.jpg
<TEXT>
begin 644 cah-20240930_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"Q0V&@3:-)?K):OH%@MP_DQR1L=J<YW<>]=YXE_X)\?\%]_^"]7[6/PYO/\
M@IK\&W^'/PQ\&WC?;I9["'2K>QLY)8WO%M;4RO<SW4Z0I&KMN1=B$LB@[@#W
MW_@N!\4/%6F?\'$G[#EEX;\>:I8Z'JESX7FO+2VU*6&WN(W\22Y,B!@K I@'
M<.G!K]/?@W_P56_X)R?M"_&^;]F_X)_ME>!/$OC:)Y4CT'2]:5WNFC!,BV[\
M1W1559B(6<A58] 2/QV_X.>?@AIW[0__  7$_9)_9SNM3N=+L/&NCZ%X?NKS
M3G\N6UMKKQ%/;R/$?X66-V*^X%<?_P ' G_!._\ 92_X)._M?_L??%_]@OX;
MOX"N]5\73_VA%9:S=W DN-+O=)DMKC=<2R,)"+J17((#!5R"<D@'[Y_M-_M?
M_LP?L9>!H_B3^U/\=/#G@71;BX^SVEWX@U%83=S8R8H8^7F<#DK&K$ $XP,U
MS'[*/_!27]A']N/4K_0_V3_VI/"?C74M+@\^_P!)TN_*WD,.0OG&WE"2F/<R
MJ9 I4%@,Y(KX$_X.%?@5_P $CKO]I;X4?M._\%4/VN_$EC8>&M*DM](^!^E0
M/=)XBMUEDDED2.T47%MYDK1++<-(J.MLD896&:_./]@3XJ?L=ZC_ ,'+7P/\
M=_\ !-;X"^,?A7\-?$$,UM%H/BH21OJ'FZ;J$-Q<Q(\\_P#HTFU2J^8P#Q,0
M%("J ?T)>/\ _@IE^P#\*_&OC3X<?$;]K;P3HVO?#K2?[3\;Z1?ZPJ7&CVNZ
MW023(>1N>ZMD51EF:>-5!+ 52\/_ /!5/_@G3XITGP%K>@?MA^"+BV^*&I/I
MW@!AJP5M;O$GCMWMX48!O-6::)"C ,#(N1R*_#7XC?L'_#3_ (*-?\':/Q=_
M9O\ C9>:H/!4CG5?%-CI%^UM+J-O;:+8/';&1>51K@V[-CG"':5;#+?_ .#D
M[]A+X2?LI^)_V'OV&OV9Y-2T#PY:ZEXAL-#NY;TRWEI)?:SILK3&;"LSK+<,
MRL>0%7GC- '[??#3_@J=_P $ZOC'^T!+^RU\+?VQ_ FN^/HIY8%\.Z=K:223
MS1 F2*&0?NYY%"L2D;,PV-D?*<-\ ?\ !5'_ ()S_%3]H.3]E7X=?MD^ ]8^
M($=U):KX<L=;1Y)[B/.^"&3_ %4TJX;,<;LXVMQ\IQ^"_P#P<N?\$I_V4_\
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M=6&);"V8KG:VS# @D$ ^W/\ @V3_ ."NGB#]O7X:?$#1OVN_VE=*UCXRZ_\
M%/4M2T+P895ADM-!CTO3 BV=JO$5I'(+@#&27\QF+.S,?U=K\*/^#,']B_\
M9T\1? #Q5^WAJ_@:67XH:!\2=5\+:5XA&K7*I#I3Z5I<S0&V$@@8[YY3O9"_
MS8W8 Q^Z] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?B5^S[\ OCMIG_!X3\2OC?J7P5\6V_@N[T:
MY6U\7S^&[I-+F8^'K*,!+LQ^4Q+JR8#?>4CJ*_;6BB@#\7O^"VGP'^./C_\
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M:_K?B1]"\0:OX=N;:RU)9/$HD0V\\B".8-'\X*$Y7D<<UV7_  1D_P""2O\
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M.UDFV4S*"9 H5LJ:_?:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/4%LO"VH>.-.LX[+4;EVVQ6YEMKF;R9I&(50X"%B%#[F4$ _3*BBB@ HHHH
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M'SHDLA'&@2QN#'Y@+ R-) RNS>2N/@'_ ((B_M@_M/\ P]_:?_:-_::^'O\
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MML>XEU&<Z)J-Q#DY4+;1V]TA7@[MPQG)_7__ ((,?\$]OV]OV/O _CKXN_\
M!1?]I+7?%?C[XDZQ]N;P<_BV?4-,\.J9)9I75-WV<7,\LI+F%=B)'&JL<L*^
M0/\ @L]_P;=_M!_MU?\ !6W0OVF_@CHVCI\-?&XT+_A;%]-K45K<V,D$JVMY
M+% 3NE)L88'&WEI-V<$Y(!X]^TY\ _%G[ W_  9\^$_!NG6TMAK'QB\7:/K_
M (Z,8*/)#J,IO8$?NI%M9Z=$P/=&!')%<?>Z[^V+^TA_P1(\(_\ !/;X6?\
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M/\&]7^"MEXC\'^-=);4_$VJQW$O]HVD*71A=+6)<))(5'RAR!N(R0.:^=?\
M@]MU#X;G]C;X-Z'?O:-XRF^)\TNAQ'!N/[-73IUO2@Z[/.?3]V.,[/:O)_\
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M[4FBZ NGZ3\/]1\;C3M6U6WMQ<7T-S:&V9KJUG2-[D[S'LD3;\\80E@#MO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y[XL
M^._^%7_#+7_B-_97V[^P])GO?L?G^5YWEH6V;]K;<XQG!QZ&@#H:*^)?^'Q?
M_5NG_EW?_<E'_#XO_JW3_P N[_[DH ^VJ*^)?^'Q?_5NG_EW?_<E'_#XO_JW
M3_R[O_N2@#[:HKXE_P"'Q?\ U;I_Y=W_ -R4?\/B_P#JW3_R[O\ [DH ^VJ*
M^)?^'Q?_ %;I_P"7=_\ <E=#\)O^"J'_  M#XFZ!\.?^%$_8?[<U:"R^V?\
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MX"_[&RQ_]'+0!^N5%%% !1110 4444 %%%% !1110 5Y%\<_^1SC_P"O!/\
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M_DYKP%_V-EC_ .CEH _7*BBB@ HHHH **** "BBB@ HHHH *\B^.?_(YQ_\
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M_P#P*MO_ (JO=** /"_^&L/C9_T8_P"._P#P*MO_ (JC_AK#XV?]&/\ CO\
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M/A?<&RC$FOJNI75C<:PLN-[033VTZ1 D*8H8W"Y<D@'W[1110 4444 %%%%
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MWXI\"3F,-!<:8UY;QP3Q9XV^?:RLI'1ER.171?\ !)3_ ).;_;;_ .SG9O\
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M %&* /8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cah-20240930_g2.jpg
<TEXT>
begin 644 cah-20240930_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^#OB?X9^$?B_2Y]6\1:!<:/=:Y%!I$DMKJT22)&?G214:1  TL$C#&0!T_\
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M5_Z[^)?_ %)-3H ^6_\ @V__ ."BW[:'A#]K_P"(_P#P1B_X*->,]0\0>,/
ML-W/X3US7-2:\NT:TD1;BQ-T^7NH7BD2Y@=\E8T<9VF-4_:FOP,T0^=_P?*W
MK>%.;=+1_P"V#!]W_DGJALX_Z:^7G_:]Z_?&66.&-III%1$4L[L<!0.I)[4
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M)_:0_9IT/Q!>ZII?@CX;>(-(T2\U*X,LYT^'6]$6TCD;NR6_E1G  ^3@ 8
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M9G(!W D$HFT _HM_9N_:E_9V_; ^&D7QA_9B^,6A>-O#<MP]O_:N@WHE2*=
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M_@XR_:,3]K">RE^)4OPS\07GCH:;('MX-2N-<T2::&,J2NR-Y#& I*@)A25
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M\?:5X7\,:+$DFK:]K=XMO:VB-(L:M)(Y 4%W51GNP'>O U_X+5_\$D'8*/\
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M?1RQ>)((K:[T][2:2*5;A(Y)$C.(_,&'(\MT;C.  >UT5\A_L(_\%L?V-/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:QV-I%90O(R0QJBM-,TCD 8!9F)9CZDDD]2:DH **** "BBB@ HHHH ****
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M?\J27PV_[&G_ -V_4:3_ (+??\JM_P"Q-_U^>$__ %&=1H ^H/\ @M1^V?\
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MLMB(_O@F^\/!?_']N/I0!^VE%%% !1110 4444 %%%% !1110 4444 %%%%
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MRQV4 >]4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G
MW[6/_)LOCW_L4[[_ -$M7H->??M8_P#)LOCW_L4[[_T2U 'Y&4444 %%%% !
M1110 5Z%^R=_R<UX"_[&RQ_]'+7GM>A?LG?\G-> O^QLL?\ T<M 'ZY4444
M%%%% !1110 4444 %%%% !7(>.OBK_PA>LKI']@_:=T"R>9]JV=21C&T^E=?
M7D7QS_Y'./\ Z\$_]">@#5_X:#_ZE'_R?_\ M='_  T'_P!2C_Y/_P#VNO-Z
M* /2/^&@_P#J4?\ R?\ _M='_#0?_4H_^3__ -KKS>B@#TC_ (:#_P"I1_\
M)_\ ^UT?\-!_]2C_ .3_ /\ :Z\WHH ](_X:#_ZE'_R?_P#M==?X%\7?\)IH
MS:O_ &?]FVSM'Y?F[^@!SG ]:\(KU[X&?\B9)_U_O_Z"E '94444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?
M?M8_\FR^/?\ L4[[_P!$M7H->??M8_\ )LOCW_L4[[_T2U 'Y&4444 %%%%
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M%.^_]$M0!^1E8/Q+^)_@#X.>"[WXB?$_Q5::+HNGH&N[^\<A$R0J@  EF)(
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M3?MA-X:LM%^#ZRR:??Z1?M<7GB*[*(BSR$L<9\J-V+!"2&^7+_)]HT4 <!\
M)/VAY-.\1_\ #1-OHT=R/%5T/#/]C$;6TC">09>3^]SYF?PKAOV%/V?OB+\
M;3XF0_$.VM(V\4_%#4]=TG[)="7=9SB/RRV/NM\IRO:O>** "O0OV3O^3FO
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MSG&1GU%?2M% 'Y8_\,2?&S_HE7CO_P )NV_^3:/^&)/C9_T2KQW_ .$W;?\
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04 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cah-20240930_g3.jpg
<TEXT>
begin 644 cah-20240930_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M96\"K\3OVD?C#X>\$>'GOX[)-:\3:G':6QN)%9DB#R$#>P1R!U.T^E>,V_\
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M&_!7PR$+2>&_AYXTAMF\2+'()C;M%I-W,C)<2*BW#32*/*!1$YX /V<HHHH
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M>.=%;():WD! P"0#Z,HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M3/\ @NC^U!JW[('_  2=^-?QH\-:BUIK(\)G1M#N8GQ)#=ZE-'I\<T?^W&;D
MRCT\O/:OE3_@GQX)\&_L+?\ !J[_ ,+"\2_"#0_&<5[\)]7\<>(_"_B*'-EK
M_P!M,ES'#<@ Y0VIMHCQRL8KIO\ @[GAU27_ ((S>)'T\-Y,?CG06OMO3ROM
M) S[>88_QQ6M\99;";_@U(232ROV?_AB_2!%M[ >'K88^OK[T >=_LZ?\%:;
M#]G[_@W%O_\ @I7\ OV-/ /@M?#^OO;V'PP\.-);:.C3>(H=/DD!0!E9A.TI
MP.7]C7AOQ-_X.GO^"BGB#]G32OVM?V8?^"8D=[\,=#L;*+XD?$'Q%9ZA+I::
MK((Q<VUF\+Q^7#%,XA\]S("Y&57*AO+/!W_*D#XK_P"QMC_]3>SKZW^#OAW1
M]/\ ^#.>\TVUL(DA;]G77;MHU0 &9Y;N=G^ID8MGUYH _0/_ ()O?MQ>"O\
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MUK]I3]L1_P#@H5^P=^V5KOP%^+-_$J^(+S28)C;ZC*(A"9TDMYHI;9WB54E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVH__ "/1_P /%_V-O^BQ?^6]J/\ \CU^7%% 'ZC_ /#Q?]C;_HL7_EO:C_\
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MWQO=1P3O''<Q7-MMF4,0'&6Z$#(^M0?\-8?&S_HQ_P =_P#@5;?_ !5>Z44
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M]KM/AA\:]&\(1>'[N#7;:+SFTG4K&W9K=!-&#Y$D9RSC!W9;RP#] **_.O\
MX*F_\%C_ !A^SW^T!X0_8^_9)\&ZGJOB:'XI>#]+^+_C.;0V?2O".G:K>VOE
M61EF7RY;V\@G78J;C'$SOD,OR?HI0 45^:/BKQW_ ,%<OVM?^"GO[3'[./[)
MO[>_A;X5^#/@M<>#XM-TS6?A19:W)<?VMH,5[(?.<HXQ,DQ^8MQ* ,!<5O\
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MW#+P"\A]!0!X=^UW\,_B9_P2K_X)=6OP!BU#QYXU^('[17Q.FF_:"^*OP_\
M#$^HZA;MJ8\[7=0M((5W*WV:(65J"$5=R2$HRX/+?\$Y_P!OS]F+6?\ @M;J
M'@+X&_LZ_%3PIX9UGX!>%O _@_1M8^'-S8_V.NGW-](K72N2;:U\K:B3-D.X
M*]:_1K]A;]DWXN?LD^!]:\)_%[]M'QY\:[O5=56[M-:\?>5Y^GQB)4-O%Y?&
MPD%^>[&M+PO^Q_X;\+_MR^+?VY+?QC?2ZKXL^'NE^$[C0G@06\$-E=7%PDZN
M/F+L;AE(/ "C% 'L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cah-20240930_g4.jpg
<TEXT>
begin 644 cah-20240930_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>A_"K7/$UFRKEHCI?B+P_?R,OU@@F4^SF@#])O\ @ZZ_:TUFV_X)D?#/P5\
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M:\4Z[XF_X,G+*+7-0EN?[+\=)8V;3.6*0+XJ9D3)[+O( [  #@"@#]P/"O\
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M6_@&U\/^'-2\9)\,5M!K/]L7][%?/L-W^Z*B\N"K%N?+7 Q@"@#]4OAS\1O
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MXM([J?PAX)LX9Y].@D&8Y+N2>6*.#>OS*FYI"I5M@5E8@'W/17R'_P $M_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA7YE?\'L>EZ=KD_[*FBZO>?9[2\\0^)X+JXR!Y4;G1E9LGT!)_"OUC_X)=?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEQ_P\7_;)_Z+%_Y;VG?_ "/1_P /%_VR?^BQ?^6]IW_R/0!^H]%?,G_!-O\
M:%^,'Q]TGQ=<_%KQ?_:SZ9<62V+?V?;P>4)%F+C]S&F[.Q>N<8XKZ;H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M *C_ -=$_P#1:USU '2?\+<^(?\ T,'_ )*0_P#Q%'_"W/B'_P!#!_Y*0_\
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M^@W%?9]?&'_!'K_D!>/?^OO3O_0;BOL^@ HHHH **** "BBB@ HHHH ****
M"BBB@#Q#XJ?\C_J/_71/_1:USU=#\5/^1_U'_KHG_HM:YZ@ HHHH **** "B
MBB@ KJ/@[_R/]I_USE_]%M7+UU'P=_Y'^T_ZYR_^BVH ]HHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"IK_P#R KW_ *])/_037XK5^U.O_P#("O?^O23_ -!-?BM0 4444 %%
M%% !1110 4444 ?<O_!'K_D!>/?^OO3O_0;BOL^OC#_@CU_R O'O_7WIW_H-
MQ7V?0 4444 %%%% !1110 4444 %%%% !1110!XA\5/^1_U'_KHG_HM:YZNA
M^*G_ "/^H_\ 71/_ $6M<]0 4444 %%%% !1110 5U'P=_Y'^T_ZYR_^BVKE
MZZCX._\ (_VG_7.7_P!%M0![11110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %37_ /D!7O\ UZ2?
M^@FOQ6K]J=?_ .0%>_\ 7I)_Z":_%:@ HHHH **** "BBB@ HHHH ^Y?^"/7
M_("\>_\ 7WIW_H-Q7V?7QA_P1Z_Y 7CW_K[T[_T&XK[/H **** "BBB@ HHH
MH **** "BBB@ HHHH \0^*G_ "/^H_\ 71/_ $6M<]70_%3_ )'_ %'_ *Z)
M_P"BUKGJ "BBB@ HHHH **** "NH^#O_ "/]I_USE_\ 1;5R]=1\'?\ D?[3
M_KG+_P"BVH ]HHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@"IK_ /R KW_KTD_]!-?BM7[4Z_\
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MBVKEZZCX._\ (_VG_7.7_P!%M0![11110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %37_ /D!7O\
MUZ2?^@FOQ6K]J=?_ .0%>_\ 7I)_Z":_%:@ HHHH **** "BBB@ HHHH ^Y?
M^"/7_("\>_\ 7WIW_H-Q7V?7QA_P1Z_Y 7CW_K[T[_T&XK[/H **** "BBB@
M HHHH **** "BBB@ HHHH \0^*G_ "/^H_\ 71/_ $6M<]70_%3_ )'_ %'_
M *Z)_P"BUKGJ "L3P[\./!'A/Q9X@\<^'?#L-KJWBJYM[CQ#?1EM][)! EO$
MSY. 5BC1!@#A?6MNB@ HHHH **** "NH^#O_ "/]I_USE_\ 1;5R]=1\'?\
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M5]GU\8?\$>O^0%X]_P"OO3O_ $&XK[/H **** "BBB@ HHHH **** "BBB@
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MY'^T_P"N<O\ Z+:N7KJ/@[_R/]I_USE_]%M0![11110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'EM_\ ML?LI:7?3Z9J
M'QRT.*XMIFBGB>5LHZDAE/R]00147_#<_P"R/_T7K0?^_P __P 37>2_#3X<
M3RM//\/]$=W8L[OI4)+$]23MY--_X5=\,_\ HG>A?^"B'_XF@#A?^&Y_V1_^
MB]:#_P!_G_\ B:/^&Y_V1_\ HO6@_P#?Y_\ XFNZ_P"%7?#/_HG>A?\ @HA_
M^)H_X5=\,_\ HG>A?^"B'_XF@#A?^&Y_V1_^B]:#_P!_G_\ B:/^&Y_V1_\
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M_P")KNO^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\ @HA_^)H X7_AN?\
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M\*N^&?\ T3O0O_!1#_\ $T <+_PW/^R/_P!%ZT'_ +_/_P#$T?\ #<_[(_\
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M+7(=&GNQ.]DMQ$L@B:0*H<KG&X*,^E 'I=%?)G_!1S_@I5\2_P!B7XQ?!_\
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M<1NQG SCI0!MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGPZTCPO:Z5I,+:CI>B1!;<Z@\:FZE&.&+R[V+=R<T >I4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
@% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cah-20240930_g5.jpg
<TEXT>
begin 644 cah-20240930_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAWQE;Z#/K=QX>UC68[>XBTZ&WEN9;I@Y 6)8()I"Q. L;'M7XL>%_P#@Y?\
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M !1110 4444 ,NKJVLK:2]O;A(884+RRRN%5% R6)/  '.:X+]FK]J;]G_\
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MQ)Z &OS%O_\ @[N_X)06/[3'_"A%G\<SZ NJ_P!GR?%&'1(#H:R;]OG@>?\
M:6M@?^6HASCD(5^:O9_@A_P5J_8@_P""I_[*'[1<_P /](\?6_A#X=^%=2T[
MQ]<7.GV4-S<V<UA>>:^GLEQ,DC&&"4HTFT;BF003@ ^J/V??VF_V>OVK_!$_
MQ)_9I^,WASQUH%MJ4FGW&L>&-4CN[>.Z1(W>$O&2 X26-BO4!U/>NYK\L_\
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M:EKO@OX#0>)O#WB_PYIXO]2\)>,+"&&YDLS(L9NH'@EECEB61XT;YE=3(N5
M8$@'VA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?B;_ ,'I=U<:A\%/V=O ]U(P
MTO5/B9>O?#.%W);11J3[[9Y?S->E_P#!Y3\/]=\4?\$D]#US0+-C9^%/C'H^
MHZH(E^6&V:QU*R5CCH/.NX%'NPJ;_@\4_9\U?XI_\$MM-^,OAZS=[GX7_$73
M]4OI8P28["Z26QD/'(_?SVASV"FON=_!OP8_X*G?\$X=,\/?%;3QJ?@[XT_#
M#3[N_6W<+)&MY:17"31-@A)H92DB$@[9(E)'&* /GK]G*_\ C?\ M@_\&ZOP
MWTO_ ()__%"V\._$2_\ @?X?T7PSXA75&M4TW4]/CMK2\0S1H[1E7M;F/A2>
MV.:_,3]G#XW?\%M?V.O^"YOP/_8/_;M_;J\0^*(_$.L6%[K&CZ=XLFOM.O+&
MX6X"QR&2*,D[H3E=N.G-;WA3_@DQ_P '/O\ P21UOQ!\'_\ @EU\9K;QE\-M
M7U*2YLI+'4]!5%+X4326.O';:7!4+O-NSJVU<NP''LG_  2E_P"#>7]O\?MW
MZ)_P5 _X*R?M%/?>-=!U(:EIWARVUH:KJ%W=+&T<0N[H P001AOE@MRX( 4-
M$!@@'EGA?]G'X3?M,?\ !YI\2/"WQI\":7XFT/0[7^VFT36K)+FTN)X?#=@D
M)EBD!60))*L@# C=&I[5I_\ !RS\*OA[JW_!1;]B/_@GS9>%-.\*?!S4O$5N
MD_A[P]:II]A"=4\06]O>LD<(5(R(\L" -IF<C&XY^M?@/_P2W_:]\!?\')OQ
M-_X*5^(_">DQ_"GQ/X;DL](U2/787NGE.F:?;@-; ^8H\RWE&2.@![UWO_!P
M+_P1J\1?\%6_@EX7\2_ OQE9^'?BY\,;^>]\&7]_.\%O?0S>69K.2:,%X7+P
MPR12X(1XR" )&=0#YX_X.S/V(_V3?"/_  2FTSXH>!O@QX6\*Z[\/O%FDV'A
M.ZT#1H+)ULYRT$M@/*5=T.TB79V: $8YSXK_ ,% _P!B[_@I)^VS^P[^PU_P
M5,_9,\/S>-?B+\,?A?HUWKFA2PPW-[/<1I:W5OJD5M<92]+R1,TL0#.V^,JC
MC=MJ>*?^"4G_  <E_P#!6KQ'X&_9W_X*M^.M*\(?"+P9JL5YJ6K0:KHLUQJA
M13$UPD.F/(UQ>&)G1'N!'&GFNV,EE;[&_P""R?\ P2<_;?\ B#'\%_CA_P $
ME?C3>>%_$'P,T^QTW2/AC=>)I;72+^TL75K%XHI&^RM/%@Q.MP LT)56<>4%
M< ^%_P!ES_@N-\,OC5_P40^&>C_\%M/^"7/AS0OBWI6J6&D>%_BDF@WNFWN@
M7)NE-I+=:;>ECM2Y(?SU<&$[F2/&0/3/^"S_ .QW_P %8OV,_P#@KS>_\%FO
M^"=_PB;XBV6L>'[2WU"RL] &LS:2\.GQ6$]O+8J?M!ADBMUE$]O@J7D#,G\=
ME_\ @E]_P7/_ ."OW[:/PA^+?_!7_P"'/@#X7> O@_J0O8]/\,7]E-<ZHAGM
MYYH8EM+N[.^=K:%&>65$B4,R(6)5_9/^"F'_  3V_P""S_PC_P""D,?_  4Q
M_P""3OQ17QS'JFF"TU?X2^-/%86SLF,*0S1P0WMQ%;FUE\J.8A)8I(YMQ7((
MP >5?\$./^"M_P"Q]^V1_P %+-0TG]HC_@G9X9^%7[4GBZSN@/'VB0SA-7G@
ML\W-LUO<DRZ?,;:!F.&?S?+;>P<C?^X%?CS_ ,$V/^"47_!3SXV?\%78_P#@
ML-_P5STGPEX.\2>'M*>T\+^!?"EU;3F28V4EE&TAM9IXT@CAFE<;IY97D*YV
MJN#^PU '\EFA? C_ (7=^R[_ ,%-=2M++S[_ ,"?$[P[XHL%VYV^1X@UN"X?
MVVVMS<G\,=Z]"_98^-FK?\%4OVW]?^/^O)-=P? ?_@G]J=E-<72G:]];>%7T
M^Y;![F_U6\D7UV;ATS7Z)?\ !,S_ ((G_M7_  =N/V\?"/[3?A+1M/T+]H_3
MKVP\&3VFN0W32QSOK/[R18R3"5%] PW<@Y[K7%_\$0O^"#7[9O[#_P"S#^U=
MH_[1/@O0K/QQ\5OAE+X7\!6MAXA@N4(>RU!9!)*A*QAYYK4?,1CRB>E '(?\
M$,/'O[&?PU_X-E?BKXN_X* >'&UOX46WQ-U+_A)=!B,GG:H^-*^S6L(CDC8R
MO<B$+\Z '!9E4,P^<_V^/VL?CE^T5_P1>U7P1^R7_P $7M.^#_[)_AJ73;C3
MOB+XKUC[5J(0ZO D-Q8&<Q2R237,HADE7[7E)9@TG)9?LO\ 9U_X(#?M=ZC_
M ,&]?Q!_X)J?&-]#\+_$S4_B/-XI\+8UE+JQD>+["\,<TL&[:LOD31DX)0LK
MD$#!\8N_^"8'_!S!^U=_P3EA_P"":WQW\._#OP%\.?AUHT,?AZW?6+&?5/&7
MV)U:PL))[2ZFBCAC*HPD=8"/*0N)&% '!_\ !6RXN+G_ (-0/V,Y+J5G8>,M
M)0%C_"NE:VJC\% 'X5^@/QT_96^!/[$G_!NIXJ\=_LZ_!+PSX>\9K^RO'I>I
M^+]'T*"#5;Z*_L[8W[S72*)9#)(S3-N8@,H(QM&/&?VU?^"-/_!1']HS_@@!
M^SO^P-X;^&6A)\4/AGXVCN?$FES>*[5;5+&"#5X(Y8[C=L<LMS;$J.078?PY
MK]0?$OPE^&4'_!/"Z^!O[66H:?I7A&+X/'1/B)>7FH1PVUE8KI?D7LK3M\D:
MQH)&\T\+MW=J /S[_P"#8/\ 8[_94^)/_!#,6?CWX7>']87XHZKX@A^(DM_8
MQ227*1W4UI%$\C LJQV\4;H,@(SEUPS$GX^_X-A[>UM/^"8O[?5K970GAB\'
M2I#.!CS%&BZN WXCFK_[#G_!(G_@L/X-TWQA^R9^PI_P5$^'%_\ LH^,M>G3
MQ-\0_ OBO3]4'V.2-%G\E$26:SOGM?+#QPS1H25S,5P]:7_!I[\*?$_Q/_X)
M\_MJ?#CP#;+<W?BK3UT+P^T\PC2>ZETG4HHU9S@*,S19)X ;- &%_P $K?\
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M8(K=65 -FU@  : /V7HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ)\$_$3Q1\*;+4O&GA'Q/\.M:?5=*NDM=3O;UEM;AXHFF;[#/=V^ HPYVC<
M,_"/P1^/NM_\%R_VD_\ @GO^P;KAFU'2/A/X2W?$N&9"4D^P74GGB4GA_-TS
M2; !SGY[YEZDY /UE_X*2?\ !>#QW_P3T_99^"R:C^SK;^)OVC?C5H%C=Z9\
M+M-GG:VTN>:.+S%DV*9YBL\RV\<2 --(KX9=AKB_^"=7_!P)^U#XU_;?TC_@
MGA_P5>_8O3X+^/\ QE9"X\#:C9P75M:WSLKM'!)#=/(0)?+D1)DE93*GE%0Q
MR/D;_@OGI?[36I?\',?P"L/V?O&GA?P[XUN_!.@Q?#/6O':,VD6UX;_5%C\T
M+%,3FX+JH$;'S'3CH:ZW]HW_ ()Q?\%??CO_ ,%$/V>OB+_P4 _X*)?L@V_C
MGX>>*=.UCP=X>L/%ESI.LZG9QZI;S.MM;'2XFNR9(-J#IO8KD;C0!]&?M]?\
M''7Q'_8@_P""H'B/]@/3?V1&\?0VOAZQ;PC;^&[FX?6==UJ]LX9;6Q6-4951
MIIMK.%9@BDJK-A3SG_!/S_@XJ_;#\>?\%*-,_P""<?\ P4P_8DT_X4Z]XN)C
M\,2Z='=V\]G.T#SVZ7,=S)()XYE1D6:(J!(5!4@L4\I\7:/IVL?\'O'A_P#M
M&U286OA;[1"LB@@2+X+N-K8/<$Y![$ ]JE_X+(6\-O\ \'7O[&MU!&$DF\-^
M&?-91@MC7]9'/KQQ]* /LZ?_ (+(?$N'_@OG#_P1\'P:T(^&Y="-^?&/V^;[
M<&_L)M3V^5_J\;QY?^[SUH_;7_X+'_$O]EC_ (+)_ __ ()C:!\&M"U70OBO
MH>EWVH>)[R_F2[L&NM0U"U98XU^1@JV2L,]W/H*^,=:O+?3O^#WK2UO)1']K
M\(F.W+G&]O\ A"I3@>OW6_*J_P#P5J\0Z3K/_!V[^R5IFFWT4TVD>&O#5KJ$
M<;@F"9M6UF<(P'0^7-$V#V<'O0!].?\ !6O_ (+V?&/]EC]KG1O^"<G_  3I
M_9;3XQ?&R]L8[S6;&YCN)K;2UDB,\=OY%LR22RFWQ<.QDCCBB9"2VYO+ZK_@
MC3_P7$\6_M__ !>\;?L7?M??L[R?"3X[^ +9KO5/#)\Y+?4+5'1)7CCG_>P2
M1M+%F)F<,DJR([+N"_F'X5\+?\%&O$__  ="_M*Z%^PC\6?ASX.^*<B:N]KJ
M'Q6@EDM+C2-^G,L%N([6Y;SS!]G=?D \F.7Y@.#]/_L)_P#!/?\ ;]TW_@OQ
MIG[9W[:/[=O[+_BCQ_HNC75A\1O GPY\831^(9+:309(+,G3&L(,8#V<I9RN
M8DW G ! -7]GG7Y/V'O^#N;XH_ 32)3:^%_VDO ZZW%IX.V-M32R^WM<'L7\
MZTU4#_KZ8<FOV:K\2_\ @H;%+??\'A7[*\'AO)NH_AK:-?>7UPI\1/)G_MA^
ME?MI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5\#?\ !<;_ ((G:I_P6+C^%4>F_M'6_P /
MO^%:WVJW#F?PJVI_VA]L^Q848N8/*V?9#S\V?,[8Y^^:* "O%_\ @H#^PK\%
M/^"CO[+'B/\ 90^/%O<KH^NI'+::GIY5;K2KV)M\%W 6! =&[$896=&RK$5[
M110!^'_@G_@T7^./B?6/"?PD_:R_X*J>*_'/P.\#ZC]HT+X?6UC>0A8LG,,$
M<]Y+!IY925+Q*Y 9@H&=P^Q/^"MW_!#G3_\ @I7J/[/T?P_^-UA\--'^ ]W=
MG3]'C\)F_CN[:4Z;Y5O'MN8?LZQIIP0</D2#@;>?ORB@#D/C_P# KX9_M.?!
M/Q3^SW\9/#ZZIX7\8Z)<:5K=D6VL\$J%24;JDBDAD<<JRJPY K\4)?\ @S?^
M-5I>W?P5T'_@JKX@MO@C>ZX-0N?![:%<EY-K J9+9;Q;22X 55^T%!R WEC&
MROW>HH ^,OVIO^"&W['/[2G_  34\._\$S;2TOO#7AKP/;0/X"\0VBI/?:1J
M$2R WK[MJSM,9IS.AVB3SW(*-L9/B;X*_P#!IW\5O$7Q9\#WO_!0W_@I/XD^
M,7PV^&DB+X4^'T]M>>4ULC(5M ;J[F6RMV$<:R10J2R*$#IM5A^TU% 'PC_P
M4G_X(OW_ .W]^W+^S]^V+IO[0=MX2@^!VLV-\_AMO"IO#JZV^IP7WEK,+F(6
M^1#Y>=CXW9P<8H_X+B?\$8=3_P""Q/A?X;>'--_:'@^'Y^'^LWU^\T_A9M3^
MW"X2!=@ N8/+V^3G.6SNZ#'/W=10!\ _\%V/^"(DG_!7_P ._#W7/ _QV'P^
M\:?#:^O7T?5)],>YM[JWNO(,D;^7(CQ2(]M$Z2*3CYP5.X,OTC_P3G_9=^)7
M[&'[&?@O]FOXP?'F]^)OB3PY%>G5?&^HPRI/J4EQ?7%V-WG33.WEK.(@S.2P
MB#87.T>VT4 ?&_\ P6-_X(Q? 7_@L%\(M(\*^/O$]UX1\9^%)II?!WCG3K);
MF2R\X*)K>>!F3[1;OL1BF]&5D4JZ_,&^-_V/?^#4K7/#O[2GAC]H?_@H]^W3
MK?QR@\"R0-X6\*7L%T]N_D/O@CN)KRXF?[,C -]EC548@!F*[D;]D** /A/_
M (+*_P#!&34_^"L/C_X'>-]/_:'@\"CX.ZWJ.H2VTWA=M1.JBZETV38&%S#Y
M.W[ 1G#Y\WH-O/W9110!\#_\%9/^")^J?\%-OVI/@C^T?8_M&V_@Q/@_?BYD
MTB7PJU^=5Q?6]UM$HN8O)_U&W.U_O9[8/U=^V%^RS\,?VV?V9/&G[*_QBL/.
M\/\ C70Y;"ZD5 TEI(<-#=1YX\V&98YD)XWQKGBO2J* /SE_X)F_\$$;[]C#
M]C?XL_L ?M*?M+VWQ>^%7Q0!D30X_"3Z3+H\\D7EW$L,INY^7V6TBX"^7+;A
MQDL:^33_ ,&A'[0XL?\ AFU/^"N/BS_AGTZ__:;> #I-UUW[\_9?MGV,S]OM
M'EXW?/Y7\%?N910!PGP"_9M^$'[-/[/7AO\ 9<^%/A6.U\&>%O#\>CZ=IEQB
M7S+94VL921^\>0EFD8CYV=B>M?"G_!'3_@W8\ _\$F/VJ?B!^TO8_'-?&;>)
M-)FTCPCIDGAHV;Z!82W:SNCRFXE^T2%8K>/S L?"/QA\#])J* /B+_@LY_P1
M.^%7_!7/P5X9U)_B5>_#[XD>!9Y)/!_CK3K'[08HW97>VGB$D;21[T1T975X
MG!920SJ_@7_!/_\ X-M/''P>_;.T3]O+_@HG^W1X@^/WC?P<L?\ PAD.L+=2
M)9S0[OL\\UQ>7$TLODEV>.)0BI+A\L>*_5JB@#X2OO\ @C'J=Y_P7)L_^"QP
M_:'@6VM-%-A_PK[_ (1=B[$Z(^F;_MOVG Y?S<>3VVY_BI/VT?\ @C#J?[6W
M_!6;X*_\%-[?]H>#08/A'INF6LG@Q_"S7+ZI]DU"]O"PNA<H(=WVL)CRGQY>
M><X'W=10!^9?_!8?_@WIU7_@H?\ M1>%_P!N#]F;]J^_^#WQ0T*QMK*\U6UL
MIG%P+=W-O=PS6\T4UM<QJY3<I8.JQCY"I+<1\%?^#7.;X/\ [;'P?_;CU3]O
M/Q%XT\7^"-8BUKXB:MXST6:^OO&.I)*Q\P7$EZ6M8Q#Y42JPG8>66+MNPOZU
MT4 ?FU_P5H_X-](?V[OVD]%_;K_90_:DUCX(?&G2K6&WO/$ND03,FI+$ABAF
M\RWFBFMKA(CY7FHS!XD1"G&ZM3_@C[_P0/T?_@G)\9/%/[7_ .T%^T=JOQE^
M-7BZVEMKOQ?J]M(B64,KJ\Y0S2RRSSRE$#W$C [!L55!<O\ HC10!^./[)OA
MJ3]MK_@[%^.'[36G1FY\+?LZ>#8_#-C?J-RQZO):+8/ 3T!WOK/_ 'Y]^/V.
MKP7]@C_@G5\ _P#@G9X1\7>&_@MJ'B'5[[QYXRNO$_B_Q-XNOH;K4M3U"?&Y
MI)8H8EV+ABJ!  9'/)8D^]4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %/Q'_R+U_\ ]>4O_H!K\%Z_>CQ'_P B]?\
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M444 %%%% !1110 4444 %%%% !1110!3\1_\B]?_ /7E+_Z :_!>OWH\1_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6=/_ .N4_P#Z*:@#Z4HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"GXC_Y%Z_\ ^O*7_P! -?@O
M7[T>(_\ D7K_ /Z\I?\ T U^"] !1110 4444 %%%% !1110!^@__!$'_D7O
MB-_U^Z9_Z!<U]VU\)?\ !$'_ )%[XC?]?NF?^@7-?=M !1110 4444 %%%%
M!1110 4444 %%%% 'S#\=_\ DK.L?]=8_P#T4E<C77?'?_DK.L?]=8__ $4E
M<C0 4444 %%%% !1110 5W'[.G_)6=/_ .N4_P#Z*:N'KN/V=/\ DK.G_P#7
M*?\ ]%-0!]*4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!3\1_\B]?_ /7E+_Z :_!>OWH\1_\
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M ,30!^)W_"I?%_\ S\Z#_P"%7IW_ ,?H_P"%2^+_ /GYT'_PJ]._^/U^V/\
MPJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 30!^)W_"I?%__ #\Z
M#_X5>G?_ !^C_A4OB_\ Y^=!_P#"KT[_ ./U^V/_  J[X9_]$[T+_P %$/\
M\31_PJ[X9_\ 1.]"_P#!1#_\30!^)W_"I?%__/SH/_A5Z=_\?H_X5+XO_P"?
MG0?_  J]._\ C]?MC_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\
M\30!\)?\$L/B=\-/V<-&\:6GQG^(F@Z-)JUS8OIZ_P!L07'FB-9PY_<,^W&]
M>N,YX[U]9_\ #<_[(_\ T7K0?^_S_P#Q-=U_PJ[X9_\ 1.]"_P#!1#_\31_P
MJ[X9_P#1.]"_\%$/_P 30!PO_#<_[(__ $7K0?\ O\__ ,31_P -S_LC_P#1
M>M!_[_/_ /$UW7_"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !-
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M'J*YW_A<GPE_Z*9H/_@UB_\ BJ^T_P#A5WPS_P"B=Z%_X*(?_B:/^%7?#/\
MZ)WH7_@HA_\ B: /BS_A<GPE_P"BF:#_ .#6+_XJC_A<GPE_Z*9H/_@UB_\
MBJ^T_P#A5WPS_P"B=Z%_X*(?_B:/^%7?#/\ Z)WH7_@HA_\ B: /BS_A<GPE
M_P"BF:#_ .#6+_XJC_A<GPE_Z*9H/_@UB_\ BJ^T_P#A5WPS_P"B=Z%_X*(?
M_B:/^%7?#/\ Z)WH7_@HA_\ B: /BS_A<GPE_P"BF:#_ .#6+_XJC_A<GPE_
MZ*9H/_@UB_\ BJ^T_P#A5WPS_P"B=Z%_X*(?_B:/^%7?#/\ Z)WH7_@HA_\
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MB_\ 9^\!^,M8@TK0?B6_Q TWQ)IMG=SG%NFJBS1&TM7)"[I-P5C\V &90#]
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MO;:Y<[0I@DCD!<A054/@*PKP;1/^"V_A/5OV,]%_;"7]E[QA<+\2?B1-X3^
MG@72[F.;6?'P\R1+:^6.1(UL(91#/*QD9A'%&'W-O0, ?<E%?+/[&O\ P4C\
M3_'SX_:Y^R!^T[^R1XG^!OQ:TCPS'XFL_">OZ[9:M:ZSHK3"!KRSO[)C#-Y<
MS(DB<%"Z\MA]OC/@_P#X+B?'KXO7NH:S^SW_ ,$@_C/X[\&V_BG4M&TWQQHF
MIZ>+'4OL5]-9RW$8=@VSS(7X/(P1VH _0RBBB@ HHHH **** "BBB@ HHHH
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M'K);;3]+LHK2QMT)Q%#&@1$&>P50/PJ[0 4444 %%%% !1110 4444 %%%%
M!7P9_P '(EQ<S_\ !,#4_"-U<R0:%XE^)'A#2/%LT;E-NES:Y:><&8?=5BJ*
M3W#$=Z^\Z\Q_;._91^&O[<?[+?C;]E#XN+,-!\:Z*]C<7-MCSK.4,LD%U'GC
MS(9XXIESQNC&01D4 >D:?I]AI-A!I6EV45M:VT*Q6]M!&$CBC4 *BJ.%4
M#@ 5^:'_  2+_9C^"_[3/[&7[4?[%7Q7\+MJOPDTO]LKQIHWA_0+:]EMH'T:
MSU.QOH;5'A96$'VD2!E0@.I=3PQKB_C+\"O^#F+Q=X6\"?L[^$_$?@O3M?\
MA[K*'2/VC?#WQ+:QL]<LU00YUO0IK6=KQWAY= I03?.N< GZH_X(>? [XE?L
MP?L*V7[-_P 9O@+K7@KQAX.\2:A;>*]2U;6X-2B\7ZC-(+N?7;6ZB(:6WN&N
M/E$J))'Y9B8,8BQ .1_X(R>#O"7P\^.'[9/@3P%X9L-%T31_VD&L])TC2[1(
M+:SMX]!TM8XHHT 5$50 %   %-_X.:'N8_\ @B7\9)+*%9)EO?"ABC9L!F_X
M2K2, GMD]Z]9_8&_9<^*_P"SS\:_VEO'/Q(M+&*P^*/QLD\3^%&M+T2M)8-I
MEE;!I5 _=OYD$GRGM@]ZJ?\ !9_]E#XO?MO_ /!-OX@_LQ? BSL+CQ5XCO-
MDTR'4[X6T#+::[I][-ND((7$-M*1ZD =Z .4_9__ &B?^"W'BOXR^'O#O[1'
M_!.?X9>$_!-W?A/$?B/1_B\E_=6%OM),D=N(QYK9"C;GO7D/_!=?2OBM^PUX
MY\&_\%H?V2](L+CQKX2LF\ ^/= OIQ#;^)=&U63R=/\ ./\ $UKJ<EM(HX)#
MG+;8P*_2ROEO_@L?^R?\7OVU_P!A#6_V?_@;9V$_B*_\4^'+^WBU*^%O$8;/
M6;.[G)<@@$10N0.YP.] $_[$O_!-7X7?L_\ [!<?[(GQUT;3O']YXP^T:O\
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5** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964414736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Oct. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardinal Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000721371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-0958666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Cardinal Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">43017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">757-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares (without par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,010,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241965076720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 52,277<span></span>
</td>
<td class="nump">$ 54,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods and Services Sold</a></td>
<td class="nump">50,375<span></span>
</td>
<td class="nump">52,907<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,902<span></span>
</td>
<td class="nump">1,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Distribution, selling, general and administrative expenses</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and employee severance</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Amortizationandotheracquisitionrelatedcosts', window );">Amortization and other acquisition-related costs</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation (recoveries)/charges, net</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings/(loss)</a></td>
<td class="nump">568<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/expense, net</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings/(loss) before income taxes</a></td>
<td class="nump">541<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for/(benefit from) income taxes</a></td>
<td class="nump">124<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">417<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings/(loss) attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 416<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings/(loss) per common share attributable to Cardinal Health, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in shares)</a></td>
<td class="nump">$ 1.71<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in shares)</a></td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share</a></td>
<td class="nump">$ 0.5056<span></span>
</td>
<td class="nump">$ 0.5006<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Amortizationandotheracquisitionrelatedcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Amortizationandotheracquisitionrelatedcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964923248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 417<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net unrealized gain/(loss) on derivative instruments, net of tax</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income/(loss)</a></td>
<td class="nump">429<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 428<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241969020048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 2,867<span></span>
</td>
<td class="nump">$ 5,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">11,781<span></span>
</td>
<td class="nump">12,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">15,619<span></span>
</td>
<td class="nump">14,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">2,591<span></span>
</td>
<td class="nump">2,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets held for sale</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">32,905<span></span>
</td>
<td class="nump">34,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,535<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangibles, net</a></td>
<td class="nump">6,388<span></span>
</td>
<td class="nump">6,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,059<span></span>
</td>
<td class="nump">45,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable, Current</a></td>
<td class="nump">30,365<span></span>
</td>
<td class="nump">31,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations and other short-term borrowings</a></td>
<td class="nump">940<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">3,373<span></span>
</td>
<td class="nump">3,447<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">34,678<span></span>
</td>
<td class="nump">35,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="nump">4,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">$ 7,433<span></span>
</td>
<td class="nump">$ 8,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value, Issued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">$ 2,827<span></span>
</td>
<td class="nump">$ 2,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings/(accumulated deficit)</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Value</a></td>
<td class="num">$ (5,963)<span></span>
</td>
<td class="num">$ (5,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Shares</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (155)<span></span>
</td>
<td class="num">$ (167)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Cardinal Health, Inc. shareholders' deficit</a></td>
<td class="num">(3,277)<span></span>
</td>
<td class="num">(3,213)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders' equity</a></td>
<td class="num">(3,276)<span></span>
</td>
<td class="num">(3,212)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; deficit</a></td>
<td class="nump">$ 43,059<span></span>
</td>
<td class="nump">$ 45,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964180320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Retained Earnings/(Accumulated Deficit)</div></th>
<th class="th"><div>Treasury Shares</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2023</a></td>
<td class="num">$ (2,957)<span></span>
</td>
<td class="nump">$ 2,746<span></span>
</td>
<td class="num">$ (642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (151)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,911)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Employee stock plans activity, net of shares withheld for employee taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee stock plans activity, net of shares withheld for employee taxes</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(500)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Share repurchase program activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Share repurchase program activity</a></td>
<td class="num">(505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2023</a></td>
<td class="num">$ (3,607)<span></span>
</td>
<td class="nump">$ 2,728<span></span>
</td>
<td class="num">(780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury, balance at end of period (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2024</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2024</a></td>
<td class="num">$ (3,212)<span></span>
</td>
<td class="nump">$ 2,917<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(167)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2024</a></td>
<td class="num">(83,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2024</a></td>
<td class="num">$ (5,677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings</a></td>
<td class="nump">417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Employee stock plans activity, net of shares withheld for employee taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee stock plans activity, net of shares withheld for employee taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(375)<span></span>
</td>
<td class="num">$ (75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Share repurchase program activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Share repurchase program activity</a></td>
<td class="num">(378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Sep. 30, 2024</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2024</a></td>
<td class="num">$ (3,276)<span></span>
</td>
<td class="nump">$ 2,827<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (155)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury, balance at end of period (in shares) at Sep. 30, 2024</a></td>
<td class="num">(85,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Sep. 30, 2024</a></td>
<td class="num">$ (5,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241962729120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 417<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (Loss) on Sale of Investments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Decrease in trade receivables</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(678)<span></span>
</td>
<td class="num">(1,073)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase/(decrease) in accounts payable</a></td>
<td class="num">(1,394)<span></span>
</td>
<td class="nump">1,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other accrued liabilities and operating items, net</a></td>
<td class="num">(508)<span></span>
</td>
<td class="num">(959)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by/(used in) operating activities</a></td>
<td class="num">(1,647)<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestitures, net of cash sold</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Proceeds from net investment hedge terminations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Reduction of long-term obligations</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation', window );">Net tax withholding from share-based compensation</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends on common shares</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(375)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(540)<span></span>
</td>
<td class="num">(666)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates changes on cash and equivalents</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and equivalents</a></td>
<td class="num">(2,266)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents at beginning of period</a></td>
<td class="nump">5,133<span></span>
</td>
<td class="nump">4,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents at end of period</a></td>
<td class="nump">$ 2,867<span></span>
</td>
<td class="nump">$ 3,870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Netproceedstaxwithholdingsfromsharebasedcompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963965152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2025 and 2024 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2025 and June 30, 2024, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments, and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2025 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2025. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the "2024 Form 10-K"). </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revision of Prior Period Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed in the 2024 Form 10-K, we revised our prior period financial statements to correct for an accounting error related to the at-Home Solutions operating segment that was not </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material, individually or in the aggregate, to our previously issued Consolidated Financial Statements, as well as other unrelated immaterial errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. See Note 1 and Note 16 to the "Consolidated Financial Statements" in the 2024 Form 10-K for additional information.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Updated Segment Reporting Structure</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. The remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics, are not significant enough to require separate reportable disclosures and are included in Other. The Pharma reportable segment consists of all businesses formerly within our Pharmaceutical segment, excluding Nuclear and Precision Health Solutions. The GMPD reportable segment consists of all businesses formerly within our Medical segment, excluding at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i088c97dfd3044fc38835caa8c41eddc8_121" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for segment results under the new reporting structure.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expired at the end of June 2024, would not be renewed. Sales to OptumRx generated 17 percent of our consolidated revenue in fiscal 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards And Disclosure Rules Not Yet Adopted </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the FASB on our consolidated financial statements as well as material updates to previous assessments, if any, from the 2024 Form 10-K.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in the 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Disclosure</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in the 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Climate-Related Disclosures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the SEC issued final rules on climate-related disclosures that will require annual disclosure of material climate-related risks and material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the rules require disclosure in the notes to the financial statements of the effects of severe weather events and other natural conditions, subject to certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates. These rules also require disclosure of climate risk oversight practices of the Board of Directors and management, and the disclosure of governance, risk management, and strategy related to material climate-related risks. In April 2024, the SEC voluntarily stayed the new rules pending the completion of judicial review. We are currently evaluating the impact of adoption of these final rules on our disclosures.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the three months ended September 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963129056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Acquisitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2024, we announced that we have entered into a definitive agreement to acquire Integrated Oncology Network ("ION"), a physician-led independent community oncology network, for a purchase price of $1.1&#160;billion in cash, subject to certain adjustments. ION includes more than 50 practice sites in 10 states representing more than 100 providers. ION supports a complete continuum of care across its member sites including medical oncology, radiation oncology, urology diagnostic testing and other ancillary services. This transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash. Specialty Networks creates clinical and economic value for providers and partners across multiple specialty group purchasing organizations ("GPOs"): UroGPO, Gastrologix and GastroGPO, and United Rheumatology. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the purchase price for the acquisition of Specialty Networks is not yet finalized and is subject to adjustment as we complete the valuation analysis of the acquisition. The pro forma results of operations and the results of operations for Specialty Networks have not been separately disclosed because the effects were not significant compared to the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241962400816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 5, 2023, we signed a definitive agreement to contribute the Outcomes&#8482; business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $53&#160;million during the three months ended September 30, 2023, which was included in <span style="-sec-ix-hidden:f-281">impairments and (gain)/loss on disposal of assets, net</span> in our condensed consolidated statements of earnings/(loss). This gain includes our initial recognition of an equity method investment in the combined entity for $147&#160;million, which was recorded in other assets in our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the divestiture of the Outcomes&#8482; business did not meet the criteria to be classified as discontinued operations. The Outcomes&#8482; business operated within our former Pharmaceutical segment and its results before the divestiture are reflected within the Pharma segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963309456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Restructuring and Employee Severance </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs, and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional project management, and costs associated with vacant facilities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2024, restructuring and employee severance costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and certain initiatives to rationalize our manufacturing operations. During the three months ended September&#160;30, 2023, restructuring and employee severance costs were primarily related to certain </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">projects resulting from reviews of our strategy, portfolio, capital-allocation framework, and operations and the implementation of certain enterprise-wide cost-savings measures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2024</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963978208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Goodwill and Other Intangible Assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2024</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,555&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,725</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,555</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,170</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,725</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight&#174; Logistics.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, we performed interim quantitative goodwill impairment testing for GMPD. This quantitative testing resulted in the carrying amount of GMPD exceeding the fair value, resulting in a pre-tax impairment charge of $585&#160;million. GMPD goodwill was fully impaired during the third quarter of fiscal 2024. </span></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,651</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,495</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,156</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">562</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,047</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">699</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,260</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,609</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,651</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,272</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,609</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,663</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,236&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,523&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,523&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $68 million and $64 million for the three months ended September&#160;30, 2024 and 2023, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2025 through 2029 is as follows: $200&#160;million, $246 million, $219 million, $191 million, and $186&#160;million.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964548768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Obligations and Other Short-Term Borrowings</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Long-Term Obligations and Other Short-Term Borrowings </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $5.2 billion and $5.1 billion at September 30, 2024 and June 30, 2024, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $30.4 billion and $31.8 billion at September 30, 2024 and June 30, 2024, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity at September 30, 2024 include a&#160;$2.0&#160;billion&#160;commercial paper program, backed by a $2.0&#160;billion&#160;revolving credit facility, which expires in February 2028. We also have a&#160;$1.0 billion committed receivables sales facility through September 2025. At September 30, 2024, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, we entered into a new 364-Day Revolving Credit Facility, under which we have access to $1.0&#160;billion of committed liquidity through October 2025. We also increased our Commercial Paper program from $2.0&#160;billion to $3.0&#160;billion. </span></div>Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of September 30, 2024, we were in compliance with this financial covenant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963978208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingent Liabilities and Litigation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Commitments, Contingent Liabilities and Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors that was assessed based on each </span></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturer or distributor's share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new opioid excise tax and limited the OSA to two years (2017 and 2018).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Since fiscal 2021, we have made certain payments to New York State for our portion of the assessment in 2017 and 2018. However, we, and other distributors, challenged the OSA as unconstitutional. In May 2024, the New York Appellate Division held that the 2017 assessment was unconstitutionally retroactive, directing a refund of assessments paid for calendar year 2017, but upheld the 2018 assessment. Both parties have appealed the decision of the New York Appellate Division to the New York Court of Appeals, the state's highest court. We have not recorded a receivable for any possible recoveries related to these assessments.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation, and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we distribute, source, manufacture, or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims, and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier, or other industry participants. Internal investigations, subpoenas, or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate </span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation, and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net, in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, other pharmaceutical wholesalers, and other participants in the pharmaceutical supply chain have been named as defendants in lawsuits related to the distribution of opioid pain medications. These lawsuits seek equitable relief and monetary damages based on a variety of legal theories, including various common law claims, such as public nuisance, negligence, unjust enrichment, personal injury, as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act, and various other statutes. Plaintiffs in these lawsuits include governmental entities, as well as private parties, such as unions and other health and welfare funds, hospital systems and other healthcare providers, businesses, and individuals.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information, subpoenas, and other requests from other DOJ offices. These investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, as of September 30, 2024, we have $5.0&#160;billion accrued for these matters, of which $789&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During fiscal 2024, we recognized expense of $340&#160;million </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in connection with opioid-related matters, including agreements in principle with counsel representing classes of third-party payors and acute care hospitals, and settlements with the City of Baltimore and the State of Alabama. This expense was partially offset by a benefit of $105&#160;million related to prepayments at a prenegotiated discount of certain future payments totaling $344&#160;million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of the agreements described below is an admission of liability or wrongdoing. Please see below for additional description of these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we along with two other national distributors (collectively, the "Distributors") entered into the National Opioid Settlement Agreement to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. In addition to the Distributors, parties to the National Opioid Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions in settling states (by population as calculated under the National Opioid Settlement Agreement) that had brought opioid-related suits against us have chosen to join the National Opioid Settlement Agreement or have had their claims addressed by state legislation (together with settling states and territories that joined the National Opioid Settlement Agreement, the "Settling Governmental Entities").</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal 2024, we recognized a $22&#160;million charge in litigation (recoveries)/charge, net in the condensed consolidated statements of earnings/(loss) related to an agreement with the Alabama Attorney General under which we agreed to pay approximately $123&#160;million to the State of Alabama over a period of ten years to resolve opioid-related claims brought by the State and its political subdivisions (the "Alabama Settlement"). Including the National Opioid Settlement Agreement, the Alabama Settlement and a prior settlement with the State of West Virginia, we have now resolved the opioid-related claims of all 50 states and the District of Columbia. Additionally, in August 2024, we entered into a settlement agreement with the City of Baltimore to resolve its opioid-related claims. Under this agreement, we agreed to pay $153&#160;million. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the National Opioid Settlement Agreement, through October 2024, we have paid the Settling Governmental Entities approximately $1.9&#160;billion. We expect to pay Settling Governmental Entities additional amounts up to $4.4&#160;billion </span></div></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through 2038. The National Opioid Settlement Agreement also includes injunctive relief terms related to Distributors&#8217; controlled substance anti-diversion programs. A monitor is overseeing compliance with these provisions until 2027. In addition, the Distributors have engaged a third-party vendor to act as a clearinghouse for data aggregation and reporting, which Distributors will fund for 10 years. As a result of the National Opioid Settlement Agreement, the vast majority of lawsuits brought against us by political subdivisions have been dismissed. We continue to engage in resolution discussions with certain nonparticipating political subdivisions. We intend to defend ourselves vigorously against all remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Settlements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the National Opioid Settlement Agreement. In July 2022, a judgment in favor of the Distributors was entered in a bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington. Plaintiffs have appealed this decision to the Fourth Circuit Court of Appeals. In July 2022, we entered into separate agreements to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions and Native American Tribes for approximately $124&#160;million over 11-years and $136&#160;million over five years, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The National Opioid Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses, and individuals alleging personal injury. There were approximately 367 lawsuits brought by private plaintiffs pending as of October 28, 2024. Of these, 98 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in all of these matters. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following resolution discussions with certain private plaintiffs, during the three months ended September 30, 2024, Distributors finalized agreements with classes of third-party payors and acute care hospitals to settle their claims for $213&#160;million. These agreements remain subject to certain contingencies, including court approval. Active litigation brought by hospital and third-party payor plaintiffs, including certain scheduled trials, has been stayed as to Distributors pending court approval of these settlements. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. Following cross-appeals, in September 2024, The Georgia Supreme Court affirmed the defense verdict in full. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in ongoing legal proceedings with insurers related to their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. During fiscal 2024, we received $34&#160;million in insurance recoveries related to these matters and $9&#160;million in the three months ended </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024. We have not recorded a receivable for any additional recoveries related to these insurance litigation matters as of September 30, 2024. Certain recoveries from our insurers are recorded in the Pharmaceutical and Specialty Solutions segment. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Department of Justice Civil Investigative Demand</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we received a Civil Investigative Demand ("CID") from the Department of Justice focused on potential violations of the Anti-Kickback Statute and False Claims Act in connection with a 2022 transaction in which we purchased a minority ownership interest in a rheumatology managed services organization and a group purchasing organization. We are cooperating with this investigation.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by plaintiffs that allege personal injuries associated with the use of inferior vena cava ("IVC") filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve approximately 4,375 claims for $275&#160;million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we made settlement payments totaling $275&#160;million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, while we have also entered into agreements to settle the vast majority of IVC filter product liability claims, these settlements will not resolve all of them, and we intend to continue to vigorously defend ourselves in the remaining lawsuits. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income of $103&#160;million during fiscal year 2023, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At September 30, 2024, we had a total of $289&#160;million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets, which includes the $275&#160;million in the qualified settlement fund.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters condensed consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided </span></div></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anti-competitive pricing information to manufacturers, and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the amended complaint. We are vigorously defending ourselves in this matter, which remains pending as of September 30, 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation Proceeds</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $43 million and $41 million, which were recognized in litigation (recoveries)/charges, net, during the three months ended September 30, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46242060621360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Income Taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of our pre-tax earnings/(loss) (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2024 and 2023, the effective tax rate was 23.0 percent and 75.1 percent, respectively. The tax rate during the three months ended September 30, 2023 reflects the impact of the tax effects of the goodwill impairment charge recognized in the same quarter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, we recognized a $585&#160;million pre-tax charge for goodwill impairment related to the GMPD segment. The net tax benefit related to this charge is $45&#160;million for fiscal 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charge during the three months ended September 30, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to pre-tax loss for three months ended September 30, 2023 resulted in recognizing an incremental interim tax benefit of approximately $102&#160;million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended September 30, 2023 and prepaid expenses and other assets in the condensed </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated balance sheets at September 30, 2023. This interim tax benefit reversed in the remainder of fiscal 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $952 million and $981 million of unrecognized tax benefits at September 30, 2024 and June&#160;30, 2024, respectively. The September 30, 2024 and June&#160;30, 2024 balances include $871&#160;million and $882 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2024 and June&#160;30, 2024, we had $69 million and $65 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) from income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits, or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $20 million, exclusive of penalties and interest.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963370768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Fair Value Measurements </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assets and Liabilities Measured on a Recurring Basis</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">678</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">678</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(37)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(37)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div>(2)&#160;&#160;&#160;&#160; The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964228704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow </span></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency revenue and expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three months ended September&#160;30, 2024 and 2023, there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2023 we entered into pay-floating interest rate swaps with total notional amounts of $100 million. These swaps were designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency, and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive income/(loss) were $3 million and immaterial for the three months ended September&#160;30, 2024 and 2023, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were a $1 million loss and a $1 million gain for the three months ended September&#160;30, 2024 and 2023, respectively. Losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be </span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reclassified into net earnings within the next 12 months are $3&#160;million. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we entered into &#165;18&#160;billion ($120&#160;million) cross-currency swaps maturing in September 2025 and &#165;18&#160;billion ($120&#160;million) cross-currency swaps maturing in June 2027. In June 2024, we terminated the &#165;18&#160;billion ($120&#160;million) cross-currency swaps with a maturity date of June 2027.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we terminated the &#165;38&#160;billion ($300&#160;million) cross-currency swaps entered into in January 2023 and received a net settlement in cash of $28&#160;million, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains and losses from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were a $22&#160;million loss and a $11&#160;million gain for the three months ended September&#160;30, 2024 and 2023, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $2&#160;million and $3&#160;million during the three months ended September&#160;30, 2024 and 2023, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions, and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $1&#160;million loss and an immaterial gain during the three months ended September 30, 2024 and 2023, respectively. The principal currencies managed through foreign currency contracts are the </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">euro, Chinese renminbi, Canadian dollar, Indian rupee, and Brazilian real.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2024 and June 30, 2024 approximate fair value due to their short-term maturities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,072</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,891&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,164</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,092&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963386128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Shareholders' Deficit </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2024, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $375 million. We received an initial delivery of 2.7 million common shares using a reference price of $109.65. The program concluded on October 30, 2024 at a volume weighted average price per common share of $110.10 resulting in a final delivery of 0.7 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 4.4&#160;million common shares using a reference price of $90.57. The program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3&#160;million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2024</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(167)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to Cardinal Health, Inc., net of tax benefit of $5 million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(133)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(155)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $3 million</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963302880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share Attributable to Cardinal Health, Inc.</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("EPS"):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">243</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units, and performance share units that were excluded from the computation of diluted EPS were immaterial for the three months ended September 30, 2024 and 2 million for the three months ended September 30, 2023, 1&#160;million of which were anti-dilutive as a result of the net loss during the period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964575680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Segment Information </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharma segment and GMPD segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, which are sold in the United States, Canada, Europe, Asia, and other markets. In addition to distributing Cardinal Health brand products, this segment also distributes a broad range of medical, surgical, and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers in the United States and Canada.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining three non-reportable operating segments included in Other are Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics. These operating segments respectively operate nuclear pharmacies and radiopharmaceutical manufacturing facilities, distribute medical products to patients' homes in the United States, and provide supply chain services and solutions to our customers.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for the two reportable segments and disaggregated revenue within the remaining operating segments, included in Other, and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47,990</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,588&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,123</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,032&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">at-Home Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">739</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Logistics</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,186</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52,299</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,671&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52,277</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,650&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,891</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,270&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52,299</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,671&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52,277</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,650&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate technology and shared functions expenses, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided, and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shareholder cooperation agreement costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets, net; we recognized a pre-tax goodwill impairment charge of $585&#160;million during the three months ended September 30, 2023; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for/(benefit from) income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending and certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $12 million and $6&#160;million for the three months ended September 30, 2024 and 2023, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">530</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">642</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(74)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(596)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">568</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160; Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Logistics.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Segment Assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for two reportable segments and the remaining operating segments, included in Other, and Corporate: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,215</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,149&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,148</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,611</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,606&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,085</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,059</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,121&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><span><br/></span></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963319760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">14. Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors, and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $4&#160;million for both the three months ended September&#160;30, 2024 and 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.98&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.19&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">90.60</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2024, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $110 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved and our total shareholder return relative to the S&amp;P 500 Health Care Index, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.03&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.78&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">98.81</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2024, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $63 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.</span></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963841568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 416<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241968975440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964944896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2025 and 2024 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2025 and June 30, 2024, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments, and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2025 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2025. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the "2024 Form 10-K"). </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revision of Prior Period Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed in the 2024 Form 10-K, we revised our prior period financial statements to correct for an accounting error related to the at-Home Solutions operating segment that was not </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material, individually or in the aggregate, to our previously issued Consolidated Financial Statements, as well as other unrelated immaterial errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. See Note 1 and Note 16 to the "Consolidated Financial Statements" in the 2024 Form 10-K for additional information.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Updated Segment Reporting Structure</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. The remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics, are not significant enough to require separate reportable disclosures and are included in Other. The Pharma reportable segment consists of all businesses formerly within our Pharmaceutical segment, excluding Nuclear and Precision Health Solutions. The GMPD reportable segment consists of all businesses formerly within our Medical segment, excluding at-Home Solutions and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Logistics. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i088c97dfd3044fc38835caa8c41eddc8_121" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for segment results under the new reporting structure.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MajorCustomersPolicyPolicyTextBlock', window );">Major Customers, Policy</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expired at the end of June 2024, would not be renewed. Sales to OptumRx generated 17 percent of our consolidated revenue in fiscal 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Financial Accounting Standards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards And Disclosure Rules Not Yet Adopted </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the FASB on our consolidated financial statements as well as material updates to previous assessments, if any, from the 2024 Form 10-K.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in the 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Disclosure</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in the 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Climate-Related Disclosures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the SEC issued final rules on climate-related disclosures that will require annual disclosure of material climate-related risks and material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the rules require disclosure in the notes to the financial statements of the effects of severe weather events and other natural conditions, subject to certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates. These rules also require disclosure of climate risk oversight practices of the Board of Directors and management, and the disclosure of governance, risk management, and strategy related to material climate-related risks. In April 2024, the SEC voluntarily stayed the new rules pending the completion of judicial review. We are currently evaluating the impact of adoption of these final rules on our disclosures.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the three months ended September 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963853280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2024</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964584144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2024</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,555&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,725</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,555</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,170</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,725</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight&#174; Logistics.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Definite and Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,651</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,495</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,156</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">562</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,047</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">699</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,260</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,609</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,651</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,272</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,609</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,663</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,236&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,523&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,523&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964251440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">678</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">678</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(37)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(37)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div>(2)&#160;&#160;&#160;&#160; The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46242060760752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,072</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,891&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,164</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,092&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964233744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2024</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(167)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to Cardinal Health, Inc., net of tax benefit of $5 million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(133)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(155)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $3 million</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963851696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("EPS"):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">243</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963318976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for the two reportable segments and disaggregated revenue within the remaining operating segments, included in Other, and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47,990</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,588&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,123</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,032&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">at-Home Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">739</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Logistics</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,186</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52,299</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,671&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52,277</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,650&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,891</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,270&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52,299</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,671&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52,277</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,650&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Segment Profit by Reportable Segment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">530</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">642</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(74)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(596)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">568</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160; Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Logistics.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Assets by Reportable Segment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for two reportable segments and the remaining operating segments, included in Other, and Corporate: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical and Specialty Solutions</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,215</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,149&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Medical Products and Distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,148</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,611</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,606&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,085</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,059</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,121&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964278768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Total Share-based Compensation Expense by Type of Award</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Transactions Related to Restricted Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.98&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.19&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">90.60</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Transactions Related to Performance Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.03&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.78&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2024</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">98.81</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964287424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>Rate</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=cah_OptumRxMember', window );">OptumRx | Revenue Benchmark | Customer Concentration Risk | Pharmaceutical and Specialty Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cah_OptumRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cah_OptumRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalAndSpecialtySolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalAndSpecialtySolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963077360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cah_IntegratedOncologyNetworkMember', window );">Integrated Oncology Network</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationPriceOfAcquisitionExpected', window );">Business Combination, Price of Acquisition, Expected</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cah_SpecialtyNetworksMember', window );">Specialty Networks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationPriceOfAcquisitionExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of expected business acquisition prior to consideration being transferred. Excludes asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479455/805-10-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationPriceOfAcquisitionExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cah_IntegratedOncologyNetworkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cah_IntegratedOncologyNetworkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cah_SpecialtyNetworksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cah_SpecialtyNetworksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963234816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jul. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long Lived Assets Held-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList', window );">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Gain (Loss) on Sale of Assets and Asset Impairment Charges<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cah_TransactionDataSystemInvestmentMember', window );">Transaction Data System Investment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long Lived Assets Held-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity Method Investments, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_OutcomesDivestitureAxis=cah_OutcomesDivestitureMember', window );">Outcomes Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long Lived Assets Held-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cah_TransactionDataSystemInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cah_TransactionDataSystemInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OutcomesDivestitureAxis=cah_OutcomesDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OutcomesDivestitureAxis=cah_OutcomesDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964396496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and employee severance</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241969208832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee- Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Exit and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963294304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241962352608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at June 30, 2024</a></td>
<td class="nump">$ 4,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired, net of purchase price adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">4,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at June 30, 2024</a></td>
<td class="nump">1,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired, net of purchase price adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">1,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalAndSpecialtySolutionsMember', window );">Pharmaceutical and Specialty Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at June 30, 2024</a></td>
<td class="nump">3,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired, net of purchase price adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">3,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember', window );">GMPD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at June 30, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired, net of purchase price adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalAndSpecialtySolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalAndSpecialtySolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964079760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">5,260<span></span>
</td>
<td class="nump">5,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">3,609<span></span>
</td>
<td class="nump">3,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,651<span></span>
</td>
<td class="nump">1,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Intangible, Total other intangible assets</a></td>
<td class="nump">$ 5,272<span></span>
</td>
<td class="nump">5,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Intangible, Total other intangible assets</a></td>
<td class="nump">1,663<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember', window );">Trademarks and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">3,651<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="nump">2,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,156<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember', window );">Trademarks, trade names and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 1,047<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 348<span></span>
</td>
<td class="nump">$ 363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964180224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite-Lived Intangible Asset, Expected Amortization, Year One</a></td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Two</a></td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Three</a></td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Four</a></td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember', window );">GMPD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241969242320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 07, 2025</div></th>
<th class="th"><div>Oct. 08, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt, Long-term and Short-term, Combined Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,400<span></span>
</td>
<td class="nump">$ 31,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet', window );">Line of Credit Facility, Increase (Decrease), Net</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember', window );">Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other Short-term Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember', window );">Short Term Credit Facilities Member | Committed Receivables Sales Facility Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241956305856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">40 Months Ended</th>
<th class="th" colspan="1">164 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($) </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>numberOfUSTerritories </div>
<div>states </div>
<div>Rate</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($) </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jun. 30, 2038 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) from Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="nump">$ 41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_IncomefromSettlementsofClassActionLawsuits', window );">Income from Settlements of Class Action Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000,000<span></span>
</td>
<td class="nump">$ 41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member] | IVC April 2023 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss Contingency, Claims Settled, Number | lawsuit</a></td>
<td class="nump">4,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">litigation settlement liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Estimated Litigation Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 789,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementLoss', window );">Litigation Settlement, Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_IncomeAsAResultOfPrepayments', window );">Income As A Result Of Prepayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease', window );">Loss Contingency Accrual, Period Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SettlingStates', window );">Settling States | states</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SettlingUSTerritories', window );">Settling U.S Territories | numberOfUSTerritories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_PercentageSettlingSubdivisions', window );">Percentage Settling Subdivisions [Line Items] | Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance Recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="nump">$ 4,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | WEST VIRGINIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | 921150 American Indian and Alaska Native Tribal Governments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | ALABAMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementLoss', window );">Litigation Settlement, Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | City of Baltimore</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Private Parties [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Private Parties [Member] | GEORGIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Class Action Lawsuits [Member] | Private Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Class Action Lawsuits [Member] | Private Parties [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease', window );">Loss Contingency Accrual, Period Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member] | IVC April 2023 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="nump">$ 275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss Contingency Accrual, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_AggregateAnnualAssessment', window );">Aggregate Annual Assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=cah_CVSHealthMember', window );">CVS Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Long-term Purchase Commitment, Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AggregateAnnualAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Annual Assessment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AggregateAnnualAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IncomeAsAResultOfPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income as a result of prepayments at a pre-negotiated discount certain future payment amounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IncomeAsAResultOfPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IncomefromSettlementsofClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income from Settlements of Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IncomefromSettlementsofClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossContingencyLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Lawsuits, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossContingencyLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_PercentageSettlingSubdivisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Settling Subdivisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_PercentageSettlingSubdivisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SettlingStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settling States</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SettlingStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SettlingUSTerritories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settling U.S Territories</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SettlingUSTerritories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AgreementsAxis=cah_IVCApril2023AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AgreementsAxis=cah_IVCApril2023AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WV">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WV</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=naics_ZZ921150">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=naics_ZZ921150</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_AL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_AL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_CityOfBaltimoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_CityOfBaltimoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_PlaintiffTypeAxis=cah_PrivatePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_GA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_GA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cah_CVSHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cah_CVSHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241962402992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for/(benefit from) income taxes</a></td>
<td class="num">$ (124)<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">75.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 981<span></span>
</td>
<td class="nump">$ 981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="nump">882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_GoodwillImpairmentAxis=cah_FY24Q1GoodwillImpairmentGMPDMember', window );">FY24 Q1 GMPD Goodwill Impairment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for/(benefit from) income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (102)<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember', window );">GMPD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_GoodwillImpairmentAxis=cah_FY24Q1GoodwillImpairmentGMPDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_GoodwillImpairmentAxis=cah_FY24Q1GoodwillImpairmentGMPDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963551056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Narrative (Details) - Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">678<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 678<span></span>
</td>
<td class="nump">$ 1,442<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480463/815-10-45-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241955170480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Narrative (Details)<br> &#165; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>JPY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Proceeds from net investment hedge terminations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_DateInitiatedAxis=cah_January2023Member', window );">January 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Proceeds from net investment hedge terminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest Income (Expense), Nonoperating</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Forecast [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Net Investment Hedging | Currency Swap [Member] | January 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount', window );">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 38,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Net Investment Hedging | Currency Swap [Member] | September 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative Asset, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount', window );">Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">&#165; 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Net Investment Hedging | Currency Swap [Member] | June 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative Asset, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 18,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) | Not Designated as Hedging Instrument | Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 25<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480238/815-25-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480627/815-20-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DateInitiatedAxis=cah_January2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DateInitiatedAxis=cah_January2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_MaturityDateAxis=cah_September2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_MaturityDateAxis=cah_September2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_MaturityDateAxis=cah_June2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_MaturityDateAxis=cah_June2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46242063085136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings', window );">Carrying Amount of Long-Term and other Short-Term Borrowings</a></td>
<td class="nump">$ 5,164<span></span>
</td>
<td class="nump">$ 5,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 5,072<span></span>
</td>
<td class="nump">$ 4,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying Amount of Long-Term and other Short-Term Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CarryingAmountofLongTermandotherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241969238960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Oct. 30, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Share repurchase program activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=cah_A375MillionShareRepurchaseProgramMember', window );">#375 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Share repurchase program activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A500MillionShareRepurchaseProgramMember', window );">$500 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Share repurchase program activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (using cost method), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Shares | $500 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (using cost method), shares</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Shares | #375 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (using cost method), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Shares | $500 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Shares | #375 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Treasury Shares | #375 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (using cost method), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Treasury Shares | #375 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=cah_A375MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=cah_A375MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A500MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A500MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=cah_A500MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=cah_A500MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A375MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A375MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241962856320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">$ (3,212)<span></span>
</td>
<td class="num">$ (2,957)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other Comprehensive Income (Loss), Tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(3,276)<span></span>
</td>
<td class="num">(3,607)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income, before reclassifications</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(133)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Gain/(Loss) on Derivatives, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income, before reclassifications</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income, before reclassifications</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">$ (155)<span></span>
</td>
<td class="num">$ (165)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241958332832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares&#8211;basic (in shares)</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted Average Number Diluted Shares Outstanding Adjustment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares&#8211;diluted (in shares)</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46242070977952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod', window );">Antidilutive Securities Excluded from computation of EPS as a result of the net loss during the period</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Antidilutive Securities Excluded from computation of EPS as a result of the net loss during the period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241962733072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>segment </div>
<div>Segments</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project Costs On Investment And Other Spending</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember', window );">GMPD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ProjectCostsOnInvestmentAndOtherSpending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ProjectCostsOnInvestmentAndOtherSpending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241962983184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Revenue by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 52,277<span></span>
</td>
<td class="nump">$ 54,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">52,299<span></span>
</td>
<td class="nump">54,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalAndSpecialtySolutionsMember', window );">Pharmaceutical and Specialty Solutions | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">47,990<span></span>
</td>
<td class="nump">50,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember', window );">GMPD | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,123<span></span>
</td>
<td class="nump">3,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Operating Segment | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Operating Segment | Nuclear and Precision Health Solutions [Member] | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Operating Segment | at-Home Solutions [Member] | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">739<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Operating Segment | OptiFreight [Member] | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalAndSpecialtySolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalAndSpecialtySolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearAndPrecisionHealthSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearAndPrecisionHealthSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_AtHomeSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_AtHomeSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_OptiFreightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_OptiFreightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964642832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Revenue by Geographical Segments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 52,277<span></span>
</td>
<td class="nump">$ 54,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">51,891<span></span>
</td>
<td class="nump">54,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">408<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">52,299<span></span>
</td>
<td class="nump">54,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (22)<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SegmentRevenuebyGeographicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Segment Revenue by Geographic [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SegmentRevenuebyGeographicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964208304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">$ 568<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">642<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical and Specialty Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | GMPD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (74)<span></span>
</td>
<td class="num">$ (596)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalAndSpecialtySolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalAndSpecialtySolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964940640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information (Assets by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 43,059<span></span>
</td>
<td class="nump">$ 45,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical and Specialty Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">29,215<span></span>
</td>
<td class="nump">29,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | GMPD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">7,148<span></span>
</td>
<td class="nump">7,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 4,085<span></span>
</td>
<td class="nump">$ 6,319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalAndSpecialtySolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalAndSpecialtySolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_GMPDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241963098784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Reportable_Segments</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit related to share-based compensation</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_VestingPeriodinyearsforShares', window );">Vesting Period in years for Shares | Reportable_Segments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="nump">240.00%<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_VestingPeriodinyearsforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Period in years for Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_VestingPeriodinyearsforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964632736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964098352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 70.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">107.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">72.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 90.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46241964641456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Performance Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 97.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">113.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">108.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 98.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %%'85D'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !11V%9_Y8Q]NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)OI^FZ(J&;B^))07!!\1:2V=U@\X=DI-VWMXV[740?P&-F?OGF
M&YA.1Z%#PN<4(B:RF*]&U_LL=-RP U$4 %D?T*E<3PD_-7<A.473,^TA*OVA
M]@AMT]R 0U)&D8(96,6%R&1GM- )%85TPAN]X.-GZ@O,:, >'7K*P&L.3,X3
MXW'L.[@ 9AAA<OF[@&8AENJ?V-(!=DJ.V2ZI81CJ855RTPX<WIX>7\JZE?69
ME-<X_<I6T#'BAITGOZ[N[K</3+9->UUQ7C5\RUNQOA7M^GUV_>%W$7;!V)W]
MQ\9G0=G!K[N07U!+ P04    " !11V%9F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M %%'85GD@S^!Q 4  ,$>   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9G_<]HV&(?_%1V[V[5W(5@R7]*.<$=HTN;6-C1DVW6[_2!L@7VU+2;+D/SW
M>V6#33?YA?/5_:'!X/>#'LN2'JSQ3JIO:2"$)L]QE*37G4#KS=M>+_4"$?/T
M4FY$ I^LI(JYAD.U[J4;);B?%\51CSG.L!?S,.E,QOE[<S49RTQ'82+FBJ19
M''/U<B,BN;ONT,[AC<=P'6CS1F\RWO"U6 C]VV:NX*A7IOAA+)(TE E18G7=
MF=*W,Y>9@OR,WT.Q2X]>$X.RE/*;.;CWKSN.:9&(A*=-!(<_6S$34622H!W_
M[$,[Y7>:PN/7A_2['!Y@ECP5,QG]$?HZN.Y<=8@O5CR+]*/<?1![H(')\V24
MYO^377%NO]\A7I9J&>^+H05QF!1_^?/^0AP5N'4%;%_ _E- ZPK<?8&;@Q8M
MR['><<TG8R5W1)FS(<V\R*]-7@TT86*Z<:$5?!I"G9[,Y%8H,H<>(UV2!ER)
M=-S3$&P^[GG[D)LBA-6$N.233'20DMO$%_[W]3UH4-DJ=FC5#4,#%V)S25SG
M@C"']2WMF>'E#YZ^)&Q@*_^N.6YYD=P\ST4OTE_39:H5W'=_VZY0D="W)YC!
M^#;=<$]<=V"TI4)M16?R\T]TZ/QBP_M!8=_!]DO8/I8^>2>]#,:I)D\O&V$C
MQ<NIT_UB0T*K&B(-2J3!>4A?,JZT4-$+>10;J;0-#X_2*K-=E!E:U1!O6.(-
MS\.;"Q5*WXQ" I.!M?/PI'+<U0X\M+XAYZCD')UY9RH.ZTB^#-3W(YZUXE%J
M[4BTK"'@50EXA3;J-M&A?B%W823(YRQ>"F4#PS-HEU)WY-K0T,*&:&]*M#?G
MH#V*=6@F4>C$SSRVWJ%XSHPK/TQX1#X('NG@@MPGWJ4-%HUI"$N=:E5USL&=
MP=VJH+'WL"X^DU_%BW5MQ:,<^#=BT*?4AHD7-^4\L@>*=T>FE!F1=V'J >=7
MP14Z_9R(ZW:=8==UK*!H95-05H&R\^:>8]([>-.N2W@83*X#*R-:UI2QLAR*
M>L7_&/?+23TE'O?%?L.VX3:TDAN*Z\D4 /T",N)K*Q4>4+MPX'5-P2K%H;B8
M[&<<F ZE@B61F]7Q@BPT#$0B%9G)#*8BF)&D;Q^8>/K#!RMR&]9#*^VAN*WL
MD9_X,[GWH4O#5>CEW,CB>2+2I5WGS>!J.!Q:>=NP'UKI#\6=9<\[]7U(3R\.
M+\A'.(\\)/9^Q2-'L+B0<DV=1]!X*W@;5D0K+:)G>5$)/C-'<%,_R5UBA<;C
MWF5+>,O*V88BT<J1Z%F25'*6HW>NY#9,K'US<R*S9N2VH4>LTB-VEAZ5H'.9
M:KC__@PWM1/4B<2^Z]"1]4E!&X+$*D%B)P0IYU2"UX/A 4-J?P#2A@ZQ2H<8
M;C ?92X(@4RP7RHG0D:#47< $Y"5KPT58I4*,=Q=#OZ^U]OB5V:8K/,A:;>A
M$XE?K0_69GA54\Y*AQAN,Z4U:*&*)ZI&W?D!W,J))]9QMF%'K+(C=I8=F5_6
MX$(PJZZELOX8.Y'SD:NU(%//$Q $,7X1:25N0XY8)4?L+#E:Q#R*R$V6PL>I
M_;[%<VI]%Z]KRE?)$#M+AFYCH=9F8+Z'!!W +!MO>&+OVH9/A/"ZIJ"5_+"S
MY&<1".A(# ^/J<=KPWE8Y3P,]Y.G4$?@."M"V:OE:[(07J: UTIXXM&0C&-P
M_V(3@[S:A3J0F28;^*&^Y5$F7EOIVQ AMQ(A%]>6)\7]?%EYB9<RLNXKX &S
MJ=7O\*JF6)7UN+BT''J1W#Y[ 4]@RJQ[VG<BZ//7Q:V5KPW]<2O]<7%S.>A!
M<<<MM/2^@:T7-]Y#ID%F$].M5N ?)#;[ZU"D#?(TLV6[G; ^<Z@S<-QQ;WL,
MV3O:)#239KYWFA+//!@H]@O+=\O]V6F^*]FK3B\V=S]Q,^>F)!(K*'4N1_#]
MJM@O+0ZTW.1;CDNIM8SSEX'@OE#F!/A\):4^')@O*'>M)_\"4$L#!!0    (
M %%'85FYN?X5PP4  *D6   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL
MK5AM;]LV$/XKA%<,"1!;$B5;3N882)RN#="L08.N'X9]H"7:)BJ)+DDYZ7[]
MCI(BR1+%I$"^6"\^GI[G>+SGR,4C%]_ECE*%GM(DDY>CG5+["\>1T8ZF1$[X
MGF;PSX:+E"AX%%M'[@4E<3$H31SLNC,G)2P;+1?%NWNQ7/!<)2RC]P+)/$V)
M^'E-$_YX.?)&SR^^L.U.Z1?.<K$G6_I U=?]O8 GI_82LY1FDO$,";JY'%UY
M%RL<Z@&%Q=^,/LK6/=)4UIQ_UP^W\>7(U8AH0B.E71"X'.B*)HGV!#A^5$Y'
M]3?UP/;]L_<_"_) 9DTD7?'D&XO5[G(T'Z&8;DB>J"_\\2.M"$VUOX@GLOA%
MCY6M.T)1+A5/J\& (&59>25/52!: \"/>0"N!N#N@&!@@%\-\ NB);*"U@U1
M9+D0_!$);0W>]$T1FV(TL&&9GL8')>!?!N/4<L6S&":%Q@CN)$]83!0\/"BX
MP&PIB?@&O2<B8]E6HC'Z^G"#3MZ=(KDC@DK$,G3'D@0F1)ZA=^W'A:, GOZ(
M$U50KDLH> "*C^YXIG82O0=(\?%X!VC5W/ SMVML=?A ]Q/DNV<(NS@PX%F]
M?KAO@>/7H?8+?_Z O]LLXBEM0HO^N5I+)2"1_S4%JW06F)WIU7TA]R2BER-8
MOI** QTM?__-F[E_F)B^D;,CWD'-.[!Y7WZA!YKEU,2Q'#@K!NJ"<UA.,0[#
MA7-H@S=8!;.I6UL=H9K6J*965"LNE<[M#YS'$I$,<AYXLPB2^H$GL0EMZ7#:
MQN'ZX;2#UF"%S]W0C'96HYU9T7X07$I8]V++,A.T6>^CWKF+.\@,1F'@FX&%
M-;#0FM2?]U00!<4!T:>]+B3RPH0O?,MD?B-G1WSG-=^Y=2)N&"Q9MLZU!ITA
MD",PV)ZA+<T@#DF11R2&.JW-B%:H.BZFL,S[,])/?X.1-Y^9I^V\IG'^PIH$
M?'FD<J&G3J.FZ3[A/RD%3@>@DD7&!7O>PZ(KZQ%<@\G4#-9S&Y%RK7"O4BX4
M^X^4R@]HN=I1 3W CYQ)IM^.!4T*Y8I@79O%Q^T!"[O8#3:S8 !\2V$]*_C;
M=$^8*,548S_90G=UZB1Z10.=F,D]EY [4(R(E%2!DF94&2EX/7ACKTNA;S,-
MO $.N.& K1P^09"W9?A/!(TXI BC\M2)H W84@MBW$<<N%W()J,AR(W:>E91
M:U>FJGUQ3G3,3XTX_7[49O,NSK[1V,<#.!MU].SR^+E(Y1-6= >G3E4NAB,:
M]$%T)<A@,Q3.1BX]NU[>9HI".57H18!] ?2[2F2P\880-A+IV37R_?$THS6%
M70Y%96"1(D_F&NSU9;&]8"K ?:-Q,%09&NWTK%*UO!?\P(H-$2!U3M8@(ANF
MT$;P]/1EW*%!/'H%K6\T]@<DWVLTT+.+X%^PO7S-HNHK5^!UU<U@-![,A4;>
M/+N^?:)27J V3D14*=QDG4!4.<HX!#A3@A<2#N$N\]L<Z[ZH]0NOU>9X ],(
M'[8+GR'2/2(K(F*6@8!\I"11NS,$&XV)B47UK=G1?,PZ- Q&8V^@R.%& [%G
M;1.[:Q-J,RAUFD+J%SO)UY$RMI;8JKZ_VEN^E;?C.#4ZB^TZ>TTDB[085!ML
MX[JJ?(3ME3\)N_EHL!J[$W>@%\.-KF*[KMZP)->-UDL@?1/(+L:^D0UCHZDX
ML*;;M^+TAL9CHGO9+459GJXAY:#%:F<=]%^YD@J:,LA-<W)9M?N7D^N-O!U'
MI9%P;)?PUR577YIQ:Y-8$3$9G0_,6B/@V"[@K\VLOA;CH-L"&8V&$#:"C>V"
MO2)R!PW[@<4TBR6*:90 S+A7SHRP2]?S%B)W,G6GO0)LMG.[.SZG=>B74NC"
M]5FH!!AYILHSLOIM?=YZ59PR=MY?>Q>K\M2T<5,>XMX5YPT2)70#+MU)".$4
MY;EH^:#XOCA:7'.E>%K<[BB)J= &\/^&<_7\H#]0GTXO_P=02P,$%     @
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MX<CXHKC[MGO-/HUOE_OE\1T]^'"ID<"56F#KP>3)HQ&BR>^]XT.P#;]KGMN
MQIX_KI3$-$ +\/O"(GO3 QW0_>>#T_\#4$L#!!0    ( %%'85G!BR?@H 0
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M&81',LCE3.\[DA)VJ/& =WO1=%_.'B<U[W*X5XI&BMK2&TC&Z:9(S^ Y=?*
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M(12U$Z#?<Z5LNW$&NK%V^0]02P,$%     @ 44=A6:89DC9E!0  V@T  !D
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M@0R7HE;NDUZ_PS:>A/VE6EG_"^O&-HDZD-;6Z:(%$X-"ELU5W+9YV %,AGL
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M5G#0A:B7) E=GS^;A$'XBE9!+Q@/Z1KWQF&RDZ[T6RT-9CTHT0=9U2;-:6Y
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MIPF/)5TBT?(">I\;.EQV R;HKZ6KOP%02P,$%     @ 44=A61Y+BN!T&
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M1 +R@"Q9)V!JV51E(:2+X_8JMLB0(K+BX(X><DN/OL]6(4GF=QOD&5,LD@0
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MZ_2OP>B7OFGE+[#,FQ[J+Q]7%MBIXPOX?=$@F/DO7"#^29Y7_P=02P,$%
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M#6<SY&I+$W%.[J8L!1G.KFRAL38/2-W Z1HSEH)XAOA+B& NQ4-%BRN%I(*
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M_+'5E5W=<(0,1S-[N_HF]M:D%N0HKHI0#IX:*O>BT4\)#E<K42.+6!'P6R&
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M+<#SE8/6T@4=T'_/=O%_4$L#!!0    ( %%'85D(:8]ODP0  "8,   9
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MQD'DM1!4,V)N+'DY5H[N=&DS>*E'SGW$]/S=4.5@<<;+5)#I'$J12]C8QPV
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MH^/E?,"T_Z[I;ZRJW+?$M;)H8=TE=8%"TP0\WRAEFQO:H/VX?/$74$L#!!0
M   ( %%'85E4#1[6104  &<.   9    >&PO=V]R:W-H965T<R]S:&5E=#(P
M+GAM;,U7VV[;.!#]E8%;% G@R)+L)L[-0)*]M MT822]/"SV@9;&%E%*5$G*
MCOOU.T/*CMRU@Q;87>R#+4KB')Z9.3,4KU;:?+8%HH/'4E7VNE<X5U\,!C8K
ML!0VTC56]&:N32D<W9K%P-8&1>Z-2C5(X_AT4 I9]297_MG43*YTXY2L<&K
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M\J0OZ5L*E<9P4T2J<?G4U)8,FB7?G942Y/7Y_(+ZR'N^'N\;^NZEZU5B7>6
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M OR^M,C>]$ '='\T<?9?4$L#!!0    ( %%'85G]W\8:&0,   $(   9
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;)U546_:,!#^*U965:VT-2% RR@@
M0==JFU8) =L>ICV8Y"!>G3BS+Z7LU^_LA$ [AE ?,+;C^^X[?^>[WDKI!Y,
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MJ*P ?9]+:587ZV"]LH_^ 5!+ P04    " !11V%9MS9QFY0#  !R"   &0
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M\Q^U,Z#WN5)V?7 !VG^4Y!]02P,$%     @ 44=A61)::JII P  <0@  !D
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MW"I:30<K!:^PUES6H'!],;D,SJXR*^\$?N>XU0=SL)&LI/QD%V^*BXEO :'
MW%@+C/Z^X#4*80T1C,^]S<G@TBH>SG?67[G8*985TW@MQ1^\,)N+R6P"!:Y9
M*\R=W-Y@'T]B[>52:#?"MI/-H@GDK3:RZI4)0<7K[I_=]WDX4)CY/U (>X70
MX>X<.90OF&&+<R6WH*PT6;,3%ZK3)G"\MH>R-(J><M(SBR66E&(#;^KN@&VF
M3MZSE4#]]'QJR(.5F^:]M:O.6O@#:Q&\E;79:'A9%U@\U)\2L@%>N(-W%8X:
M7&)S"I'O0>B'\8B]: @W<O:BOPGW#ANI#*]+^'BYTD81.?Y\+-S.6ORX-5LP
M9[IA.5Y,J"(TJB\X6?S\4Y#ZST>PQ@/6>,SZ8DD%6+0"0:[A>]P'!^;!ZNL@
M\=$='KS'>P-70N:?'HUKW/,=?L&Z)2,;A+445+C6HW&&7:"UT521G1#! $."
M9BMIS\)S<KK#HX'5!11<L[)46#*#Q:"YY6;#:Z>LT#80ZX7:C6(NPIT%#WB=
MBY8(11-X1^+*<U:OI2)W9/*,D"K$!^2CA#0&JQ4JQY\34JVX$)0N_=2QR0X1
MW&X893''UO"<"6=VV6#.F3"44RE:FV -3R#.O/G<ITGB>\EL!J^%7)'"6RR<
MXJV219OWX;[@1"F^<KH0>0'YB3P_"N&W-A?(E!.Z5>3&];8;)&^; V]11@J$
MD)EG-[+"@R=9-(<TS>!=8_@KY5H.$.&R^#G\*DMRRW,2BB'UNT1!X 6SE$8_
M">"]-(2T3^MP"DGHA?,Y)+&79L$^IW 2/(63,+0#S3K=G<X3IY5E=D)ZB>^D
M][H[N9PP$RAM*6R/&06G'M9U&=KBM4'U[%M -CG2@=_MU-( (QKFCCY&.EL[
M>IR.E%HRE%IR%.'72E;P\IY0U13MM6N_J+2MK]<H2\6:#<_ADMY^^LA"&_=[
M5(&1\W+OG)'S?\#W#S6W.5P:2J6E=1)XLWG0G6.8^=167/#VA"@#L3^CW_^1
M.>G G'2\2?<0J/[7W-BSNMOWP/[A8[P8MSK*BUW43>?RF/[[WVBQ263[:YRD
MQS?7&01AW^DLCP(_AGGZ#5W[/*5Q"$D:'_(TBXFCR3S=D72?&&K2-E5Z>B*D
MIF@(7#JC\22RM':,K1K%-26A)^AX>H]K_-[W';\[AK%V/\;B;&!Q-LJW2ZW1
MZ./9.VKM\<^B44H;EW[6H7"$_I?)_)"K#WGLF/M+6^-^=32%P[D7!DDW">+Y
M\43.2'Q&HQ]G/9]#+PT"._KI 6=CSY\ED'I1,.])VV>-"H>^,9*YJR#ZY C@
M,5Y,#VX*]&8KW7U(4[=M:]-=&H;=X<IUV=TT]N+=?>TM4R6GH 6N2=4_S>A5
MI[H[4+<PLG'WCI4T]!IUTPU=&U%9 7J^EM+L%M;!<!%=_ 502P,$%     @
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MT?=1X!RD2"?D!OHD!36XP CN<CY?I^L$"YFCRY0R$?^'BW:N QFTUG<#9WP
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M4K)$7VX JXU1UD"]7S$F]S=9!^4I7O ?4$L#!!0    ( %%'85D"-W" (@4
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MXFMQ4:9WR??U&]]Z8PAM=J.:B6H6JMFHYFRTYZO9X6#2'T-H>1O5/%3S42U
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MPA3H[]><JZ<;<RY2G8-%_P%02P,$%     @ 44=A6:CB7M-""   @E,  !D
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M'PFC2!A#PC@(9HCC>"..8]2XXABI$R3,1\(H$L:0, Z"&3HYV>CDY*GSA;6
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M4BB-H6BFK(U-Y?6RJ;[GZ<F>J;>R4#L+2J-0&D/1S!'0V%D>U,[RH'86E!9
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MA(,P 2(@8.9YZW@=84%\\%7>8&!.8SEK O4Z-P3<)AZ-"3C[C7)^?@[.;HC
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M'[721P_*'<R:W+VKBC45\*$C-*WC?66-I4Y!!0ZS["MU09H;MBLRHS_3<Y+
M/RVB[O2-6PWC_Z^_K!'TCPH<=U37\$1 E\UI!89' Z! O?5ST9!GE;1UBVM/
MV]$[\Q/GY'Q.([F>H+]IZGE^P_262P,"-T0978S)(UW/R'IC5>G'S%I9&EI^
MF=/?"M3.@-YOE+*'C?M ^T<E^0502P,$%     @ 44=A6=?57/K! @  #@8
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MZR_P^<9P/72&#]#_ K+?4$L#!!0    ( %%'85D%O&JD,@,  $D,   9
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ML:6,(PI7'(EEDA#^> HQ6_<MUWK:N([F"ZDW[+"7DCF,0-ZF5URM[))E&B5
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M. :N#=3^BC&Y?] OJ":5X7]02P,$%     @ 44=A6<^QH]]2 P  NP\  !D
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M#&/54@/7 >K[DC&YG^@-RB8]^ M02P,$%     @ 44=A6:#0@ _0 P  $@T
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ML %$=7W '"U\$S&]"\@J12MN3+M/KMA"=C?=@\++ W%!1+ " GE'F2+/E._
M@O5I60LM_@X9&2<EA>3_Y^1.9XZ$<[#U=%E^:BEYD_V*L_M1:W@A,..R/L6-
M!>*K%+T6DM<<MZL!$/5;@TN@RK(2-Q_BE9R]%E/G'%,_:<7#"Y#*8A WGN)-
M*7PMQ.ZKT[DL O$55> \G:]%V#N+M6'4Z@ZKSS>(P\HU-0>U=I=Q35*Y$\;?
M6(O1XL(_]=?<<KG_6WBD"C-&$PXK%,7S'SVE_ 7<=XS<NDOO4AJ\0KOF!G]:
M0-D%.+^2TIPZUD#Q&S3Y#U!+ P04    " !11V%9MG0+.] #   3#0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6RUE_]OZC80P/^54_8TM1(E7Z!
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M<3+'=+#WV8OLR>9KA_!17\3Z8RT+:F/?XW/NL7U#W/8KO13L;L:8#A:YD-6
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M>6OJ[CV?#7^R7+T"4$L! A0#%     @ 44=A60=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !11V%9
M_Y8Q]NX    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !11V%9F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %%'85GD@S^!Q 4
M ,$>   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " !11V%9N;G^%<,%  "I%@  &               @($'
M#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 44=A6=-_
M2_:' P  5 L  !@              ("! !0  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( %%'85D3-@$<5P8  ,4;   8
M  " @;T7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !1
M1V%92]>8X,4(  !=3P  &               @(%*'@  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ 44=A62DPL0]N!@  *1L  !@
M         ("!12<  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( %%'85FCUT7BH0L  (@@   8              " @>DM  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !11V%9P8LGX* $  !&"@
M&               @(' .0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ 44=A62&!,*.J P  S <  !@              ("!ECX  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( %%'85G6WUIE.P0
M .(*   9              " @79"  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ 44=A6:89DC9E!0  V@T  !D              ("!
MZ$8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !11V%9
MB!.O\F4$  "B"@  &0              @(&$3   >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( %%'85D>2XK@=!@  )Y'   9
M      " @2!1  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ 44=A6>3@5*,F!P  ^!,  !D              ("!RVD  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !11V%9>T&'=X\#  "2"
M&0              @($H<0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( %%'85EA)WYC\ L  -LF   9              " @>YT  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ 44=A60AICV^3
M!   )@P  !D              ("!%8$  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " !11V%9=C-*>F4#  !&"   &0
M@('?A0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( %%'
M85GQ8%M!I H  &@>   9              " @7N)  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ 44=A650-'M9%!0  9PX  !D
M         ("!5I0  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " !11V%9!1?<FCX"  "7!0  &0              @('2F0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( %%'85D >H^K0P(  (H&
M   9              " @4><  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ 44=A6>!AUSK&"P  0"$  !D              ("!P9X
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !11V%9_=_&
M&AD#   !"   &0              @(&^J@  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( %%'85DYV-BTD 0  +X+   9
M  " @0ZN  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M44=A6;<V<9N4 P  <@@  !D              ("!U;(  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " !11V%96.XGBMH"  !=!@  &0
M            @(&@M@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( %%'85D26FJJ:0,  '$(   9              " @;&Y  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 44=A65*Z28W^ @
MT08  !D              ("!4;T  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " !11V%90WO$H\T$  "4#@  &0              @(&&
MP   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( %%'85F1
M>+ RK0,  %L*   9              " @8K%  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ 44=A62X(4D:% @  S@4  !D
M     ("!;LD  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %%'85G68C[?A (  &4&   9              "
M@?S9  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 44=A
M61Y)-4$)!   NA4  !D              ("!M]P  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " !11V%9!6=+G0L%   5'   &0
M        @('WX   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( %%'85D9(O$%^0,  -$3   9              " @3GF  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 44=A60(W<( B!0  MR4
M !D              ("!:>H  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " !11V%9F=:8"+T1  "Z+0$ &0              @('"[P
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( %%'85D7W(:V
M404  /(C   9              " @;8! 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ 44=A65I,29R? P  $Q,  !D
M ("!/@<! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !1
M1V%9J.)>TT((  ""4P  &0              @($4"P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( %%'85G0# T0W@(  (0(   9
M          " @8T3 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#
M%     @ 44=A61AXN) V!@  ;3X  !D              ("!HA8! 'AL+W=O
M<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " !11V%9Q8&;"D %   !
M'   &0              @($/'0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM
M;%!+ 0(4 Q0    ( %%'85EG5.SM$@,  +0(   9              " @88B
M 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ 44=A6=?5
M7/K! @  #@8  !D              ("!SR4! 'AL+W=O<FMS:&5E=',O<VAE
M970U,"YX;6Q02P$"% ,4    " !11V%9!;QJI#(#  !)#   &0
M    @(''* $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M %%'85G7O#DZFP0  (4;   9              " @3 L 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ 44=A60Q8G@!N P  ^ \  !D
M             ("! C$! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " !11V%9,=B<7NH#  "U%   &0              @(&G- $ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( %%'85G/L:/?4@,
M +L/   9              " @<@X 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ 44=A63KX GY !   618  !D              ("!
M43P! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !11V%9
M:W6VX P#  "P"P  &0              @('(0 $ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( %%'85F@T( /T ,  !(-   9
M      " @0M$ 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ 44=A6;9T"SO0 P  $PT  !D              ("!$D@! 'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !11V%9JNVX$T\#  #*%
M#0              @ $93 $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %%'
M85F7BKL<P    !,"   +              "  9-/ 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( %%'85G,E]2IP 0  &<G   /              "  7Q0 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !11V%9678!^/4!   X(P  &@
M            @ %I50$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " !11V%9%\C,&]L!  #1(@  $P              @ &65P$ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     0P!# $P2  "B60$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>194</ContextCount>
  <ElementCount>247</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings</Role>
      <ShortName>Condensed Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statement of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/Divestitures</Role>
      <ShortName>Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Restructuring and Employee Severance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</Role>
      <ShortName>Restructuring and Employee Severance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Commitments, Contingent Liabilities and Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Restructuring and Employee Severance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</Role>
      <ShortName>Restructuring and Employee Severance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstruments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/AcquisitionsDetails</Role>
      <ShortName>Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/Acquisitions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Divestitures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/DivestituresDetails</Role>
      <ShortName>Divestitures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/Divestitures</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails</Role>
      <ShortName>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails</Role>
      <ShortName>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Restructuring and Employee Severance Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails</Role>
      <ShortName>Restructuring and Employee Severance Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Income Taxes Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Fair Value Measurements Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Financial Instruments Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails</Role>
      <ShortName>Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Shareholders' Equity Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Segment Information Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Revenue by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Segment Information Revenue by Geographical Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails</Role>
      <ShortName>Segment Information Revenue by Geographical Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Segment Profit by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Assets by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Share-Based Compensation Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cah-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="cah-20240930.htm">cah-20240930.htm</File>
    <File>cah-20240930.xsd</File>
    <File>cah-20240930_cal.xml</File>
    <File>cah-20240930_def.xml</File>
    <File>cah-20240930_lab.xml</File>
    <File>cah-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cah-20240930_g1.jpg</File>
    <File>cah-20240930_g2.jpg</File>
    <File>cah-20240930_g3.jpg</File>
    <File>cah-20240930_g4.jpg</File>
    <File>cah-20240930_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="576">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cah-20240930.htm": {
   "nsprefix": "cah",
   "nsuri": "http://www.cardinal.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "cah-20240930.htm"
     ]
    },
    "schema": {
     "local": [
      "cah-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cah-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cah-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cah-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cah-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 231,
   "keyCustom": 16,
   "axisStandard": 28,
   "axisCustom": 9,
   "memberStandard": 46,
   "memberCustom": 29,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 1
   },
   "contextCount": 194,
   "entityCount": 1,
   "segmentCount": 79,
   "elementCount": 598,
   "unitCount": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 576,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.cardinal.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
     "longName": "9952151 - Statement - Condensed Consolidated Statements of Earnings",
     "shortName": "Condensed Consolidated Statements of Earnings",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "longName": "9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952153 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
     "longName": "9952154 - Statement - Condensed Consolidated Statement of Shareholders' Equity",
     "shortName": "Condensed Consolidated Statement of Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-21",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-21",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "longName": "9952156 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.cardinal.com/role/Acquisitions",
     "longName": "9952157 - Disclosure - Acquisitions",
     "shortName": "Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.cardinal.com/role/Divestitures",
     "longName": "9952158 - Disclosure - Divestitures",
     "shortName": "Divestitures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance",
     "longName": "9952159 - Disclosure - Restructuring and Employee Severance",
     "shortName": "Restructuring and Employee Severance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets",
     "longName": "9952160 - Disclosure - Goodwill and Other Intangible Assets",
     "shortName": "Goodwill and Other Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings",
     "longName": "9952161 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation",
     "longName": "9952162 - Disclosure - Commitments, Contingent Liabilities and Litigation",
     "shortName": "Commitments, Contingent Liabilities and Litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cardinal.com/role/IncomeTaxes",
     "longName": "9952163 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cardinal.com/role/FairValueMeasurements",
     "longName": "9952164 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cardinal.com/role/FinancialInstruments",
     "longName": "9952165 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cardinal.com/role/ShareholdersEquity",
     "longName": "9952166 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc",
     "longName": "9952167 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.cardinal.com/role/SegmentInformation",
     "longName": "9952168 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.cardinal.com/role/ShareBasedCompensation",
     "longName": "9952169 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables",
     "longName": "9954474 - Disclosure - Restructuring and Employee Severance (Tables)",
     "shortName": "Restructuring and Employee Severance (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables",
     "longName": "9954475 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cardinal.com/role/FairValueMeasurementsTables",
     "longName": "9954476 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.cardinal.com/role/FinancialInstrumentsTables",
     "longName": "9954477 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cardinal.com/role/ShareholdersEquityTables",
     "longName": "9954478 - Disclosure - Shareholders' Equity (Tables)",
     "shortName": "Shareholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables",
     "longName": "9954479 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.cardinal.com/role/SegmentInformationTables",
     "longName": "9954480 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.cardinal.com/role/ShareBasedCompensationTables",
     "longName": "9954481 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954482 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-38",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "rate",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "us-gaap:MajorCustomersPolicyPolicyTextBlock",
       "div",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-38",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "rate",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "us-gaap:MajorCustomersPolicyPolicyTextBlock",
       "div",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.cardinal.com/role/AcquisitionsDetails",
     "longName": "9954483 - Disclosure - Acquisitions (Details)",
     "shortName": "Acquisitions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-39",
      "name": "us-gaap:BusinessCombinationPriceOfAcquisitionExpected",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-39",
      "name": "us-gaap:BusinessCombinationPriceOfAcquisitionExpected",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.cardinal.com/role/DivestituresDetails",
     "longName": "9954484 - Disclosure - Divestitures (Details)",
     "shortName": "Divestitures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-43",
      "name": "us-gaap:EquityMethodInvestmentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-43",
      "name": "us-gaap:EquityMethodInvestmentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
     "longName": "9954485 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
     "longName": "9954486 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails",
     "longName": "9954487 - Disclosure - Restructuring and Employee Severance Narrative (Details)",
     "shortName": "Restructuring and Employee Severance Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
     "longName": "9954488 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails",
     "longName": "9954489 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
     "longName": "9954490 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)",
     "shortName": "Goodwill and Other Intangible Assets Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
     "longName": "9954491 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
     "longName": "9954492 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)",
     "shortName": "Commitments, Contingent Liabilities and Litigation Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cah:IncomefromSettlementsofClassActionLawsuits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954493 - Disclosure - Income Taxes Narrative (Details)",
     "shortName": "Income Taxes Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9954494 - Disclosure - Fair Value Measurements Narrative (Details)",
     "shortName": "Fair Value Measurements Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-106",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-106",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
     "longName": "9954495 - Disclosure - Financial Instruments Narrative (Details)",
     "shortName": "Financial Instruments Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails",
     "longName": "9954496 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)",
     "shortName": "Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
     "longName": "9954497 - Disclosure - Shareholders' Equity Narrative (Details)",
     "shortName": "Shareholders' Equity Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
     "longName": "9954498 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails",
     "longName": "9954499 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails",
     "longName": "9954500 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
     "longName": "9954501 - Disclosure - Segment Information Narrative (Details)",
     "shortName": "Segment Information Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
     "longName": "9954502 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)",
     "shortName": "Segment Information (Revenue by Reportable Segment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-155",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
     "longName": "9954503 - Disclosure - Segment Information Revenue by Geographical Segments (Details)",
     "shortName": "Segment Information Revenue by Geographical Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-171",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
     "longName": "9954504 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)",
     "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-167",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
     "longName": "9954505 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)",
     "shortName": "Segment Information (Assets by Reportable Segment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-175",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "div",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
     "longName": "9954506 - Disclosure - Share-Based Compensation Narrative (Details)",
     "shortName": "Share-Based Compensation Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
     "longName": "9954507 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
     "longName": "9954508 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-183",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-187",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
     "longName": "9954509 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-193",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-193",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cah-20240930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "cah_A375MillionShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "A375MillionShareRepurchaseProgramMember",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "#375 million share repurchase program",
        "label": "$375 million share repurchase program [Member]",
        "documentation": "$375 million share repurchase program"
       }
      }
     },
     "auth_ref": []
    },
    "cah_A500MillionShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "A500MillionShareRepurchaseProgramMember",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$500 million share repurchase program",
        "label": "$500 million share repurchase program [Member]",
        "documentation": "$500 million share repurchase program [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_AL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "AL",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ALABAMA",
        "label": "ALABAMA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable, Current",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r767"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r995"
     ]
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation Adjustments",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r14",
      "r23",
      "r96",
      "r97",
      "r186",
      "r589",
      "r893",
      "r894"
     ]
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r14",
      "r23"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r98",
      "r175",
      "r580",
      "r613",
      "r614"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14",
      "r23",
      "r489",
      "r492",
      "r528",
      "r609",
      "r610",
      "r892",
      "r893",
      "r894",
      "r901",
      "r902",
      "r903",
      "r905"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cah_AggregateAnnualAssessment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "AggregateAnnualAssessment",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Annual Assessment",
        "label": "Aggregate Annual Assessment",
        "documentation": "Aggregate Annual Assessment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r812",
      "r822",
      "r854"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r805",
      "r815",
      "r825",
      "r857"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "cah_AgreementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "AgreementsAxis",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreements [Axis]",
        "label": "Agreements [Axis]",
        "documentation": "Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "cah_AgreementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "AgreementsDomain",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreements [Domain]",
        "label": "Agreements [Domain]",
        "documentation": "Agreements [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r816",
      "r826",
      "r850",
      "r858",
      "r862",
      "r870"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operating Segment",
        "label": "Other Operating Segment [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r730",
      "r731"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r438"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r293",
      "r300",
      "r737"
     ]
    },
    "cah_Amortizationandotheracquisitionrelatedcosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "Amortizationandotheracquisitionrelatedcosts",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization and other acquisition-related costs",
        "label": "Amortization and other acquisition-related costs",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "cah_AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from computation of EPS as a result of the net loss during the period",
        "label": "Antidilutive Securities Excluded from computation of EPS as a result of the net loss during the period",
        "documentation": "Antidilutive Securities Excluded from computation of EPS as a result of the net loss during the period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14",
      "r23",
      "r892",
      "r893",
      "r894"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r156",
      "r171",
      "r202",
      "r232",
      "r239",
      "r258",
      "r262",
      "r274",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r477",
      "r481",
      "r512",
      "r576",
      "r653",
      "r730",
      "r731",
      "r767",
      "r793",
      "r951",
      "r952",
      "r987"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r178",
      "r202",
      "r274",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r477",
      "r481",
      "r512",
      "r767",
      "r951",
      "r952",
      "r987"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r80",
      "r81",
      "r121",
      "r163",
      "r164"
     ]
    },
    "cah_AtHomeSolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "AtHomeSolutionsMember",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "at-Home Solutions [Member]",
        "label": "at-Home Solutions [Member]",
        "documentation": "at-Home Solutions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies [Abstract]",
        "label": "Basis of Presentation and Summary of Significant Accounting Policies [Abstract]",
        "documentation": "Basis of Presentation and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.cardinal.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r471",
      "r750",
      "r751"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.cardinal.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r471",
      "r750",
      "r751"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.cardinal.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/Acquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination Disclosure",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r472"
     ]
    },
    "us-gaap_BusinessCombinationPriceOfAcquisitionExpected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationPriceOfAcquisitionExpected",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Price of Acquisition, Expected",
        "label": "Business Combination, Price of Acquisition, Expected",
        "documentation": "Purchase price of expected business acquisition prior to consideration being transferred. Excludes asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "cah_CVSHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "CVSHealthMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVS Health",
        "label": "CVS Health [Member]",
        "documentation": "CVS Health [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cah_CarryingAmountofLongTermandotherShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "CarryingAmountofLongTermandotherShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "label": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r167",
      "r721"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r967",
      "r968"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and equivalents at beginning of period",
        "periodEndLabel": "Cash and equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r112",
      "r199"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r112"
     ]
    },
    "us-gaap_CashFlowHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowHedgingMember",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flow Hedging [Member]",
        "label": "Cash Flow Hedging [Member]",
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "cah_CityOfBaltimoreMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "CityOfBaltimoreMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City of Baltimore",
        "label": "City of Baltimore [Member]",
        "documentation": "City of Baltimore"
       }
      }
     },
     "auth_ref": []
    },
    "cah_ClassActionLawsuitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "ClassActionLawsuitsMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Action Lawsuits [Member]",
        "label": "Class Action Lawsuits [Member]",
        "documentation": "Class Action Lawsuits [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r234",
      "r378",
      "r379",
      "r380",
      "r382",
      "r385",
      "r390",
      "r392",
      "r618",
      "r619",
      "r620",
      "r621",
      "r744",
      "r880",
      "r898"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper [Member]",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r338",
      "r785",
      "r786",
      "r787",
      "r790"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments, Contingent Liabilities and Litigation",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r328",
      "r329",
      "r706",
      "r939",
      "r945"
     ]
    },
    "cah_CommittedReceivablesSalesFacilityProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "CommittedReceivablesSalesFacilityProgramMember",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Committed Receivables Sales Facility Program [Member]",
        "label": "Committed Receivables Sales Facility Program [Member]",
        "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash dividends declared per common share",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r782",
      "r783",
      "r785",
      "r786",
      "r787",
      "r790",
      "r901",
      "r902",
      "r905",
      "r966",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares, without par value:",
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Shares Authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r641"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Shares, Issued",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Value, Issued",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r579",
      "r767"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r183",
      "r185",
      "r192",
      "r572",
      "r590",
      "r591"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income/(loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r137",
      "r183",
      "r185",
      "r191",
      "r571",
      "r590"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r76",
      "r77",
      "r269",
      "r705"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r76",
      "r77",
      "r269",
      "r616",
      "r705"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r76",
      "r77",
      "r269",
      "r705",
      "r889"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk, Percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r76",
      "r77",
      "r269"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r32",
      "r76",
      "r143",
      "r705"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r76",
      "r77",
      "r269",
      "r705"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r204",
      "r232",
      "r241",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r730",
      "r731",
      "r951",
      "r952"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r204",
      "r232",
      "r241",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r730",
      "r731",
      "r951",
      "r952"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate",
        "verboseLabel": "Corporate",
        "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r910"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Goods and Services Sold",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r536"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r949"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r949",
      "r950"
     ]
    },
    "us-gaap_CurrencySwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrencySwapMember",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency Swap [Member]",
        "label": "Currency Swap [Member]",
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r269"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r936",
      "r937"
     ]
    },
    "cah_DateInitiatedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "DateInitiatedAxis",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date Initiated [Axis]",
        "label": "Date Initiated [Axis]",
        "documentation": "Date Initiated"
       }
      }
     },
     "auth_ref": []
    },
    "cah_DateInitiatedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "DateInitiatedDomain",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date Initiated [Domain]",
        "label": "Date Initiated [Domain]",
        "documentation": "Date Initiated [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r200",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r337",
      "r338",
      "r350",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r366",
      "r373",
      "r374",
      "r376",
      "r523"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r85",
      "r86",
      "r145",
      "r147",
      "r204",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r766",
      "r899",
      "r940",
      "r941",
      "r942",
      "r985",
      "r986"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r511",
      "r740",
      "r741",
      "r968",
      "r969",
      "r970",
      "r971",
      "r978"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r375",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r766",
      "r899",
      "r985",
      "r986"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r204",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r766",
      "r899",
      "r940",
      "r941",
      "r942",
      "r985",
      "r986"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information by period of debt redemption feature under terms of debt agreement."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r45",
      "r48",
      "r78",
      "r130",
      "r131",
      "r204",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r375",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r766",
      "r899",
      "r985",
      "r986"
     ]
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, Long-term and Short-term, Combined Amount",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes and other liabilities",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r232",
      "r244",
      "r262",
      "r730",
      "r731"
     ]
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetNotionalAmount",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset, Notional Amount",
        "label": "Derivative Asset, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r694",
      "r696",
      "r698",
      "r963",
      "r964",
      "r965"
     ]
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Contract",
        "label": "Derivative Assets (Liabilities), at Fair Value, Net",
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r969",
      "r970",
      "r971"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, Name [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r633",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r667",
      "r668",
      "r669",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676",
      "r691",
      "r693",
      "r697",
      "r699",
      "r781",
      "r783",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r979",
      "r980"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r70",
      "r72",
      "r139",
      "r631",
      "r633",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r667",
      "r668",
      "r669",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676",
      "r691",
      "r693",
      "r697",
      "r699",
      "r723",
      "r781",
      "r783",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r979",
      "r980"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r68",
      "r70"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r140"
     ]
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r890"
     ]
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityNotionalAmount",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional Amount",
        "label": "Derivative Liability, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r694",
      "r695",
      "r698",
      "r963",
      "r964",
      "r965"
     ]
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r61",
      "r62",
      "r63",
      "r67",
      "r69",
      "r70",
      "r73",
      "r74",
      "r75",
      "r494"
     ]
    },
    "cah_DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount",
        "label": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount",
        "documentation": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated as Hedging Instrument",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Developed technology and other",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r936",
      "r937"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r406",
      "r434",
      "r435",
      "r437",
      "r753"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r897",
      "r938"
     ]
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/Divestitures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r120"
     ]
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Dividends",
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r132"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r221",
      "r223",
      "r225",
      "r226",
      "r227",
      "r231",
      "r469",
      "r475",
      "r497",
      "r498",
      "r573",
      "r592",
      "r724"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings/(loss) per common share attributable to Cardinal Health, Inc.:",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r223",
      "r225",
      "r226",
      "r227",
      "r231",
      "r469",
      "r475",
      "r497",
      "r498",
      "r573",
      "r592",
      "r724"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Earnings Per Share Attributable to Cardinal Health, Inc.",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r228",
      "r229",
      "r230"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates changes on cash and equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r755"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit related to share-based compensation",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee- Related Costs",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r160",
      "r186",
      "r187",
      "r188",
      "r205",
      "r206",
      "r207",
      "r209",
      "r214",
      "r216",
      "r218",
      "r233",
      "r275",
      "r276",
      "r306",
      "r393",
      "r456",
      "r457",
      "r466",
      "r467",
      "r468",
      "r470",
      "r474",
      "r475",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r496",
      "r514",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r524",
      "r526",
      "r528",
      "r589",
      "r609",
      "r610",
      "r611",
      "r626",
      "r679"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails",
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r465",
      "r882",
      "r883",
      "r884",
      "r959",
      "r960",
      "r961",
      "r962"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Ownership Percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments, Fair Value Disclosure",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investments accounted under the equity method."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r967",
      "r968",
      "r978"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r812",
      "r822",
      "r854"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r809",
      "r819",
      "r851"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "cah_FY24Q1GoodwillImpairmentGMPDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "FY24Q1GoodwillImpairmentGMPDMember",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FY24 Q1 GMPD Goodwill Impairment [Member]",
        "label": "FY24 Q1 Goodwill Impairment - GMPD [Member]",
        "documentation": "FY24 Q1 Goodwill Impairment - GMPD"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FacilityClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FacilityClosingMember",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Exit and Other Costs",
        "label": "Facility Closing [Member]",
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "cah_FacilityExitAndOtherCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "FacilityExitAndOtherCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Exit and Other Costs",
        "label": "Facility Exit and Other Costs",
        "documentation": "Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r508",
      "r759"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r508",
      "r759"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r499",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r508",
      "r510",
      "r530",
      "r531",
      "r532",
      "r740",
      "r741",
      "r747",
      "r748",
      "r749",
      "r759",
      "r762"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r504",
      "r759",
      "r970",
      "r981"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueHedgingMember",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hedging",
        "label": "Fair Value Hedging [Member]",
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel12And3Member",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 1, 2 and 3",
        "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]",
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3)."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r956",
      "r968",
      "r979"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a01",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r395",
      "r400",
      "r501",
      "r508",
      "r530",
      "r747",
      "r748",
      "r749",
      "r759"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a02",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r395",
      "r400",
      "r501",
      "r502",
      "r508",
      "r531",
      "r740",
      "r741",
      "r747",
      "r748",
      "r749",
      "r759"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a03",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r501",
      "r502",
      "r503",
      "r504",
      "r508",
      "r532",
      "r740",
      "r741",
      "r747",
      "r748",
      "r749",
      "r759",
      "r762"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r504",
      "r759",
      "r970",
      "r981"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r499",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r508",
      "r510",
      "r530",
      "r531",
      "r532",
      "r740",
      "r741",
      "r747",
      "r748",
      "r749",
      "r759",
      "r762"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r981"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments Disclosure",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r278",
      "r299",
      "r737"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r718",
      "r737"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r718",
      "r737"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r718",
      "r737"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r718",
      "r737"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r303",
      "r304",
      "r537",
      "r538",
      "r718"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Intangible",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r299",
      "r538",
      "r737"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r299",
      "r303",
      "r304",
      "r305",
      "r537",
      "r718",
      "r737"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r303",
      "r304",
      "r718"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Intangible",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r934"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Amortization Period (Years)",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_ForeignExchangeContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignExchangeContractMember",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Exchange Contract [Member]",
        "label": "Foreign Exchange Contract [Member]",
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r747",
      "r758",
      "r759"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r816",
      "r826",
      "r858"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r816",
      "r826",
      "r858"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r816",
      "r826",
      "r858"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r816",
      "r826",
      "r858"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r816",
      "r826",
      "r858"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "stpr_GA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "GA",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GEORGIA",
        "label": "GEORGIA"
       }
      }
     },
     "auth_ref": []
    },
    "cah_GMPDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "GMPDMember",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GMPD",
        "label": "GMPD [Member]",
        "documentation": "Medical [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (Loss) on Sale of Investments",
        "label": "Gain (Loss) on Sale of Investments",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossRelatedToLitigationSettlement",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Litigation (recoveries)/charges, net",
        "terseLabel": "Gain (Loss) from Litigation Settlement",
        "label": "Gain (Loss) from Litigation Settlement",
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r946"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at June 30, 2024",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r279",
      "r569",
      "r731",
      "r736",
      "r760",
      "r767",
      "r918",
      "r925"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill acquired, net of purchase price adjustments",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r736"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r928"
     ]
    },
    "cah_GoodwillImpairmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "GoodwillImpairmentAxis",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill Impairment [Axis]",
        "label": "Goodwill Impairment [Axis]",
        "documentation": "Goodwill Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "cah_GoodwillImpairmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "GoodwillImpairmentDomain",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill Impairment [Domain]",
        "label": "Goodwill Impairment [Domain]",
        "documentation": "Goodwill Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r280",
      "r286",
      "r291",
      "r736",
      "r760"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r736"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross margin",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r103",
      "r155",
      "r202",
      "r274",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r512",
      "r725",
      "r730",
      "r907",
      "r909",
      "r911",
      "r912",
      "r913",
      "r951"
     ]
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r486"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "cah_IPRDTrademarksandOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "IPRDTrademarksandOtherMember",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks and patents",
        "label": "IPR&amp;D,TrademarksandOther [Member]",
        "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": []
    },
    "cah_IVCApril2023AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "IVCApril2023AgreementMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IVC April 2023 Agreement",
        "label": "IVC April 2023 Agreement [Member]",
        "documentation": "IVC April 2023 Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "cah_IncomeAsAResultOfPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "IncomeAsAResultOfPrepayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income As A Result Of Prepayments",
        "label": "Income As A Result Of Prepayments",
        "documentation": "Income as a result of prepayments at a pre-negotiated discount certain future payment amounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings/(loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r150",
      "r155",
      "r574",
      "r585",
      "r725",
      "r730",
      "r907",
      "r909",
      "r911",
      "r912",
      "r913"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r315",
      "r320",
      "r505",
      "r506",
      "r509",
      "r606",
      "r608",
      "r664",
      "r718",
      "r761",
      "r997"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r320",
      "r505",
      "r506",
      "r509",
      "r606",
      "r608",
      "r664",
      "r718",
      "r761",
      "r997"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r443",
      "r444",
      "r449",
      "r454",
      "r755",
      "r958"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r443",
      "r444",
      "r449",
      "r454",
      "r755",
      "r958"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r440",
      "r443",
      "r445",
      "r446",
      "r447",
      "r452",
      "r453",
      "r458",
      "r460",
      "r463",
      "r464",
      "r623",
      "r755"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for/(benefit from) income taxes",
        "negatedTerseLabel": "Provision for/(benefit from) income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r217",
      "r218",
      "r232",
      "r247",
      "r262",
      "r442",
      "r443",
      "r459",
      "r593",
      "r755"
     ]
    },
    "cah_IncomefromSettlementsofClassActionLawsuits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "IncomefromSettlementsofClassActionLawsuits",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from Settlements of Class Action Lawsuits",
        "label": "Income from Settlements of Class Action Lawsuits",
        "documentation": "Income from Settlements of Class Action Lawsuits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increase in inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other accrued liabilities and operating items, net",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in trade receivables",
        "label": "Increase (Decrease) in Receivables",
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r297",
      "r302",
      "r737"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r302",
      "r305",
      "r737"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Intangible",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r302",
      "r737"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r297",
      "r302",
      "r737"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r816",
      "r826",
      "r850",
      "r858",
      "r862",
      "r870"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r874"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r874"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r874"
     ]
    },
    "us-gaap_InsuranceRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance Recoveries",
        "label": "Insurance Recoveries",
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Intangible, Total other intangible assets",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Intangible, Total other intangible assets",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r934",
      "r935"
     ]
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and other intangibles, net",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "cah_IntegratedOncologyNetworkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "IntegratedOncologyNetworkMember",
     "presentation": [
      "http://www.cardinal.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Integrated Oncology Network",
        "label": "Integrated Oncology Network [Member]",
        "documentation": "Integrated Oncology Network [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, net",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r239",
      "r243",
      "r249",
      "r262",
      "r522",
      "r730",
      "r731"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Income (Expense), Nonoperating",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r895",
      "r909"
     ]
    },
    "us-gaap_InterestRateSwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestRateSwapMember",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swap",
        "label": "Interest Rate Swap [Member]",
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r788",
      "r789"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Internal Revenue Service (IRS) [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r722",
      "r767"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other investments",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r967",
      "r968",
      "r978"
     ]
    },
    "cah_January2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "January2023Member",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2023",
        "label": "January 2023 [Member]",
        "documentation": "January 2023"
       }
      }
     },
     "auth_ref": []
    },
    "cah_June2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "June2027Member",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2027",
        "label": "June 2027 [Member]",
        "documentation": "June 2027"
       }
      }
     },
     "auth_ref": []
    },
    "cah_LawsuitTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "LawsuitTypeAxis",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Axis]",
        "documentation": "Lawsuit Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r149",
      "r583",
      "r767",
      "r900",
      "r914",
      "r982"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Shareholders\u2019 Deficit",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r166",
      "r202",
      "r274",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r478",
      "r481",
      "r482",
      "r512",
      "r767",
      "r951",
      "r987",
      "r988"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Increase (Decrease), Net",
        "label": "Line of Credit Facility, Increase (Decrease), Net",
        "documentation": "Amount of increase (decrease) of the credit facility."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r88"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case Type",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "litigation settlement liability recorded",
        "label": "Estimated Litigation Liability",
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r946"
     ]
    },
    "us-gaap_LitigationReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationReserveCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Litigation Liability, Current",
        "label": "Estimated Litigation Liability, Current",
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r946"
     ]
    },
    "us-gaap_LitigationSettlementLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Settlement, Loss",
        "label": "Litigation Settlement, Loss",
        "documentation": "Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "cah_LitigationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "LitigationTypeDomain",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Type [Domain]",
        "label": "Litigation Type [Domain]",
        "documentation": "[Domain] for Litigation Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsHeldForSaleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongLivedAssetsHeldForSaleLineItems",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long Lived Assets Held-for-sale [Line Items]",
        "label": "Long-Lived Assets Held-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term obligations, less current portion",
        "label": "Long-Term Debt and Lease Obligation",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r577"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of long-term obligations and other short-term borrowings",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r940",
      "r941",
      "r942"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r42",
      "r940",
      "r941",
      "r942"
     ]
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermPurchaseCommitmentPeriod",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Purchase Commitment, Period",
        "label": "Long-Term Purchase Commitment, Period",
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency Nature [Axis]",
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r336",
      "r439",
      "r615",
      "r738",
      "r947",
      "r948"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r336",
      "r439",
      "r738",
      "r947",
      "r948"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r336",
      "r439",
      "r738",
      "r947",
      "r948"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency Accrual",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r881"
     ]
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss Contingency Accrual, Period Increase (Decrease)",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency Accrual, Payments",
        "label": "Loss Contingency Accrual, Payments",
        "documentation": "Amount of cash outflow reducing loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyClaimsSettledNumber",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Claims Settled, Number",
        "label": "Loss Contingency, Claims Settled, Number",
        "documentation": "Number of claims settled."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r948"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Estimate of Possible Loss",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r335",
      "r336",
      "r439",
      "r738"
     ]
    },
    "cah_LossContingencyLawsuitsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "LossContingencyLawsuitsNumber",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Lawsuits, Number",
        "label": "Loss Contingency, Lawsuits, Number",
        "documentation": "Loss Contingency, Lawsuits, Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Nature [Domain]",
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r336",
      "r439",
      "r615",
      "r738",
      "r947",
      "r948"
     ]
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNumberOfPlaintiffs",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of plaintiffs",
        "label": "Loss Contingency, Number of Plaintiffs",
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r948"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r269",
      "r746",
      "r776",
      "r780",
      "r955",
      "r996",
      "r998",
      "r999",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_MajorCustomersPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MajorCustomersPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major Customers, Policy",
        "label": "Major Customers, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r118"
     ]
    },
    "cah_MaturityDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "MaturityDateAxis",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity Date [Axis]",
        "label": "Maturity Date [Axis]",
        "documentation": "Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "cah_MaturityDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "MaturityDateDomain",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity Date [Domain]",
        "label": "Maturity Date [Domain]",
        "documentation": "Maturity Date [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r401",
      "r439",
      "r504",
      "r535",
      "r605",
      "r607",
      "r615",
      "r632",
      "r633",
      "r684",
      "r686",
      "r688",
      "r689",
      "r700",
      "r716",
      "r717",
      "r735",
      "r744",
      "r752",
      "r762",
      "r763",
      "r764",
      "r765",
      "r777",
      "r953",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r401",
      "r439",
      "r504",
      "r535",
      "r605",
      "r607",
      "r615",
      "r632",
      "r633",
      "r684",
      "r686",
      "r688",
      "r689",
      "r700",
      "r716",
      "r717",
      "r735",
      "r744",
      "r752",
      "r762",
      "r763",
      "r764",
      "r777",
      "r953",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r148",
      "r202",
      "r274",
      "r339",
      "r342",
      "r343",
      "r344",
      "r348",
      "r349",
      "r512",
      "r582",
      "r643"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r269",
      "r746",
      "r776",
      "r780",
      "r955",
      "r996",
      "r998",
      "r999",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net earnings/(loss) attributable to Cardinal Health, Inc.",
        "terseLabel": "Net earnings",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r114",
      "r151",
      "r164",
      "r181",
      "r184",
      "r188",
      "r202",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r224",
      "r274",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r469",
      "r475",
      "r498",
      "r512",
      "r588",
      "r661",
      "r677",
      "r678",
      "r791",
      "r951"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests",
        "negatedLabel": "Less: comprehensive income attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r138",
      "r181",
      "r184",
      "r214",
      "r217",
      "r218",
      "r587",
      "r894"
     ]
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetInvestmentHedgingMember",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Investment Hedging",
        "label": "Net Investment Hedging [Member]",
        "documentation": "Hedges of a net investment in a foreign operation."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net tax withholding from share-based compensation",
        "label": "Net proceeds/(tax withholdings) from share-based compensation",
        "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Financial Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cah_NewYorkOpioidStewardshipActMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "NewYorkOpioidStewardshipActMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York Opioid Stewardship Act [Member]",
        "label": "New York Opioid Stewardship Act [Member]",
        "documentation": "New York Opioid Stewardship Act"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r816",
      "r826",
      "r850",
      "r858"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-US [Member]",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interests",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r393",
      "r901",
      "r902",
      "r903",
      "r905",
      "r1027"
     ]
    },
    "us-gaap_NondesignatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NondesignatedMember",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not Designated as Hedging Instrument",
        "label": "Not Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "cah_NuclearAndPrecisionHealthSolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "NuclearAndPrecisionHealthSolutionsMember",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nuclear and Precision Health Solutions [Member]",
        "label": "Nuclear and Precision Health Solutions [Member]",
        "documentation": "Nuclear and Precision Health Solutions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r908"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Reportable Segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r734",
      "r908"
     ]
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open Tax Year",
        "label": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating earnings/(loss)",
        "terseLabel": "Total operating earnings",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r725",
      "r907",
      "r909",
      "r911",
      "r912",
      "r913"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r730",
      "r731"
     ]
    },
    "cah_OpioidLawsuitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "OpioidLawsuitsMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opioid Lawsuits [Member]",
        "label": "Opioid Lawsuits [Member]",
        "documentation": "Opioid Lawsuits [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cah_OpioidLitigationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "OpioidLitigationAxis",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opioid Litigation",
        "label": "Opioid Litigation [Axis]",
        "documentation": "Opioid Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "cah_OpioidLitigationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "OpioidLitigationDomain",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opioid Litigation [Domain]",
        "label": "Opioid Litigation [Domain]",
        "documentation": "Opioid Litigation [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cah_OptiFreightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "OptiFreightMember",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OptiFreight [Member]",
        "label": "OptiFreight [Member]",
        "documentation": "OptiFreight"
       }
      }
     },
     "auth_ref": []
    },
    "cah_OptumRxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "OptumRxMember",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OptumRx",
        "label": "OptumRx [Member]",
        "documentation": "OptumRx"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r767"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive income, before reclassifications",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r23",
      "r187",
      "r514",
      "r517",
      "r520",
      "r589",
      "r892"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r589"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r483",
      "r484",
      "r487"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments and other",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r589"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income/(loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r20",
      "r182",
      "r185",
      "r190",
      "r214",
      "r514",
      "r515",
      "r520",
      "r570",
      "r589",
      "r892",
      "r893"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income/(loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income, net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r14",
      "r137",
      "r182",
      "r185",
      "r214"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTax",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss), Tax",
        "label": "Other Comprehensive Income (Loss), Tax",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r186",
      "r190",
      "r442",
      "r461",
      "r462",
      "r514",
      "r518",
      "r520",
      "r570",
      "r589"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other (income)/expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Nonoperating Income (Expense)",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_OtherShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Short-term Borrowings",
        "label": "Other Short-Term Borrowings",
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r640"
     ]
    },
    "cah_OutcomesDivestitureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "OutcomesDivestitureAxis",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outcomes Divestiture [Axis]",
        "label": "Outcomes Divestiture [Axis]",
        "documentation": "Outcomes Divestiture"
       }
      }
     },
     "auth_ref": []
    },
    "cah_OutcomesDivestitureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "OutcomesDivestitureDomain",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outcomes Divestiture [Domain]",
        "label": "Outcomes Divestiture [Domain]",
        "documentation": "Outcomes Divestiture [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cah_OutcomesDivestitureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "OutcomesDivestitureMember",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outcomes Divestiture",
        "label": "Outcomes Divestiture [Member]",
        "documentation": "Outcomes Divestiture"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r804",
      "r814",
      "r824",
      "r856"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r807",
      "r817",
      "r827",
      "r859"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r807",
      "r817",
      "r827",
      "r859"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for Legal Settlements",
        "label": "Payments for Legal Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Share repurchase program activity",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments and other adjustments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r896"
     ]
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDividendsCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends on common shares",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to Acquire Businesses, Gross",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r473"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions to property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "cah_PercentageSettlingSubdivisions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "PercentageSettlingSubdivisions",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage Settling Subdivisions [Line Items]",
        "label": "Percentage Settling Subdivisions",
        "documentation": "Percentage Settling Subdivisions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Share Units",
        "verboseLabel": "Performance Share Unit",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "cah_PharmaceuticalAndSpecialtySolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "PharmaceuticalAndSpecialtySolutionsMember",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmaceutical and Specialty Solutions",
        "label": "Pharmaceutical and Specialty Solutions [Member]",
        "documentation": "Pharmaceutical and Specialty Solutions"
       }
      }
     },
     "auth_ref": []
    },
    "cah_PlaintiffTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "PlaintiffTypeAxis",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Axis]",
        "documentation": "Plaintiff Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cah_PlaintiffTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "PlaintiffTypeDomain",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plaintiff Type [Domain]",
        "label": "Plaintiff Type [Domain]",
        "documentation": "[Domain] for Plaintiff Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares, without par value:",
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Shares Authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r641"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Shares Issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r378"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Value, Issued",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r578",
      "r767"
     ]
    },
    "cah_PrivatePartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "PrivatePartiesMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Parties [Member]",
        "label": "Private Parties [Member]",
        "documentation": "Private Parties [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from divestitures, net of cash sold",
        "label": "Proceeds from Divestiture of Businesses",
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ProceedsFromHedgeInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromHedgeInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from net investment hedge terminations",
        "label": "Proceeds from Hedge, Investing Activities",
        "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r887"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposal of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "cah_ProductLiabilityLawsuitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "ProductLiabilityLawsuitsMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Liability Lawsuits [Member]",
        "label": "Product Liability Lawsuits [Member]",
        "documentation": "Product Liability Lawsuits [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net earnings/(loss)",
        "terseLabel": "Net earnings/(loss)",
        "verboseLabel": "Net earnings",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r181",
      "r184",
      "r195",
      "r202",
      "r208",
      "r214",
      "r217",
      "r218",
      "r274",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r469",
      "r475",
      "r476",
      "r479",
      "r480",
      "r498",
      "r512",
      "r574",
      "r586",
      "r625",
      "r661",
      "r677",
      "r678",
      "r756",
      "r757",
      "r792",
      "r894",
      "r951"
     ]
    },
    "cah_ProjectCostsOnInvestmentAndOtherSpending": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "ProjectCostsOnInvestmentAndOtherSpending",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Project Costs On Investment And Other Spending",
        "label": "Project Costs On Investment And Other Spending",
        "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r527",
      "r575",
      "r584",
      "r767"
     ]
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for bad debts",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r277"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r394",
      "r401",
      "r429",
      "r430",
      "r431",
      "r439",
      "r504",
      "r533",
      "r534",
      "r535",
      "r605",
      "r607",
      "r615",
      "r632",
      "r633",
      "r684",
      "r686",
      "r688",
      "r689",
      "r700",
      "r716",
      "r717",
      "r735",
      "r744",
      "r752",
      "r762",
      "r763",
      "r764",
      "r765",
      "r777",
      "r783",
      "r943",
      "r953",
      "r970",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r394",
      "r401",
      "r429",
      "r430",
      "r431",
      "r439",
      "r504",
      "r533",
      "r534",
      "r535",
      "r605",
      "r607",
      "r615",
      "r632",
      "r633",
      "r684",
      "r686",
      "r688",
      "r689",
      "r700",
      "r716",
      "r717",
      "r735",
      "r744",
      "r752",
      "r762",
      "r763",
      "r764",
      "r765",
      "r777",
      "r783",
      "r943",
      "r953",
      "r970",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables, net",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amounts reclassified to earnings",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r23",
      "r187",
      "r514",
      "r519",
      "r520",
      "r589",
      "r892"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI, Net of Tax [Roll Forward]",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets by Reportable Segment",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Profit by Reportable Segment",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39"
     ]
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r39"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r809",
      "r819",
      "r851"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reduction of long-term obligations",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r621"
     ]
    },
    "us-gaap_ReportingUnitAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReportingUnitAxis",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Unit [Axis]",
        "label": "Reporting Unit [Axis]",
        "documentation": "Information by reporting unit."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r736"
     ]
    },
    "us-gaap_ReportingUnitDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReportingUnitDomain",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Unit [Domain]",
        "label": "Reporting Unit [Domain]",
        "documentation": "Level of reporting at which goodwill is tested for impairment."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r736"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r810",
      "r820",
      "r852"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r811",
      "r821",
      "r853"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r818",
      "r828",
      "r860"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Restricted Share Unit",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Activities [Abstract]",
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeverance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Employee Severance",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r319",
      "r322",
      "r327"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restructuring and employee severance",
        "totalLabel": "Total restructuring and employee severance",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r323",
      "r324",
      "r944"
     ]
    },
    "us-gaap_RestructuringChargesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringChargesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges [Abstract]",
        "label": "Restructuring Charges [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r324",
      "r325"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Restructuring Costs",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r325"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings/(accumulated deficit)",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r132",
      "r581",
      "r612",
      "r614",
      "r622",
      "r642",
      "r767"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings/(Accumulated Deficit)",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r205",
      "r206",
      "r207",
      "r209",
      "r214",
      "r216",
      "r218",
      "r275",
      "r276",
      "r306",
      "r456",
      "r457",
      "r466",
      "r467",
      "r468",
      "r470",
      "r474",
      "r475",
      "r488",
      "r490",
      "r491",
      "r493",
      "r496",
      "r524",
      "r526",
      "r609",
      "r611",
      "r626",
      "r1027"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r189",
      "r202",
      "r232",
      "r240",
      "r241",
      "r256",
      "r262",
      "r265",
      "r267",
      "r269",
      "r274",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r512",
      "r574",
      "r730",
      "r951"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility [Member]",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r888"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r402",
      "r904"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r402",
      "r881",
      "r904"
     ]
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r983",
      "r984"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.cardinal.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r471"
     ]
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails",
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r465",
      "r882",
      "r883",
      "r884",
      "r959",
      "r960",
      "r961",
      "r962"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r967",
      "r968"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Finite-Lived [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r299",
      "r303",
      "r304",
      "r305",
      "r537",
      "r718",
      "r737"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Table]",
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r736"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill by Reportable Segment",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r736",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Indefinite-Lived [Table]",
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r302",
      "r305",
      "r737"
     ]
    },
    "us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfLongLivedAssetsHeldForSaleTable",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long Lived Assets Held-for-sale [Table]",
        "label": "Long-Lived Asset, Held-for-Sale [Table]",
        "documentation": "Disclosure of information about long-lived asset held for sale. Includes, but is not limited to, description of fact and circumstance leading to expected disposal, manner and timing of disposal, amount of asset held for sale, gain (loss) recognized in statement of income, and statement of income caption that includes gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r17"
     ]
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans",
        "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restructuring and Employee Severance",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r122",
      "r123"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r124"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r128",
      "r130",
      "r131",
      "r132",
      "r172",
      "r173",
      "r174",
      "r234",
      "r378",
      "r379",
      "r380",
      "r382",
      "r385",
      "r390",
      "r392",
      "r618",
      "r619",
      "r620",
      "r621",
      "r744",
      "r880",
      "r898"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Definite and Indefinite-Lived Intangible Assets",
        "label": "Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r232",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r269",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r305",
      "r321",
      "r326",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r727",
      "r730",
      "r731",
      "r736",
      "r779",
      "r996",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r628",
      "r629",
      "r630",
      "r685",
      "r687",
      "r690",
      "r701",
      "r704",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r720",
      "r745",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r778",
      "r783",
      "r955",
      "r996",
      "r998",
      "r999",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r252",
      "r254",
      "r255",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r726",
      "r728",
      "r729",
      "r730",
      "r732",
      "r733",
      "r734"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "cah_SegmentRevenuebyGeographicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "SegmentRevenuebyGeographicLineItems",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Revenue by Geographic [Line Items]",
        "label": "Segment Revenue by Geographic [Line Items]",
        "documentation": "[Line Items] for Segment Revenue by Geographic [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cah_SegmentRevenuebyGeographicTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "SegmentRevenuebyGeographicTable",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Revenue by Geographic [Table]",
        "label": "Segment Revenue by Geographic [Table]",
        "documentation": "Segment Revenue by Geographic [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribution, selling, general and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "cah_September2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "September2025Member",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "September 2025",
        "label": "September 2025 [Member]",
        "documentation": "September 2025"
       }
      }
     },
     "auth_ref": []
    },
    "cah_SettlingStates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "SettlingStates",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settling States",
        "label": "Settling States",
        "documentation": "Settling States"
       }
      }
     },
     "auth_ref": []
    },
    "cah_SettlingUSTerritories": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "SettlingUSTerritories",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settling U.S Territories",
        "label": "Settling U.S Territories",
        "documentation": "Settling U.S Territories"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee-related costs",
        "terseLabel": "Severance Costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Canceled and forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled and forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested at beginning of period (in shares)",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Performance Share Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested at beginning of period (in usd per share)",
        "periodEndLabel": "Nonvested at end of period (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share",
        "verboseLabel": "Weighted-Average Grant Date Fair Value per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ]
    },
    "cah_ShareRepurchaseProgramAggregatePurchasePriceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "ShareRepurchaseProgramAggregatePurchasePriceAxis",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program aggregate purchase price [Axis]",
        "label": "Share repurchase program aggregate purchase price [Axis]",
        "documentation": "Share repurchase program aggregate purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "cah_ShareRepurchaseProgramAggregatePurchasePriceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "ShareRepurchaseProgramAggregatePurchasePriceDomain",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program aggregate purchase price [Domain]",
        "label": "Share repurchase program aggregate purchase price [Domain]",
        "documentation": "Share repurchase program aggregate purchase price [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Target performance goal (as a percent)",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "cah_ShortTermCreditFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "ShortTermCreditFacilitiesMember",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Credit Facilities Member",
        "label": "Short Term Credit Facilities Member",
        "documentation": "Other short-term credit facilities and an unsecured line of credit"
       }
      }
     },
     "auth_ref": []
    },
    "cah_SpecialtyNetworksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "SpecialtyNetworksMember",
     "presentation": [
      "http://www.cardinal.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Specialty Networks",
        "label": "Specialty Networks [Member]",
        "documentation": "Specialty Networks"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Operating and Reportable Segment",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r162",
      "r232",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r269",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r305",
      "r309",
      "r321",
      "r326",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r727",
      "r730",
      "r731",
      "r736",
      "r779",
      "r996",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r91",
      "r93",
      "r94",
      "r160",
      "r186",
      "r187",
      "r188",
      "r205",
      "r206",
      "r207",
      "r209",
      "r214",
      "r216",
      "r218",
      "r233",
      "r275",
      "r276",
      "r306",
      "r393",
      "r456",
      "r457",
      "r466",
      "r467",
      "r468",
      "r470",
      "r474",
      "r475",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r496",
      "r514",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r524",
      "r526",
      "r528",
      "r589",
      "r609",
      "r610",
      "r611",
      "r626",
      "r679"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r628",
      "r629",
      "r630",
      "r685",
      "r687",
      "r690",
      "r701",
      "r704",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r720",
      "r745",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r778",
      "r783",
      "r955",
      "r996",
      "r998",
      "r999",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r233",
      "r526",
      "r536",
      "r617",
      "r627",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r641",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r662",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r679",
      "r784"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r402",
      "r881",
      "r885",
      "r904"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r233",
      "r270",
      "r526",
      "r536",
      "r617",
      "r627",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r641",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r662",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r679",
      "r784"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r813",
      "r823",
      "r855"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock plans activity, net of shares withheld for employee taxes (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r90",
      "r91",
      "r132"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock plans activity, net of shares withheld for employee taxes",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r90",
      "r91",
      "r132"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Cardinal Health, Inc. shareholders' deficit",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r93",
      "r94",
      "r119",
      "r643",
      "r659",
      "r680",
      "r681",
      "r767",
      "r793",
      "r900",
      "r914",
      "r982",
      "r1027"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 deficit:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders' equity",
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r160",
      "r161",
      "r187",
      "r205",
      "r206",
      "r207",
      "r209",
      "r214",
      "r216",
      "r275",
      "r276",
      "r306",
      "r393",
      "r456",
      "r457",
      "r466",
      "r467",
      "r468",
      "r470",
      "r474",
      "r475",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r496",
      "r514",
      "r516",
      "r520",
      "r525",
      "r528",
      "r610",
      "r611",
      "r624",
      "r643",
      "r659",
      "r680",
      "r681",
      "r702",
      "r792",
      "r900",
      "r914",
      "r982",
      "r1027"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r201",
      "r377",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r393",
      "r495",
      "r682",
      "r683",
      "r703"
     ]
    },
    "us-gaap_StockholdersEquityOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityOther",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Stockholders' Equity, Other",
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsAxis",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Axis]",
        "label": "Subsegments [Axis]",
        "documentation": "Information by business subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsDomain",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Domain]",
        "label": "Subsegments [Domain]",
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r529"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r529"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r529"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "cah_TaxMatterAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "TaxMatterAxis",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Matter [Axis]",
        "label": "Tax Matter [Axis]",
        "documentation": "Tax Matter [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cah_TaxMatterDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "TaxMatterDomain",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Matter [Domain]",
        "label": "Tax Matter [Domain]",
        "documentation": "[Domain] for Tax Matter [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cah_TotalOpioidLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "TotalOpioidLitigationMember",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Opioid Litigation [Member]",
        "label": "Total Opioid Litigation [Member]",
        "documentation": "Total Opioid Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "cah_TrademarksAndPatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "TrademarksAndPatentsMember",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks, trade names and patents",
        "label": "Trademarks And Patents Member",
        "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "cah_TransactionDataSystemInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "TransactionDataSystemInvestmentMember",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails",
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction Data System Investment [Member]",
        "label": "Transaction Data System Investment [Member]",
        "documentation": "Transaction Data System Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury shares acquired, average price per share (in usd per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Shares",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock, Shares",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)",
        "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share repurchase program activity (in shares)",
        "terseLabel": "Treasury shares acquired (using cost method), shares",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r91",
      "r132"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury Stock, Value",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period",
        "negatedPeriodEndLabel": "Treasury, balance at end of period",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r91",
      "r93"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share repurchase program activity",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r49",
      "r132"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r324",
      "r325"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UNITED STATES",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r450",
      "r754"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r754"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r754"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "cah_VestingPeriodinyearsforShares": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cardinal.com/20240930",
     "localname": "VestingPeriodinyearsforShares",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Period in years for Shares",
        "label": "Vesting Period in years for Shares",
        "documentation": "Vesting Period in years for Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "stpr_WV": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "WV",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WEST VIRGINIA",
        "label": "WEST VIRGINIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares\u2013diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r227"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares\u2013basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r227"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of common shares outstanding:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "naics_ZZ921150": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/naics/2024",
     "localname": "ZZ921150",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "921150 American Indian and Alaska Native Tribal Governments",
        "label": "921150 American Indian and Alaska Native Tribal Governments [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480463/815-10-45-5"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "25",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479455/805-10-15-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0000721371-24-000121-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000721371-24-000121-xbrl.zip
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MUR;AG'@F[KV,U;!>?]6%QT!J[3:[?.%22_,SW"8[]K?8_@]02P,$%     @
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MSH=<BHQ]O^3=GT(1_*QYVOTR28L2[UR]JK3U7]C&X:AX*NZ]C-407W_5A<<
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M%28 /(U^WZVJPKXB+SH+"0'VLHL"!+\G4SA=*IO,9&;BTXI_$.)UA^0ZCF%
M)WA(XAUII:J9E?'7((TXY%5OE6-E[P%P=*>N)6C\3'%\90?LACBAEAM5'!C"
M1>J@@<>@NS6WVG-NHXT&$8JA %8=[2CVQ0;28"+9GK[]Q\7;"_&EPIU'F@#&
M_A9Y!/8?SQ/6 RSTFD-%& 58 C."5L '>R-Y,?F;J70>7#9P80Y&@ UNJLX>
MO%&(91!^-Z ^"XH4MA@RF>7ZN6)Y8B:$/,R"3K5MQ9!"KJRBO\9\V -D#C.
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MCIOI?3XQ*3)!0&0WHQK#L)DYEN]04("$("H/MO<W/XY"4&F\@8/_;;1[&)6
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M5_U".,"?:FTJ1)VQ<"HVNJO4BLVY7"DD^;S%3K[%#HJ/!@@B:33-JIV*.:N
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MP=<$,!8\,+ =F%=-LTU3G;KL(OCC1]UPIZ8Z@S6;AL5J]*,?D\/ABY^90WD
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M W'-_S6FW,X7A&U5+COM1K.WA9W9[!RMG2E(AI&4J0.<:DSA5>R5:;YG/&.
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MH_0DZCAF6!Q& 4^HJ-$T;]'@!"KD-#C[8)RAD )32($;2D%%47F30?R8O:+
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M?FL%ZNS\WN\!0E4.1*1KU1V3HKSYTS>>51./L!(':3\X2 >S@S)*Z1W8HUK
M'RSB#V6@F@1 3&9"JWZN# ([P5L*N8V..FA 4I?ONO5F_#=_]RV6?+RN;'F"
MH(%#<_9=;J9$PHYJX)D;[#3Q9OTLF$1@T.+GD3;AJ@.& 4,#Y^%;+P:/*8B8
MA,5&=,U&;WVQG6_XG:9.#;1%P,ZSP;4+/%/ZP=W4\R</KQR(6M6$M4A#(:BS
MJ7C&1(P_56?<G@1Z/<.B09?5E>NU*PLLJT W@M%I)Q&J(R!R]#>$!2?>QN'/
MS\Z2^.=S!YTZ@NV8".T,MJR'P0?X_%EU/66B_F&#5S0+2&1/#1LDPU1?7-^
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M#!)JRC.!;XDL8LPN%!0A'=*H=QO=,\1CX$F[5<PPP OK5O09%:M80B\0)M%
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M(?Q.>59-G_'K34)'H"02PPO-Q2BQ"PY&QZ'S@Z>=! DIJ+<'U/@.4P'PJ/)
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M_UFNVX.D%N*<[L*O>F?YI'ZVZOW>ZKNDS$,AO':F<_K[S2*]>47\9S5,'WC
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M VO,92[V++R4 >\MC.@$_!ICTP4K*V+FT)#3,1G?C^YY3 .TA@C(<RF+F27
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M7+C+_@Q,5X0.)BQZHX ^;L%E"\?UO03H5^!M>CQ,"?H0X!3?EN?AGUXP!SH
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ML\[K0D2DPG^!'8=KV>%:6-\ CP:N/J,>%CZ8NB@@43H*F81E'9CZ#\36CK
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M,HK%,1DZN0WQ-J7;4;J)>9)8ULQ;$*R>I;OI+!V@+G: +BZYL.((35Q*[J-
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MJG)?U/DXHCZNNI_(A$T=EQ&A:A.?/C/O@"ZI^I+X$21.9)%_<IWY#3QJV@&
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M=BAI6H>3D]BM7YCG79*D]D.H+QJ?\/D4OD/L%3<-&+/"3U/&DJU[6.GP:1\
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MR)@Z5/,;IT=?8X?MD?.=%?14.S7_"2V1E60]LD6M"P%:>B/92N]_JE<H<X*
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MR*_PNYE'/@(E ^6R!5 NI@;UNNTBH>]F!%;$M@RF.Z+#ZB7(/.;BKX#839O
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M3AH'!ZVK4=JW$-F')PZW\53#:HWI0L 9 G#2*72Q\5Q'(_9D-Y8T8OE.V@2
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MB[GX*R!MTR;P,@L^SC?JL<#<S1HC 6CH_1RG+64KUQ@HV=9+J@[C?"K:L[&
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MYI#DI\(Z?6&4PYB7M/P]L!D N$-6KW::,&01BAS\@ER\8@037A#",_%^#S?
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MX$+9.RA^5#Q"@8N+M3E_?32-@*LV7&41U_KPX+('^%4;+UH@3XQWH)<%>;R
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M_P@,,RQ;>#39T_YL&:&^1N"Y67/-@GE1)&Y[-*]QS/G[3! TSZ3CR!&C6V9
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M2+9DDYJ$)1Z9>]G?XKDR#L'U"9%ZRNRX3&6ECG7"=(J.@Z0='BKKJV4OO-F
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M2#8S_WM@,SERY#Q'CF3?N!PY4A:"<N1(59#<,7+D? HSY32,<]S<N5=KG/?
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M?IYNEVMHI&TKT,S4ZQA3AVJ_7.^Z0ZY1IJMG^8Z7":Q/=>([LN(I:MJH"^>
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M\9%,76=>D#N?4BZ-<W#GXEBP(WWED"<:87+GKA-UUEP*#<R-^FDMYKWT'UV
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MPM)%Z#UF0X]G0@( ,-\*#R@<L5.RE9N ;;DN7T./XQV\;0;[62*>4*Q69"H
M3K\T O>%)R]&G 4;1G77Y2+!WWB=%%A $#PXL&%TKVTZ>;!8 )1QYRB10138
M9,)FU)KRE% ?77H8:#'A_GWN["/7P0.@!8H(A5\,')$GI*+Z11]<QATF*)X
M%/!-[ *,]3CN(L*44:'$N2P2:X80:C\8^1-L2'@&=A8Z+;F\6[N0>.'0M4B7
M_IJZNYI61$F-:3-[]U_!?OFGX_X@MPO3,0UR[[,GZAK88)I<Z\V+M"!2+UP3
M\TN449OC$@_1(F+%9UU@4K0![&02& ^@8 F[+'1\"2S/!@=Y@]^U;N^O6V^Y
MRYO GZC[A<G80#1 -0_XOF+:_ ;?KTYGE]?1DM<\UQMS0CUOGO3V+@W_$7;<
MRLAT3F3)BWSQ>!%D$A@_F%,[ .44.:8K9+YA>KYK3@+?@0] T?1Y#8!X$EUD
MPDZS":/Z;(>NG\*>S##PG#Y?A$F#'6VH_/4])I"$R0GB@W2@.*D+9JGJ0E7+
M4.#4TG%I;?^LU*-21/)FT5V3N-?_!V;)#)EVR'5%?!(LB\4,EA%(PRWNI*<9
M;!-C91WN#%D2%\BY*(A)02 ! #$G!S'5-JC+Y5L;Y!+ RL;?P:- JJ"+W@<3
M#]X#[[!>VAFTBIX61U E>]9-#[9+GSFF6B:(WHAN@1XQPO3D"$E*WN#J826%
M,GK;/"?4/[BG"(R,$(U#24-,E.D\4.<Z$PYC3J0TCJR]$%!, -(,E1T>(1(1
M0'XSW!,(MX(J NICHIX$;L%$NW!9&**T8W_5'*-P.M $FJE)61[?E>"TT] G
M&(6N(Y&^Y#GAG<>WTB%_<Y[0R,67M1.Q[B0/:A-0M"S HH?$5<,! QL-9M_T
M WP;M;AB\RM]"0U?_&6\P>O%@EE8W$H^F(^FA[N;,<L0D,-?BFTM=_J4\0+0
M9%SFNP[EL; V;-+%L!@&7>&+:8"[GR86"4.I")85*N O U((?!(LPFWP'8P2
M#W?(SP *H;G!I0O'(9P"%A*_1['A)<"\[:QAZ#7^R0U<$P\G7_,5/0$M#V\1
M6,,,D!!CP3K^BNMW_.VVXZ-C W.0#'[BR,<1:M:@YSF>QVN/\&=PJ\+;826B
MOUX2';RZ:WA?0/Q:Y,YU=,;09UYG+6\C#YG 7<S1_X,>*[@([D0%LF?\2DS^
M%=+; A@Z(((56_R"'D$%P:IPQWT!/H#Y%5MNK:Y0^+1^9,[;#(:&!\H[S@6
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MX:=0=:&;!9QG\ZZ3*U42\XW%A/$H48M'[81> T3X*!X48K/MB\UQ8Y(P>%>
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MCE=DA/ Q>83F_&?8^M%/_0D?R)5K*9Q4<)FDQLT/3->M[>I)T34E=>/!M)/
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M-#Y>"*LXM;.ED+T>D/52<X6:*V3A"K&6MF?G"H/$0;(U4ZB90LT4+L048BV
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M"![Y#LK&%Y.PJG@;;-#J9T#D#QO#TB@+PV0K:C+] 1G&3;>5D <U52S&\S1
M+ U['XK?=$;BD[X:"PU(7[5:$N6Z 9X9ID4JQ(R!&K7F*(,"+P'UW NF[T&-
MTX&BX*KY'</?H/,37K G9>4 SE@AC0]?LG%, !Q\ 4@ ^J2A<L0$! *Z51&-
MX'H5"WYAX>?!QP&!IAI2^+,&2$)B6B'*%D); YOB29LY *JI T\S+,E'3D-:
M24OZ#HQA8[(GS7 L4&3Y\5!+%<C,50!+6BK FZ:,Z9CYIU@V3^HCEHO_M)>:
M%>0W2;R&LZ3Y"B-(ZE+1%PQ!1[L$/  8>^JLALDA-_X6GAB(+@X$#AV&MBO
MC$C09NI2!SQ9;.DGI+"!JNSHG)F)=@*62W5(DC,34%.7IMO G88WRS?8JIP@
MP?N,<$+@1SR1$N ]-152@1%0"Z:3JK&AGZO,(>)L2M8&6 _PG&WL&WS*>$+;
M<,G J'3PFJ0E\2=5$3<,2&&A#@-89<P F-X=_P9"!95O&TD "0TPQF/6*\O
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M!,0M6".5AT$;5K(12U K;L8*V_E%SC4'#<)VC&=R,+GVY2;34BF8AM.(4*J
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MQIO7);:I:M,?UHKE=X8T70U\?_WU?+A@Q.UW^X<K!0VE@#R6.G2+X0RT@@D
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M9N6<J])H/ZU7H\#O,'RA]2)0F;()@F3F V9+$@<?EP,F3\$(FT%3%RL;_@*
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M^-I'-UN@//7]MJ:D[RN ::  U^E,#P-KU79C&Z@3M>"H0=W#ZG"$W/O9&58
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M729<YS)"'$3Q#RAQV28- 9?H8A??:=L#GCB1=017^65\.QFGJWA]LOAM#5D
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M+%&_/GOR1.TIJ8IOU,@/XO3B?_]OQQE3]$(S(85TF@#+B4A%&0D!#-&91J/
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M,B017*J=PMFO,G2R$_WHPCZR;J(#,YB,_/ =?('1%;R'R9=!A%?OWB\C(BU
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M^=K:8^5=L<YN?@UY#6S>P6C>IWX\F@U&5WX48?H!)I>#1:^<-_F>[[CN+IA
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MZF+; ]I!6AVMUN>G:8WYPWJ9_O</ F3U_L,?5U/1-#?:E9H43@^*,B)"2,$
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M_;]SX:@K!4T2G?&.^W-M$$5-8T>$-M_(^?0[,*><5W[JEM9/V*Q@/5-?;5I
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MTZS[VK9I1I2!U[UG<XZ_W72(-(R#[ 9N$B%W:5B'S%%L7T%$Z3-L$W3]\MC
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M3,V6JR&Y3OGKS3V6BY06-R9LM[K=<L:F)USGRQ?^/T/)^H_7_4>-C,'2OKC
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M5A,^$R5I^8RY5,Y.LU7[.(X!+;*\;L>"U>3I<,5/3^Z=,I]4S#F:?/.NSH$
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M.[K$H&WJE?].+&D-Q#-@O8;%138F$M.#4T;)"P^HS6EBD#%XQU'KS]-2H-+
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M?J?:+8+O-6O3)N'UI*:@Q]*WR+0&#&1GY(*(H9@"50X?YA;24$@S"#V'<"=
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M?:"#E.SA*]D\,I>P^\WU;HU?7<'-*IG&>SVNO$L0D'TXV[(F6W?"+LZ0<L=
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MQ4]&6AM9'AHE*'B&7#H)A@1M\WV+G].?D=?IF37J?"PAV!6.#&T#VX+)IWG
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M\>O\_H*S@<&ZKQY EOV&))UJ"\!$6P:@75?\G^ZRX"51Q?WV53T4R%'T9BW
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M/L:;A!M8[68L6QN%U#IACM(PB_&*6X!.C<<MVV#U/*.ECOA/IZ'2Q')20G4
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M_]@[ZLVRB&J1#PL]7U^5SP>Z_ES8Z^9N)9:(_OBL+I]P&#><('WL\W#AGB%
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M5"N9GZHCPP,N8^D1.P.7Y1C%_MZZ#_IV TZ;]LZI*W:?8N? ;+3<AJTI$^;
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M#M96AZ&QD1,>A^Z6*V=EN8B1J:-W,ZQUV 30DZ=J1GJCHE*W]<\?SA B#QJ
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M^]CNZ-038_I-8F5<DS%#ORJ.X_"+:*<=43FJ\]Z=A<Z]I.M,JE\SOG \&NI
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MKS.?3K\I27$%GDT9/7P#R!Q#/'JW'<$XP(D$?_:Q75BIR9 D5YUE&)^DUQ2
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M]XI*#Z<ZS <"<HL40?37TQD0&;;>8Z=6E'XO1Q%7M*SX &:9#SQ] =RZ\+\
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M[N5WS ]SKG,=F_]Y'/_CG',$'P1T8/5^>R=[0$A8"#B%_ ""KX"<C5_8:7_
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M+1#D8FK:K,W8CSO1B;63BH$4]2.-]:,. 92TA4UY5WLJQ A?_862U<C3A%0
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M>09I/B@8%$%Z#&QUV@AU;LS32Z[;R#I!$M=P,1RX4Y%>_'&"Y3OZ*63DU^B
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M;XL0FE+^D7.%AV:0@9@S?:TM<N]TG@Z80/AR_9U.^@I^]V2R+CU8>K0'O8F
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M /7=\X\>36*+SZ+7UNZL-"@.+$GY=*ZP3/L6[[G-JB,XUI@ J,;P52O$80&
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MDW<2C',0VSC!*U];!O<0N$JC#&5F'$>90-G;;#S^FH'J"@CV&&F/?.I0<,$
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M\Z*>W,!1OZ0@'F,ZU9YM%S[G/)1JXGKKG8[8I#:."47&D1O,*R.<1XY3V?M
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M7\8&+ 2>K[2N7_G[B7I+27FY9W13[5@I3OFBDI"H\Z*SBN]@PS.G1"<% 9!
M)X+FZ-G\S+5\<:X.[QF9_K1<GS7P=EEP 7G^2P?"WV?ZH)+!_2ZAR]/N(N6^
M;B=8^C=5DJ^7=2VB0/UXKLQ/: V3[RP@&_\0X'PK'YSY(%]P:JH,Z9+?&<JW
M?1U^M/2'?U_+'*+Q67B-D+J#8\KU5B)YUP/I0[,0FR2E$9I^4I *_ &"BIW#
M*PB&@BM.A_M-W8IZ!AQ.=7->*-B]XU;?G@_/K+>0%70AC+;B6_@%3G$5OQ#H
M3SNVMX#:B<^E#OZD,!^>+BZ,W/+(/:3=W\T(YHEN4E!/FO;I_<";KDAR,.4]
M(=/3:/4#S-U0DG\%EKGRED-#G*Y 5<"^"4XWEIG8@[I6%2%KD#3=P:RU/1)Z
M_W/Z^<*!2Q*6O:C,3<)+J2$HMCNQPMZN0VA' W<C,QU,<)9@N)9QJ@,"%97P
MPZ+!5+%)9&$II*'UK'JDSK$G!EDR-E%>B*:OQT0[(7E/ +5X$-CP.)?X [06
MHU+. 2KV,/SZQ*?<53"J?0]&^GG+O_O*TWX?C8*4_LK\31@#I^ZK!^6#1GI<
MV?234("[032C-=V<-J$)3__)X#=>PZ^B&*%?^9-&<L)CL)<I_=3O/ZTO+/TR
M&9B"IGR+! +R02T=XN8II#37?M0.SAK#.;!JNB)_CPZNN?WI>]GZJO75RM9;
MY&(MNQ/:5,=YK<+\^XJV*<9#2. H83Q^QGOQ+$<%-&9'@A36W/H,)M/.6G'^
M&P[SN&L/ZHE;S+68*U8)PT>8/Y[-;/_X_46&I;*M2\O@?H0:%*Q@ CT'+4"@
MOT"+->5+@)SN]4!9%C%U9PE:%/OS:(/_/8-V>D5D CT4U>3?T1U4.GCGUN%7
M7$J'%2^?0/]:=[F+W%23ACQ/ '>M,X?KN)=2WC;LGU8"JA>54='\0\O)MIDD
MHYV$1FT8+237<UN22M:2,^\FM,R;-[8^0/.K6"!!?7@^7Q1+0_$>TH%=H&W=
M@LV-EF%L0+/\T^PGL>.6(LI[_]KBWSI?_+MZ5:J=-PX5 H#D*A;RQ8A/"10/
M<@0J&=ET+9^IAJ%W@TB\T;DA7: 67>:M/++N[U@Q9ZS'<YYD$MZ4CR&]\6/H
MAH$N!#6,?8Y5LTAB975]!C9@N;'6%XRJ3DGI5J5+27U-F/V4%I)W3B^7]1Q+
M.ER1A+0FT.^1@0-JRV-=;"NPD0/##Q&;WK3V+*>B%01NF>_CZOP[\LINQ>G'
MI/O61TMX=$A3=E+'Z19&K[OJW\U'DA\BFO;5;\#2HJ :S,]&,HA'R;Q'TS ;
MC]$ SBH;W7(M9X#*U RTPO&] >^E$ 6!3MP67BE>!O\)V3B:MGEDGNJ@F#=*
M*5<"N%<=RAZ=#D*;CI^,5'%#M">(A][*^#L^5MX,U'!EA_E28P"<*Q?,?@)>
MY[B/<2^C55HSS>\UY8O-%V#/CW=</VLX\?G72FDF?G"'3]WLZI:^3N0V''PH
M8I?@C#%H\),K:\OPYBH.4 )5OA)G/)>[EC,UA<O=[!"S=39]3)%=4W>F)[ W
M;C7=6G:,#8G#WE<Z<<B&?)U 04+TE8I2QVGR&IM0U'Z^A!XG%ILRNY[+58<<
M[U21?M%Z0O?^ER6.W>KIP-,>!AUN5[ SQ[(*&"M]63P_*!OD($J7;+(03P1.
MER)!@XM0)OA'>BB,$3JA#VX$9-?;:,^7\JGL^]+H3WV%U&A"5B%[$.JR=X'0
MW,I5+*63N K3-'9ZRH$4AF;I([_W]#Z@\73'$[;'03;PXI7RKAU3[!=W5XB:
M@0F?13>+;@[-54+PI>:_$>@/(7:MG+H!BX:/E[))9-">=>A@?4M#^[>H"X]B
M+AI.?7HS:>;_26%DU*3V]F1URM->AX-5K;* -U_J<BD=PHEZ@,">_8;$(&6Q
MPY!$&-$:Z="*F#8;#.WH8.55%=2O"G<75]<%R_P]ON=%67J1S^OH3GXS5'VE
M:, K'[0:0E!?LPL'"='D\4/LJA$',5SX4-W9UG:6T2VACR4%W6F[0E<-Y[(B
M(V]D_ V,,!/-E)6(>=6,I.>3@?T\!$0%6(4]2$BW,(4Y+A%D%;P%]M6$?R19
M>8$]I.5[2+_V\[%/!@T#=M4R]MTYTI1ZSP.7-F 5YL=$9_,72QE/D%$DT%9Y
M-IUI4>,<C3/DV& MD5O':(\GZQ=6_ Q3WJ+VQW<T;L#PUT!>'DF8EXRDEZ%A
MF[=!(;8=G\:7C-#<\6VY/6%6GR0/DKNGC3K2?I_XNB;.>EE5M"LH(#MMSW68
MB(M=D0[GV_^01\O__]I.LA#<[-$-V']KY[NCFMJZ?3?R*5(D(.T 0D"*(B!'
M$=$CLD%%F@B"B-0H-I!F 0D8$I%>(UA0$*,B8J$HO00B15!0JH* D@*("DA"
M"5NRL_-VOO?&?>_H.^..>[]QWQWWON^/-08PR-Q9L_SF;^XUUUP8-T(N!;!]
M:)%F:(VX=D$ \"-0LG-7!5;Z7^<._WMANM%$AH%3Z+*TR464>7=O#/@^!-DC
M*V/03RZVA"SQ^\!YR6Q>Y5\>"9DUMU'*2;"FN0&538,U:?X\K2<_!,#0#M-Q
MA8:9&V<'U *T$)4)Y/$BXDKCN9X1 &H"8*QP$KO0#_+EK[_J%BLC-:/5WGMS
M =!>)0!.Y_T?_XU_*R\R16</@ N.M-DB5.HC%")K!,"3* %P/01Y[V-L!5PT
MA4VZ^"XS\%,2]PG(+"9]HY#&/=%X=4OML5!_*P!6G1< !WD"8 .=_Z3*7(W8
M36=3H%)Z$TJQ$Z.N=MFJ=B'=<UNG=]'#.Y0[-_4W1!6/<D,%0*:P&!A ^<6\
MBY-8[[7_<H8Q/PK-" "=4VAQ4HP"[)<'Q7MK9](%P.RA,/+2)!9)MAOS^]/L
MF5^V[8;Q;IOZ*I2!,L)BE+1\>7@7D_^/W $M8($_E$H$P&0[C@\,,.J)\W@R
M8C4I )9FLP0HBX>,?F'1V+NHG?9@?R@U:)$&OM]"U>4U\*F"G07+BB%6,XGT
M!=Y#TA<ED\6@OU0_H9E#1^PZ41UX'Q, /;9>:6'TGWSP3R<YOVRZ6+V./-B'
MBJ ( "]4.ST.%EB[ U;RP+]SB3BVD&:-<*B:K]&61$H:(_E??O*02Q+Z;VFG
M*;'FVZ!Q=B-1#3)F'6]0B)\\&+W XQUI\B\?UW[[M^ '$8%TO8_G5CH_.)J&
M)Z$4>$F),_!RE2K3*,TD+9QI%9]W"AM;$C;X:8QGFUCQBHP_)%Z=_F3S,O7\
M1Z*3V?JC-$C/\661-"8%Q#0L@W=!"4_P 8U_Y-://!V5S%7XZ#5BK9(1$MC@
M<2-H5M.[6B/K$'A&Y2OI!#T9*]4@@K3=T89*3G"X$VWF4CT+JG5I4O1AJELM
M@;0^Q?[*JY;R_':1ZY:W2E<TE8O,\Q5^\'D;OM'+MY8]1-X-=25F<\RBHIA/
M)3\4!;E3)VTGRAJRUZ]5<QVUWN.ZYJF&Z+9'I%/T)-3P1405@E7(X/A,CB-G
M!869)M8DN[\OEJ0PXG&S^(U/B+GO]LT=Z<8RT\D 7^Q^#2V&+C7O&$.2+,?&
M-:@KEW?/ORI:[5"]N;2D"W5H?_IYR@637B>Q+^ OSD,0=IY9"H",BRQ3/O$K
M96GYVZCAOZSLL+_#X<)(*20-H-$U[^RFY1W>1OJA_T<;/XPL *QTSFWYD\W=
MSO+^(+UV[T,=_QKJZWI/$_XS( :SD5]D;@@[05KLD0&64C,YOH.5<]';=SEG
M:^X:(YV6R&.G.F_([S+=QCA_13182R)@8F8PKY4T1,(V;"1^0'&T068R$FSN
M((G&QM@&&7C8%^&&U]KYK'<;WZBHYZ)EUF[<(6/>BP+/[_Q\@F.$ ) $&0FP
MO'1([-(T/7Y^4C^1:O5 AYP3D5_84WW9C?S>PRV0+;HW3^-9\8X7N%)R*WF(
MTMA@ *4Q@ERIH@^@%-8PGF+11[!Z*,=-/.8V^_ B04'SCL6%9QOLL-2M5Y=$
MT-!VYTG"!OR'5'V>'^' .Z(.P5XE5O%AHYEC:*AK/"BSKW^6?\?&LT-D#_C[
MD9N=S-L#]V#<U1:Z*NB7>ZZC<9FM+P0RZNIR1&2Z<E@7)]T4V\7V_O["5/K;
M7/KU^3B3M<E;3Z:;.+<96+0Z/KZ+24$YS<VLRG!0IF(;@J5_RU+1A,+S:*EI
M4U72*:S,+NX5PO?,T0O3U#,[GTYOV).FU=DB63W&.+:N_\8E$'4N1B(X:T38
M*P!*/AFC:%=34A? -/H5Y?\2/7\DC-+@Z[G'D-HVE)YE4@=8%S)&'65@4\Z*
M:#:]A?WECF9#3W#1O.')SP-=Z4T<UHEX9MZKN67;W?0S<JN[3+[B_@1[XQ3E
M"E*2#Q:R905=9 PD&%20%3]\<7-35^TU4;:SC(K,,-XM^DSC4;A$S:O6J3$G
ML7'<5!W[F <_DR9L2)4$3X5$8RN4TLPU\%\)X.-/Q/>BGN\FLO;MF-:JKKQN
M-JYZF_K-;976X]E22W\KXDVD']D.\=D37.( U86WD;"ADE- OCI5B:BR^0L?
M+HN?O/-YO8>_5VGT&CVM-\WGQGVUSDUHS>D[\.^:!0D;7_F5X,D@>V;;5 R+
M!,#.T"E6WU/"!8Y.5]SP_LIG5>1VSQQP9](-F\^'\ZUL$X_H'%1-V8Y]0"LS
MFG8)X-GA$UBF"=,-"A"YV9I)3Y\Q,]%IK0_4<G O^E@R-)W(ZS;?7-#=+39!
M@^6,6>"T)GLWUXM?BVCB9U[:LC#)ZBLYX8G%(6$VEC?$*U)V2%[N;4V]^UML
MSXV#0WE'@/5K, 80AE_$4X#JN%OXSV$%GC.^N66(/JU<;/40]N@ULV3MC@AZ
M+/GZ2+KM(>-7 ?[!$IDO$S.WC.]GT#W^?GO79%0 B$-=W$_OR$TU"_I/9])'
MUM9UASKX;JV(\7Y=O6F/=H8RX?'^=YN7AXG,Q73#+CQ3I(LN IZF#XLQ[F3P
M](DO&K9 KBR,.,$:IP"?N=JBRW78T=SSP4O<MR_H>$W(]1,9N#%QU>#0WS8D
M= #SI&B?K2$)%+:K./4BJPB'>PXEW(,/01DD3NWL_$C4'?J+,_Z3NEG:*&\Z
MSS49BJ>'<$3(S!(JR+CA(\/1K6 '>/.?F6M_/>>)+QL=2-+A1(TIB6[^\'7C
M?<.U;3O[]>5CHP<?1G8)NT9.HUBI%(BHDQK-"?H7#=#?5 E.AK"#3MGUS+ZF
M2M7@!?]P3/5QJ^3!\\VJF6)F;B]'5*K[Y\F0_MO*F/R/T&4Z:[ID>MW9DUL>
M':=Z^C4HZB;>L9'%S!\]O>GZZ(X7.\]:8$O>?R1V4F8/H9BZ- XBR:>9D]7\
M7'"L$$WD"^TDOOP[D?G\?^!5GCS\,YJ6C)!E!<"K>I( \'%&2<(*VO(OOTSR
MF\?^RM<:5J,ZT1!^E*.*T$*[^,L^-TS_0O_^A0;>%+Z7?^W>#TX6DI;T]#.*
MZ_Z$ 34J_X(.1ZNB"Y0,ERDKV!7&[65@#E#L<+I&IEVS6<1/==RY].JN_#^2
M ?T_J^5]\\!/J>F1Z%>[?Z!!3 _ZB<_AZM6UT+0:*0 0:CX*<*N(DMT_]\[\
M_YJ0__MR_MEA 3!\C.O<.U/09X))]UCCIMBWQ:5EMO+ NROM1)^[ES<80<&D
M02R2TH_NC83RZJ3B65P\17K=]0(*$TG\/N7^:?Z1K6]DYH59?QK[:8,RRKIW
M=-/8!S "0,YBC1%L"DX)#3N)N@@-19F6'I2?=/%05^N)[";-S D CLDG4E,Q
M=$H [)G9]?>C+=@!^Q\H23V\B(CNNO3$2%JX?PB';NFO4YDA2^ JZ]B(7B]Y
M;00=;# 2 )1<,0$@48_&-'E@F@QOF(DGS>^?-X+E=__/)TO4,2E\N7I)-.')
MH$_>(@+EHG_,>BD YN;00HCI5D#B+(%,9XB&$$.Q\(;Y&03$58(_?QOKGR1W
MB['"X0TX)0'0U8DJ/,X'E=KV!?W!GB4 ?OSH)K&?]M$@OI#E_>L[Q2;1V8\)
M:/D"_H%!%"+1P,/F(0I&*#N:F$"5V%2R7P",+O"._;J;7]0($->1FO(Y)!C^
M D*N7^DPD?SOU!-:$*YN9H4W.PXV[^7D%[22$K.ETW2+SOLNH= 3:'GV<V+_
MF8E%*=[9^LC1[:/U4:?^L_WEGY+^7TO"KB.X\^\25^)S6.KYQ7XDA7+EZ6#M
MW5*TH0/%#"TGO._*,?7[-73(BR).^O+0#X1,4)=.+BD7AAT!)>SWP^^1&/>Q
MB"X9<J5+H<B8^P4'K4] L0LM#4#F.6'*NG\+C5)&OQ&R@?S?5$YMR64!4&[]
M@B8.[RX;,+/D'+.LJDC>OB=3 /CE,<H#Q21LOUF?7BI %,*;P:5UD4J(A*8
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MZHJ/UNM2U>A?L2]M*26U7C_E=<ZK:R(?P+1>1"Q*"(D9C*4_ A%E&<1^Q%5
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MVP _X7('P'D,"249I"()(AKP"#&C/!=S%B9V3QI%$LOB6P74NSUI<PQ+LUK
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M0N56\AUA56J=\+M\M6HB^@1H9S?4_HM>A\<(B:2EA$+53$ 8^1"'408%X:'
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MBAL@EL6WJBWKEF\X 7C+BF$R@@7,>LOLM."9J;]*KVVPVW"C-@JO%$,2PI_
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M>ZJG5NPQF/I!!GT41BQ.4Q8'Q"@8>6_ZJ0\P&V*&T<;[\NLMW?92&1Y--G3
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MTZ;YOZH3;'//^D[NFQ3$-3\6E]^')*:8Q#$2+@\0)AY!64(H2L,H2B,W]M,
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MY?B N[?G0FX).CZ@O39T]*D9UUC6$C!<F:\@>.P!D-A62*%#<MU( :"$BP
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M&-WO6E>.GO.R(C#,?75DG,_\6=WS;A]NG$-;7[7'K_G3C7/@2UWZ=HB]"^
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MR03!*!2I7"!%*+>@ 8X1(9Z0NT]/_@]4.#I&;&%CW)-V>K2=WQ7UIF!P9-V
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MS@1OGXJ=G$[L;Z[(EC57MU_4S:WZP:O#O>V]AR,>9%FBFKYQA(,LDKM7X:-
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MHR'92+ R-GJUN$1#A'X(HO.X(7PQ?>1LM^&?1!/FO)*!#.L?%33Y)KGJ1-V
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M.*+")S:C /H(SAV=[YO>5UNO9< [<G#EU3S8#0/H%:%A_.U0,,  >Y),K,<
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M*E,4ID%*>1XJ[RDWON!F1G-FJ_@OB@OOL6'#*S4?7G%@Q'MJ. '<%S,4Y'B
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M[%XTSN9?7U)8>+1U+\3+J=7]C]JIX'M2Z)$GY:TH]EF>%;LGJ1[/&$:(DC!
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M%=1TO;O5HSZV_?7S[<>3(8$ M>N%;Z!X+I #56\ ]!SJ-H;03N%Z5UU.Y<:
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M[:ZLMH]*-=Z\_")T^ZZG;RMV70C2=-T]GEQ1$>=!1$,DHBQ4?@2+$/&57LN
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M",>10"1F#&5Q$A&1)9$(C?JOC1&:.WEP/B+BRM.4O=\;VI/F YW(RLR.N9
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MS?]>?GUF;P_CHTVK_CO>G5GY;K5WH8O<#]6\I?=5%,^KMOLUH-R_"_BPOKG
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M01$V<^6<#Y8WL"F?)&(_A'0<G&S-Z"YP\RG\^383^Z9ENGWSNG2H9;2%.YF
MG*9$OI21X)W40!:S".1>&Y9;A"0>67X_K'0<N6S'W"Y0\BIGDL'J\K??IG/D
M=#$*76268+*SH))#('@7B"A(1_(4BY4-$+)CZ?W0T7$0LPU3>T+&:_KRW?+3
MXH_YI&A6A.'D9 >DJU,8 YY8 0F3EJ$XKO&TIXY'%MX/%=T'-4]C:$^8V%R.
M[Y;OEXNOTWG"B;,A*TP9#+?D8R$Q)P8RK+"4K)$N2'*XV@'CWNK[H:/[8&<#
MUO8$D?>+U3K,_K_IEXWQQ(-Q(LM*>U*@K+3UE==!D,:[Z#+/JD7D<]?:^\&C
M^_CGR6P=.PA:][#$L*';^"(#>@Y.EEC3RA303BP8D1B:)%$X=Q(<;J^V'P!Z
MCG8>R[J115YS[6;O/R_F5T]YSOM4F*XOM[*^XA!2(P\(&G6,-HD0PFGVP_T5
M]Q-]QT'-DUC8Q75P&:K?/N5/YV?U?KM832Q#B39H\%S0M292 (]D_B@K),:H
M5/:AQ5/8SM7WRZ7J.*;9C+5=0.3MG#Z-V#']BF_".EQN:U)LD4KS#-H+<J4Y
M_>*B<:"\-$5+*TKR#2"R>_7](-)QT+,9:[N 2,T'6;XFR_ALL?PV0=3)26?
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M JLG3NB$+I5H0LA0E-R,>)!TT.C<V808F$XIB=;)X$^0,V[%9R=:\R"9--.
M+_&$\%.8A7G"CY\1U\VZ8-[]T.&>!YX@OOUCP"]$T#Q-P^S]8MM>XQIT5J"-
MEG"14O"@@O00%$=@7G,E?&3:M'[NVX>N4W7492>'JUUFQXSD@0QLSUB=HBS
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MN8GGWHSI'>B6MR2"^=F4[/TM@[8/-EOE62=W_#&=S<C\=\5:\A.Y=&3^<Y7
M<\;!L:*YU(7<@/8F]/-T]6!:-P%4<R%T *Q;-F!]Z;M4KZD@*DP)0JD#/D+V
MX(,1@)9%QZ2)Q@^2$'R?D!XL[B;0.9W-'6!E2_]$Z52\]9X@'6L/X8C@;&W_
MY3@+)2?G=>LPX7;E'FSBAC'E@QC9@1'SVS3$Z6RZGN)F3E2M /N\F!'35_5F
M77^[9@T++C)7)VT(1;".*8,7F@/=J=X:ZVUN/@=E7]JZ*1H8YD5K$!%UH'EN
M[>N^3\&3(5.N=KGP)8$261*[M 3DUABC!*K8VL]ZG)IQ7RJ&D?[C$#M%%!V
MZE5*BXOY>O4^?*N!]"O7DANADZX5_+DVL'?6 "GW NAX$5H*)UESQWTG)=V
MZ20YW[_Z3F=Z!]#Y;3$_^X3+\S<8UYN7O"_3>LO6].AW<78Y%.$Z6)%X4@8#
M VTB^9HL:_#9(T06I-529WQRKO91*NH0 L>]% <"VG BZ@!_6W<BI>4%+?V
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MF:5*/MO/I-L6WQ _(ME]89[P"-WW_&<V48@'DMY(2]Y9];(-W34<K>8!4U;
MM/>@9%3@R#8'H3E3#@L7LG63CJ?H.3VM\=9G;R(WL_KF?O.HNNM4<!G\IL L
M.TD\4$5"2-Q X%PK*656N763VF/H'%?/-4/1P\3'@476JR+[=;'(?TQG,U($
MF[8%;^DSYV?3.,-M#\DC]-BS']E$C1U&>",M=K4H(>3^>C< N08D=^B4#@X*
MED+V?-)U!AH!4A13LO"^J-9FS$$$GMQ9=I_%;HZ+R3HQ.J' K)>@--OTP>#
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M#LOE-UIM<[;JZC^OUM/S&C"Z/G%U(##&]7T9WIH;4430SBHPLK: ]\R"8RA
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MP3X%DR.XW %0'O;,UKX@UORL)&1M3TF79R05"5[(R!F6_*#@:J2F\\,-(AA
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M==!:&0C(=2G>:JG<'C?%KL_N1?#'2FO1D'5CVP>SL%J]2IOHP]U-F&AR<+Z
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MEF5+9,#?QTU:67W2Z3.;FG"4J+M/33B"[^T!:--I)J*FU%P3;J D :%&]I"
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M WIF.V-YN0E4G9M67/-+:AFE'ITU2:&\ZC-!/$*  )?!<Z/PNNZ[(N0!4=U
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MU63T/PAH_]?Z',TON87(:7G_HL4I#;X\K+% +)XOSK(.U-9NT+6'E ;+?NJ
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MLFEJ%9'N ,D9_&T@$OSA.LR7DY\6K[[B/TK <WETE'2@=-"H71ERI:09N2B
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MY+8SL-N1?UNGX0TL-A,RRMBL>_-8YV=PQ'/FI!&E5SLZFC*@2^BHCP2=4.6
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MT(1))M&+9YI8HRUQB7JP7##\?P>Q/UAX8"NTFLC/X]B XI[/%I>W=A3R??G
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M/H8%]QFPVM:50\NX 9R_![QT1A%OI0^+:?S7[Y/18O[^P^^;D72*:84^'@F
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M_'^FG _PKW^-OOZ#\H_@Y_#__E__/U!+ 0(4 Q0    ( %)'85E37@M1H@<
M ,PF   ?              "  0    !A,C5Q,5\Q,'%X,#DS,#(T>&5X:&EB
M:70S,3$N:'1M4$L! A0#%     @ 4D=A65ZMI$N;!P  S"8  !\
M     ( !WP<  &$R-7$Q7S$P<7@P.3,P,C1X97AH:6)I=#,Q,BYH=&U02P$"
M% ,4    " !21V%95)HC_9($  #T%@  'P              @ &W#P  83(U
M<3%?,3!Q># Y,S R-'AE>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    ( %)'85GT
MTD;'I1D  ,RA   ?              "  884  !A,C5Q,5\Q,'%X,#DS,#(T
M>&5X:&EB:70Y.3$N:'1M4$L! A0#%     @ 4D=A61 ?=N6T/@$ 9<@0 !
M             ( !:"X  &-A:"TR,#(T,#DS,"YH=&U02P$"% ,4    " !2
M1V%9>5]P=$@0  #*LP  $               @ %*;0$ 8V%H+3(P,C0P.3,P
M+GAS9%!+ 0(4 Q0    ( %)'85EQ#TZS814  %S$   4              "
M <!] 0!C86@M,C R-# Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( %)'85FJ#\^E
M(&@  )&T!  4              "  5.3 0!C86@M,C R-# Y,S!?9&5F+GAM
M;%!+ 0(4 Q0    ( %)'85G!_!M'<T,   E5   3              "  :7[
M 0!C86@M,C R-# Y,S!?9S$N:G!G4$L! A0#%     @ 4D=A69(6]"H!0
M*D\  !,              ( !23\" &-A:"TR,#(T,#DS,%]G,BYJ<&=02P$"
M% ,4    " !21V%9@MZFR04T  !N0@  $P              @ %[?P( 8V%H
M+3(P,C0P.3,P7V<S+FIP9U!+ 0(4 Q0    ( %)'85FNO!O.Q38  .-+   3
M              "  ;&S @!C86@M,C R-# Y,S!?9S0N:G!G4$L! A0#%
M  @ 4D=A6??>>P)[6P  AV\  !,              ( !I^H" &-A:"TR,#(T
M,#DS,%]G-2YJ<&=02P$"% ,4    " !21V%9X!XVZT\" 0"[[PD %
M        @ %31@, 8V%H+3(P,C0P.3,P7VQA8BYX;6Q02P$"% ,4    " !2
M1V%9#'1A$D"@  ":AP< %               @ '42 0 8V%H+3(P,C0P.3,P
>7W!R92YX;6Q02P4&      \ #P#] P  1ND$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>cah-20240930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cah="http://www.cardinal.com/20240930"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:naics="http://xbrl.sec.gov/naics/2024"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cah-20240930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2024-10-25</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:OptumRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cah:IntegratedOncologyNetworkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cah:SpecialtyNetworksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cah:TransactionDataSystemInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OutcomesDivestitureAxis">cah:OutcomesDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cah:TransactionDataSystemInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-10</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2025-10-07</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:CityOfBaltimoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2038-06-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">naics:ZZ921150</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:IVCApril2023AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-30</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:IVCApril2023AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:AgreementsAxis">cah:IVCApril2023AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:FY24Q1GoodwillImpairmentGMPDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:FY24Q1GoodwillImpairmentGMPDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:September2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:June2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:MaturityDateAxis">cah:September2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:DateInitiatedAxis">cah:January2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:DateInitiatedAxis">cah:January2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cah:A375MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cah:A375MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A375MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A375MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-10-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cah:A375MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-10-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearAndPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearAndPrecisionHealthSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:AtHomeSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:AtHomeSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:OptiFreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:OptiFreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalAndSpecialtySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:GMPDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="states">
        <measure>cah:states</measure>
    </unit>
    <unit id="numberofusterritories">
        <measure>cah:numberOfUSTerritories</measure>
    </unit>
    <unit id="lawsuit">
        <measure>cah:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>cah:plaintiff</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="segment">
        <measure>cah:segment</measure>
    </unit>
    <unit id="segments">
        <measure>cah:Segments</measure>
    </unit>
    <unit id="reportable_segments">
        <measure>cah:Reportable_Segments</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0000721371</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList contextRef="c-3" id="f-281">http://fasb.org/us-gaap/2024#GainLossOnSalesOfAssetsAndAssetImpairmentCharges</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">1-11373</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Cardinal Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">OH</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">31-0958666</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">7000 Cardinal Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">43017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">614</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">757-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common shares (without par value)</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">CAH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="0" id="f-24" unitRef="shares">242010503</dei:EntityCommonStockSharesOutstanding>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-30">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-31">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-32">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-33">false</ecd:NonRule10b51ArrTrmntdFlag>
    <us-gaap:Revenues contextRef="c-1" decimals="-6" id="f-34" unitRef="usd">52277000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-3" decimals="-6" id="f-35" unitRef="usd">54650000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-6" id="f-36" unitRef="usd">50375000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-3" decimals="-6" id="f-37" unitRef="usd">52907000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-6" id="f-38" unitRef="usd">1902000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-3" decimals="-6" id="f-39" unitRef="usd">1743000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-40" unitRef="usd">1277000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-3" decimals="-6" id="f-41" unitRef="usd">1186000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-6" id="f-42" unitRef="usd">24000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-3" decimals="-6" id="f-43" unitRef="usd">25000000</us-gaap:RestructuringCharges>
    <cah:Amortizationandotheracquisitionrelatedcosts contextRef="c-1" decimals="-6" id="f-44" unitRef="usd">74000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts contextRef="c-3" decimals="-6" id="f-45" unitRef="usd">64000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges contextRef="c-1" decimals="-6" id="f-46" unitRef="usd">1000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges contextRef="c-3" decimals="-6" id="f-47" unitRef="usd">-541000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-1" decimals="-6" id="f-48" unitRef="usd">40000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-3" decimals="-6" id="f-49" unitRef="usd">41000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-6" id="f-50" unitRef="usd">568000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-3" decimals="-6" id="f-51" unitRef="usd">-32000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-52" unitRef="usd">5000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-3" decimals="-6" id="f-53" unitRef="usd">-1000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-6" id="f-54" unitRef="usd">32000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-3" decimals="-6" id="f-55" unitRef="usd">11000000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-56" unitRef="usd">541000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-3" decimals="-6" id="f-57" unitRef="usd">-44000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-58" unitRef="usd">124000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-3" decimals="-6" id="f-59" unitRef="usd">-33000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-60" unitRef="usd">417000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-3" decimals="-6" id="f-61" unitRef="usd">-11000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-62" unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-3" decimals="-6" id="f-63" unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-64" unitRef="usd">416000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-3" decimals="-6" id="f-65" unitRef="usd">-12000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-66"
      unitRef="usdPerShare">1.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-3"
      decimals="2"
      id="f-67"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-68"
      unitRef="usdPerShare">1.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-3"
      decimals="2"
      id="f-69"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-6" id="f-70" unitRef="shares">243000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-3" decimals="-6" id="f-71" unitRef="shares">249000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-6" id="f-72" unitRef="shares">245000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-3" decimals="-6" id="f-73" unitRef="shares">249000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-74"
      unitRef="usdPerShare">0.5056</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-3"
      decimals="INF"
      id="f-75"
      unitRef="usdPerShare">0.5006</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-76" unitRef="usd">417000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-3" decimals="-6" id="f-77" unitRef="usd">-11000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-6" id="f-78" unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-3" decimals="-6" id="f-79" unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" decimals="-6" id="f-80" unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-3" decimals="-6" id="f-81" unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-82" unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-6" id="f-83" unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-84" unitRef="usd">429000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-6" id="f-85" unitRef="usd">-25000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-86" unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-3" decimals="-6" id="f-87" unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-6" id="f-88" unitRef="usd">428000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-3" decimals="-6" id="f-89" unitRef="usd">-26000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-6" id="f-90" unitRef="usd">2867000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-6" id="f-91" unitRef="usd">5133000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent contextRef="c-4" decimals="-6" id="f-92" unitRef="usd">11781000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-5" decimals="-6" id="f-93" unitRef="usd">12084000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-6" id="f-94" unitRef="usd">15619000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-6" id="f-95" unitRef="usd">14957000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-6" id="f-96" unitRef="usd">2591000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-6" id="f-97" unitRef="usd">2663000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-4" decimals="-6" id="f-98" unitRef="usd">47000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-5" decimals="-6" id="f-99" unitRef="usd">47000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-6" id="f-100" unitRef="usd">32905000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-6" id="f-101" unitRef="usd">34884000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-6" id="f-102" unitRef="usd">2535000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-6" id="f-103" unitRef="usd">2529000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="c-4" decimals="-6" id="f-104" unitRef="usd">6388000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="c-5" decimals="-6" id="f-105" unitRef="usd">6450000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-6" id="f-106" unitRef="usd">1231000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-6" id="f-107" unitRef="usd">1258000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-6" id="f-108" unitRef="usd">43059000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-6" id="f-109" unitRef="usd">45121000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-6" id="f-110" unitRef="usd">30365000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-6" id="f-111" unitRef="usd">31759000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-4" decimals="-6" id="f-112" unitRef="usd">940000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-5" decimals="-6" id="f-113" unitRef="usd">434000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-6" id="f-114" unitRef="usd">3373000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-6" id="f-115" unitRef="usd">3447000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-6" id="f-116" unitRef="usd">34678000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-6" id="f-117" unitRef="usd">35640000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-4" decimals="-6" id="f-118" unitRef="usd">4224000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-5" decimals="-6" id="f-119" unitRef="usd">4658000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent contextRef="c-4" decimals="-6" id="f-120" unitRef="usd">7433000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent contextRef="c-5" decimals="-6" id="f-121" unitRef="usd">8035000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-122" unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-123" unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="-3" id="f-124" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="-3" id="f-125" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-6" id="f-126" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-6" id="f-127" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-128" unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-129" unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-130" unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="-3" id="f-131" unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-6" id="f-132" unitRef="usd">2827000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-6" id="f-133" unitRef="usd">2917000000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-6" id="f-134" unitRef="usd">14000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-6" id="f-135" unitRef="usd">-286000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="-3" id="f-136" unitRef="shares">85000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-5" decimals="-3" id="f-137" unitRef="shares">83000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-4" decimals="-6" id="f-138" unitRef="usd">5963000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-5" decimals="-6" id="f-139" unitRef="usd">5677000000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-6" id="f-140" unitRef="usd">-155000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-6" id="f-141" unitRef="usd">-167000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-6" id="f-142" unitRef="usd">-3277000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-6" id="f-143" unitRef="usd">-3213000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-4" decimals="-6" id="f-144" unitRef="usd">1000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-5" decimals="-6" id="f-145" unitRef="usd">1000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-6" id="f-146" unitRef="usd">-3276000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-6" id="f-147" unitRef="usd">-3212000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-6" id="f-148" unitRef="usd">43059000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-6" id="f-149" unitRef="usd">45121000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="-6" id="f-150" unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-6" id="f-151" unitRef="usd">2917000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-152" unitRef="usd">-286000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-8" decimals="-6" id="f-153" unitRef="shares">83000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-8" decimals="-6" id="f-154" unitRef="usd">5677000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-6" id="f-155" unitRef="usd">-167000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-6" id="f-156" unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-6" id="f-157" unitRef="usd">-3212000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-158" unitRef="usd">416000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss contextRef="c-11" decimals="-6" id="f-159" unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-160" unitRef="usd">417000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-6" id="f-161" unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-6" id="f-162" unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-13" decimals="-6" id="f-163" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-13" decimals="-6" id="f-164" unitRef="usd">-15000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-14" decimals="-6" id="f-165" unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-14" decimals="-6" id="f-166" unitRef="usd">17000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-6" id="f-167" unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-13" decimals="-6" id="f-168" unitRef="usd">75000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-14" decimals="-6" id="f-169" unitRef="shares">3000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-14" decimals="-6" id="f-170" unitRef="usd">303000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-6" id="f-171" unitRef="usd">378000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends contextRef="c-15" decimals="-6" id="f-172" unitRef="usd">119000000</us-gaap:Dividends>
    <us-gaap:Dividends contextRef="c-1" decimals="-6" id="f-173" unitRef="usd">119000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther contextRef="c-15" decimals="-6" id="f-174" unitRef="usd">3000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-11" decimals="-6" id="f-175" unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-1" decimals="-6" id="f-176" unitRef="usd">2000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued contextRef="c-16" decimals="-6" id="f-177" unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-6" id="f-178" unitRef="usd">2827000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-6" id="f-179" unitRef="usd">14000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-18" decimals="-6" id="f-180" unitRef="shares">85000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-18" decimals="-6" id="f-181" unitRef="usd">5963000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-6" id="f-182" unitRef="usd">-155000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-20" decimals="-6" id="f-183" unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-6" id="f-184" unitRef="usd">-3276000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued contextRef="c-21" decimals="-6" id="f-185" unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-6" id="f-186" unitRef="usd">2746000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-6" id="f-187" unitRef="usd">-642000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-23" decimals="-6" id="f-188" unitRef="shares">76000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-23" decimals="-6" id="f-189" unitRef="usd">4911000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-6" id="f-190" unitRef="usd">-151000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-191" unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-192" unitRef="usd">-2957000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-3" decimals="-6" id="f-193" unitRef="usd">-12000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss contextRef="c-27" decimals="-6" id="f-194" unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-3" decimals="-6" id="f-195" unitRef="usd">-11000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-28" decimals="-6" id="f-196" unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-3" decimals="-6" id="f-197" unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-29" decimals="-6" id="f-198" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-29" decimals="-6" id="f-199" unitRef="usd">-18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-30" decimals="-6" id="f-200" unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-30" decimals="-6" id="f-201" unitRef="usd">25000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-3" decimals="-6" id="f-202" unitRef="usd">7000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-29" id="f-203" unitRef="usd" xsi:nil="true"/>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-30" decimals="-6" id="f-204" unitRef="shares">5000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-30" decimals="-6" id="f-205" unitRef="usd">505000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-3" decimals="-6" id="f-206" unitRef="usd">505000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends contextRef="c-31" decimals="-6" id="f-207" unitRef="usd">125000000</us-gaap:Dividends>
    <us-gaap:Dividends contextRef="c-3" decimals="-6" id="f-208" unitRef="usd">125000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther contextRef="c-31" decimals="-6" id="f-209" unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-27" decimals="-6" id="f-210" unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-3" decimals="-6" id="f-211" unitRef="usd">-2000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued contextRef="c-32" decimals="-6" id="f-212" unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-6" id="f-213" unitRef="usd">2728000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-6" id="f-214" unitRef="usd">-780000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-34" decimals="-6" id="f-215" unitRef="shares">80000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-34" decimals="-6" id="f-216" unitRef="usd">5391000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-6" id="f-217" unitRef="usd">-165000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-6" id="f-218" unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="-6" id="f-219" unitRef="usd">-3607000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-220" unitRef="usd">417000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-3" decimals="-6" id="f-221" unitRef="usd">-11000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-6" id="f-222" unitRef="usd">182000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-3" decimals="-6" id="f-223" unitRef="usd">172000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfInvestments contextRef="c-1" decimals="-6" id="f-224" unitRef="usd">1000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments contextRef="c-3" decimals="-6" id="f-225" unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges contextRef="c-1" decimals="-6" id="f-226" unitRef="usd">1000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges contextRef="c-3" decimals="-6" id="f-227" unitRef="usd">-541000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-6" id="f-228" unitRef="usd">30000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-3" decimals="-6" id="f-229" unitRef="usd">29000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-6" id="f-230" unitRef="usd">16000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-3" decimals="-6" id="f-231" unitRef="usd">9000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-1" decimals="-6" id="f-232" unitRef="usd">-288000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-3" decimals="-6" id="f-233" unitRef="usd">-58000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-6" id="f-234" unitRef="usd">678000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-3" decimals="-6" id="f-235" unitRef="usd">1073000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-6" id="f-236" unitRef="usd">-1394000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-3" decimals="-6" id="f-237" unitRef="usd">1762000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-6" id="f-238" unitRef="usd">508000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-3" decimals="-6" id="f-239" unitRef="usd">959000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-240" unitRef="usd">-1647000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-3" decimals="-6" id="f-241" unitRef="usd">528000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-1" decimals="-6" id="f-242" unitRef="usd">2000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-3" decimals="-6" id="f-243" unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-244" unitRef="usd">90000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-3" decimals="-6" id="f-245" unitRef="usd">92000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-246" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-3" decimals="-6" id="f-247" unitRef="usd">1000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromHedgeInvestingActivities contextRef="c-1" decimals="-6" id="f-248" unitRef="usd">0</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:ProceedsFromHedgeInvestingActivities contextRef="c-3" decimals="-6" id="f-249" unitRef="usd">28000000</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-250" unitRef="usd">-88000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-3" decimals="-6" id="f-251" unitRef="usd">-63000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-6" id="f-252" unitRef="usd">9000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-3" decimals="-6" id="f-253" unitRef="usd">7000000</us-gaap:RepaymentsOfLongTermDebt>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation contextRef="c-1" decimals="-6" id="f-254" unitRef="usd">-28000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation contextRef="c-3" decimals="-6" id="f-255" unitRef="usd">-28000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-1" decimals="-6" id="f-256" unitRef="usd">128000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-3" decimals="-6" id="f-257" unitRef="usd">131000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-6" id="f-258" unitRef="usd">375000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-3" decimals="-6" id="f-259" unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-260" unitRef="usd">-540000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-3" decimals="-6" id="f-261" unitRef="usd">-666000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-6" id="f-262" unitRef="usd">9000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-6" id="f-263" unitRef="usd">-5000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-6" id="f-264" unitRef="usd">-2266000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-3" decimals="-6" id="f-265" unitRef="usd">-206000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-6" id="f-266" unitRef="usd">5133000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-6" id="f-267" unitRef="usd">4076000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-6" id="f-268" unitRef="usd">2867000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-37" decimals="-6" id="f-269" unitRef="usd">3870000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-270">&lt;div style="width:100.000%"&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;1. Basis of Presentation and Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2025 and 2024 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2025 and June 30, 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments, and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2025 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2025. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the "2024 Form 10-K"). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Revision of Prior Period Consolidated Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed in the 2024 Form 10-K, we revised our prior period financial statements to correct for an accounting error related to the at-Home Solutions operating segment that was not &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;material, individually or in the aggregate, to our previously issued Consolidated Financial Statements, as well as other unrelated immaterial errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. See Note 1 and Note 16 to the "Consolidated Financial Statements" in the 2024 Form 10-K for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Updated Segment Reporting Structure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. The remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Logistics, are not significant enough to require separate reportable disclosures and are included in Other. The Pharma reportable segment consists of all businesses formerly within our Pharmaceutical segment, excluding Nuclear and Precision Health Solutions. The GMPD reportable segment consists of all businesses formerly within our Medical segment, excluding at-Home Solutions and OptiFreight&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Logistics. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i088c97dfd3044fc38835caa8c41eddc8_121" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 13&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for segment results under the new reporting structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expired at the end of June 2024, would not be renewed. Sales to OptumRx generated 17 percent of our consolidated revenue in fiscal 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards And Disclosure Rules Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the FASB on our consolidated financial statements as well as material updates to previous assessments, if any, from the 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in the 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Tax Disclosure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in the 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Climate-Related Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the SEC issued final rules on climate-related disclosures that will require annual disclosure of material climate-related risks and material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the rules require disclosure in the notes to the financial statements of the effects of severe weather events and other natural conditions, subject to certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates. These rules also require disclosure of climate risk oversight practices of the Board of Directors and management, and the disclosure of governance, risk management, and strategy related to material climate-related risks. In April 2024, the SEC voluntarily stayed the new rules pending the completion of judicial review. We are currently evaluating the impact of adoption of these final rules on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the three months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-271">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2025 and 2024 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2025 and June 30, 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments, and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2025 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2025. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the "2024 Form 10-K"). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Revision of Prior Period Consolidated Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed in the 2024 Form 10-K, we revised our prior period financial statements to correct for an accounting error related to the at-Home Solutions operating segment that was not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;material, individually or in the aggregate, to our previously issued Consolidated Financial Statements, as well as other unrelated immaterial errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. See Note 1 and Note 16 to the "Consolidated Financial Statements" in the 2024 Form 10-K for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Updated Segment Reporting Structure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. The remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Logistics, are not significant enough to require separate reportable disclosures and are included in Other. The Pharma reportable segment consists of all businesses formerly within our Pharmaceutical segment, excluding Nuclear and Precision Health Solutions. The GMPD reportable segment consists of all businesses formerly within our Medical segment, excluding at-Home Solutions and OptiFreight&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Logistics. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i088c97dfd3044fc38835caa8c41eddc8_121" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 13&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for segment results under the new reporting structure.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:MajorCustomersPolicyPolicyTextBlock contextRef="c-1" id="f-272">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expired at the end of June 2024, would not be renewed. Sales to OptumRx generated 17 percent of our consolidated revenue in fiscal 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:MajorCustomersPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-38" decimals="2" id="f-273" unitRef="rate">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-274">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards And Disclosure Rules Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the FASB on our consolidated financial statements as well as material updates to previous assessments, if any, from the 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in the 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adoption of this guidance on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Tax Disclosure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in the 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Climate-Related Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the SEC issued final rules on climate-related disclosures that will require annual disclosure of material climate-related risks and material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the rules require disclosure in the notes to the financial statements of the effects of severe weather events and other natural conditions, subject to certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates. These rules also require disclosure of climate risk oversight practices of the Board of Directors and management, and the disclosure of governance, risk management, and strategy related to material climate-related risks. In April 2024, the SEC voluntarily stayed the new rules pending the completion of judicial review. We are currently evaluating the impact of adoption of these final rules on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the three months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-275">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;2. Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2024, we announced that we have entered into a definitive agreement to acquire Integrated Oncology Network ("ION"), a physician-led independent community oncology network, for a purchase price of $1.1&#160;billion in cash, subject to certain adjustments. ION includes more than 50 practice sites in 10 states representing more than 100 providers. ION supports a complete continuum of care across its member sites including medical oncology, radiation oncology, urology diagnostic testing and other ancillary services. This transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash. Specialty Networks creates clinical and economic value for providers and partners across multiple specialty group purchasing organizations ("GPOs"): UroGPO, Gastrologix and GastroGPO, and United Rheumatology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the purchase price for the acquisition of Specialty Networks is not yet finalized and is subject to adjustment as we complete the valuation analysis of the acquisition. The pro forma results of operations and the results of operations for Specialty Networks have not been separately disclosed because the effects were not significant compared to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationPriceOfAcquisitionExpected contextRef="c-39" decimals="-6" id="f-276" unitRef="usd">1100000000</us-gaap:BusinessCombinationPriceOfAcquisitionExpected>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-40" decimals="-6" id="f-277" unitRef="usd">1200000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-278">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;3. Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 5, 2023, we signed a definitive agreement to contribute the Outcomes&#x2122; business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $53&#160;million during the three months ended September 30, 2023, which was included in &lt;span style="-sec-ix-hidden:f-281"&gt;impairments and (gain)/loss on disposal of assets, net&lt;/span&gt; in our condensed consolidated statements of earnings/(loss). This gain includes our initial recognition of an equity method investment in the combined entity for $147&#160;million, which was recorded in other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the divestiture of the Outcomes&#x2122; business did not meet the criteria to be classified as discontinued operations. The Outcomes&#x2122; business operated within our former Pharmaceutical segment and its results before the divestiture are reflected within the Pharma segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-41" decimals="2" id="f-279" unitRef="number">0.16</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-42" decimals="-6" id="f-280" unitRef="usd">53000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure contextRef="c-43" decimals="-6" id="f-282" unitRef="usd">147000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-283">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;4. Restructuring and Employee Severance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance costs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.974%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs, and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional project management, and costs associated with vacant facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2024, restructuring and employee severance costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and certain initiatives to rationalize our manufacturing operations. During the three months ended September&#160;30, 2023, restructuring and employee severance costs were primarily related to certain &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;projects resulting from reviews of our strategy, portfolio, capital-allocation framework, and operations and the implementation of certain enterprise-wide cost-savings measures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.191%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.810%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-284">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance costs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.974%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1 contextRef="c-1" decimals="-6" id="f-285" unitRef="usd">16000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-3" decimals="-6" id="f-286" unitRef="usd">7000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts contextRef="c-1" decimals="-6" id="f-287" unitRef="usd">8000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts contextRef="c-3" decimals="-6" id="f-288" unitRef="usd">18000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-6" id="f-289" unitRef="usd">24000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-3" decimals="-6" id="f-290" unitRef="usd">25000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-291">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.191%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.810%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-44" decimals="-6" id="f-292" unitRef="usd">92000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-45" decimals="-6" id="f-293" unitRef="usd">5000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-5" decimals="-6" id="f-294" unitRef="usd">97000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCosts contextRef="c-46" decimals="-6" id="f-295" unitRef="usd">7000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts contextRef="c-47" decimals="-6" id="f-296" unitRef="usd">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts contextRef="c-1" decimals="-6" id="f-297" unitRef="usd">7000000</us-gaap:RestructuringCosts>
    <us-gaap:PaymentsForRestructuring contextRef="c-46" decimals="-6" id="f-298" unitRef="usd">5000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-47" decimals="-6" id="f-299" unitRef="usd">5000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-1" decimals="-6" id="f-300" unitRef="usd">10000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-48" decimals="-6" id="f-301" unitRef="usd">94000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-49" decimals="-6" id="f-302" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-4" decimals="-6" id="f-303" unitRef="usd">94000000</us-gaap:RestructuringReserve>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-304">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;5. Goodwill and Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.751%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.887%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.332%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and Specialty Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Global Medical Products and Distribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,555&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight&#xae; Logistics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2023, we performed interim quantitative goodwill impairment testing for GMPD. This quantitative testing resulted in the carrying amount of GMPD exceeding the fair value, resulting in a pre-tax impairment charge of $585&#160;million. GMPD goodwill was fully impaired during the third quarter of fiscal 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.070%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.070%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.409%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,651&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,495&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;562&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;415&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,047&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;699&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,609&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,651&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,609&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,663&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.308%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.643%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.312%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortization of intangible assets was $68 million and $64 million for the three months ended September&#160;30, 2024 and 2023, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2025 through 2029 is as follows: $200&#160;million, $246 million, $219 million, $191 million, and $186&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-305">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.751%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.887%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.332%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and Specialty Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Global Medical Products and Distribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,555&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight&#xae; Logistics.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-50" decimals="-6" id="f-306" unitRef="usd">3555000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-51" decimals="-6" id="f-307" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-52" decimals="-6" id="f-308" unitRef="usd">1170000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-6" id="f-309" unitRef="usd">4725000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-53" decimals="-6" id="f-310" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-54" decimals="-6" id="f-311" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-55" decimals="-6" id="f-312" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-1" decimals="-6" id="f-313" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill contextRef="c-56" decimals="-6" id="f-314" unitRef="usd">3555000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-57" decimals="-6" id="f-315" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-58" decimals="-6" id="f-316" unitRef="usd">1170000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-6" id="f-317" unitRef="usd">4725000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-59" decimals="-6" id="f-318" unitRef="usd">585000000</us-gaap:GoodwillImpairmentLoss>
    <cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-319">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.070%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.070%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.409%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,651&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,495&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;562&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;415&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,047&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;699&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,609&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,651&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,609&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,663&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.308%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.643%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.312%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-60" decimals="-6" id="f-320" unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-60" decimals="-6" id="f-321" unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-4" decimals="-6" id="f-322" unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-4" decimals="-6" id="f-323" unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-61" decimals="-6" id="f-324" unitRef="usd">3651000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-61" decimals="-6" id="f-325" unitRef="usd">2495000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-61" decimals="-6" id="f-326" unitRef="usd">1156000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-61" id="f-327">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-62" decimals="-6" id="f-328" unitRef="usd">562000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-62" decimals="-6" id="f-329" unitRef="usd">415000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-62" decimals="-6" id="f-330" unitRef="usd">147000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-62" id="f-331">P7Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-63" decimals="-6" id="f-332" unitRef="usd">1047000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-63" decimals="-6" id="f-333" unitRef="usd">699000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-63" decimals="-6" id="f-334" unitRef="usd">348000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-63" id="f-335">P7Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-6" id="f-336" unitRef="usd">5260000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-6" id="f-337" unitRef="usd">3609000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-6" id="f-338" unitRef="usd">1651000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-4" id="f-339">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-4" decimals="-6" id="f-340" unitRef="usd">5272000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-6" id="f-341" unitRef="usd">3609000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-6" id="f-342" unitRef="usd">1663000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-64" decimals="-6" id="f-343" unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-64" decimals="-6" id="f-344" unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-5" decimals="-6" id="f-345" unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-5" decimals="-6" id="f-346" unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-65" decimals="-6" id="f-347" unitRef="usd">3628000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-65" decimals="-6" id="f-348" unitRef="usd">2431000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-65" decimals="-6" id="f-349" unitRef="usd">1197000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-66" decimals="-6" id="f-350" unitRef="usd">561000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-66" decimals="-6" id="f-351" unitRef="usd">408000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-66" decimals="-6" id="f-352" unitRef="usd">153000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-67" decimals="-6" id="f-353" unitRef="usd">1047000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-67" decimals="-6" id="f-354" unitRef="usd">684000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-67" decimals="-6" id="f-355" unitRef="usd">363000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-5" decimals="-6" id="f-356" unitRef="usd">5236000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-6" id="f-357" unitRef="usd">3523000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="-6" id="f-358" unitRef="usd">1713000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-5" decimals="-6" id="f-359" unitRef="usd">5248000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-6" id="f-360" unitRef="usd">3523000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-6" id="f-361" unitRef="usd">1725000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-6" id="f-362" unitRef="usd">68000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-3" decimals="-6" id="f-363" unitRef="usd">64000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-4" decimals="-6" id="f-364" unitRef="usd">200000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-6" id="f-365" unitRef="usd">246000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-6" id="f-366" unitRef="usd">219000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-6" id="f-367" unitRef="usd">191000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-6" id="f-368" unitRef="usd">186000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-369">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;6. Long-Term Obligations and Other Short-Term Borrowings &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had total long-term obligations, including the current portion and other short-term borrowings, of $5.2 billion and $5.1 billion at September 30, 2024 and June 30, 2024, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $30.4 billion and $31.8 billion at September 30, 2024 and June 30, 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Financing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to cash and equivalents and operating cash flow, other sources of liquidity at September 30, 2024 include a&#160;$2.0&#160;billion&#160;commercial paper program, backed by a $2.0&#160;billion&#160;revolving credit facility, which expires in February 2028. We also have a&#160;$1.0 billion committed receivables sales facility through September 2025. At September 30, 2024, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2024, we entered into a new 364-Day Revolving Credit Facility, under which we have access to $1.0&#160;billion of committed liquidity through October 2025. We also increased our Commercial Paper program from $2.0&#160;billion to $3.0&#160;billion. &lt;/span&gt;&lt;/div&gt;Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of September 30, 2024, we were in compliance with this financial covenant.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount contextRef="c-4" decimals="-6" id="f-370" unitRef="usd">5200000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount contextRef="c-5" decimals="-6" id="f-371" unitRef="usd">5100000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c-4" decimals="-6" id="f-372" unitRef="usd">30400000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c-5" decimals="-6" id="f-373" unitRef="usd">31800000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-68" decimals="-6" id="f-374" unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-69" decimals="-6" id="f-375" unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-70" decimals="-6" id="f-376" unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:OtherShortTermBorrowings contextRef="c-71" decimals="-6" id="f-377" unitRef="usd">0</us-gaap:OtherShortTermBorrowings>
    <us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet contextRef="c-72" decimals="-6" id="f-378" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-68" decimals="-6" id="f-379" unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-73" decimals="-6" id="f-380" unitRef="usd">3000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-381">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;7. Commitments, Contingent Liabilities and Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Generic Sourcing Venture with CVS Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New York Opioid Stewardship Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors that was assessed based on each &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;manufacturer or distributor's share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new opioid excise tax and limited the OSA to two years (2017 and 2018).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Since fiscal 2021, we have made certain payments to New York State for our portion of the assessment in 2017 and 2018. However, we, and other distributors, challenged the OSA as unconstitutional. In May 2024, the New York Appellate Division held that the 2017 assessment was unconstitutionally retroactive, directing a refund of assessments paid for calendar year 2017, but upheld the 2018 assessment. Both parties have appealed the decision of the New York Appellate Division to the New York Court of Appeals, the state's highest court. We have not recorded a receivable for any possible recoveries related to these assessments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We become involved from time to time in disputes, litigation, and regulatory matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we determine that products we distribute, source, manufacture, or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims, and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier, or other industry participants. Internal investigations, subpoenas, or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="width:100.000%"&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for contingencies related to disputes, litigation, and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net, in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Opioid Lawsuits and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardinal Health, other pharmaceutical wholesalers, and other participants in the pharmaceutical supply chain have been named as defendants in lawsuits related to the distribution of opioid pain medications. These lawsuits seek equitable relief and monetary damages based on a variety of legal theories, including various common law claims, such as public nuisance, negligence, unjust enrichment, personal injury, as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act, and various other statutes. Plaintiffs in these lawsuits include governmental entities, as well as private parties, such as unions and other health and welfare funds, hospital systems and other healthcare providers, businesses, and individuals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information, subpoenas, and other requests from other DOJ offices. These investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, as of September 30, 2024, we have $5.0&#160;billion accrued for these matters, of which $789&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During fiscal 2024, we recognized expense of $340&#160;million &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in connection with opioid-related matters, including agreements in principle with counsel representing classes of third-party payors and acute care hospitals, and settlements with the City of Baltimore and the State of Alabama. This expense was partially offset by a benefit of $105&#160;million related to prepayments at a prenegotiated discount of certain future payments totaling $344&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of the agreements described below is an admission of liability or wrongdoing. Please see below for additional description of these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;States &amp;amp; Political Subdivisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, we along with two other national distributors (collectively, the "Distributors") entered into the National Opioid Settlement Agreement to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. In addition to the Distributors, parties to the National Opioid Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions in settling states (by population as calculated under the National Opioid Settlement Agreement) that had brought opioid-related suits against us have chosen to join the National Opioid Settlement Agreement or have had their claims addressed by state legislation (together with settling states and territories that joined the National Opioid Settlement Agreement, the "Settling Governmental Entities").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal 2024, we recognized a $22&#160;million charge in litigation (recoveries)/charge, net in the condensed consolidated statements of earnings/(loss) related to an agreement with the Alabama Attorney General under which we agreed to pay approximately $123&#160;million to the State of Alabama over a period of ten years to resolve opioid-related claims brought by the State and its political subdivisions (the "Alabama Settlement"). Including the National Opioid Settlement Agreement, the Alabama Settlement and a prior settlement with the State of West Virginia, we have now resolved the opioid-related claims of all 50 states and the District of Columbia. Additionally, in August 2024, we entered into a settlement agreement with the City of Baltimore to resolve its opioid-related claims. Under this agreement, we agreed to pay $153&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the National Opioid Settlement Agreement, through October 2024, we have paid the Settling Governmental Entities approximately $1.9&#160;billion. We expect to pay Settling Governmental Entities additional amounts up to $4.4&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="width:100.000%"&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;through 2038. The National Opioid Settlement Agreement also includes injunctive relief terms related to Distributors&#x2019; controlled substance anti-diversion programs. A monitor is overseeing compliance with these provisions until 2027. In addition, the Distributors have engaged a third-party vendor to act as a clearinghouse for data aggregation and reporting, which Distributors will fund for 10 years. As a result of the National Opioid Settlement Agreement, the vast majority of lawsuits brought against us by political subdivisions have been dismissed. We continue to engage in resolution discussions with certain nonparticipating political subdivisions. We intend to defend ourselves vigorously against all remaining lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Settlements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;West Virginia subdivisions and Native American tribes were not a part of the National Opioid Settlement Agreement. In July 2022, a judgment in favor of the Distributors was entered in a bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington. Plaintiffs have appealed this decision to the Fourth Circuit Court of Appeals. In July 2022, we entered into separate agreements to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions and Native American Tribes for approximately $124&#160;million over 11-years and $136&#160;million over five years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Private Plaintiffs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The National Opioid Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses, and individuals alleging personal injury. There were approximately 367 lawsuits brought by private plaintiffs pending as of October 28, 2024. Of these, 98 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in all of these matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following resolution discussions with certain private plaintiffs, during the three months ended September 30, 2024, Distributors finalized agreements with classes of third-party payors and acute care hospitals to settle their claims for $213&#160;million. These agreements remain subject to certain contingencies, including court approval. Active litigation brought by hospital and third-party payor plaintiffs, including certain scheduled trials, has been stayed as to Distributors pending court approval of these settlements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. Following cross-appeals, in September 2024, The Georgia Supreme Court affirmed the defense verdict in full. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Insurance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in ongoing legal proceedings with insurers related to their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. During fiscal 2024, we received $34&#160;million in insurance recoveries related to these matters and $9&#160;million in the three months ended &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2024. We have not recorded a receivable for any additional recoveries related to these insurance litigation matters as of September 30, 2024. Certain recoveries from our insurers are recorded in the Pharmaceutical and Specialty Solutions segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Department of Justice Civil Investigative Demand&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, we received a Civil Investigative Demand ("CID") from the Department of Justice focused on potential violations of the Anti-Kickback Statute and False Claims Act in connection with a 2022 transaction in which we purchased a minority ownership interest in a rheumatology managed services organization and a group purchasing organization. We are cooperating with this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis IVC Filter Matters &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named as a defendant in product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by plaintiffs that allege personal injuries associated with the use of inferior vena cava ("IVC") filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve approximately 4,375 claims for $275&#160;million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we made settlement payments totaling $275&#160;million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, while we have also entered into agreements to settle the vast majority of IVC filter product liability claims, these settlements will not resolve all of them, and we intend to continue to vigorously defend ourselves in the remaining lawsuits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized income of $103&#160;million during fiscal year 2023, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At September 30, 2024, we had a total of $289&#160;million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets, which includes the $275&#160;million in the qualified settlement fund.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Civil Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pharmaceutical Pricing Antitrust Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters condensed consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;anti-competitive pricing information to manufacturers, and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the amended complaint. We are vigorously defending ourselves in this matter, which remains pending as of September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust Litigation Proceeds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $43 million and $41 million, which were recognized in litigation (recoveries)/charges, net, during the three months ended September 30, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="c-74" id="f-382">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <cah:AggregateAnnualAssessment contextRef="c-75" decimals="-6" id="f-383" unitRef="usd">100000000</cah:AggregateAnnualAssessment>
    <us-gaap:LitigationReserve contextRef="c-76" decimals="-7" id="f-384" unitRef="usd">5000000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserveCurrent contextRef="c-76" decimals="-6" id="f-385" unitRef="usd">789000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationSettlementLoss contextRef="c-77" decimals="0" id="f-386" unitRef="usd">340000000</us-gaap:LitigationSettlementLoss>
    <cah:IncomeAsAResultOfPrepayments contextRef="c-77" decimals="-6" id="f-387" unitRef="usd">105000000</cah:IncomeAsAResultOfPrepayments>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease contextRef="c-77" decimals="-6" id="f-388" unitRef="usd">-344000000</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
    <cah:SettlingStates contextRef="c-78" decimals="0" id="f-389" unitRef="states">48</cah:SettlingStates>
    <cah:SettlingUSTerritories
      contextRef="c-78"
      decimals="0"
      id="f-390"
      unitRef="numberofusterritories">5</cah:SettlingUSTerritories>
    <cah:PercentageSettlingSubdivisions contextRef="c-79" decimals="3" id="f-391" unitRef="rate">0.99</cah:PercentageSettlingSubdivisions>
    <us-gaap:LitigationSettlementLoss contextRef="c-80" decimals="-6" id="f-392" unitRef="usd">22000000</us-gaap:LitigationSettlementLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-81" decimals="-6" id="f-393" unitRef="usd">123000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-82" decimals="-6" id="f-394" unitRef="usd">153000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-83" decimals="-6" id="f-395" unitRef="usd">1900000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-84" decimals="-6" id="f-396" unitRef="usd">4400000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-85" decimals="-6" id="f-397" unitRef="usd">124000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-86" decimals="-6" id="f-398" unitRef="usd">136000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <cah:LossContingencyLawsuitsNumber contextRef="c-87" decimals="0" id="f-399" unitRef="lawsuit">367</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber contextRef="c-88" decimals="0" id="f-400" unitRef="lawsuit">98</cah:LossContingencyLawsuitsNumber>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-89" decimals="-6" id="f-401" unitRef="usd">213000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="c-90"
      decimals="0"
      id="f-402"
      unitRef="plaintiff">21</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:InsuranceRecoveries contextRef="c-91" decimals="-6" id="f-403" unitRef="usd">34000000</us-gaap:InsuranceRecoveries>
    <us-gaap:InsuranceRecoveries contextRef="c-79" decimals="-6" id="f-404" unitRef="usd">9000000</us-gaap:InsuranceRecoveries>
    <us-gaap:LossContingencyClaimsSettledNumber contextRef="c-92" decimals="0" id="f-405" unitRef="lawsuit">4375</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-93" decimals="-6" id="f-406" unitRef="usd">275000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualPayments contextRef="c-94" decimals="-6" id="f-407" unitRef="usd">275000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease contextRef="c-95" decimals="-6" id="f-408" unitRef="usd">-103000000</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-96" decimals="-6" id="f-409" unitRef="usd">289000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualPayments contextRef="c-94" decimals="-6" id="f-410" unitRef="usd">275000000</us-gaap:LossContingencyAccrualPayments>
    <cah:IncomefromSettlementsofClassActionLawsuits contextRef="c-1" decimals="-6" id="f-411" unitRef="usd">43000000</cah:IncomefromSettlementsofClassActionLawsuits>
    <cah:IncomefromSettlementsofClassActionLawsuits contextRef="c-3" decimals="-6" id="f-412" unitRef="usd">41000000</cah:IncomefromSettlementsofClassActionLawsuits>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-413">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;8. Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in our provision for/(benefit from) income taxes as a percentage of our pre-tax earnings/(loss) (&#x201c;effective tax rate&#x201d;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effective Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2024 and 2023, the effective tax rate was 23.0 percent and 75.1 percent, respectively. The tax rate during the three months ended September 30, 2023 reflects the impact of the tax effects of the goodwill impairment charge recognized in the same quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Goodwill Impairment Charge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2023, we recognized a $585&#160;million pre-tax charge for goodwill impairment related to the GMPD segment. The net tax benefit related to this charge is $45&#160;million for fiscal 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effect of the goodwill impairment charge during the three months ended September 30, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to pre-tax loss for three months ended September 30, 2023 resulted in recognizing an incremental interim tax benefit of approximately $102&#160;million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended September 30, 2023 and prepaid expenses and other assets in the condensed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated balance sheets at September 30, 2023. This interim tax benefit reversed in the remainder of fiscal 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $952 million and $981 million of unrecognized tax benefits at September 30, 2024 and June&#160;30, 2024, respectively. The September 30, 2024 and June&#160;30, 2024 balances include $871&#160;million and $882 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2024 and June&#160;30, 2024, we had $69 million and $65 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) from income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits, or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $20 million, exclusive of penalties and interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Tax Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-414" unitRef="number">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-3" decimals="3" id="f-415" unitRef="number">0.751</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-59" decimals="-6" id="f-416" unitRef="usd">585000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-97" decimals="-6" id="f-417" unitRef="usd">-45000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-98" decimals="-6" id="f-418" unitRef="usd">102000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-6" id="f-419" unitRef="usd">952000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-6" id="f-420" unitRef="usd">981000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-4" decimals="-6" id="f-421" unitRef="usd">871000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-5" decimals="-6" id="f-422" unitRef="usd">882000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-4" decimals="-6" id="f-423" unitRef="usd">69000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-5" decimals="-6" id="f-424" unitRef="usd">65000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible contextRef="c-99" decimals="-6" id="f-425" unitRef="usd">0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible contextRef="c-100" decimals="-6" id="f-426" unitRef="usd">20000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:OpenTaxYear contextRef="c-101" id="f-427">2015</us-gaap:OpenTaxYear>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;9. Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;678&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;678&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160; The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-429">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;678&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;678&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160; The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-102" decimals="-6" id="f-430" unitRef="usd">678000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-103" decimals="-6" id="f-431" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-104" decimals="-6" id="f-432" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-105" decimals="-6" id="f-433" unitRef="usd">678000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-102" decimals="-6" id="f-434" unitRef="usd">105000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-103" decimals="-6" id="f-435" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-104" decimals="-6" id="f-436" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-106" decimals="-6" id="f-437" unitRef="usd">105000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="c-102" decimals="-6" id="f-438" unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="c-103" decimals="-6" id="f-439" unitRef="usd">-37000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="c-104" decimals="-6" id="f-440" unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="c-106" decimals="-6" id="f-441" unitRef="usd">-37000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-107" decimals="-6" id="f-442" unitRef="usd">1442000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-108" decimals="-6" id="f-443" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-109" decimals="-6" id="f-444" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-110" decimals="-6" id="f-445" unitRef="usd">1442000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-107" decimals="-6" id="f-446" unitRef="usd">108000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-108" decimals="-6" id="f-447" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-109" decimals="-6" id="f-448" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-111" decimals="-6" id="f-449" unitRef="usd">108000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="c-107" decimals="-6" id="f-450" unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="c-108" decimals="-6" id="f-451" unitRef="usd">-87000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="c-109" decimals="-6" id="f-452" unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="c-111" decimals="-6" id="f-453" unitRef="usd">-87000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-454">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;10. Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Currency Exchange Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commodity Price Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three months ended September&#160;30, 2024 and 2023, there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2023 we entered into pay-floating interest rate swaps with total notional amounts of $100 million. These swaps were designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency, and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gains recognized in other comprehensive income/(loss) were $3 million and immaterial for the three months ended September&#160;30, 2024 and 2023, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were a $1 million loss and a $1 million gain for the three months ended September&#160;30, 2024 and 2023, respectively. Losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reclassified into net earnings within the next 12 months are $3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, we entered into &#xa5;18&#160;billion ($120&#160;million) cross-currency swaps maturing in September 2025 and &#xa5;18&#160;billion ($120&#160;million) cross-currency swaps maturing in June 2027. In June 2024, we terminated the &#xa5;18&#160;billion ($120&#160;million) cross-currency swaps with a maturity date of June 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, we terminated the &#xa5;38&#160;billion ($300&#160;million) cross-currency swaps entered into in January 2023 and received a net settlement in cash of $28&#160;million, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gains and losses from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were a $22&#160;million loss and a $11&#160;million gain for the three months ended September&#160;30, 2024 and 2023, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $2&#160;million and $3&#160;million during the three months ended September&#160;30, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Economic (Non-Designated) Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions, and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $1&#160;million loss and an immaterial gain during the three months ended September 30, 2024 and 2023, respectively. The principal currencies managed through foreign currency contracts are the &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;euro, Chinese renminbi, Canadian dollar, Indian rupee, and Brazilian real.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2024 and June 30, 2024 approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.986%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 contextRef="c-1" decimals="-6" id="f-455" unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:DerivativeLiabilityNotionalAmount contextRef="c-112" decimals="-6" id="f-456" unitRef="usd">100000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-113" decimals="-6" id="f-457" unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-114" decimals="-6" id="f-458" unitRef="usd">1000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-115" decimals="-6" id="f-459" unitRef="usd">1000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-116" decimals="-6" id="f-460" unitRef="usd">3000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-117" decimals="-6" id="f-461" unitRef="jpy">18000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-117" decimals="-6" id="f-462" unitRef="usd">120000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-118" decimals="-6" id="f-463" unitRef="jpy">18000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-118" decimals="-6" id="f-464" unitRef="usd">120000000</us-gaap:DerivativeAssetNotionalAmount>
    <cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount contextRef="c-119" decimals="-6" id="f-465" unitRef="jpy">18000000000</cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount>
    <cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount contextRef="c-119" decimals="-6" id="f-466" unitRef="usd">120000000</cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount>
    <cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount contextRef="c-120" decimals="-6" id="f-467" unitRef="jpy">38000000000</cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount>
    <cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount contextRef="c-120" decimals="-6" id="f-468" unitRef="usd">300000000</cah:DerivativesHedgeDiscontinuancesTerminationOfHedgingInstrumentNotionalAmount>
    <us-gaap:ProceedsFromHedgeInvestingActivities contextRef="c-121" decimals="-6" id="f-469" unitRef="usd">28000000</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-122" decimals="-6" id="f-470" unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-123" decimals="-6" id="f-471" unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-122" decimals="-6" id="f-472" unitRef="usd">2000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-123" decimals="-6" id="f-473" unitRef="usd">3000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-124" decimals="-6" id="f-474" unitRef="usd">1000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="c-1" id="f-475">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.986%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFairValue contextRef="c-125" decimals="-6" id="f-476" unitRef="usd">5072000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-126" decimals="-6" id="f-477" unitRef="usd">4891000000</us-gaap:DebtInstrumentFairValue>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings contextRef="c-4" decimals="-6" id="f-478" unitRef="usd">5164000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings contextRef="c-5" decimals="-6" id="f-479" unitRef="usd">5092000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-480">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;11. Shareholders' Deficit &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2024, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $375 million. We received an initial delivery of 2.7 million common shares using a reference price of $109.65. The program concluded on October 30, 2024 at a volume weighted average price per common share of $110.10 resulting in a final delivery of 0.7 million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 4.4&#160;million common shares using a reference price of $90.57. The program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3&#160;million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.050%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income attributable to Cardinal Health, Inc., net of tax benefit of $5 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.050%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $3 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-127" decimals="-6" id="f-481" unitRef="usd">375000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-128"
      decimals="-5"
      id="f-482"
      unitRef="shares">2700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-129"
      decimals="2"
      id="f-483"
      unitRef="usdPerShare">109.65</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-130"
      decimals="2"
      id="f-484"
      unitRef="usdPerShare">110.10</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-131"
      decimals="-5"
      id="f-485"
      unitRef="shares">700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-132" decimals="-6" id="f-486" unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-133"
      decimals="-5"
      id="f-487"
      unitRef="shares">4400000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-134"
      decimals="2"
      id="f-488"
      unitRef="usdPerShare">90.57</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-135"
      decimals="2"
      id="f-489"
      unitRef="usdPerShare">88.22</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-136"
      decimals="-5"
      id="f-490"
      unitRef="shares">1300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-491">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.050%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income attributable to Cardinal Health, Inc., net of tax benefit of $5 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.050%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $3 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-137" decimals="-6" id="f-492" unitRef="usd">-138000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-138" decimals="-6" id="f-493" unitRef="usd">-29000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-139" decimals="-6" id="f-494" unitRef="usd">-167000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-140" decimals="-6" id="f-495" unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-141" decimals="-6" id="f-496" unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-12" decimals="-6" id="f-497" unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-140" decimals="-6" id="f-498" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-141" decimals="-6" id="f-499" unitRef="usd">-1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-12" decimals="-6" id="f-500" unitRef="usd">-1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="c-1" decimals="-6" id="f-501" unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-140" decimals="-6" id="f-502" unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-141" decimals="-6" id="f-503" unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-142" decimals="-6" id="f-504" unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-143" decimals="-6" id="f-505" unitRef="usd">-133000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-144" decimals="-6" id="f-506" unitRef="usd">-22000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-145" decimals="-6" id="f-507" unitRef="usd">-155000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-146" decimals="-6" id="f-508" unitRef="usd">-137000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-147" decimals="-6" id="f-509" unitRef="usd">-14000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-148" decimals="-6" id="f-510" unitRef="usd">-151000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-149" decimals="-6" id="f-511" unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-150" decimals="-6" id="f-512" unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-28" decimals="-6" id="f-513" unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-149" decimals="-6" id="f-514" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-150" decimals="-6" id="f-515" unitRef="usd">2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-28" decimals="-6" id="f-516" unitRef="usd">2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="c-3" decimals="-6" id="f-517" unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-149" decimals="-6" id="f-518" unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-150" decimals="-6" id="f-519" unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-151" decimals="-6" id="f-520" unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-152" decimals="-6" id="f-521" unitRef="usd">-148000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-153" decimals="-6" id="f-522" unitRef="usd">-17000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-154" decimals="-6" id="f-523" unitRef="usd">-165000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-524">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;12. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("EPS"):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;243&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units, and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units, and performance share units that were excluded from the computation of diluted EPS were immaterial for the three months ended September 30, 2024 and 2 million for the three months ended September 30, 2023, 1&#160;million of which were anti-dilutive as a result of the net loss during the period.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="c-1" id="f-525">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("EPS"):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;243&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units, and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-6" id="f-526" unitRef="shares">243000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-3" decimals="-6" id="f-527" unitRef="shares">249000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-6" id="f-528" unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-3" decimals="-6" id="f-529" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-6" id="f-530" unitRef="shares">245000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-3" decimals="-6" id="f-531" unitRef="shares">249000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-3" decimals="-6" id="f-532" unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <cah:AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod contextRef="c-3" decimals="-6" id="f-533" unitRef="shares">1000000</cah:AntidilutiveSecuritiesExcludedFromComputationOfEPSAsAResultOfTheNetLossDuringThePeriod>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-534">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;13. Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2024, we operated under an updated organizational structure and re-aligned our reporting structure under two reportable segments: Pharma segment and GMPD segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Logistics. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. Our previously reported segment results have been recast to conform to this re-aligned reporting structure and reflect changes in the elimination of inter-segment revenue and allocated corporate technology and shared function expenses, which are driven by the reporting structure change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Pharma segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, which are sold in the United States, Canada, Europe, Asia, and other markets. In addition to distributing Cardinal Health brand products, this segment also distributes a broad range of medical, surgical, and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers in the United States and Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining three non-reportable operating segments included in Other are Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Logistics. These operating segments respectively operate nuclear pharmacies and radiopharmaceutical manufacturing facilities, distribute medical products to patients' homes in the United States, and provide supply chain services and solutions to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="width:100.000%"&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue for the two reportable segments and disaggregated revenue within the remaining operating segments, included in Other, and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and Specialty Solutions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47,990&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Global Medical Products and Distribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;739&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OptiFreight&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; Logistics&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52,299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52,277&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;408&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52,299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52,277&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Segment Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;amp;A") expenses. Segment SG&amp;amp;A expenses include share-based compensation expense as well as allocated corporate technology and shared functions expenses, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided, and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not allocate the following items to our segments: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;last-in first-out, or ("LIFO"), inventory charges/(credits); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;state opioid assessment related to prior fiscal years;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;shareholder cooperation agreement costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;restructuring and employee severance;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;amortization and other acquisition-related costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;impairments and (gain)/loss on disposal of assets, net; we recognized a pre-tax goodwill impairment charge of $585&#160;million during the three months ended September 30, 2023; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;litigation (recoveries)/charges, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;other (income)/expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;interest expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;loss on early extinguishment of debt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;provision for/(benefit from) income taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, certain investment spending and certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $12 million and $6&#160;million for the three months ended September 30, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and Specialty Solutions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Global Medical Products and Distribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;568&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160; Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Logistics.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Segment Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for two reportable segments and the remaining operating segments, included in Other, and Corporate: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and Specialty Solutions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Global Medical Products and Distribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,148&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,611&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c-1" decimals="0" id="f-535" unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-55"
      decimals="0"
      id="f-536"
      unitRef="segments">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-537">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue for the two reportable segments and disaggregated revenue within the remaining operating segments, included in Other, and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and Specialty Solutions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47,990&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Global Medical Products and Distribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;739&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OptiFreight&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; Logistics&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52,299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52,277&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues contextRef="c-155" decimals="-6" id="f-538" unitRef="usd">47990000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-156" decimals="-6" id="f-539" unitRef="usd">50588000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-157" decimals="-6" id="f-540" unitRef="usd">3123000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-158" decimals="-6" id="f-541" unitRef="usd">3032000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-159" decimals="-6" id="f-542" unitRef="usd">373000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-160" decimals="-6" id="f-543" unitRef="usd">324000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-161" decimals="-6" id="f-544" unitRef="usd">739000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-162" decimals="-6" id="f-545" unitRef="usd">667000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-163" decimals="-6" id="f-546" unitRef="usd">74000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-164" decimals="-6" id="f-547" unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-165" decimals="-6" id="f-548" unitRef="usd">1186000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-166" decimals="-6" id="f-549" unitRef="usd">1051000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-167" decimals="-6" id="f-550" unitRef="usd">52299000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-168" decimals="-6" id="f-551" unitRef="usd">54671000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-169" decimals="-6" id="f-552" unitRef="usd">-22000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-170" decimals="-6" id="f-553" unitRef="usd">-21000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-6" id="f-554" unitRef="usd">52277000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-3" decimals="-6" id="f-555" unitRef="usd">54650000000</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-556">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;408&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52,299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52,277&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues contextRef="c-171" decimals="-6" id="f-557" unitRef="usd">51891000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-172" decimals="-6" id="f-558" unitRef="usd">54270000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-173" decimals="-6" id="f-559" unitRef="usd">408000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-174" decimals="-6" id="f-560" unitRef="usd">401000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-167" decimals="-6" id="f-561" unitRef="usd">52299000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-168" decimals="-6" id="f-562" unitRef="usd">54671000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-169" decimals="-6" id="f-563" unitRef="usd">-22000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-170" decimals="-6" id="f-564" unitRef="usd">-21000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-6" id="f-565" unitRef="usd">52277000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-3" decimals="-6" id="f-566" unitRef="usd">54650000000</us-gaap:Revenues>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-59" decimals="-6" id="f-567" unitRef="usd">585000000</us-gaap:GoodwillImpairmentLoss>
    <cah:ProjectCostsOnInvestmentAndOtherSpending contextRef="c-1" decimals="-6" id="f-568" unitRef="usd">12000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending contextRef="c-3" decimals="-6" id="f-569" unitRef="usd">6000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-570">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and Specialty Solutions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Global Medical Products and Distribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;568&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160; Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Logistics.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss contextRef="c-155" decimals="-6" id="f-571" unitRef="usd">530000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-156" decimals="-6" id="f-572" unitRef="usd">456000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-157" decimals="-6" id="f-573" unitRef="usd">8000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-158" decimals="-6" id="f-574" unitRef="usd">12000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-165" decimals="-6" id="f-575" unitRef="usd">104000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-166" decimals="-6" id="f-576" unitRef="usd">96000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-167" decimals="-6" id="f-577" unitRef="usd">642000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-168" decimals="-6" id="f-578" unitRef="usd">564000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-169" decimals="-6" id="f-579" unitRef="usd">-74000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-170" decimals="-6" id="f-580" unitRef="usd">-596000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-6" id="f-581" unitRef="usd">568000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-3" decimals="-6" id="f-582" unitRef="usd">-32000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock contextRef="c-1" id="f-583">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for two reportable segments and the remaining operating segments, included in Other, and Corporate: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical and Specialty Solutions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Global Medical Products and Distribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,148&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,611&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets contextRef="c-175" decimals="-6" id="f-584" unitRef="usd">29215000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-176" decimals="-6" id="f-585" unitRef="usd">29149000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-177" decimals="-6" id="f-586" unitRef="usd">7148000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-178" decimals="-6" id="f-587" unitRef="usd">7047000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-179" decimals="-6" id="f-588" unitRef="usd">2611000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-180" decimals="-6" id="f-589" unitRef="usd">2606000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-181" decimals="-6" id="f-590" unitRef="usd">4085000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-182" decimals="-6" id="f-591" unitRef="usd">6319000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-6" id="f-592" unitRef="usd">43059000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-6" id="f-593" unitRef="usd">45121000000</us-gaap:Assets>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-594">&lt;div style="width:100.000%"&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;14. Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain stock incentive plans (collectively, the &#x201c;Plans&#x201d;) for the benefit of certain of our officers, directors, and employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total tax benefit related to share-based compensation was $4&#160;million for both the three months ended September&#160;30, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;90.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2024, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $110 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved and our total shareholder return relative to the S&amp;amp;P 500 Health Care Index, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;98.81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2024, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $63 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-595">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.343%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-183" decimals="-6" id="f-596" unitRef="usd">19000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-184" decimals="-6" id="f-597" unitRef="usd">21000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-185" decimals="-6" id="f-598" unitRef="usd">11000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-186" decimals="-6" id="f-599" unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-6" id="f-600" unitRef="usd">30000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-3" decimals="-6" id="f-601" unitRef="usd">29000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-6" id="f-602" unitRef="usd">4000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-3" decimals="-6" id="f-603" unitRef="usd">4000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-183" id="f-604">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-605">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;90.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-187"
      decimals="-5"
      id="f-606"
      unitRef="shares">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-187"
      decimals="2"
      id="f-607"
      unitRef="usdPerShare">70.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-183"
      decimals="-5"
      id="f-608"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-183"
      decimals="2"
      id="f-609"
      unitRef="usdPerShare">107.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-183"
      decimals="-5"
      id="f-610"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-183"
      decimals="2"
      id="f-611"
      unitRef="usdPerShare">72.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-183"
      decimals="-5"
      id="f-612"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-183"
      decimals="2"
      id="f-613"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-188"
      decimals="-5"
      id="f-614"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-188"
      decimals="2"
      id="f-615"
      unitRef="usdPerShare">90.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-188" decimals="-6" id="f-616" unitRef="usd">110000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-183" id="f-617">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cah:VestingPeriodinyearsforShares
      contextRef="c-185"
      decimals="0"
      id="f-618"
      unitRef="reportable_segments">3</cah:VestingPeriodinyearsforShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-189" decimals="2" id="f-619" unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-190" decimals="2" id="f-620" unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-191" decimals="2" id="f-621" unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-192" decimals="2" id="f-622" unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock contextRef="c-1" id="f-623">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;98.81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-193"
      decimals="-5"
      id="f-624"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-193"
      decimals="2"
      id="f-625"
      unitRef="usdPerShare">97.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-185"
      decimals="-5"
      id="f-626"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-185"
      decimals="2"
      id="f-627"
      unitRef="usdPerShare">113.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-185"
      decimals="-5"
      id="f-628"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-185"
      decimals="2"
      id="f-629"
      unitRef="usdPerShare">108.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-185"
      decimals="-5"
      id="f-630"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-185"
      decimals="2"
      id="f-631"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-194"
      decimals="-5"
      id="f-632"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-194"
      decimals="2"
      id="f-633"
      unitRef="usdPerShare">98.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-194" decimals="-6" id="f-634" unitRef="usd">63000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-185" id="f-635">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
